
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="ASCII"?-->
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 24 04:58:35 UTC 2022 -->

     <title> </title>

<meta content="text/html" http-equiv="Content-Type">

<div style="font: 10pt Times New Roman, Times, Serif"><div>



</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>FORM
<span><ix:nonnumeric contextref="c0" name="dei:DocumentType" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Fiscal Year Ended <span><ix:nonnumeric contextref="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span>, <span><ix:nonnumeric contextref="c0" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span></ix:nonnumeric></span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" inside-table="false" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span>
<span style="font-size: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _________ to _________.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span><ix:nonnumeric contextref="c0" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-38716</ix:nonnumeric></span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 66px; width: 300px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_001.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_001.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span><ix:nonnumeric contextref="c0" name="dei:EntityRegistrantName" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span style="text-decoration:underline">GAMIDA
CELL LTD.</span></b></span></ix:nonnumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span><ix:nonnumeric contextref="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Israel</b></span></ix:nonnumeric></span></td> <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: hidden-fact-0"><span><ix:nonnumeric contextref="c0" id="fact-identifier-9" name="dei:EntityTaxIdentificationNumber" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">Not Applicable</ix:nonnumeric></span></span></b></span></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br>
of incorporation)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br> Identification No.)</span></td></tr>
</tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span><ix:nonnumeric contextref="c0" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>116 Huntington Avenue</b></span></ix:nonnumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><ix:nonnumeric contextref="c0" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Boston,</ix:nonnumeric></span> <span><ix:nonnumeric contextref="c0" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MA</ix:nonnumeric></span> </b></span></p></td> <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span><ix:nonnumeric contextref="c0" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>02116</b></span></ix:nonnumeric></span></p></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip code)</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline"><span><ix:nonnumeric contextref="c0" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">(713)</ix:nonnumeric></span>
<span><ix:nonnumeric contextref="c0" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400-6400</ix:nonnumeric></span></span></b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Telephone
</span><span style="font-family: Times New Roman, Times, Serif">Number)</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td> <td style="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td> <td style="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span><ix:nonnumeric contextref="c0" name="dei:Security12bTitle" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares, NIS 0.01 par value</span></ix:nonnumeric></span></td> <td style="text-align: center; vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span><ix:nonnumeric contextref="c0" name="dei:TradingSymbol" inside-table="true" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMDA</span></ix:nonnumeric></span></td> <td style="text-align: center; vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span><ix:nonnumeric contextref="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" inside-table="true" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span> Stock Market LLC</span></td></tr>
</tbody></table><div>

</div><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: <b><span style="text-decoration:underline">None</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;☐&nbsp;&nbsp;&nbsp;<span><ix:nonnumeric contextref="c0" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span>&nbsp;☒</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 of Section 15(d) of the Act. Yes&nbsp;☐&nbsp;&nbsp;&nbsp;<span><ix:nonnumeric contextref="c0" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span>&nbsp;☒</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. <span><ix:nonnumeric contextref="c0" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>&nbsp;☒&nbsp;&nbsp;&nbsp;No&nbsp;☐</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). <span><ix:nonnumeric contextref="c0" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>&nbsp;☒&nbsp;&nbsp;&nbsp;No&nbsp;☐</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated
filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange
Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</span></td> <td style="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</span></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">☒</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span><ix:nonnumeric contextref="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif">☒</span></ix:nonnumeric></span></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span><ix:nonnumeric contextref="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif">☒</span></ix:nonnumeric></span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span><ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" inside-table="false" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span><ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" inside-table="false" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;☐&nbsp;&nbsp;&nbsp;No&nbsp;<span><ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting and non-voting
common equity held by non-affiliates of the registrant as of June 30, 2021 (the last day of the registrant’s most recently completed
second fiscal quarter) based on the closing sale price of $6.41 as reported on the Nasdaq Global Market as of that date was approximately
$<span style="-sec-ix-hidden: hidden-fact-1"><span><ix:nonfraction contextref="c2" decimals="0" id="fact-identifier-29" name="dei:EntityPublicFloat" unitref="usd" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="hidden-fact-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">379.9</ix:nonfraction></span></span> million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant had <span><ix:nonfraction contextref="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitref="shares" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,002,190</ix:nonfraction></span> ordinary shares
outstanding as of March 24, 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Documents incorporated by reference: None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%; font-family: Times New Roman, Times, Serif"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>





</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">TABLE
OF CONTENTS</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: justify; width: 9%; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: justify; width: 81%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_001" tabindex="18">Forward
    Looking Statements</a></span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; width: 9%; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">ii</span></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#a_002" tabindex="18">Part I</a></b></span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_003" tabindex="18">Item 1.</a></span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_003" tabindex="18">Business</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">1</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_004" tabindex="18">Item
    1a.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_004" tabindex="18">Risk
    Factors</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">32</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_005" tabindex="18">Item
    1b.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_005" tabindex="18">Unresolved
    Staff Comments</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">85</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_006" tabindex="18">Item
    2.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_006" tabindex="18">Properties</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">85</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_007" tabindex="18">Item
    3.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_007" tabindex="18">Legal
    Proceedings</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">85</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_008" tabindex="18">Item
    4.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_008" tabindex="18">Mine
    Safety Disclosure</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">85</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#a_009" tabindex="18">Part II</a></b></span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_010" tabindex="18">Item
    5.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_010" tabindex="18">Market
    For Registrant’s Common Equity, Related Shareholder Matters And Issuer Purchases Of Equity Securities</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">86</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_011" tabindex="18">Item
    6.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_011" tabindex="18">[Reserved]</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">92</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_012" tabindex="18">Item
    7.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_012" tabindex="18">Management’s
    Discussion And Analysis Of Financial Condition And Results Of Operations</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">93</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_013" tabindex="18">Item
    7a.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_013" tabindex="18">Quantitative
    And Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">101</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_014" tabindex="18">Item
    8.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_014" tabindex="18">Financial
    Statements&nbsp;and Supplementary Data</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">101</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_015" tabindex="18">Item
    9.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_015" tabindex="18">Changes
    In And Disagreements With Accountants On Accounting And Financial Disclosure</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">102</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_016" tabindex="18">Item
    9a.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_016" tabindex="18">Controls
    And Procedures</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">102</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_017" tabindex="18">Item
    9b.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_017" tabindex="18">Other
    Information</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">103</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_018" tabindex="18">Item
    9c.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_018" tabindex="18">Disclosure
    Regarding Foreign Jurisdiction that Prevent Inspections</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">103</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#a_019" tabindex="18">Part III</a></b></span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_020" tabindex="18">Item
    10.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_020" tabindex="18">Directors,
    Executive Officers And Corporate Governance</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">104</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_021" tabindex="18">Item
    11.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_021" tabindex="18">Executive
    Compensation</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">117</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_022" tabindex="18">Item
    12.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_022" tabindex="18">Security
    Ownership Of Certain Beneficial Owners And Management And Related Shareholder Matters</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">132</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_023" tabindex="18">Item
    13.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_023" tabindex="18">Certain
    Relationships And Related Transactions, And Director Independence</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">134</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_024" tabindex="18">Item
    14.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_024" tabindex="18">Principal
    Accounting Fees And Services</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">135</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#a_025" tabindex="18">Part IV</a></b></span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_026" tabindex="18">Item
    15.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_026" tabindex="18">Exhibits,
    Financial Statement Schedules</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">136</span></td></tr>
</tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">FORWARD
LOOKING STATEMENTS</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part&nbsp;I, Item&nbsp;1:
“Business,” Part&nbsp;I, Item&nbsp;1A: “Risk Factors,” and Part&nbsp;II, Item&nbsp;7: “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” but are also contained elsewhere in this annual
report. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”,
“expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”,
“predict”, “potential” or “continue”, the negative of such terms or other comparable terminology.
These statements speak only as of the date of this annual report and involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements.&nbsp;We have based these forward-looking statements
largely on our current expectations and projections about future events and financial trends that we believe may affect our business,
financial condition and results of operations.&nbsp;Forward-looking statements in this annual report include statements as to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         expectations regarding timing of submission of regulatory applications or receipt of
                                         regulatory approvals for omidubicel, GDA-201 or any of our other product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing of initiation of our clinical trials of GDA-201 and our other product candidates,
                                         as well as statements regarding the conduct, progress and results of current and future
                                         preclinical studies and clinical trials, and our research and development programs;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         plans to manufacture omidubicel at a commercial scale, if and when approved for marketing;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         clinical utility and potential advantages of omidubicel, GDA-201 and our other product
                                         candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         plans regarding utilization of regulatory pathways that would allow for accelerated marketing
                                         approval in the United States, the European Union and other jurisdictions;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&nbsp;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our recurring losses from operations, our estimates regarding anticipated capital requirements and our needs for additional financing;</span></td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ongoing and planned discovery and development of product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         expectations regarding future growth, including our ability to develop, and obtain regulatory
                                         approval for, new product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         expectations regarding when certain patents may be issued and the protection and enforcement
                                         of our intellectual property rights;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding the commercial potential, and our commercial marketing plan, for omidubicel and our other product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manufacture omidubicel and our other product candidates at levels sufficient for commercialization or clinical development, as applicable;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to maintain relationships with certain third parties;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         planned level of capital expenditures;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         expectations regarding licensing, acquisitions and strategic partnering; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of government laws and regulations.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should refer to “Item&nbsp;1A.
Risk Factors” in this annual report for a discussion of important factors that may cause our actual results to differ materially
from those expressed or implied by our forward-looking statements. Such risks and uncertainties may be amplified by the COVID-19 pandemic
and the conflict in the Ukraine, and their potential impact on our business and the global economy. As a result of these factors, we cannot
assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements
prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements,
you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and
plans in any specified time frame, or at all. The forward-looking statements in this annual report represent our views as of the date
of this annual report. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect
to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not
rely on these forward-looking statements as representing our views as of any date subsequent to the date of this annual report.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual
report completely and with the understanding that our actual future results may be materially different from what we expect. We
qualify all of our forward-looking statements by these cautionary statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this report all references to (i) “Gamida,” “Gamida Cell,” “we,” “us,” “our”
or the “Company” mean Gamida Cell Ltd. and its wholly-owned subsidiary, Gamida Cell Inc., unless the context otherwise
requires; (ii) “SEC” refers to the Securities and Exchange Commission; (iii) “Securities Act” refers to
the United States Securities Act of 1933, as amended; (iv) “Exchange Act” refers to the United States Securities Exchange
Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">PART
I</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_003"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
1. BUSINESS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overview</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an advanced cell therapy
company committed to cures for blood cancers and serious hematologic diseases. We harness our cell expansion platform to create therapies
with the potential to redefine standards of care in areas of serious medical need. While cell therapies have the potential to address
a variety of diseases, they are limited by availability of donor cells, matching a donor to the patient, and the decline in donor cell
functionality when expanding the cells to achieve a therapeutic dose. We have leveraged our NAM platform, or nicotinamide cell expansion
technology platform, to develop a pipeline of product candidates designed to address the limitations of other cell therapies. Our proprietary
technology allows for the proliferation and enhancement of donor cells, which allows for maintaining the cells’ functional therapeutic
characteristics, providing a potential treatment alternative for patients.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
therapies involve the delivery of human cells to replace or repair damaged tissue or cells in order to treat a variety of cancers
and other diseases. Hematopoietic stem cell transplantation with donor cells, or allogeneic HSCT, also called bone marrow transplantation,
is the most frequently used cell therapy to treat a variety of hematologic malignancies and other serious conditions. HSCT involves
reconstituting a patient’s bone marrow from a seed population of stem cells obtained from a donor whose blood-forming and
immune-system-forming cells are both cancer free and effective at carrying out their functions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are multiple sources of donor cells. The best source for donor cells is a sibling who is a matched related donor, or MRD, but
the chances of having a sibling match in the United States are only 25% to 30%. The majority of patients rely on alternate sources
of donor cells, including matched unrelated donor, or MUD, haploidentical, or “half-matched” donors, and mismatched
unrelated donor, or MMUD, as well as umbilical cord blood. However, due to disease progression and other complications during
the time needed to find a suitable donor, unfortunately many patients cannot find an appropriate donor. According to the CIBMTR,
in the U.S., there are approximately 8,000 patients above the age of 12 with hematologic malignancies who undergo an allogeneic
stem cell transplant each year and we believe that number of patients may grow over time. We estimate that there are approximately
1,000 patients each year, who are above the age of 12 and are deemed eligible for an allogeneic stem cell transplant but cannot
find an appropriate donor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the various potential sources of donor cells, HSCT is subject to a number of significant limitations, including: (i) delays in
finding a suitable match, during which disease progression may make patients ineligible for transplant; (ii) an insufficient
number or delayed engraftment of donor cells, leaving patients without a functioning immune system and leading to potentially
life-threatening immune deficiency following transplant; (iii) a lack of long-term compatibility between the donor cells
and the patient’s own cells, resulting in potentially fatal graft versus host disease, or GvHD; and (iv) older donor age
may correspond to a negative impact on the patient’s outcome. In addition, there is ethnic and racial disparity in access
to HSCT: data from 2018 indicate that white patients of European descent are approximately four times more likely to receive a
transplant than Black patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Umbilical
cord blood is a readily available source of stem cells for patients who need HSCT and do not have a matched related donor. It
is easier to find a match when using stem cells derived from cord blood, since a full match is not required for a successful transplant
using cord blood. However, on average, a typical cord blood graft contains approximately one-tenth the number of stem and progenitor
cells compared to stem cell grafts from adult bone marrow or peripheral blood donors. This lower number of cells may delay engraftment
of the donor cells and reconstitution of the immune system. This, in turn, increases both time in the hospital and the likelihood
that a patient might contract a life-threatening infection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel,
our lead product candidate, is designed to address the limitations of HSCT. Omidubicel consists of NAM-expanded and enhanced hematopoietic
stem cells and differentiated immune cells, including T cells. The final cell therapy product is cryopreserved until the patient
is ready to begin the transplant, when it is thawed and infused. Omidubicel has the potential to be a universal stem cell graft
in two broad patient groups: (i) patients with high-risk leukemias and lymphomas who require HSCT but who lack access to an appropriate
matched related donor; and (ii) patients with severe hematologic disorders such as severe aplastic anemia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the complete results from our pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic
malignancies were published in the peer-reviewed medical journal <i>Blood</i>. The trial achieved its primary endpoint of time
to neutrophil engraftment as well as all three of the prespecified secondary endpoints. These secondary endpoints were the proportion
of patients who achieved platelet engraftment by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive
fungal infections in the first 100 days following transplant, and the number of days alive and out of the hospital in the first
100 days following transplant. All three secondary endpoints demonstrated statistical significance in an intent-to-treat analysis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we also reported data from an analysis of a subset of 37 patients from the Phase 3 randomized trial of omidubicel
at Annual Meeting of the American Society of Hematology, or ASH. The analysis was aimed at investigating the reduced infection
rates observed in the study and showed that the omidubicel-treated patients had more rapid recovery of a wide variety of immune
cells including CD4+ T cells, B cells, NK cells and dendritic cell subtypes. The robust recovery of the immune system provides
rationale for fewer severe bacterial, fungal and viral infections in patients treated with omidubicel. Additional analyses are
ongoing to further characterize the immune recovery following omidubicel transplantation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
early 2022, the FDA agreed that the initiation of our rolling biologics license application, or BLA, submission for omidubicel
was appropriate and we initiated the rolling submission process. We plan to complete submission of the BLA in the first half of
2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have applied our NAM cell expansion technology to natural killer, or NK, cells, to develop our initial NK product
candidate, GDA-201, an investigational, NK cell-based immunotherapy for the treatment of hematologic and solid tumors in combination
with standard of care antibody therapies. GDA-201 is currently being evaluated in a Phase 1/2 investigator-sponsored trial for
the treatment of relapsed or refractory non-Hodgkin lymphoma, or NHL, and multiple myeloma, or MM. Data from the trial demonstrate
that GDA-201 was well-tolerated and no dose-limiting toxicities were observed in 19 patients with NHL and 16 patients with MM.
The data show that therapy using GDA-201 with monoclonal antibodies demonstrated significant clinical activity in heavily pretreated
patients with advanced NHL. Of the 19 patients with NHL, 13 complete responses and one partial response were observed, with an
overall response rate of 74% and a complete response rate of 68%. At the December 2021 Annual Meeting of ASH, we reported two-year
follow-up data from this clinical trial on outcomes and cytokine biomarkers associated with survival. The data demonstrated a
median duration of response of 16 months (range 5-36 months), an overall survival at two years of 78% (95% CI, 51%–91%)
and a safety profile similar to that reported previously.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2021, we submitted
an investigational new drug application, or IND, for a Phase 1/2 clinical trial of GDA-201 in patients with follicular and diffuse large
B-cell lymphomas. The FDA placed this IND on clinical hold prior to the initiation of patient dosing. The FDA has requested modifications
in donor eligibility procedures and assay qualifications. We are in active communication with the FDA with the objective to address these
requests to satisfy the requirements for IND acceptance and study initiation. We expect to initiate our Phase 1/2 study of GDA-201 in
patients with follicular and diffuse large B-cell lymphomas in 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are led by an experienced management team with extensive expertise in developing oncology therapies and manufacturing cell therapies
and other complex biologics. Our director and chief executive officer, Julian Adams, played a central role in the discovery and
development of bortezomib, or Velcade®, a widely used therapy for MM and other blood cancers approved by the FDA in 2003.
Dr. Adams also led research and development, or R&amp;D, efforts at Infinity Pharmaceuticals, Inc., which helped lead to the 2018
FDA approval of duvelisib, also known as Copiktra®, for the treatment of certain leukemias and lymphomas.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pipeline</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
figure below summarizes key information about our current pipeline of product candidates:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 401px; width: 700px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_002.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_002.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Strategy</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to deliver curative cell therapies to patients with serious and life-threatening medical conditions. The key strategies
to achieve our goal are the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtain
                                         regulatory approval for omidubicel in hematologic malignancies. </i></b></span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed an international, multicenter, randomized, pivotal Phase 3 clinical trial evaluating transplantation with omidubicel
compared to standard umbilical cord blood in 125 patients with various hematological malignancies, including acute lymphocytic
leukemia, or ALL, acute myeloid leukemia, or AML, myelodysplastic syndrome, or MDS, chronic myeloid leukemia, or CML, and lymphoma.
The primary endpoint was time to neutrophil engraftment. The trial achieved its primary endpoint, as well as all three of the
prespecified secondary endpoints. In February 2022, we initiated submission of the BLA for omidubicel on a rolling basis. We plan
to submit the full BLA for omidubicel in the first half of 2022, and if approved in the United States, we plan to seek regulatory
approval in the European Union and other geographies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Maximize
                                         commercial value of our product candidates. </i></b></span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
parallel with our rolling BLA submission for omidubicel, we are assessing alternatives for the commercialization of omidubicel,
including potential&nbsp;U.S.&nbsp;or global partnerships. We also reported the results of an analysis of resource utilization
data from the first 100 days after transplant for 108 patients in the pivotal Phase 3 trial that will help to inform pricing and
reimbursement. Additionally, we are developing a reimbursement strategy modeled upon recently approved cell therapies in oncology,
including potentially through the New Technology Add-on Payment program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reducing
                                         operating expenses.</i></b></span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With the objective of extending
our cash runway into mid-2023, consistent with the timeline for potential U.S. approval of omidubicel, we are reducing operating expenses
primarily by delaying hiring and planned spending in 2022 and implementation of a workforce reduction of approximately 10% in January
2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursue
                                         the potential of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas.</i></b></span></td></tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have applied our NAM technology
platform to develop the lead product candidate, GDA-201, in our NK cell pipeline. GDA-201 is currently being evaluated in an investigator-sponsored,
Phase 1/2 clinical study in patients with NHL or MM, in combination with rituximab or elotuzumab, respectively. At the December 2021 Annual
Meeting of ASH, we reported two-year follow-up data from the clinical trial on outcomes and cytokine biomarkers associated with survival.
The data demonstrated a median duration of response of 16 months (range 5- 36 months), an overall survival at two years of 78% (95% CI,
51%–91%) and a safety profile similar to that reported previously. In September 2021, we submitted an IND for a Phase 1/2 clinical
trial of GDA-201 in patients with follicular and diffuse large B-cell lymphomas. The FDA placed this IND on clinical hold prior to the
initiation of patient dosing. The FDA has requested modifications in donor eligibility procedures and assay qualifications. We are in
active communication with the FDA with the objective to address these requests and enable IND acceptance. We expect to initiate our Phase
1/2 study of GDA-201 in patients with follicular and diffuse large B-cell lymphomas in 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advancing
                                         genetically modified NK cell immunotherapy programs. </i></b></span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to continue to leverage our platform technology with a goal of discovering additional product candidates and expanding into
new therapeutic areas. We continue to advance our NAM-enabled genetically modified NK cell pipeline, which utilizes CAR, membrane
bound- and CRISPR-mediated strategies to increase targeting, potency and persistence against hematologic malignancies and solid
tumors. We plan to execute preclinical proof of concept studies for our genetically modified NK therapeutic targets and to select
pipeline candidates for IND enabling studies by the end of 2022. We also believe our technology can be applied to other cells
with therapeutic potential, and we plan to continue to invest in our research and development activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAM
Cell Expansion Technology</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
cell-based therapies have the potential to address a variety of medical conditions, one of the key technical challenges for developing
treatments with this approach is the expansion of therapeutically functional cells. In order for cell therapies to be clinically
effective, there must be a sufficient quantity of therapeutically active cells for treatment, which requires the donor cells to
be expanded in cell culture. While this may increase the number of cells, the functionality of those cells often diverges from
the therapeutic functionality of the original donor cells. This shortcoming in the cells used for treatment can result in suboptimal
clinical outcomes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our NAM cell expansion technology
is designed to address this challenge by leveraging the biochemical properties of the small molecule nicotinamide in our manufacturing
process. We expand and enhance the number of donor cells while maintaining their functional therapeutic characteristics through the proprietary
combination of NAM, intended to maintain silencing of cell differentiation and preservation of gene expression, and particular cytokines
which promote cell growth. Our optimized manufacturing process results in robust and replicable batch production, enabling the generation
of standardized donor-derived cell products, potentially resulting in better clinical outcomes.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have presented research describing the mechanism of action for the role of NAM in expanding CD34+ stem cells. The research included
transcriptome, transcription factor, and pathway analysis to elucidate the factors that lead to the preservation of engraftment
after ex vivo expansion of CD34+ hematopoietic stem cells derived from umbilical cord blood (the starting point for omidubicel)
compared to CD34+ cells grown in the absence of NAM. Analyses showed that the presence of NAM reduced the expression of genes
involved in the production of reactive oxygen and nitrogen species, suggesting that cell stress was minimized during expansion.
In addition, NAM also decreased growth factor of pathways responsible for activation and differentiation of hematopoietic stem
cells, suggesting NAM expanded cells while keeping them in an undifferentiated state. The presence of NAM also led to a decrease
in the expression of genes responsible for matrix metalloproteinase secretion, simulating the microenvironment of the bone marrow.
Additionally, NAM led to an increased expression of telomerase genes, which is believed to enable cells to remain in a more quiescent,
stem-like state. These data provide further scientific rationale for the favorable stem cell engraftment and patient outcomes
that were observed in the Phase 3 clinical study of omidubicel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also applied NAM technology in developing GDA-201 and the other product candidates in our NK cell pipeline, and we are exploring
this technology for other cells with therapeutic potential.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hematologic
Malignancies and Allogeneic HSCT</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overview</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hematologic
malignancies are characterized by an abnormal and excessive proliferation of malignant blood cells that replace normal blood cells
in the bone marrow and the circulation. In some patients, these cancerous cells proliferate rapidly, requiring urgent treatment.
Patients are initially treated with chemotherapy in order to destroy the malignant cells in a rapid manner. However, in most patients,
remission is temporary and the disease will return after initial treatment. One of the most effective treatment options for these
patients is hematopoietic stem cell transplantation, or HSCT, where the blood-forming cells in the patient are destroyed using
chemotherapy, radiation or a combination of both. These patients then receive new bone marrow stem cells from a healthy donor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allogeneic
HSCT is the transplantation of hematopoietic stem cells, derived from a donor’s bone marrow or peripheral blood, or standard
umbilical cord blood. HSCT involves reconstituting a person’s entire blood and bone marrow from a seed population of cells.
In some clinical settings, autologous HSCT may be performed, in which cells are derived from the patient and reinfused at a later
date. In leukemia and other hematologic malignancies, it is more appropriate to use allogeneic HSCT obtained from a donor, which
ensures that the graft does not contain the patient’s malignant cells and leverages the ability of donor cells to fight
against a patient’s cancer, which is known as the “graft versus leukemia” effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
HSCT, a patient is treated with chemotherapy and/or radiation to destroy the residual cancerous or defective cells that reside
in the bone marrow. This procedure, called myeloablation, also destroys the hematopoietic stem cells that are responsible for
forming red blood cells, platelets and white blood cells. Stem cells from a donor are then infused into a patient, migrate and
home to the bone marrow and begin to proliferate and differentiate into various types of blood cells, eventually leading to a
full reconstitution of the bone marrow and immune system.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 265px; width: 550px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_003.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_003.jpg"></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intent of HSCT is to cure patients of their hematologic malignancies. As of 2016, more than 500,000 allogeneic HSCT procedures
have been performed worldwide over the past 50 years with over 30,000 being performed per year, of which 8,500 are in the United
States. Approximately half of such patients are cured of their hematologic malignancies. From 2006 to 2016, the number of patients
receiving an allogeneic HSCT procedure increased by approximately 5% per year in the United States due to multiple factors, including
an aging population and new transplant modalities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
90% of HSCT procedures performed in the United States are for patients with various hematologic malignancies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although the number of allogeneic
HSCT procedures performed is growing and there are new modalities for the procedure, HSCT continues to have a number of limitations. There
are two major areas of unmet need. First, of those who receive a transplant, there is concomitant morbidity and mortality associated with
the treatment. Second, a significant number of patients who are candidates for transplant do not receive one in a timely fashion. We believe
that omidubicel can address these significant limitations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
Sources of Donor Cells for Allogeneic HSCT</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are multiple potential sources of donor cells for transplants. For each donor, there are various baseline requirements including
age and overall health. In general, younger donors produce more and better cells for HSCT than older donors. Donor matching is
determined by human leukocyte antigens, or HLA, which are proteins present on most cells and inherited genetically. HLA are recognized
by the immune system, and “foreign” or nonmatching HLA may be rejected. Therefore, matching of HLA between bone marrow
donor and recipient is needed for a successful transplant outcome.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
optimal source of donor cells is a matched sibling, but the chances of having a sibling match are only 25% to 30%. An alternate
source of donor cells is a MUD, but only 30% of patients requiring a transplant have a good to intermediate probability of finding
a MUD. Furthermore, it takes approximately four months on average to identify an appropriate MUD who is medically suitable and
willing to donate. During this lengthy time period, there is a risk of disease recurrence. Over time, the patient may also become
ineligible due to other health complications. Moreover, prolonged donor searches heighten anxiety for patients and their families.
In addition, there is ethnic and racial disparity in access to HSCT: data from 2018 indicate that white patients of European descent
are approximately four times more likely to receive a transplant than Black patients. The ability to find a match through this
process is particularly challenging for individuals of ethnic backgrounds that are not well represented in donor databases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a matched donor cell source is not identified, there are three alternatives for transplant candidates: mismatched unrelated donor,
haploidentical donors and umbilical cord donors. Haploidentical, or “half-matched” donors, and MUD are only partially
compatible with the recipient. Because of the immune incompatibility in transplants from such donors, there is a high risk of
GvHD, infection and other complications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alternatively,
donor cells can be obtained from umbilical cord blood. In contrast to MUD transplants, which require a greater degree of matching,
matching requirements for cord blood are less stringent than those from unrelated donors, leading to a greater probability for
finding a match: 96% for Caucasians of European descent, 81% for Black patients, and 82-91% of other minorities. This obviates
the need to go through a prolonged search process with uncertain outcomes in order to find a donor and arrange for the collection
of donor cells. Because the donor T cells in cord blood are naïve, meaning that they have not matured, they readily adapt
to the recipient and are associated with a low risk of a patient developing GvHD, in particular chronic GvHD. Furthermore, transplantation
with cord blood reduces the risk of potential transmission of an infection from an adult donor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitations
of Allogeneic HSCT</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are three critical limitations to successful HSCT:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                         in finding a suitable match, during which disease progression may make patients ineligible
                                         for a transplant;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
                                         number or delayed engraftment of donor cells, leaving patients without a functioning
                                         immune system and leading to potentially life-threatening immune deficiency following
                                         transplant; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
                                         of long-term compatibility between the donor cells and the patient’s own cells,
                                         resulting in potentially fatal GvHD.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
is Designed to Address the Limitations of HSCT</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the general limitations of HSCT, the low number of hematopoietic cells in standard umbilical cord blood is a major
clinical constraint. With standard umbilical cord blood, the small number of stem cells infused leads to a prolonged time to engraftment,
the process by which donor stem cells home to the bone marrow, differentiate, and repopulate the recipient’s blood cells.
Longer time to engraftment is associated with a higher rate of post-transplant complications, longer hospitalization time, and
an increase in transplant-related mortality. Omidubicel is designed to address the limitations of allogeneic HSCT because it expands
the number of donor cord blood stem cells while maintaining the cells’ functional therapeutic characteristics. The omidubicel
manufacturing process also enhances cell functionality.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Omidubicel consists of two
fractions of a unit of cord blood separated based on the expression of a marker on the surface of individual cells known as CD133. A cell’s
CD133 status reflects its “stem cell” properties. Those cells that express CD133 represent a pool of stem or progenitor cells,
cells that are capable of generating blood cells that can differentiate into a variety of cell subtypes. The CD133-positive stem or progenitor
cells are also capable of reproducing themselves. Once the cells bearing this marker, are isolated, they are cultured using the proprietary
NAM technology platform to expand their number while maintaining their regenerative properties. After approximately three weeks, the cells
are harvested and cryopreserved. The United States Adopted Names Council selected omidubicel as the name for these cells.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
cells that do not express CD133 represent other types of more mature, differentiated cells, including essential components of
the immune system such as T cells. These mature cells cannot engraft but can provide immunological support until T cells derived
from the stem cell graft recover. The CD133-negative cells are also cryopreserved and retained for use as the second component
of omidubicel. We refer to the two components collectively as “omidubicel.”</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
is shipped cryogenically to transplant centers where both components are thawed and infused to patients on the day of transplantation.
The thawing process occurs in a closed system and can also be performed at the patient’s bedside for ease of administration.
The cryopreserved product resulted in engraftment results similar to those obtained with non-cryopreserved product in a Phase
1 pilot study at Duke University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
                                         is a stem cell graft with less stringent matching requirements than conventional HSCT,
                                         intended to reduce problems with donor matching. If approved, this will provide an option
                                         for the patients who have lengthy searches to find a suitable match and may never receive
                                         one, thereby creating an opportunity to improve outcomes and access to HSCT for such
                                         patients.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
                                         is designed to deliver a therapeutic dose of stem cells that may lead to rapid engraftment
                                         and immune reconstitution.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
                                         provides a compatible graft, observed to reduce morbidities including GvHD and infections.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these characteristics, omidubicel may serve as a new alternative to existing graft modalities as well as expand the transplant
market for those who are unable to find a match.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel:
Clinical Trial Results</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials of omidubicel include an initial safety evaluation of omidubicel in a Phase 1 pilot study at Duke University,
a Phase 1/2 clinical trial that enrolled 36 patients in an international, multicenter, open-label, single-arm trial, and a Phase
3 clinical trial that evaluated 125 patients in a pivotal, international, multi-center, randomized trial. All patients in our
clinical trials of omidubicel had been previously treated for various hematologic malignancies, including ALL, AML, MDS, CML and
lymphoma. These patients were deemed to be in remission and at high risk of subsequent relapse.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pivotal
Phase 3 Trial</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, we enrolled the last patient in the pivotal, international, multi-center, randomized Phase 3 trial of omidubicel.
Initiated in 2017, the study compared omidubicel to single or double standard, unmanipulated umbilical cord blood transplantation.
Randomization was stratified by treatment center, disease risk, age and intent to perform single or double cord blood transplant.
The primary endpoint of time to neutrophil engraftment was met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
secondary endpoints—time to platelet engraftment, the incidence of grade 2 or grade 3 bacterial or invasive fungal infections
and the number of days alive and out of hospital during the first 100 days following transplantation—were also met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="height: 169px; width: 600px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_004.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_004.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
3 Study Schema</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 125 patients were randomized at 33 centers in the United States, South America, Europe and Asia. These 125 patients formed
the basis of the intent-to-treat, or ITT, analysis. Of the 62 patients randomized to omidubicel, 52 were transplanted per protocol
with the omidubicel graft. Of the 63 patients randomized to the control arm, 56 were transplanted as per protocol.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 308px; width: 600px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_005.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_005.jpg"></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
3 Patient Disposition and Analysis Populations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
demographics were well-balanced in the two study arms, with a median age in the early 40s. The study population was diverse, with
approximately 40% either Black, Asian, Latino or patients characterized under “other”. The majority of patients (over
70%) had acute leukemia. With respect to the transplant, all patients received myeloablative conditioning regimens, with approximately
half of the patients receiving a total-body-irradiation regimen, and approximately half receiving a chemotherapy-only conditioning
regimen. Myeloablative conditioning therapy is a combination of chemotherapy agents, and in some cases radiotherapy, that is expected
to produce low blood counts and is administered in order to reduce the tumor burden, suppress the patient’s immune system,
and allow engraftment of donor stem cells. Over 70% of patients had a 4/6 HLA matching cord, either serving as the starting material
for omidubicel, or as the standard control. A double cord transplant was intended for two-thirds of patients randomized to the
standard cord arm. The omidubicel unit was expanded a median 133-fold to a median of 6.6 x 10e8 CD34+ cells. This provided the
patients with a median CD34+ cell dose of 9 x 10e6 CD34+ cells/kg, which is a larger cell dose than can be collected from many
healthy adult stem cell donors. In contrast, recipients on the control arm received a median 0.3 x 10e6 CD34+ cells/kg.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 316px; width: 600px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_006.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_006.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
3 Patient Demographics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 332px; width: 600px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_007.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_007.jpg"></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
3 Baseline Disease and Transplant Characteristics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoint was time to neutrophil engraftment, based on recovery of neutrophils, a type of white blood cell that helps fight
infections. In the ITT population, the patients randomized to omidubicel engrafted at median of 12 days following transplantation
(95% confidence interval 10-15 days). Those randomized to the control arm engrafted at a median of 22 days (95% confidence interval
19-25 days). This was statistically significant (p&lt;0.001). In the as-treated, or AT, analysis, patients who received omidubicel
had a median time to neutrophil engraftment of 10 days, vs 20.5 days for the control. The cumulative incidence of neutrophil engraftment
was 96% for omidubicel recipients and 89% for the controls.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 199px; width: 700px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_008.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_008.jpg"></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cumulative
Incidence of Neutrophil and Platelet Engraftment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The results of the study were
published in October 2021 in the peer reviewed ASH journal <i>Blood</i>. Results included statistically significant positive results in
all three secondary endpoints: platelet engraftment, infections, and hospitalization. Platelets are required for normal blood clotting.
Platelet engraftment on day 42 after transplant was achieved in 55% of those randomized to omidubicel and 35% of those randomized to the
control arm (ITT). This difference had a p value of 0.028.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
randomized to omidubicel were less likely to develop a grade 2 or grade 3 bacterial or invasive fungal infection: 37% versus 57%
for those randomized to the control arm (p=0.03). The cumulative incidence of first grade 3 viral infection during the first year
after transplantation was also lower for those randomized to omidubicel (10% vs 26%; p=0.02). When looking at the overall number
and rate of infections, or infection density, during the first year after transplantation, the risk ratio for all infections,
irrespective of severity, was significantly lower among recipients of omidubicel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 222px; width: 700px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_009.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_009.jpg"></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incidence
of Serious Bacterial and Viral Infection Post-Transplant</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 348px; width: 500px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_010.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_010.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relative
Risk (95% CI) for Bacterial, Viral, and all Infections at One Year</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
randomized to omidubicel spent a median of 60.5 days alive and out of the hospital during the first 100 days following transplantation,
compared to 48 days for control patients (p=0.005).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ITT population, the cumulative incidence of non-relapse mortality at 210 days following randomization was 11% for omidubicel
and 24% for control. The incidence of relapse at 15 months following randomization was 25% for omidubicel and 17% for the controls.
These differences were not statistically different.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 255px; width: 700px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_011.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_011.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incidence
of Non-Relapse Mortality and Incidence of Relapse</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">There
was no statistically significant difference between the omidubicel arm and the control arm in one year overall survival or disease-free
survival. The Hazard Ratio of overall survival was 0.57 in favor of omidubicel, p=0.09.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="height: 260px; width: 700px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_012.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_012.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disease-Free
Survival and Overall Survival</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The safety profile for omidubicel
recipients in this study was consistent with the expected toxicities of allogeneic stem cell transplantation following conditioning therapy,
and there was no increase in adverse events, serious adverse events, or infusion reactions in the omidubicel arm compared to control.
GvHD is a multisystem disorder that is common in allogeneic HSCT. GvHD occurs when immune cells from a donor graft recognize the transplant
recipient host as foreign and initiate an immune reaction. Acute GvHD usually presents around the time of engraftment and manifests as
rash, nausea, vomiting, abdominal pain, diarrhea, or increased serum bilirubin. Chronic GvHD is usually diagnosed later during the first
year post-transplant, and clinical manifestations include skin involvement, gastrointestinal disease, and increased bilirubin. There was
no statistically significant difference between omidubicel and control patients in the cumulative incidence of acute GvHD in the first
100 days post-transplant.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grade
2-4 acute GvHD was observed in 56% of omidubicel recipients and 43% of controls. The numbers for grade 3/4 (severe) acute GvHD
were 14% and 21% for omidubicel and control, respectively. There was also no statistically significant difference in the cumulative
incidence of chronic GvHD (all grades, including mild, moderate and severe) in the first year, 35% vs 29% for omidubicel and control,
respectively. Overall, the results of the Phase 3 study showed superior hematopoietic recovery, decreased risk of serious infection,
and shorter duration of hospitalization in patients treated with omidubicel, with an acceptable safety profile.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In November 2021, we completed
a Type B Pre-BLA meeting with the FDA for omidubicel during which the FDA requested that we provide revised analysis of the manufacturing
data generated at our manufacturing facility in Kiryat Gat, Israel to demonstrate the analytical comparability of the omidubicel produced
at Kiryat Gat to the omidubicel that was produced at the clinical manufacturing sites for the Phase 3 study. In January 2022, we received
positive Type B meeting correspondence from the FDA that we had established the requisite analytical comparability. Based on the positive
Phase 3 trial results and the comparability analysis, the FDA agreed that the initiation of a rolling BLA submission is appropriate. In
February 2022, we initiated the rolling submission process with the FDA, and we plan to submit the full BLA for omidubicel to the FDA
in the first half of 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
has Breakthrough Therapy Designation from the FDA. Additionally, omidubicel received orphan drug designation from both the FDA
and the EMA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
1/2 Clinical Trial</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main objective of the Phase 1/2 study was to evaluate the safety and efficacy of omidubicel treatment in patients with hematologic
malignancies following myeloablative conditioning therapy. The study compared outcomes against a group of historic controls that
were identified from data collected by the Center for International Blood and Marrow Transplant Research, or CIBMTR, which tracks
all allogeneic transplants conducted in the United States. From the CIBMTR database, we identified 146 age and disease matched
patients who received standard cord blood transplants and served as historic controls.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The primary endpoint of this
study was also time to neutrophil engraftment, which was also met. Patients treated with omidubicel recovered their neutrophils (500 cells
per microliter) with a median recovery of 11.5 days after transplantation, which is significantly shorter than the 21 days observed in
the historic controls (p&lt;0.001). Platelet counts recovered within a median time period of 34 days in the omidubicel treated patients,
compared to 46 days in the historic controls (p&lt;0.001). For both neutrophils and platelets, the percentage of patients who achieved
engraftment was higher than in the historic controls. The age-adjusted cumulative incidence of neutrophil engraftment at 42 days following
transplantation was 94% for omidubicel recipients and 85% for the CIBMTR comparator cohort.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rates
of acute GvHD, chronic GvHD, infections, and hospitalization, as well as safety findings, were similar to those observed in the
Phase 3 study.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Omidubicel:
Health Economic Implications</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential clinical advantages of omidubicel could lead to societal benefits such as enabling patients to return to work, spend
time with loved ones and enjoy improved quality of life. Omidubicel may also reduce the costs to the healthcare system versus
standard cord HSCT due to potentially shortened isolation and intensive care hospital stays, reduced re-admission rates and decreased
severity and rates of infections. At the December 2021 Annual Meeting of ASH, we reported the results of an analysis of resource
utilization data from the first 100 days after transplant for 108 patients in the Phase 3 trial showing that the omidubicel-treated
patients had significantly shorter durations of hospitalization and intensive care unit stays, and fewer consultant visits, procedures,
and transfusions than the patients in the control arm. These data provide further evidence of the clinical benefit associated
with the more rapid hematopoietic recovery in patients treated with omidubicel and the corresponding reduction in healthcare resource
utilization. These data will help to inform pricing and reimbursement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Omidubicel
for the Treatment of Bone Marrow Failure Disorders</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to hematologic malignancies, we are pursuing the development of omidubicel for the treatment of severe aplastic anemia
and other bone marrow failure disorders. Severe aplastic anemia is a rare disease, with an estimated incidence in the United States
of 600-900 patients per year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
causes include autoimmune disease, certain medications or toxic substances, and inherited conditions. However, the cause is unknown
in approximately half of all cases of severe aplastic anemia. The disease is characterized by stem cells in the bone marrow that
are damaged and unable to produce enough new blood cells. This leads to extremely low blood cell counts and platelet levels, and
often requires patients to be immediately hospitalized for treatment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allogeneic
HSCT is the treatment of choice for patients with severe aplastic anemia who have an available matched sibling donor. Among the
2,471 patients with severe aplastic anemia receiving HSCT with a matched sibling donor between 2005 and 2015, the three-year probability
of survival was 91% for those younger than 18 years, and 78% for patients 18 years of age or older. Among the 1,751 recipients
of HSCT with a MUD during the same period, the probabilities of survival were 78% and 68% for severe aplastic anemia patients
under 18 years and greater than or equal to 18 years, respectively. We believe omidubicel may be able to provide a treatment option
for those patients who are unable to locate such a donor in time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
goal in treating these diseases is to replace defective bone marrow cells with cells derived from cord blood donors. Omidubicel
is currently being evaluated in a Phase 1/2 NIH-sponsored clinical trial. In this trial, omidubicel is administered in combination
with a reduced conditioning preparative protocol, which is designed to minimize toxicity, in up to 62 patients with severe aplastic
anemia or hypoplastic myelodysplastic syndrome, another bone marrow failure disease. This research protocol is designed to evaluate
the safety and effectiveness of transplantation with omidubicel to overcome the high incidence of graft rejection associated with
standard cord blood HSCT in severe aplastic anemia patients, where graft rejection occurs in up to 50% of subjects. In December
2020, we reported updated and expanded data at the Annual Meeting of ASH that demonstrated that patients with severe aplastic
anemia treated with omidubicel achieved sustained early engraftment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Omidubicel
for the Treatment of Non-Malignant Disorders</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
has also been tested in patients with sickle cell disease, or SCD, for which HSCT is currently the only clinically established
cure. The results of our Phase 1/2 clinical trial were published in <i>Blood</i>. Overall, 16 patients with severe SCD were treated,
13 patients with omidubicel in conjunction with a standard unit of cord blood, and three patients with standalone omidubicel.
All patients initially engrafted at a median of seven days for double cord and eight days for single cord. Two of the patients
died, one due to chronic GvHD and the other due to secondary graft failure. The rate of grades II-IV acute GvHD was 69%, and the
rate of grades III-IV acute GvHD was 23%. The engraftment results were favorable when compared to those from a study of 29 patients
with SCD who underwent HSCT with cells from a MUD donor. In that study, 27 of the patients had neutrophil engraftment, and the
median time to engraftment was 12 days. There were eight deaths, seven due to GvHD and one due to graft rejection; 19 of
29 were disease-free at two years. While the clinical study in patients with SCD is currently closed, we continue to believe that
omidubicel has potential to replace other allogeneic HSCT procedures in certain hematologic diseases and some metabolic disorders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
NK Cell Pipeline</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our pipeline of NK cell-based
cancer immunotherapies is comprised of GDA-201 and four additional preclinical programs that involve modifications intended to direct
NK cells against specific tumor markers to improve their cancer killing capabilities in both hematological and solid tumors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GDA-201
is our lead investigational NK cell-based cancer immunotherapy product candidate. GDA-201 addresses a key limitation in the therapeutic
potential of NK cells by increasing the cytotoxicity and <i>in vivo</i> retention and proliferation in the bone marrow and lymphoid
organs of NK cells expanded in culture conditions. GDA-201 is currently being evaluated in an investigator-sponsored Phase 1/2
trial for the treatment of NHL and MM. We believe that GDA-201 may have broad potential in both hematologic malignancies and in
solid tumors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In September 2021, we submitted
an IND for a Phase 1/2 clinical trial of GDA-201 for the treatment of patients with follicular and diffuse large B-cell lymphomas. In
October 2021, the FDA placed this IND on clinical hold prior to the initiation of patient dosing. The FDA has requested modifications
in donor eligibility procedures and assay qualifications. We are in active communication with the FDA with the objective to address these
requests and to enable IND acceptance. We expect to initiate our Phase 1/2 study of GDA-201 in patients with follicular and diffuse large
B-cell lymphomas in 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitations
of Therapeutic Antibodies in Cancer Treatment</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHL
is the most common malignancy of B cells. An estimated 77,240 new cases of NHL were diagnosed in the United States in 2020. The
five-year survival rate for those with NHL is approximately 73%. The combination of an antibody such as rituximab and chemotherapy
is the standard of care for patients with NHL. However, many patients develop resistance to rituximab, and when used as monotherapy,
only 15% of patients respond. One mechanism that contributes to this resistance is the inability of patient or autologous NK cells
to locate and kill tumor cells that rituximab has bound to. Treatment with donor-derived NK cells may overcome this resistance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NK
Cells: Broad Anti-Cancer Potential</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive
research efforts are ongoing to generate cellular products for the treatment of cancer patients. There is much interest in the
field in the potential of NK cells because they have potent anti-tumor properties. In contrast to other immune cell therapies,
NK cells can be used independently from genetic matching, potentially enabling NK cells to serve as a universal donor-based therapy
when combined with certain antibodies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NK
cells’ tumor killing activity is greatly enhanced by antibodies that recognize tumor cells, which trigger ADCC. In ADCC,
the binding of an antibody to a cell marks it for destruction by NK cells. A number of antibody products have been approved by
the FDA as therapeutics in oncology, each of which has limited efficacy as monotherapy. The effectiveness of these antibodies
can potentially be enhanced through coadministration with NK cells. A key limitation in the application of NK cells in cell therapy
has been the traditionally challenging task of generating sufficient numbers of highly functional NK cells in culture.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Solution: GDA-201</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed GDA-201, a cell therapy product candidate generated by expansion of NK cells using our NAM technology. We believe
that GDA-201 has potential application in boosting the innate immune response to cancer. Functional studies have shown that our
GDA-201 cells expanded in culture with our NAM technology and the cytokine IL-15 display increased tumor killing activity over
NK cells expanded with IL-15 but without NAM. We have also demonstrated ADCC with GDA-201 in combination with antibodies, including
rituximab.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investigator-sponsored Phase 1/2 clinical study of GDA-201 in patients with MM or NHL was initiated in 2017 at the University
of Minnesota. These patients have relapsed or refractory NHL or MM, meaning that their disease has come back after standard therapy
and/or they are not responding to standard therapy for their disease. In combination with GDA-201, these patients also receive
therapeutic antibodies, which, in the case of NHL, includes rituximab, and in the case of MM, elotuzumab. At the December 2021
Annual Meeting of ASH, we reported two-year follow-up data from the clinical trial on outcomes and cytokine biomarkers associated
with survival. The safety profile was consistent with that reported previously: there were no dose limiting toxicities in the
35 treated patients. In 19 patients with lymphoma, the data demonstrated a median duration of response of 16 months (range 5-
36 months), an overall survival at two years of 78% (95% CI, 51%–91%).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" style="height: 135px; width: 700px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_013.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_013.jpg"></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
1/2 Study of GDA-201 in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
included lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by two doses of GDA-201 (Days 0 and 2) and
low-dose IL-2 (6 million units subcutaneously). Three doses of monoclonal antibodies were administered pre and post GDA-201. The
study was designed to determine the maximum tolerated dose of GDA-201 cells. Patients who derived clinical benefit received a
second cycle of GDA-201 infusion without lymphodepleting chemotherapy. A total of 35 patients were treated in three cohorts of
escalating cellular doses of GDA-201, with a maximum dose of 200 million cell/kg. Sixteen patients with MM and 19 patients with
NHL were evaluable. The median age was 61 and the oldest patient was 83 years old. Among the patients with NHL, eight had diffuse
large B-cell lymphoma, or DLBC, 10 had follicular lymphoma, or FL, and one had mantle cell lymphoma. Patients were heavily pre-treated
with a median of three lines of prior chemotherapy (range 1-8 lines). Four of the NHL patients and three of the MM patients had
prior HSCT.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no dose limiting toxicities at any of the doses administered. One patient, who initially was thought to have cytokine release
syndrome, died of E-coli sepsis. The most common Grade 3 or 4 adverse events were decreased neutrophil count, febrile neutropenia,
anemia and low platelet count, generally attributed to lymphodepleting chemotherapy. No neurotoxic events, GvHD or marrow aplasia
were observed.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the 16 patients with MM, one patient achieved a complete response, and four patients achieved stable disease. Among the 19 patients
with NHL, 13 achieved a complete response and one achieved a partial response. Overall response rate among the 19 NHL patients
was 74%, with responses observed in 8 patients with FL and 5 patients with DLBCL. Median duration of response was 10 months with
a range of 1 – 28 months. In three patients, an initial partial response deepened over time to a complete response: one
(patient 009) without any further therapy, and two in the context of a second cycle of GDA-201 and rituximab. Two patients with
complete response who received a second cycle of GDA-201 after initial complete response had maintained a complete response after
a total of 6 and 12 months, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="height: 455px; width: 700px" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_014.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/img_014.jpg"></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Responses
in Patients with Lymphoma Treated with GDA-201</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Given the results of this study,
we have developed a cryopreserved, allogeneic, readily available formulation of GDA-201 to enable further clinical trials. In September
2021, we submitted an IND for a Phase 1/2 clinical trial of GDA-201 for the treatment of patients with follicular and diffuse large B-cell
lymphomas. In October 2021, the FDA placed this IND on clinical hold prior to the initiation of patient dosing. The FDA has requested
modifications in donor eligibility procedures and sterility assay qualification. We are in active communication with the FDA with the
objective to address these requests and to enable IND acceptance. We expect to initiate our Phase 1/2 trial of GDA-201 in patients with
follicular and diffuse large B-cell lymphomas in 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Additional NK Cell Programs</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to advance the other programs in our NAM-enabled genetically modified NK cell pipeline, which utilize CAR, membrane bound-
and CRISPR-mediated strategies to increase targeting, potency and persistence against hematologic malignancies and solid tumors.
We plan to execute preclinical proof of concept studies and to select pipeline candidates for IND enabling studies in the following
targets by the end of 2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">GDA-301:
                                         Knockout of CISH (cytokine inducible SH2 containing protein) in NK cells using CRISPR/Cas9
                                         in combination with a membrane-bound IL-15/IL-15Ra. Designed to improve tumor killing
                                         by promoting activation of NK cells and inhibiting negative feedback signals. Potential
                                         applications exist across a range of solid tumors and hematologic malignancies.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">GDA-401:
                                         Undisclosed target genetically engineered to enhance NK cell survival in the solid tumor
                                         microenvironment for potential application across a broad range of solid tumors.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">GDA-501:
                                         CAR-engineered NK cells to target HER2+ solid tumors with the potential to enhance homing
                                         and activation against cancers with HER2 overexpression, including breast, ovarian, lung,
                                         bladder, and gastric cancers.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">GDA-601:
                                         Knockout of CD38 on NK cells to avoid fratricide by CD38-targeting antibodies in combination
                                         treatment of multiple myeloma, combined with a CD38 CAR designed to enhance killing of
                                         multiple myeloma cells.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary products. While we believe that our technology platform, development experience and scientific knowledge
provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical,
specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research
institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new
therapies that may become available in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate intensifying competition in the field of cell therapies as new therapies are approved and advanced technologies become
available.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors will have substantially greater financial, technical and human resources. Competitors may also have more experience
developing, obtaining approval for, and marketing novel treatments in the indications we are pursuing. These factors could give
our competitors an advantage over us in recruiting and retaining qualified personnel, completing clinical development, and commercializing
their products. Competitors that are able to obtain FDA or other regulatory approval for their products more rapidly than we can
for our products may also establish a stronger market position, diminishing our commercial opportunity. Key considerations that
would impact our capacity to effectively compete include the efficacy, safety, ease of use, as well as pricing and reimbursement
of our products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several clinical-stage development programs that seek to improve human umbilical cord blood transplantation through the use
of an allogeneic HSCT graft. In addition, there are clinical-stage development programs that focus on natural killer cells. Companies
active in these areas include, but are not limited to:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allogeneic
HSCT Graft</b>: Magenta Therapeutics, ExCellThera, Garuda Therapeutics and Bellicum Pharmaceuticals; and</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Natural
Killer Cell product</b>: Takeda Pharmaceutical Company, Fate Therapeutics, Artiva, Sanofi, MiNK Therapeutics, ONK Therapeutics,
Shoreline, Cellularity, NKarta, Wugen, Century Therapeutics, Appia Bio and FujiFilm Cellular Dynamics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel
is currently manufactured at our Kiryat Gat, Israel facility using a scalable self-assembly process with well-defined unit operations.
This highly specialized and precisely controlled manufacturing process enables us to manufacture product candidates reproducibly
and efficiently for clinical and commercial applications. We anticipate using the Kiryat Gat facility to also manufacture our
other pipeline therapies, including our NK cell therapies.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently rely on third-party
clinical cell processing facilities and contract manufacturers for all our required raw materials, active ingredients and finished products
for our preclinical research and clinical trials. We previously relied on a third party, Lonza Netherlands B.V., or Lonza, to conduct
a material portion of our product manufacturing for omidubicel until production was increased at our Kiryat Gat manufacturing facility.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In June 2019, we entered
into a Manufacturing Services Agreement, or the Services Agreement, with Lonza, to provide for the future commercial production after
potential FDA approval of omidubicel. Under the Services Agreement, Lonza agreed to construct and dedicate production suites prior to
anticipated commercial launch. Additionally, the Services Agreement gives us the option to increase the number of Lonza’s dedicated
production suites over time to ensure commercial supply of omidubicel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the Services Agreement is the shorter of seven years from the date of execution or five years from the date of the first
FDA approval of omidubicel. The Services Agreement may be terminated in the event of an uncured material breach by one of the
parties. The Services Agreement also provides that if we have not received FDA approval of omidubicel by December 31, 2021, we
have the right to terminate the Services Agreement upon 30 days’ written notice. Either party may terminate without cause
after the referenced time periods, but only after the Initial Term expires, which will happen on June 10, 2022. Further, the Services
Agreement may be terminated by either party upon notice in the event of dissolution, termination of existence, liquidation or
business failure of the other party, the uncured appointment of a custodian or receiver to the other party or un-dismissed institution
of insolvency, reorganization or bankruptcy proceedings.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2021, we engaged
in discussions with Lonza executive leadership regarding our desire to wind down Lonza’s manufacturing of omidubicel under the Services
Agreement and our desire to affect a mutual termination of the Services Agreement. These discussions are ongoing. As of December 31, 2021,
we have paid Lonza an aggregate of approximately $28.2 million pursuant to the Services Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a contract through the end of 2022 with Hadasit Medical Research Services &amp; Development Co. Ltd., a technology transfer
company of Hadassah Medical Center in Jerusalem, for the manufacture of GDA-201 and we plan to begin manufacturing GDA-201 at
our Kiryat Gat facility in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing,
Sales and Distribution</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to ensure omidubicel is made available to appropriate patients, and we are evaluating strategic alternatives for commercialization
of omidubicel, if approved, which include commercializing omidubicel ourselves or entering into potential strategic alliances
or licensing arrangements with pharmaceutical companies and other partners. We are preparing for potential approval of omidubicel
and our commercial launch thereafter, and we have added sales, marketing, and supply chain personnel to our workforce. Our Chief
Commercial and Chief Operating Officer, Michele Korfin, is based in the U.S., and we have a wholly-owned U.S. subsidiary, Gamida
Cell Inc., to support our U.S. development efforts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we receive regulatory approvals for our products in markets outside of the United States, we intend, where appropriate, to pursue
commercialization relationships, including strategic alliances and licensing arrangements with pharmaceutical companies and other
strategic partners that are equipped to market or sell our products through their well-developed sales, marketing and distribution
organizations in such countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
Property</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect and enhance the proprietary technologies, inventions, products and product candidates, methods of manufacture,
methods of using our products and product candidates, and improvements thereof that are commercially important to our business.
We protect our proprietary intellectual property by, among other things, filing patent applications in the United States and in
jurisdictions outside of the United States covering our proprietary technologies, inventions, products and product candidates,
methods, and improvements that are important to the development and implementation of our business.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 12, 2022, we own 32 issued patents and 61 pending patent applications worldwide, including six U.S. issued patents,
six pending U.S. non-provisional patent applications and three pending U.S. provisional patent applications.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own two issued patents in the United States and 17 issued foreign patents related to our omidubicel product candidate. The patents
that we own outside of the United States are granted in Australia, Canada, Europe, Hong Kong, Israel, Japan, Singapore, and South
Africa. In addition, we own two pending U.S. non-provisional patent applications and 16 pending foreign patent applications related
to our omidubicel product candidate. These patents and pending patent applications contain composition-of-matter claims to our
omidubicel product candidate, and claims to methods of producing and methods of treatment using omidubicel. Not accounting for
any patent term adjustment, regulatory extension or terminal disclaimers, and assuming that all annuity and/or maintenance fees
are paid timely, these patents, and if granted, these patent applications, will expire from 2023 to 2038. In particular, U.S.
Patent No. 7,955,852, EP Patent No. 1576089, EP Patent No. 2206773, JP Patent No. 4738738, and IL Patent No. 163180, which relate
to methods of expanding a population of hematopoietic stem cells by culturing the cells with nicotinamide or nicotinamide analogs,
and transplantable cell populations produced by these methods, expire in 2023, not accounting for any patent term adjustment,
regulatory extension or terminal disclaimers, and assuming that all annuity and/or maintenance fees are paid timely and U.S. Patent
No. 8,846,393, EP Patent No. 1974012, JP Patent No. 5102773 and IL Patent No. 191669, which relate to methods of enhancing cell
homing and engraftment potential of hematopoietic stem cells by expansion in the presence of nicotinamide, expire in 2026, not
accounting for any patent term adjustment, regulatory extension or terminal disclaimers, and assuming that all annuity and/or
maintenance fees are paid timely.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own nine issued foreign patents related to GDA-201. The patents that we own outside of the United States are granted in Australia,
Canada, Europe, Hong Kong, Israel, Canada, and Japan. In addition, we own four pending U.S. non-provisional patent applications,
one U.S. provisional patent applications and 36 pending foreign patent applications related to our GDA-201 product candidate.
These patents and pending patent applications contain composition-of-matter claims to our GDA-201 product candidate, and claims
to methods of producing and methods of treatment using our GDA-201 product candidate. Not accounting for any patent term adjustment,
regulatory extension or terminal disclaimers, and assuming that all annuity and/or maintenance fees are paid timely, these patents,
and if granted, the U.S. non-provisional patent applications and foreign patent applications, will expire from 2030 to 2040, and
patents, and if granted, patent applications claiming priority to the U.S. provisional patent application will expire in 2042.
In particular, EP Patent No. 2519239, EP Patent No. 3184109, JP Patent No. 5943843, JP Patent No. 6215394 and IL Patent No. 220660
and CA Patent No. 2,785,627, which relate to methods of expanding a population of natural killer cells by culturing the cells
with nicotinamide or nicotinamide analogs, and transplantable cell populations produced by these methods, expire in 2030, not
accounting for any patent term adjustment, regulatory extension or terminal disclaimers, and assuming that all annuity and/or
maintenance fees are paid timely.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own one U.S. provisional application related to GDA-301 and GDA-601. This pending provisional patent application contains composition-of-matter
claims to our GDA-301 and GDA-601 product candidates, and claims to methods of producing and methods of treatment using our GDA-301
and GDA-601 product candidates. Not accounting for any patent term adjustment, regulatory extension or terminal disclaimers, and
assuming that all annuity and/or maintenance fees are paid timely, patent applications claiming priority to this U.S. provisional
application, if granted, would expire in 2042.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own two U.S. provisional applications related to GDA-501. These pending provisional patent applications contain composition-of-matter
claims to our GDA-501 product candidate, and claims to methods of producing and methods of treatment using our GDA-501 product
candidate. Not accounting for any patent term adjustment, regulatory extension or terminal disclaimers, and assuming that all
annuity and/or maintenance fees are paid timely, patent applications claiming priority to these U.S. provisional applications,
if granted, would expire in 2042.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we filed for and obtained trademark registration in the China, Europe, Hong Kong, Mexico, Canada, Brazil, Russian Federation,
Israel, Great Britain and WIPO (International) for “Gamida Cell”, and in Israel for “Symrepliq”, “Gamida-Cell
Assist”, “Nampluri”, “Namrepli”, “Namtypic”, “Omisirge” and “Omplusto”.
We also rely upon trade secrets, know-how and continuing technological innovation to develop, strengthen and maintain our competitive
position.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries
in which we have filed, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional
patent application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates
a patentee for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally
disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for
patent term extension when FDA approval is granted for a portion of the term effectively lost as a result of the FDA regulatory
review period, subject to certain limitations and provided statutory and regulatory requirements are met. Any such patent term
extension can be for no more than five years, only one patent per approved product can be extended, the extension cannot extend
the total patent term beyond 14 years from approval, and only those claims covering the approved drug, a method for using it or
a method for manufacturing it may be extended. We may not receive an extension if we fail to exercise due diligence during the
testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant
patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request.
In the future, if and when our product candidates receive approval from the FDA or foreign regulatory authorities, we expect to
apply for patent term extensions on issued patents we may obtain in the future covering those products, depending upon the length
of the clinical trials for each product and other factors. There can be no assurance that any of our pending patent applications
will issue or that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisional
patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application
within 12 months of filing of one or more of our related provisional patent applications. If we do not timely file any non-provisional
patent applications, we may lose our priority date with respect to our provisional patent applications and any patent protection
on the inventions disclosed in our provisional patent applications.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with other biotechnology and pharmaceutical companies, our ability to establish and maintain our proprietary and intellectual
property position for our product candidates will depend on our success in obtaining effective patent claims and enforcing those
claims if granted. There can be no assurance that any of our current or future patent applications will result in the issuance
of patents or that any of our current or future issued patents will provide any meaningful protection of our product candidates
or technology. For more information regarding the risks related to our intellectual property, see “Item&nbsp;1A: Risk Factors—Risks
Related to Our Intellectual Property.”</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
Grants</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grants
under the Innovation Law</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Encouragement of
Research, Development and Technological Innovation in the Industry Law 5744-1984, and the provisions of the applicable regulations, rules,
procedures and benefit tracks, (collectively, the “<b><i>Innovation Law</i></b>”), research and development programs that
meet specified criteria and are approved by a committee of the IIA are eligible for grants. The grants awarded are typically up to 50%
of the project’s expenditures, as determined by the research committee and subject to the benefit track under which the grant was
awarded. A company that receives a grant from the IIA, or a grant recipient, is typically required to pay royalties to the IIA on income
generated from products incorporating know-how developed using such grants (including income derived from services associated with such
products), until 100% of the U.S. dollars linked grant plus annual LIBOR interest is repaid. The rate of royalties to be paid may vary
between different benefits tracks, as shall be determined by the IIA. Under the regular benefits tracks the rate of royalties varies from
3% to 3.5% of the income generated from the IIA-supported products. The obligation to pay royalties is contingent on actual income generated
from such products and services. In the absence of such income, no payment of such royalties is required.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the grants under the Innovation Law also generally require that the products developed as part of the programs under
which the grants were given be manufactured in Israel and that the know-how developed thereunder may not be transferred outside
of Israel, unless a prior written approval is received from the IIA (such approval is not required for the transfer of a portion
of the manufacturing capacity which does not exceed, in the aggregate, 10% of the portion declared to be manufactured outside
of Israel in the applications for funding, in which case only notification is required) and additional payments are required to
be made to the IIA. It should be noted that this does not restrict the export of products that incorporate the funded know-how.
See “Item&nbsp;1A: Risk Factors—Risks Related to Israeli Law and Our Operations in Israel” for additional information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our incorporation, we have received grants from the IIA relating to various projects. We were members of Bereshit Consortium,
sponsored by IIA in which certain of our technologies were developed, such program does not require payments of royalties to the
IIA, but all other restrictions under the Innovation Law, such as local manufacturing obligations and know-how transfer limitations,
as further detailed hereunder, are applicable to the know how developed by us with the funding received in such consortium program.
No royalties have been paid to the IIA in respect of any grant. Our total outstanding obligation to the IIA, including the interest
accrued through December 31, 2021, amounts to approximately $44.7 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
Regulation</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other regulatory authorities at federal, state, and local levels, as well as in non-U.S. countries, extensively regulate,
among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling,
packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval
reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the
various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which
we wish to conduct studies or seek approval or licensure of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                         of preclinical laboratory tests and animal studies performed in accordance with the FDA’s
                                         current Good Laboratory Practices, or GLP, regulation;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                         to the FDA of an IND, which must become effective before clinical trials may begin and
                                         must be updated annually or when significant changes are made;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                         by an independent Institutional Review Board, or IRB, or ethics committee at each clinical
                                         site before the trial is commenced;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                         of adequate and well-controlled human clinical trials to establish the safety, purity
                                         and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
                                         of and submission to the FDA of a Biologics License Application, or BLA, after completion
                                         of all pivotal clinical trials;</span></td></tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         determination by the FDA within 60 days of its receipt of a BLA to file the application
                                         for review; satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                         completion of an FDA pre-approval inspection of the manufacturing facility or facilities
                                         at which the proposed product is produced to assess compliance with current Good Manufacturing
                                         Practices, or cGMP, and to assure that the facilities, methods and controls are adequate
                                         to preserve the biological product’s continued safety, purity and potency, and
                                         of selected clinical investigation sites to assess compliance with Good Clinical Practices,
                                         or GCP; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                         review and approval of the BLA to permit commercial marketing of the product for particular
                                         indications for use in the United States.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
and Clinical Development</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization
from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general
investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing
the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing,
and controls information; and any available human data or literature to support the use of the investigational product. An
IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt
by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial.
In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or
questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin
a clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         1: The investigational product is initially introduced into patients with the target
                                         disease or condition. These studies are designed to test the safety, dosage tolerance,
                                         absorption, metabolism and distribution of the investigational product in humans, the
                                         side effects associated with increasing doses, and, if possible, to gain early evidence
                                         on effectiveness.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         2: The investigational product is administered to a limited patient population with a
                                         specified disease or condition to evaluate the preliminary efficacy, optimal dosages
                                         and dosing schedule and to identify possible adverse side effects and safety risks. Multiple
                                         Phase 2 clinical trials may be conducted to obtain information prior to beginning larger
                                         and more expensive Phase 3 clinical trials.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         3: The investigational product is administered to an expanded patient population to further
                                         evaluate dosage, to provide statistically significant evidence of clinical efficacy and
                                         to further test for safety, generally at multiple geographically dispersed clinical trial
                                         sites. These clinical trials are intended to establish the overall risk/benefit ratio
                                         of the investigational product and to provide an adequate basis for product approval.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to
gain more information about the product. These so- called Phase 4 studies may be made a condition to approval of the BLA. Concurrent
with clinical trials, companies may complete additional animal studies and develop additional information about the biological
characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in
accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the
product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the
final product, or for biologics, the safety, purity and potency. Compliance with Good Tissue Practices, or GTPs, is also required
to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities
and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products, or HCT/Ps, which are human
cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the
GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction,
transmission and spread of communicable disease. Good Tissue Practices regulations also require tissue establishments to register
and list their HCT/Ps with the FDA and when applicable, to evaluate donors through screening and testing. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not
undergo unacceptable deterioration over its shelf life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BLA
Submission and Review</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the
product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical
studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to
the product’s chemistry, manufacturing, controls, and propose labeling, among other things. The submission of a BLA requires
payment of a substantial application user fee to FDA, unless a waiver or exemption applies.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a BLA has been submitted, the FDA’s goal is to review standard applications within ten months after it accepts the application
for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing.
The FDA may issue a refusal-to-file letter if the BLA is not sufficiently complete to permit substantive review. In both standard
and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification.
The FDA reviews a BLA to determine among other things, whether a product is safe, pure and potent and the facility in which it
is manufactured, processed, packed, or held meets standards designed to assure the product’s continued safety, purity and
potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving
a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and
adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA,
the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application,
manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often
will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA
ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product will be produced,
the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the
product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies
that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate
to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted
product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that
the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification.
The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing
or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations
on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation
and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage
a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines
by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use,
such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval
on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved,
the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems
occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance
to further assess and monitor the product’s safety and effectiveness after commercialization, and may limit further marketing
of the product based on the results of these post-marketing studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Approval
Requirements</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the
FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting,
product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved
product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are
continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA.
Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies,
and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose
certain procedural and documentation requirements upon us and our third-party manufacturers.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to
expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects
of regulatory compliance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions
to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new
safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences
include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                         on the marketing or manufacturing of a product, complete withdrawal of the product from
                                         the market or product recalls;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                         warning letters or holds on post-approval clinical studies;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                         of the FDA to approve pending applications or supplements to approved applications, or
                                         suspension or revocation of existing product approvals;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                         seizure or detention, or refusal of the FDA to permit the import or export of products;
                                         or</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                         or the imposition of civil or criminal penalties.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating
to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved
label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure
to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising
and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described
in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common
across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied
circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict
manufacturer’s communications on the subject of off-label use of their products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Breakthrough
Therapy Designation</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor may seek FDA designation of a product candidate as a “breakthrough therapy” if the product is intended, alone
or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary
clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. The designation allows more
intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval
and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough
therapy, the FDA will work to expedite the development and review of such drug.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Healthcare Regulations</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party
payers, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations,
including how we research, market, sell and distribute our product candidates, if approved. Such laws include those described
below.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward,
or in return for, the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or
order of, any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The
federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand
and prescribers, purchasers, and formulary managers on the other hand. The term remuneration has been interpreted broadly to include
anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to
be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception
or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor
does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will
be evaluated on a case-by-case basis based on a cumulative review of all facts and circumstances. Additionally, the Patient Protection
and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA,
amended the intent requirement of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person
or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it,
to have violated the statute. The PPACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the
government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes
a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil and criminal false claims laws, including the federal civil False Claims Act, or FCA, prohibit, among other things,
any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the
U.S. federal government, including the Medicare and Medicaid programs, or knowingly making, using, or causing to be made or used
a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money
to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes
“any request or demand” for money or property presented to the U.S. government.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payers if
they are deemed to “cause” the submission of false or fraudulent claims. The FCA also permits a private individual
acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the FCA and
to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides
for treble damages and mandatory penalties. Government enforcement agencies and private whistleblowers have investigated pharmaceutical
companies for or asserted liability under the FCA for a variety of alleged impermissible promotional and marketing activities,
such as providing free product to customers with the expectation that the customers would bill federal programs for the product;
providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for
“off-label” uses; and submitting inflated best price information to the Medicaid Rebate Program.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that
prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property
owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payer is public or private,
knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation
of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device a material
fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare
benefits, items or services relating to healthcare matters. Additionally, the PPACA amended the intent requirement of some of
these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the
specific intent to violate it, to have committed a violation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the PPACA and
its implementing regulations, require some manufacturers of drugs, devices, biologicals and medical supplies for which payment
is available under Medicare, Medicaid or the Children’s Health Insurance Program (with specified exceptions) to report annually
information related to specified payments or other transfers of value provided to physicians (defined to include doctors, dentists,
optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners)
and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians, and teaching
hospitals and to report annually specified ownership and investment interests held by physicians and their immediate family members.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may be subject to data privacy and security regulation of both the federal government and the states in which we
conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH,
and their implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable
health information held by covered entities subject to the law, such as health plans, healthcare clearinghouses, and certain healthcare
providers, and their business associates, defined as independent contractors or agents of covered entities that create, receive,
maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity
and their subcontractors that use, disclose, access, or otherwise process protected health information. Among other things, HITECH
created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties and HIPAA’s security standards
directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or
injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing
federal civil actions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services
reimbursed by any third-party payer, including commercial insurers. We may also be subject to state laws that require pharmaceutical
companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government, state and local laws that require the registration of pharmaceutical sales representatives,
state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures and pricing information, and/or state laws governing the privacy and
security of health information in certain circumstances, many of which differ from each other in significant ways and may not
have the same effect, thus complicating compliance efforts.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations
will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with
current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.
If our operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us,
we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible
exclusion from government funded healthcare programs, contractual damages, reputational harm, diminished profits and future earnings,
additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve
allegations of non-compliance with these laws, and curtailment of our operations, any of which could substantially disrupt our
operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance
with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Coverage
and Reimbursement</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.
In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial
sale will depend, in part, on the extent to which third-party payers provide coverage, and establish adequate reimbursement levels
for such products. In the United States, third-party payers include federal and state healthcare programs, private managed care
providers, health insurers and other organizations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process for determining whether a third-party payer will provide coverage for a product may be separate from the process for setting
the price of a product or for establishing the reimbursement rate that such a payer will pay for the product. Third-party payers
may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the
FDA-approved products for a particular indication. Third-party payers are increasingly challenging the price, examining the medical
necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety
and efficacy.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of
our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically
necessary or cost-effective. Payer’s decision to provide coverage for a product does not imply that an adequate reimbursement
rate will be approved. Further, the determination of one payer to provide coverage for a product does not assure that other payers
will also provide such coverage for the product.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return
on our investment in product development.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Different
pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products
through their pricing and reimbursement rules and control of national health care systems that in some countries subsidize a large
part of the cost of those products for consumers. Some jurisdictions operate positive and negative list systems under which products
may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries
may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to then available
therapies. Other EU member states allow companies to fix their own prices for medicines, but monitor and control company profits.
The downward pressure on health care costs has become very intense.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border
imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any of product candidates for which we receive regulatory approval for commercial sale may suffer if the government
and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United
States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party
reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products
for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Healthcare
Reform Measures</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some non-U.S. jurisdictions are considering or have enacted a number of legislative and regulatory proposals
designed to change the healthcare system. Among policy makers and payers in the United States and elsewhere, there is significant
interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or
expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by major legislative initiatives.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the pharmaceutical industry in the United States has been affected by the passage of PPACA, which, among other things:
imposed new fees on entities that manufacture or import certain branded prescription drugs; expanded pharmaceutical manufacturer
obligations to provide discounts and rebates to certain government programs; implemented a licensure framework for follow-on
biologic products; expanded health care fraud and abuse laws; revised the methodology by which rebates owed by manufacturers
to the state and federal government under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including
products that are inhaled, infused, instilled, implanted or injected; imposed an additional rebate similar to an inflation
penalty on new formulations of drugs; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals
enrolled in Medicaid managed care organizations; expanded the 340B program which caps the price at which manufacturers can
sell covered outpatient pharmaceuticals to specified hospitals, clinics and community health centers; and provided incentives
to programs that increase the federal government’s comparative effectiveness research.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been judicial and Congressional challenges to certain aspects of the PPACA. While Congress has not passed comprehensive repeal
legislation, several bills affecting the implementation of certain taxes under the PPACA have been signed into law. The Tax Act
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on
certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as
the “individual mandate”. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that
argued the PPACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus,
the PPACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President
Biden issued an executive order to initiate a special enrollment period from February 26, 2021 through August 15, 2021 for purposes
of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed certain governmental
agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining
Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers
to obtaining access to health insurance coverage through Medicaid or the PPACA. It is possible that the PPACA will be subject
to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of
the Biden administration.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the PPACA was enacted. In August 2011, the Budget
Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2.0% per fiscal year,
which went into effect in April 2013, and due to subsequent legislative amendments, including the BBA, will remain in effect through
2031 with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 unless additional U.S. Congressional
action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in
the final fiscal year of this sequester. In addition, in January 2013, President Obama signed into law the American Taxpayer Relief
Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. Additional
changes that may affect our business include new quality and payment programs such as Medicare payment for performance initiatives
for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which ended the use of the statutory
formula for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program.
In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program but its overall impact remains
unclear. Additionally, Congress is considering additional health reform measures.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been particular and increasing legislative and enforcement interest in the United States with respect to drug
pricing practices in recent years, particularly with respect to drugs that have been subject to relatively large price increases
over relatively short time periods. Specifically, there have been several recent U.S. Presidential executive orders, Congressional
inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product
pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of prescription drugs under
Medicare and reform government program reimbursement methodologies for pharmaceutical products. For example, on July 24, 2020
and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that
seek to implement several of the administration’s proposals. As a result, the FDA concurrently released a final rule and
guidance in September 2020 providing pathways for states to build and submit importation plans for drugs from Canada. Further,
on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers
to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by
law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response
to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as
a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of
which have also been delayed by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final
rule implementing the Trump administration’s Most Favored Nation executive order, which would tie Medicare Part B payments
for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January
1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule
that rescinds the Most Favored Nation model interim final rule.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
in July 2021, the Biden administration released an executive order, “Promoting Competition in the American Economy,”
with multiple provisions aimed at prescription drugs. In response to Biden’s executive order, on September 9, 2021, HHS
released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a
variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take
to advance these principles. No legislation or administrative actions have been finalized to implement these principles. It is
unclear whether these or similar policy initiatives will be implemented in the future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, individual states in the United States have become increasingly active in passing legislation and implementing regulations
designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. In the future, there will likely continue to be proposals relating to the reform of
the U.S. healthcare system, some of which could further limit coverage and reimbursement of products. It is also possible that
additional governmental action is taken in response to the COVID-19 pandemic.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Foreign Corrupt Practices Act</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment
or offering of anything of value, directly or indirectly, to any non-U.S. official, political party or candidate for the purpose
of influencing any act or decision of the non-U.S. entity in order to assist the individual or business in obtaining or retaining
business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions
requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies, including
international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-U.S.
Government Regulation</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any of our product candidates, once approved, are sold in a country outside of the United States, we may be subject
to similar non-U.S. laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety
surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other
transfers of value to healthcare professionals.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market our future products in the EEA (which is comprised of the 27 Member States of the European Union plus Norway,
Iceland and Liechtenstein) and many other jurisdictions, we must obtain regulatory approvals from such jurisdictions. More precisely,
in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types
of marketing authorizations:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         Community MA, which is issued by the European Commission through the Centralized Procedure,
                                         based on the opinion of the Committee for Medicinal Products for Human Use of the European
                                         Medicines Agency, or EMA, and which is valid throughout the entire territory of the EEA.
                                         The Centralized Procedure is mandatory for certain types of products, such as biotechnology
                                         medicinal products, orphan medicinal products and medicinal products indicated for the
                                         treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral
                                         diseases. The Centralized Procedure is optional for products containing a new active
                                         substance not yet authorized in the EEA, or for products that constitute a significant
                                         therapeutic, scientific or technical innovation or which are in the interest of public
                                         health in the European Union; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
                                         MAs, which are issued by the competent authorities of the Member States of the EEA and
                                         only cover their respective territory, are available for products not falling within
                                         the mandatory scope of the Centralized Procedure. Where a product has already been authorized
                                         for marketing in a Member State of the EEA, this National MA can be recognized in another
                                         Member State through the Mutual Recognition Procedure. If the product has not received
                                         a National MA in any Member State at the time of application, it can be approved simultaneously
                                         in various Member States through the Decentralized Procedure.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the above-described
procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit
balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Data
and Marketing Exclusivity</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants
from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a
generic or biosimilar marketing authorization in the European Union during a period of eight years from the date on which the
reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar
applicant from commercializing its product in the European Union until 10 years have elapsed from the initial authorization of
the reference product in the European Union. The 10-year market exclusivity period can be extended to a maximum of eleven years
if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more
new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant
clinical benefit in comparison with existing therapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pediatric
Investigation Plan</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies
conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA’s
Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication
of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some
or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults.
Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate
because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended
occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments
for pediatric patients. Once the marketing authorization is obtained in all Member States of the European Union and study results
are included in the product information, even when negative, the product is eligible for six months’ supplementary protection
certificate extension.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Drug Designation</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for
the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five
in ten thousand persons in the European Union when the application is made, or that the product is intended for the diagnosis,
prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Community
and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify
the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method
of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists,
the drug will be of significant benefit to those affected by that condition.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval
to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this
market exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing
authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market
exclusivity is extended by two years for medicines that have also complied with an agreed PIP.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets
the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity.
Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability
to supply sufficient quantities of the product, demonstration of “clinical superiority” by a similar medicinal product,
or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing
exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs
pursuant are eligible for incentives made available by the European Union and its Member States to support research into, and
the development and availability of, orphan drugs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employees</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had 166 full-time employees and 2 part-time employees, 120 of whom are based in Israel and 48 of whom
are based in the United States. Of these employees, 122 are primarily engaged in research and development activities and 46 are
primarily engaged in general and administrative and commercialization matters. A total of 16 employees have an M.D. or Ph.D. degree.
None of our employees is represented by a labor union. We have never experienced any employment-related work stoppages and believe
our relationships with our employees are good Israeli labor laws govern the length of the workday and workweek, minimum wages
for employees, procedures for hiring and dismissing employees, determination of severance pay, annual leave, sick days, advance
notice of termination, payments to the National Insurance Institute, and other conditions of employment and include equal opportunity
and anti-discrimination laws. While none of our employees is party to any collective bargaining agreements, certain provisions
of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau
of Economic Organizations (including the Industrialists’ Associations) are applicable to our employees in Israel by order
of the Israeli Ministry of Economy and Industry. These provisions primarily concern pension fund benefits for all employees, insurance
for work-related accidents, recuperation pay and travel expenses. We generally provide our employees with benefits and working
conditions beyond the required minimums.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2022, we announced a workforce reduction plan, or the Plan, pursuant to which we downsized our then current workforce
by approximately 10%. The Plan was enacted to better align our resources to fund operations into mid-2023 which is the anticipated
timeline for potential approval of omidubicel in the United States. Affected employees were offered separation benefits, including
severance payments and temporary healthcare coverage assistance, which severance payments, in Israel, are required under applicable
law.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an equal opportunity employer that pledges to not discriminate against employees based on race, color, religion, sex, national
origin, age, disability or genetic information. Our human capital resources objectives include, as applicable, identifying, recruiting,
retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive
plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation
awards. We strive to create a diverse environment, and our commitment to diversity, equity and inclusion begins with our leadership
team of diverse backgrounds and experiences, including three women on the board of directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to the Environmental Health and Safety (EHS) safety of our employees. We continuously strive to maintain our strong
safety performance as we continue to grow our business around the globe. The keys to our EHS success are a workforce that is engaged,
a management team who supports and invests in employee safety, and the leadership of our skilled EHS team. In the last several
years, the team has added dedicated EHS professionals to individual sites to train employees and ensure compliance with applicable
safety standards and regulations. The team hosts regular meetings to share information and discuss best practices across plants.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also committed to developing our future leaders at every level. Our talent processes start with understanding what current
and future talent is needed to deliver business goals, followed by a talent review process to assist managers with evaluating
talent. Learning and development is a critical part of creating our culture of high performance, innovation, and inclusion. We
believe on-the-job experience is an outstanding way to learn, and performance and development plans ensure that managers and employees
have conversations about career aspirations, mobility, developmental goals and interests.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to creating an open and accountable workplace where employees feel empowered to speak up and raise issues. In an
ongoing effort to understand our employees’ needs, and deliver on our values of trust, accountability and collaboration,
we listen. We regularly host company-wide and business unit town halls to offer employees an opportunity to ask questions about
Company activities and policies that impact them. We solicit and receive questions and feedback from our employees through this
process. We also provide multiple channels to speak up, ask for guidance, and report concerns.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Environmental,
Health and Safety Matters</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel,
governing, among other things: the use, storage, registration, handling, emission and disposal of chemicals, waste materials and
sewage; chemicals, air, water and ground contamination; air emissions and the cleanup of contaminated sites, including
any contamination that results from spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our
operations use chemicals and produce waste materials and sewage and require permits from various governmental authorities including,
local municipal authorities, the Ministry of Environmental Protection and the Ministry of Health. The Ministry of Environmental
Protection and the Ministry of Health, local authorities and the municipal water and sewage company conduct periodic inspections
in order to review and ensure our compliance with the various regulations. These laws, regulations and permits could potentially
require the expenditure by us of significant amounts for compliance or remediation. If we fail to comply with such laws, regulations
or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits
and licenses necessary to continue our business activities. In addition, we may be required to pay damages or civil judgments
in respect of third-party claims, including those relating to personal injury (including exposure to hazardous substances we use,
store, handle, transport, manufacture or dispose of), property damage or contribution claims. Some environmental, health and safety
laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be identified
as a responsible party under such laws. Such developments could have a material adverse effect on our business, financial condition
and results of operations. In addition, laws and regulations relating to environmental, health and safety matters are often subject
to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to penalties
for activities that were previously permitted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Values</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
Gamida Cell, our actions are guided by five core values that are the foundation of who we are and who we aspire to be. We live
these values on a daily basis. For our values to impact our goal of bringing life-changing cell therapies to patients, they must
be at the center of everything we do:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Put
                                         Patients First: Our reason to wake up each day.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be
                                         Respectful: We are ethical and kind.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drive
                                         to Success: We work hard and play hard.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Embrace
                                         Change: Our adaptability advances medicine.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be
                                         Bold: We strive for cures.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to promoting integrity, honesty and professionalism and maintaining the highest standards of ethical conduct in
all of the Company’s activities. The Company’s success depends on its reputation for integrity and fairness. Therefore,
it is essential that the highest standards of conduct and professional integrity be observed in all contacts made by the Company’s
directors and employees, including officers, with customers, shareholders, suppliers, government officials, fellow employees and
members of the general public. In this regard, Gamida Cell has established this written set of policies dealing with the rules
and policies of conduct to be used in conducting the business affairs of the Company, which is available on our website (https://investors.gamida-cell.com/corporate-governance/documents-charters).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Environmental
matters</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
the nature of our operations and the size of our facility in Kiryat Gat, Israel, we do not consume a significant amount of energy.
Our clean rooms are designed to limit our energy consumption, and we do not have significant emissions from our operations. We
will continue to assess the environmental impact of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
1A. RISK FACTORS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our ordinary shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
in addition to the other information set forth in this annual report on Form 10-K, including the consolidated financial statements
and the related notes included elsewhere in this annual report on Form 10-K, before purchasing our ordinary shares. If any of
the following risks actually occurs, our business, financial condition, cash flows and results of operations could be negatively
impacted. In that case, the trading price of our ordinary shares would likely decline and you might lose all or part of your investment.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business
operations.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Risk Factors</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks that you should be aware of before making an investment decision. These risks are described
more fully in this “Risk Factors” section and include, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         have incurred significant losses since our inception. We anticipate that we will continue
                                         to incur significant losses for the foreseeable future, and we may never achieve or maintain
                                         profitability.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         will need to raise substantial additional funding, which may not be available on acceptable
                                         terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis
                                         may require us to curtail, delay or discontinue our product development efforts or other
                                         operations.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not have the ability to raise the funds necessary to repurchase our 5.875% convertible senior notes due 2026, or the Notes, for cash upon a fundamental change.</span></td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Indenture governing the Notes contains restrictions and other provisions regarding events
                                         of default that may make it more difficult to execute our strategy or to effectively
                                         compete or that could adversely affect our liquidity.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
                                         additional capital may cause dilution to our shareholders and our share price to fall,
                                         restrict our operations or require us to relinquish rights to our technologies or product
                                         candidates.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         have never generated any revenue from product sales and may never be profitable.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         business has been and could continue to be adversely affected by the evolving and ongoing
                                         COVID-19 global pandemic in regions where we or third parties on which we rely have significant
                                         manufacturing facilities, concentrations of clinical trial sites or other business operations.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         are heavily dependent on the success of our product candidates, including obtaining regulatory
                                         approval to market our product candidates in the United States, the European Union and
                                         other geographies.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         have experienced delays in regulatory approvals for omidubicel and GDA-201, and we may
                                         be unable to obtain further regulatory approvals for omidubicel, GDA-201, and our other
                                         potential product candidates.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         results of earlier studies and trials may not be predictive of future trial results,
                                         and our clinical trials may fail to adequately demonstrate the safety and efficacy of
                                         our product candidates.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim,
                                         “topline” and preliminary data from our clinical trials that we announce
                                         or publish from time to time may change as more patient data become available and are
                                         subject to audit and verification procedures that could result in material changes in
                                         the final data.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         success of our NAM technology platform and our product candidates is substantially dependent
                                         on developments within the emerging field of cellular therapies, some of which are beyond
                                         our control.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
                                         our product candidates are based on novel technologies, it is difficult to predict the
                                         time and cost of development and our ability to successfully complete clinical development
                                         of these product candidates and obtain the necessary regulatory approvals for commercialization.</span></td></tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         may find it difficult to enroll patients in our clinical studies, which could delay or
                                         prevent us from proceeding with clinical trials.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         product candidates and the administration process may cause undesirable side effects
                                         or have other properties that could delay or prevent their regulatory approval, limit
                                         the commercial profile of an approved label or result in significant negative consequences
                                         following marketing approval, if any, and result in costly and damaging product liability
                                         claims against us.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in">&nbsp;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize any of our product candidates, and the approval may be for a narrower indication than we seek or be subject to other limitations or restrictions that limit its commercial profile.</span></td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                         if we obtain regulatory approval for a product candidate, our products will remain subject
                                         to regulatory scrutiny.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                         Breakthrough Therapy Designation by the FDA may not lead to a faster development or regulatory
                                         review or approval process and it does not increase the likelihood that our product candidates
                                         will receive marketing approval.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         may be unable to maintain the benefits associated with orphan drug designations that
                                         we have obtained, including market exclusivity, which may cause our revenue, if any,
                                         to be reduced.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enacted
                                         and future healthcare legislation may increase the difficulty and cost for us to obtain
                                         marketing approval of and commercialize our product candidates and may affect the prices
                                         we may set.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         business operations and current and future relationships with investigators, healthcare
                                         professionals, consultants, third-party payers, patient organizations and customers will
                                         be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
                                         or regulatory healthcare reforms in the United States may make it more difficult and
                                         costly for us to obtain regulatory clearance or approval of our product candidates and
                                         to produce, market and distribute our products after clearance or approval is obtained.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the
foreseeable future, and we may never achieve or maintain profitability.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a clinical-stage biopharmaceutical
company. We have incurred net losses each year since our inception in 1998, including net losses of $89.8 million and $61.6 million for
the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $337.5 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have devoted substantially all our financial resources to designing and developing our product candidates, including conducting
preclinical studies and clinical trials, building a manufacturing facility at Kiryat Gat, Israel and providing general and administrative
support for these operations. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable
future. Our ability to ultimately achieve recurring revenue and profitability, which we do not expect to occur for at least several
years, is dependent upon our ability to successfully complete the development of our product candidates, and to obtain necessary
regulatory approvals for and successfully manufacture, market and commercialize our products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our expenses will increase substantially based on a number of factors, including to the extent that we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prepare
                                         for potential commercialization and/or strategic partnerships for omidubicel, if and
                                         when approved for marketing;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                         our clinical development of omidubicel, GDA-201 and other potential product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                         regulatory and marketing approvals for our product candidates that successfully complete
                                         clinical studies;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify,
                                         assess, acquire, license and/or develop other product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                         and validate our commercial-scale manufacturing facilities in accordance with current
                                         good manufacturing practices, or cGMP;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                         a sales, marketing and distribution infrastructure to commercialize any products for
                                         which we may obtain marketing approval;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                         personnel and invest in additional infrastructure to support our operations as a public
                                         company and expand our product development;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                         into agreements to license intellectual property from, or to, third parties;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop,
                                         maintain, protect and expand our intellectual property portfolio; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
                                         any delays or encounter issues with respect to any of the above, including but not limited
                                         to, failed studies, complex results, manufacturing issues or other regulatory challenges
                                         that require longer follow-up of existing studies, additional major studies or additional
                                         supportive studies in order to pursue marketing approval.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have financed our operations primarily through our public offerings of equity securities, private placements of debt
and equity securities and royalty-bearing grants that we received from the Israeli Innovation Authority, or the IIA, formerly
known as the Office of the Chief Scientist of the Ministry of Economy and Industry, including from Bereshit Consortium, sponsored
by the IIA. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to
obtain funding through equity or debt financings, strategic collaborations, or grants. Even if we obtain regulatory approval to
market omidubicel or any other product candidates, our future revenue will depend upon the size of any markets in which such product
candidates receive approval, and our ability to achieve sufficient market acceptance, pricing and reimbursement from third-party
payers for such product candidates. Further, the net losses that we incur may fluctuate significantly from quarter to quarter
and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future
performance. We may also incur other unanticipated costs from our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
our business and servicing our debt requires a significant amount of cash, and we will need to obtain additional funding in the
future to continue to sufficiently fund our operations and pay our substantial debt, including our convertible senior notes that
mature in February 2026.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to fund
further operations we will be required to raise additional funds, seek alternative means of financial support, or both, in order to
continue operations. We may seek these funds through a combination of private and public equity offerings, debt financings,
government grants, strategic collaborations and licensing arrangements. Additional financing may not be available when we need it or
may not be available on terms that are favorable to us. If we are unable to raise the requisite funds, we will need to curtail or
cease operations.</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
our product candidates is expensive, and we expect our research and development expenses to increase substantially in connection
with our ongoing activities, particularly as we advance our product candidates through preclinical studies and clinical development
in an effort to obtain regulatory approval. We recently initiated submission of a Biologics License Application, or BLA, for omidubicel
on a rolling basis, and we plan to submit the full BLA to the FDA in the first half of 2022. We also plan to continue our Phase
1/2 investigator-sponsored clinical trial of omidubicel for the treatment of severe aplastic anemia and, pending FDA clearance
of our IND for a Phase 1/2 clinical trial of GDA-201 in patients with follicular and diffuse large B-cell lymphomas, we expect
to initiate a clinical trial of GDA-201 in 2022.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, our ability
to make scheduled payments of the principal of, to pay interest on, or to refinance our indebtedness, including the Notes, depends on
our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may never
generate cash flow from operations sufficient to support our operations, service our debt and make necessary capital expenditures. As
a result, we may be required to adopt one or more alternatives, subject to the restrictions contained in the Indenture between Gamida
Cell Ltd., Gamida Cell Inc., and Wilmington Savings Fund Society, FSB, entered into on February 16, 2021, or the Indenture, governing
the Notes, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous and which are
likely to be highly dilutive. As of December 31, 2021, we had cash and cash equivalents and trading financial assets of $95.9 million.
In February 2021, we raised an additional $75.0 million through a sale of convertible notes, and we currently believe that our existing
capital resources will be sufficient to meet our projected operating requirements into mid-2023. We will require significant additional
financing in the future to fund our operations. Our future funding requirements will depend on many factors, including, but not limited
to:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         cost, timing and outcomes of regulatory reviews of omidubicel, GDA-201 and our other
                                         potential product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         progress, results and costs of our current and planned clinical trials of GDA-201 and
                                         our other product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         costs of qualifying our planned commercial-scale cGMP manufacturing facility at Kiryat
                                         Gat, Israel, and/or engaging third-party manufacturers;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         scope, progress, results and costs of product development, laboratory testing, manufacturing,
                                         preclinical development and clinical trials for any other product candidates that we
                                         may develop or otherwise obtain in the future;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         cost of our future activities, including establishing sales, marketing and distribution
                                         capabilities for any product candidates in any particular geography where we receive
                                         marketing approval for such product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         terms and timing of any collaborative, licensing and other arrangements that we may establish;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         costs of preparing, filing and prosecuting patent applications, maintaining and enforcing
                                         our intellectual property rights and defending intellectual property-related claims;
                                         and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         level of revenue, if any, received from commercial sales of any product candidates for
                                         which we receive marketing approval.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval
and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenue,
if any, will be derived from or based on sales of product candidates that may not be commercially available for many years, if
at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Any additional
fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop
and commercialize our product candidates. We cannot guarantee that future financing will be available in sufficient amounts or
on terms acceptable to us, if at all, and the terms of any financing may adversely affect the interests or rights of our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may not have the ability to raise the funds necessary to repurchase the Notes for cash upon a fundamental change.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of the Notes have the right to require us to repurchase their Notes for cash upon the occurrence of a fundamental change at a
repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any.
This use of cash may have a material adverse effect on our liquidity. Furthermore, we may not have enough available cash or be
able to obtain financing at the time we are required to repurchase the Notes. In addition, our ability to repurchase the Notes
for cash may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase
Notes for cash at a time when the repurchase is required by the Indenture pursuant to which the Notes were issued would constitute
a default under the Indenture.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Indenture governing the Notes contains restrictions and other provisions regarding events of default that may make it more difficult
to execute our strategy or to effectively compete or that could adversely affect our liquidity.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain exceptions and qualifications, the Indenture governing the Notes restricts our ability to, among other things, (i)
pay dividends or make other payments or distributions on capital stock, or purchase, redeem, defease or otherwise acquire or retire
for value any capital stock, (ii) incur indebtedness or issue preferred stock, other than certain forms of permitted debt, (iii)
sell assets or dispose of certain material assets, (iv) enter into certain transactions with affiliates or (v) merge, consolidate
or sell all or substantially all assets. The Indenture also requires us to make an offer to repurchase the Notes upon the occurrence
of certain asset sales or disposition of certain material assets. These restrictions may make it difficult to successfully execute
our business strategy or effectively compete with companies that are not similarly restricted. The Indenture governing the Notes
also provides that a number of events will constitute an event of default, including, among other things, (i) a failure to pay
interest or additional amounts for 30 days, (ii) failure to pay the principal of the notes when due at maturity, upon redemption,
upon any required repurchase, upon declaration of acceleration or otherwise, (iii) failure to comply with our obligation to exchange
the Notes in accordance with the Indenture upon a holder’s exercise of its exchange right, (iv) not issuing certain notices
required by the Indenture within a timely manner, (v) failure to comply with the other covenants or agreements in the Notes or
the Indenture, (vi) a default or other failure by us to make required payments under our other indebtedness having an outstanding
principal amount of $10.0 million or more, (vii) failure by us to pay final judgments aggregating in excess of $20.0 million,
and (viii) certain events of bankruptcy or insolvency. In the case of an event of default arising from certain events of bankruptcy
or insolvency with respect to us, all outstanding Notes will become due and payable immediately without further action or notice.
If any other event of default occurs and is continuing, the trustee or the holders of at least 25% in aggregate principal amount
of the then outstanding Notes may declare all the Notes to be due and payable immediately. Such acceleration of our debt could
have a material adverse effect on our liquidity if we are unable to negotiate mutually acceptable terms with the holders of the
Notes or if alternate funding is not available to us. Furthermore, if we are unable to repay the Notes upon an acceleration or
otherwise, we would be forced into bankruptcy or liquidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Raising
additional capital may cause dilution to our shareholders and our share price to fall, restrict our operations or require us to
relinquish rights to our technologies or product candidates.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we expect to obtain additional capital through a combination
of equity offerings, debt financings, collaborations and strategic and licensing arrangements. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such
securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if
available, may involve covenants restricting our operations or our ability to incur additional debt. If we raise additional funds
through collaboration and licensing arrangements with third parties, it may be necessary to relinquish certain rights to our technologies
or our product candidates, or to grant licenses on terms that are not favorable to us.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market
conditions are favorable or if we have specific strategic considerations. The issuance of additional securities, whether equity
or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also entered into an Open Market Sale Agreement, or the Sales Agreement under which we may offer and sell our ordinary shares
having an aggregate gross sales price of up to $50 million from time to time through Jefferies LLC. Pursuant to the Sales Agreement
and upon delivery of notice by the Company, Jefferies may sell our ordinary shares under an “at the market offering”.
The sale of a substantial amount of our ordinary shares in this manner may depress the market price for our ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on acceptable terms and on a timely basis, we may be required to significantly curtail, delay
or discontinue one or more of our research, development or manufacturing programs or the commercialization of any approved product,
or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially
affect our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have never generated any revenue from product sales and may never be profitable.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products approved for marketing in any jurisdiction, and we have never generated any revenue from product sales. Our ability
to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully
complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product
candidates. Our ability to generate future revenue from the commercialization of omidubicel is uncertain. If we decide to commercialize
omidubicel on our own, we will have to undertake sufficient costs to build out a sales and distribution team. If we enter into
one or more partnerships for the commercialization of omidubicel, we will surrender a portion of our revenue to our partner or
partners, and if we securitize royalty streams related to omidubicel, future revenues would be held in trust for beneficiaries
of the financing in exchange for which we would receive certain payments based on an assessment of future sales. Furthermore,
revenue from product sales will depend heavily on our ability to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                         regulatory approvals and marketing authorizations for omidubicel and those of our other
                                         product candidates for which we complete clinical studies;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                         and obtain regulatory approval for a sustainable and scalable in-house and/or third-party
                                         manufacturing process for omidubicel that meets all applicable regulatory standards;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                         and maintain supply and, if applicable, manufacturing relationships with third parties
                                         that can provide adequate, in both amount and quality, products to support clinical development
                                         and the market demand for our product candidates, if and when approved;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
                                         research and preclinical and clinical development of our product candidates in a timely
                                         and successful manner;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch
                                         and commercialize our product candidates for which we obtain regulatory and marketing
                                         approval, either directly by establishing a sales force, marketing and distribution infrastructure,
                                         and/or with collaborators or distributors;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expose,
                                         educate and train physicians and other medical professionals to use our products;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
                                         omidubicel and our other product candidates, if and when approved, in a manner designed
                                         to encourage market acceptance from the medical community and third-party payers;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure
                                         procedures utilizing our product candidates are approved for coverage and adequate reimbursement
                                         from governmental agencies, private insurance plans, managed care organizations, and
                                         other third-party payers in jurisdictions where they have been approved for marketing;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address
                                         any competing technological and market developments that impact our product candidates
                                         or their prospective usage by medical professionals;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify,
                                         assess, acquire and/or develop new product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiate
                                         favorable terms in any collaboration, licensing or other arrangements into which we may
                                         enter and perform our obligations under such collaborations;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
                                         protect and expand our portfolio of intellectual property rights, including patents,
                                         patent applications, trade secrets and knowhow;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid
                                         and defend against third-party interference, infringement or other intellectual property
                                         related claims; attract, hire and retain qualified personnel; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">locate
                                         and lease or acquire suitable facilities to support our clinical development, manufacturing
                                         facilities and commercial expansion.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if one or more of our product candidates is approved for marketing and sale, we anticipate incurring significant incremental costs
associated with commercializing such product candidates. Our expenses could increase beyond expectations if we are required by
the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies or
ethical committees in medical centers, to change our manufacturing processes or assays or to perform clinical, nonclinical, or
other types of studies in addition to those that we currently anticipate. Even if we are successful in obtaining regulatory approvals
to market one or more of our product candidates, our revenue earned from such product candidates will be dependent in part upon
the size of the markets in the territories for which we gain regulatory approval for such products, the accepted price for such
products, our ability to obtain reimbursement for such products at any price, whether we own the commercial rights for that territory
in which such products have been approved and the expenses associated with manufacturing and marketing such products for such
markets. Therefore, we may not generate significant revenue from the sale of such products, even if approved. Further, if we are
not able to generate significant revenue from the sale of our approved products, we may be forced to curtail or cease our operations.
Due to the numerous risks and uncertainties involved in product development, it is difficult to predict the timing or amount of
increased expenses, or when, or if, we will be able to achieve or maintain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business could be adversely affected by the evolving and ongoing COVID-19 global pandemic in regions where we or third parties
on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.
The COVID-19 pandemic could adversely affect our operations, as well as the business or operations of our manufacturers, CROs
or other third parties with whom we conduct business.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely affected by the effects of the recent and evolving COVID-19 pandemic, which was declared by the World
Health Organization as a global pandemic. The COVID-19 pandemic has resulted in travel and other restrictions in order to reduce
the spread of the disease including in the Commonwealth of Massachusetts, where our U.S. operations are focused.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary
to manufacture product to conduct preclinical tests and clinical trials are located in countries affected by COVID-19. Quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct
of business operations could occur, whether related to COVID-19 or other infectious diseases could impact personnel at third-party
manufacturing facilities, or the availability or cost of materials, which would disrupt our supply chain, and should they experience
additional disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these
tests and trials. Currently, we expect no material impact on the clinical supply of omidubicel or GDA-201.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials may also be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed
due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical
trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and
retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19
and adversely impact our clinical trial operations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The spread of COVID-19, which has caused a broad impact globally, may
materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess
or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital,
which could in the future negatively affect our liquidity. In addition, a recession or other market corrections resulting from the spread
of COVID-19 could materially affect our business and the value of our ordinary shares.</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global pandemic of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic impacts our business, our clinical
development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence,
such as the ultimate geographic spread of the disease, the duration of the outbreak, efficacy of vaccines, travel restrictions,
quarantines, social distancing requirements and business closures in the United States and other countries, business disruptions
and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Accordingly,
we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare
systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results
of operations and growth prospects.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have
the effect of heightening many of the other risks and uncertainties described in this “Risk Factors” section and in
the “Risk Factors” incorporated by reference herein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to the Discovery, Development and Clinical Testing of Our Product Candidates</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
are heavily dependent on the success of our product candidates, including obtaining regulatory approval to market our product
candidates in the United States, the European Union and other geographies.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have deployed all our efforts and financial resources to: (i) research and develop our NAM, or nicotinamide, cell expansion
platform, our lead product candidate, omidubicel, for the treatment of hematologic malignancies, and our second product candidate,
GDA-201, for the treatment of NHL, and our other potential product candidates, including conducting preclinical and clinical studies
and providing general and administrative support for these operations; and (ii) develop and secure our intellectual property
portfolio for our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory
approval for and commercialize one or more of our current and future product candidates. Our product candidates’ marketability
is subject to significant risks associated with successfully completing current and future clinical trials and commercializing
our product candidates that receive regulatory approval, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to develop, qualify and maintain a commercially viable manufacturing process
                                         that is compliant with cGMP and produces omidubicel that has the same treatment profile
                                         as the products used in our clinical trials, whether at our facility at Kiryat Gat or
                                         through third party manufacturers;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                         of the Phase 1/2 clinical trial of GDA-201 and the acceptance by the FDA of the sufficiency
                                         of early development data to support approval of the IND application that we submitted;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                         by the FDA, EMA or other regulatory agencies of our parameters for regulatory approval
                                         relating to omidubicel and our other product candidates, including our proposed indications,
                                         primary and secondary endpoint assessments and measurements, safety evaluations and regulatory
                                         pathways;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         acceptance by the FDA, EMA or other regulatory agencies of the number, design, size,
                                         conduct and implementation of our clinical trials, our trial protocols and the interpretation
                                         of data from preclinical studies or clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to successfully complete the clinical trials of our product candidates, including
                                         timely patient enrollment and acceptable safety and efficacy data and our ability to
                                         demonstrate the safety and efficacy of the product candidates undergoing such clinical
                                         trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         acceptance by the FDA of the sufficiency of the data we collect from our preclinical
                                         studies and our investigator-sponsored Phase 1/2 clinical trial of omidubicel for the
                                         treatment of severe aplastic anemia;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         willingness of the FDA, EMA or other regulatory agencies to schedule an advisory committee
                                         meeting in a timely manner to evaluate and decide on the approval of our regulatory filings,
                                         if such advisory committee meetings are required;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         recommendation of the FDA’s advisory committee to approve our applications to market
                                         omidubicel and our other product candidates in the United States, and the EMA in the
                                         European Union, if such advisory committee reviews are scheduled, without limiting the
                                         approved labeling, specifications, distribution or use of the products, or imposing other
                                         restrictions;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         satisfaction of the FDA, EMA or other regulatory agencies with the safety and efficacy
                                         of our product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         prevalence and severity of adverse events associated with our product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timely and satisfactory performance by third-party contractors, trial sites and principal
                                         investigators of their obligations in relation to our clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         success in educating medical professionals and patients about the benefits, administration
                                         and use of our product candidates, if approved;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         availability, perceived advantages, relative cost, safety and efficacy of alternative
                                         and competing treatments for the indications addressed by our product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         effectiveness of our marketing, sales and distribution strategy, and operations, as well
                                         as that of any current and future licensees;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         extent to which third-party payers provide coverage and adequate reimbursement for procedures
                                         utilizing our products; and/or</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to obtain, maintain, protect and enforce our intellectual property rights with
                                         respect to our product candidates and to regulatory guidelines.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of these clinical, regulatory and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able
to advance any of our product candidates through clinical development, or to obtain regulatory approval of or commercialize any
of our product candidates. If we fail to achieve these objectives or overcome the challenges presented above, we could experience
significant delays or an inability to successfully commercialize our product candidates. Accordingly, we may not be able to generate
sufficient revenue through the sale of our product candidates to enable us to continue our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may be unable to obtain regulatory approval for our product candidates.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping,
marketing, distribution, post-approval monitoring and reporting and export and import of drug products are subject to extensive
regulation by the FDA, the EMA and by regulatory authorities in other countries. These regulations differ from country to country.
To gain approval to market our product candidates, we must provide data from well-controlled clinical trials that adequately demonstrate
the safety and efficacy of the product for the intended indication to the satisfaction of the FDA, EMA or other regulatory authority.
We have not yet obtained regulatory approval to market any of our product candidates in the United States or any other country.
The FDA, EMA or other regulatory agencies can delay, limit or deny approval of our product candidates for many reasons, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         requests for additional analyses, reports, data, non-clinical and preclinical studies
                                         and clinical trials, including with respect to our and our third-party manufacturer’s
                                         production of omidubicel in commercial processes that has the same treatment profile
                                         as the product used in our successful Phase 3 clinical trial;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         inability to demonstrate that the product candidates are safe and effective for the target
                                         indication to the satisfaction of the FDA, EMA or other regulatory agencies;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         requests to provide additional data regarding analytical and clinical comparability from
                                         our planned commercial manufacturing sites, or the failure of a regulatory agency to
                                         accept the manufacturing processes or facilities at our manufacturing site or those of
                                         third-party manufacturers with which we contract;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         FDA’s, EMA’s, or other regulatory agencies’ disagreement with our clinical
                                         trial protocol, the interpretation of data from preclinical studies or clinical trials,
                                         or adequacy of the conduct and control of clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                         holds, other regulatory objections to commencing or continuing a clinical trial or the
                                         inability to obtain regulatory approval to commence a clinical trial in countries that
                                         require such approvals, including the clinical hold the FDA placed on our GDA-201 IND
                                         prior to the initiation of patient dosing for our planned Phase 1/2 study in NHL;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         population studied in the clinical trial may not be sufficiently broad or representative
                                         to assess safety in the patient population for which we seek approval;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
                                         or inconclusive results of clinical trials and supportive non-clinical studies, including
                                         unfavorable results regarding safety or efficacy of our product candidates observed in
                                         clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         inability to demonstrate that clinical or other benefits of our product candidates outweigh
                                         any safety or other perceived risks;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         determination that a clinical trial presents unacceptable health risks to subjects;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         inability to obtain approval from institutional review boards, or IRBs, to conduct clinical
                                         trials at their respective sites;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         non-approval of the formulation, labeling or the specifications of our product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         potential for approval policies or regulations of the FDA, EMA or other regulatory agencies
                                         to significantly change in a manner rendering our clinical data insufficient for approval;
                                         or</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resistance
                                         to approval from the advisory committees of the FDA, EMA or other regulatory agencies
                                         for any reason including safety or efficacy concerns.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we are required to submit a BLA to obtain FDA approval before marketing omidubicel or any of our product candidates.
A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate’s
safety, purity and potency, or efficacy, for each desired indication. The BLA must also include significant information regarding
the chemistry, manufacturing and controls for the product. In November 2021, we completed a Type B Pre-Biologics License Application,
or pre-BLA meeting with the FDA for omidubicel during which the FDA requested that we provide revised analysis of the manufacturing
data generated at our wholly-owned commercial manufacturing facility in Kiryat Gat, Israel to demonstrate the comparability to
the omidubicel that was produced at the clinical manufacturing sites for the Phase 3 study. Although the FDA has agreed that we
established analytical comparability between the omidubicel product that is manufactured at our commercial manufacturing facility
and the omidubicel product that was manufactured for the Phase 3 trial, there is no guarantee that we will continue to meet the
FDA’s manufacturing requirements in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our BLA submission, the FDA may conduct an inspection of our Kiryat Gat, Israel manufacturing facility to ensure
that it can manufacture omidubicel and our other product candidates, if and when approved, in compliance with the applicable regulatory
requirements. The FDA may also inspect our clinical trial sites to ensure that our studies are properly conducted. Obtaining approval
of a BLA is a lengthy, expensive and uncertain process, and approval may not be obtained. Upon submission of a BLA, the FDA must
make an initial determination that the application is sufficiently complete to accept the submission for filing. We cannot be
certain that our rolling BLA submission for omidubicel, or any future submissions, will be accepted for filing and review by the
FDA, or ultimately be approved. If our planned application for omidubicel is not accepted for review or approval, the FDA may
require that we conduct additional clinical or preclinical trials, or take other actions before it will reconsider our application.
If the FDA requires additional studies or data, we would incur increased costs and delays in the marketing approval process, which
may require us to expend more resources than we have available. In addition, the FDA may not consider any additional information
to be complete or sufficient to support approval.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities outside of the United States, such as in the European Union, also have requirements for approval of biologics for
commercial sale with which we must comply prior to marketing in those areas. Regulatory requirements can vary widely from country
to country and could delay or prevent the introduction of our product candidates. Clinical trials conducted in one country may
not be accepted by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that
regulatory approval will be obtained in any other country.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our ability to obtain approval in
a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing and validation
and additional administrative review periods. Seeking additional regulatory approvals outside the United States and European Union
could require additional nonclinical studies or clinical trials, which could be costly and time consuming. These regulatory approvals
may include all of the risks associated with obtaining FDA or EMA approval. For all of these reasons, if we seek such regulatory
approvals for any of our other product candidates, we may not obtain such approvals on a timely basis, if at all.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we receive approval of any regulatory filing for omidubicel, the FDA may grant any such approval contingent on the performance
of costly and potentially time-consuming additional post-approval clinical trials or subject to contraindications, black box warnings,
restrictive surveillance or a Risk Evaluation and Mitigation Strategy, or REMS. Further, the FDA, EMA or other regulatory authorities
may also approve our product candidates for a more limited indication or a narrower patient population than we originally requested,
and these regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful commercialization
of our product candidates. Following any approval for commercial sale of omidubicel or our product candidates, certain changes
to the product, such as changes in manufacturing processes and additional labeling claims, as well as new safety information,
will be subject to additional FDA notification, or review and approval. Also, regulatory approval for any of our product candidates
may be withdrawn. To the extent we seek regulatory approval in jurisdictions outside of the United States and European Union,
we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent
commercialization of our product candidates and would thus negatively impact our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
development is difficult to design and implement and involves a lengthy and expensive process with uncertain outcomes.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Bone marrow transplant and
cell-based therapies that appear promising in the early phases of development may fail to reach the market. Further, a failure
of one or more of our clinical trials can occur at any time during the clinical trial process. We do not know whether future clinical
trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule,
if at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including failure to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">generate
                                         sufficient preclinical, toxicology, or other in vivo or in vitro data to support the
                                         initiation or continuation of clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                         regulatory approval, or feedback on trial design, in order to commence a trial;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify,
                                         recruit and train suitable clinical investigators;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reach
                                         agreement on acceptable terms with prospective contract research organizations, or CROs,
                                         and clinical trial sites, the terms of which can be subject to extensive negotiation
                                         and may vary significantly among CROs and clinical trial sites, and have such CROs and
                                         sites effect the proper and timely conduct of our clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                         and maintain IRB approval at each clinical trial site;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify,
                                         recruit and enroll suitable patients to participate in a trial;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
                                         a sufficient number of patients complete a trial or return for post-treatment follow-up;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure
                                         clinical investigators and clinical trial sites observe trial protocol or continue to
                                         participate in a trial;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address
                                         any patient safety concerns that arise during the course of a trial;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address
                                         any conflicts with new or existing laws or regulations;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
                                         a sufficient number of clinical trial sites;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
                                         sufficient quantities at the required quality of product candidate for use in clinical
                                         trials; or</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise
                                         sufficient capital to fund a trial.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability
to receive marketing approval or commercialize our product candidates, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may receive feedback from regulatory authorities that requires us to modify the design
                                         of our clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                         trials of our product candidates may produce negative or inconclusive results, and we
                                         may decide, or regulators may require us, to conduct additional clinical trials or abandon
                                         development programs;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         number of patients required for clinical trials of our product candidates may be larger
                                         than we anticipate, enrollment in these clinical trials may be slower than we anticipate
                                         or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         third-party contractors may fail to comply with regulatory requirements or meet their
                                         contractual obligations to us in a timely manner, or at all;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
                                         or IRBs may not authorize us or our investigators to commence a clinical trial or conduct
                                         a clinical trial at a prospective trial site or amend a trial protocol;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts
                                         or clinical trial protocols with prospective trial sites and CROs;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         or our investigators might have to suspend or terminate clinical trials of our product
                                         candidates for various reasons, including noncompliance with regulatory requirements,
                                         a finding that our product candidates have undesirable side effects or other unexpected
                                         characteristics, or a finding that the participants are being exposed to unacceptable
                                         health risks;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         supply or quality of our product candidates or other materials necessary to conduct clinical
                                         trials of our product candidates may be insufficient or inadequate;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                         may be changes in government regulations or administrative actions;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         product candidates may have undesirable adverse effects or other unexpected characteristics;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may not be able to demonstrate that a product candidate’s clinical and other benefits
                                         outweigh its safety risks;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may not be able to demonstrate that a product candidate provides an advantage over current
                                         standards of care of future competitive therapies in development;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
                                         may revise the requirements for approving our product candidates, or such requirements
                                         may not be as we anticipate; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         future collaborators that conduct clinical trials may face any of the above issues, and
                                         may conduct clinical trials in ways they view as advantageous to them but that are suboptimal
                                         for us.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such
trials are being conducted, by the trial’s data safety monitoring board, by the FDA, EMA or other regulatory agencies. Such
authorities may suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct
the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial
operations or trial site by the FDA, EMA or other regulatory agencies resulting in the imposition of a clinical hold, unforeseen
safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations
or administrative actions or lack of adequate funding to continue the clinical trial.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
conducting clinical trials in countries outside of the United States and European Union, as we plan to do for our product candidates,
presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients
in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing
additional administrative burdens associated with jurisdiction-specific regulatory schemes, as well as political and economic
risks relevant to such jurisdictions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter difficulties or delays in
initiating, screening, enrolling, conducting, or completing our ongoing and planned preclinical studies and clinical trials. Clinical
site initiation and patient screening and enrollment may be delayed due to prioritization of hospital resources toward the COVID-19
pandemic. Investigators and patients may not be able to comply with clinical trial protocols if quarantines impede patient movement
or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff
who, as healthcare providers, may have heightened exposure to COVID-19, could be limited, which in turn could adversely impact
our clinical trial operations. Additionally, we may experience interruption of key clinical trial activities, such as clinical
trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal
or state governments, employers and others in connection with the ongoing COVID-19 pandemic. As a result of the COVID-19 pandemic,
we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials.
Specifically, the initial timeline for submission of our BLA for omidubicel was delayed, in part, as a result of the impact of
the COVID-19 pandemic on our operations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial prospects of our
product candidates may be harmed, and our ability to generate product revenue from any of these product candidates will be delayed.
In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development
and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may significantly
harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately
demonstrate the safety and efficacy of our product candidates.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Results from preclinical
studies or early-stage clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical
trial are not necessarily indicative of final results. For example, our Phase 1/2 clinical trial of GDA-201 demonstrated significant clinical
activity in patients with non-Hodgkin lymphoma, with 13 complete responses and one partial response observed in 19 patients, for a response
rate of 74%. However, further clinical trials may show that the response rate in a larger sample size is lower than 74%. A decrease in
the response rate could cause us to abandon further development of GDA-201 in this indication.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a high failure rate for product candidates proceeding through clinical trials. Many companies in the pharmaceutical industry
have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing
and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations,
including conclusions about relapse rates that are based on small sample sizes of data, which may delay, limit or prevent regulatory
approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including due to changes
in regulatory policy during the period of our product candidate development. Success in preclinical testing and early clinical
trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate
the efficacy and safety of a product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interim,
“topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as
more patient data become available and are subject to audit and verification procedures that could result in material changes
in the final data.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim, “top-line” or preliminary data from our clinical studies. Interim data from
clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as
patient enrollment continues and more patient data become available. Preliminary or “top-line” data also remain subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data previously
published. In addition, successful results in one or a few patients may not be indicative of the final results after completion
of treatment of all patients in a clinical trial. As a result, interim and preliminary data should be viewed with caution until
the final data are available. Adverse changes between preliminary or interim data and final data could significantly harm our
business prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
success of our NAM technology platform and our product candidates is substantially dependent on developments within the emerging
field of cellular therapies, some of which are beyond our control.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
NAM expansion technology platform and our product candidates are designed to increase the therapeutic functionality of cell therapy
products, which represents a novel development within the field of cellular therapeutics. Stem cell therapies in turn represent
a relatively new therapeutic area that presents a number of scientific, clinical, regulatory and ethical challenges. Any adverse
developments in the field of stem cell therapies generally, and in the practice of hematopoietic stem cell transplant in particular,
will negatively impact our ability to develop and commercialize our product candidates. In particular, we currently anticipate
that omidubicel and any additional product candidates that we develop from our NAM technology platform would be adopted into the
current standard of care for hematopoietic stem cell transplant, or HSCT, procedures. If the market for HSCT procedures declines
or fails to grow at anticipated levels for any reason, or if the development and commercialization of therapies targeted at the
underlying cause of diseases addressed by omidubicel obviate the need for patients to undergo HSCT procedures, our business prospects
will be significantly harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Because
our product candidates are based on novel technologies, it is difficult to predict the time and cost of development and our ability
to successfully complete clinical development of these product candidates and obtain the necessary regulatory approvals for commercialization.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are based on our novel NAM technology platform, and unexpected problems related to this new technology may
arise that could cause us to delay, suspend or terminate our development efforts. Regulatory approval of novel product candidates
such as ours can be more expensive and take longer, than for other more well-known or extensively studied pharmaceutical or biopharmaceutical
product candidates due to our and regulatory agencies’ lack of experience with them. Stem cell therapies represent a relatively
new therapeutic area, and the FDA has cautioned consumers about potential safety risks associated with these therapies. To date,
there are relatively few approved stem cell products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
requirements governing cell therapy products have changed frequently and may continue to change in the future. For example, the
FDA established the Office of Cellular, Tissue and Gene Therapies within its Center for Biologics Evaluation and Research, or
CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee
to advise CBER on its review. In addition, adverse developments in clinical trials of potential stem cell therapies conducted
by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.
These regulatory authorities and advisory groups and the new requirements or guidelines they promulgate may lengthen the regulatory
review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions
and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval
limitations or restrictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may find it difficult to enroll patients in our clinical studies, which could delay or prevent us from proceeding with clinical
trials.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of
our clinical trials depends in part on the speed at which we can recruit patients to participate in testing our product candidates,
and we may experience delays in our clinical trials if we encounter difficulties in enrollment. Patient enrollment and retention
in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, our
ability to recruit clinical trial investigators with the appropriate competencies and experience, the existing body of safety
and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of
competing drugs for the same indication, the proximity of patients to clinical sites, clinicians’ and patients’ perceptions
as to the potential advantages of the product candidate being studied in relation to other available therapies, including any
drugs that may be approved for the indications we are investigating, the eligibility criteria for the study, our ability to obtain
and maintain patient consents and the risk that patients enrolled in clinical trials will drop out of the trials before completion.
For example, patients may prefer to undergo treatment with stem cell transplantation with cells sourced from matched related donors,
matched unrelated donors or haploidentical donors, as opposed to being treated with omidubicel, which would adversely affect the
enrollment of our clinical trials.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies because of the
perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical
studies, the proximity and availability of clinical study sites for prospective patients and the patient referral practices of
physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting
studies, and obtaining regulatory approval of potential products will be delayed.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any negative results we may report in clinical trials of our product candidate may make it difficult or impossible to
recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment
or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop
our product candidates, or could render further development impossible. For example, the impact of public health epidemics, such
as the ongoing COVID-19 pandemic, may delay or prevent patients from enrolling or from receiving treatment in accordance with
the protocol and the required timelines, which could delay our clinical trials, or prevent us from completing our clinical trials
at all, and harm our ability to obtain approval for such product candidate. Further, if patients drop out of our clinical trials,
miss follow-up visits, or otherwise fail to follow clinical trial protocols, whether as a result of the COVID-19 pandemic or actions
taken to slow the spread of COVID-19 or otherwise, the integrity of data from our clinical trials may be compromised or not accepted
by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program. In addition,
we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend
to enter into agreements governing their services, we will be limited in our ability to compel their actual performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
product candidates and the administration process may cause undesirable side effects or have other properties that could delay
or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences
following marketing approval, if any, and result in costly and damaging product liability claims against us.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects, including toxicology, caused by our product candidates, or the drugs encapsulated by our product candidates, could
cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or
the delay or denial of regulatory approval by the FDA, EMA or other regulatory agencies. Results of our studies could reveal a
high and unacceptable severity and prevalence of these or other side effects. In such an event, our clinical studies could be
suspended or terminated, and the FDA, EMA or other regulatory agencies could order us to cease further development of or deny
or withdraw approval of our product candidates for any or all targeted indications. Moreover, during the conduct of clinical trials,
patients report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not
possible to determine whether or not the product candidate being studied caused these conditions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug-related,
drug-product related, formulation-related and administration-related side effects could affect patient recruitment, the ability
of enrolled patients to complete the clinical study or result in potential product liability claims, which could exceed our clinical
trial insurance coverage. We obtain clinical trial insurance policies with respect to all our clinical studies. The insurance
policies are in accordance with the local regulations applicable in the jurisdictions where the studies are performed outside
of clinical trials.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have
both known and unknown significant pre-existing and potentially life-threatening health risks. Severe (grade 4) infusion reactions
have also been reported in approximately 4% of patients treated with omidubicel. The most common adverse events related to omidubicel
were graft versus host disease, or GvHD, (10%), pain (8%), transplant failure (4%), hypertension (4%), and dyspnea (2%). During
the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates.
In our Phase 1/2 clinical trial of omidubicel for the treatment of sickle cell disease, or SCD, which is a chronic illness, two
of the patients died: one due to chronic GvHD and the other due to secondary graft failure. In our Phase 1/2 trial of omidubicel
for the treatment of hematologic malignancies, approximately 10% of patients who received omidubicel experienced serious GvHD.
In our Phase 1/2 clinical trial of GDA-201, adverse events included one patient who died of E. coli sepsis. There was also a low
level of sporadic engraftment failures. Such events could subject us to costly litigation, require us to pay substantial amounts
of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market
our products, or require us to suspend or abandon our commercialization efforts.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance
may be time-consuming or inconclusive. For instance, allogeneic bone marrow transplant, the area in which omidubicel is being
used, is associated with serious complications, including death. In addition, there are expected toxicities for patients who receive
an allogeneic bone marrow transplant, such as infertility. Thus, while not directly associated with omidubicel, there are attendant
risks with the space in which our product candidates operate, and any related investigations may interrupt our development and
commercialization efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our product
candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could
have a material adverse effect on our business, financial condition or results of operations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including, but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         authorities may suspend or withdraw approvals of such product;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         authorities may require additional warnings on the label, such as a “black box”
                                         warning or contraindication;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                         restrictions may be imposed on the marketing of the particular product or the manufacturing
                                         processes for the product or any component thereof;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be required to create a REMS, which could include a medication guide outlining the
                                         risks of such side effects for distribution to patients, a communication plan for healthcare
                                         providers and/or other elements to assure safe use;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be required to recall a product, change the way a product candidate is administered
                                         or conduct additional clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         could be sued and held liable for harm caused to patients;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         product may become less competitive; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         reputation may suffer.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved,
and could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Government Regulation</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize
any of our product candidates, and the approval may be for a narrower indication than we seek or be subject to other limitations
or restrictions that limit its commercial profile<span style="font-weight: normal">.</span></i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
Even if our current or future product candidates meet safety and efficacy endpoints in clinical trials, the regulatory authorities
may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays
may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In
addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative
action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations
in the form of warnings or a REMS. These regulatory authorities may require precautions or contra-indications with respect to
conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition,
regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization
of any of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product
candidates and materially and adversely affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling,
packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety,
efficacy, and other post- market information, including both federal and state requirements in the United States and European
Union and requirements of comparable regulatory authorities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
and manufacturers’ facilities are required to comply with extensive FDA, EMA and the requirements of additional regulatory
authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and
our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to
commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time,
money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect
to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with
the information in the product’s approved label. As such, we may not promote our products “off-label” for indications
or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications
and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be
asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient
subsets. An unsuccessful post- marketing study or failure to complete such a study could result in the withdrawal of marketing
approval.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or
frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling
of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product
from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may,
among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
                                         warning letters;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
                                         civil or criminal penalties;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                         or withdraw regulatory approval;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                         any of our clinical studies;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
                                         to approve pending applications or supplements to approved applications submitted by
                                         us;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
                                         restrictions on our operations, including closing our contract manufacturers’ facilities;
                                         or</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
                                         or detain products, or require a product recall.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and
could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely
affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory
approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent
of government regulation that may arise from future legislation or administrative or executive action, either in the United States
or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may
not achieve or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>A
Breakthrough Therapy Designation by the FDA may not lead to a faster development or regulatory review or approval process and
it does not increase the likelihood that our product candidates will receive marketing approval.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained Breakthrough Therapy Designation for omidubicel for the treatment of hematologic malignancies and may receive it
in the future if the clinical data support such a designation for one or more of our other product candidates. A breakthrough
therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics,
to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic,
may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. Biologics designated as breakthrough
therapies by the FDA may also be eligible for accelerated approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our current or future product
candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make
such designation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any event, the receipt of a Breakthrough Therapy Designation for omidubicel for the treatment of hematologic malignancies may
not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA
review procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that the product no
longer meets the conditions to qualify for Breakthrough Therapy Designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may be unable to maintain the benefits associated with orphan drug designations that we have obtained, including market exclusivity,
which may cause our revenue, if any, to be reduced.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained orphan drug designation for omidubicel from the FDA and the EMA for the treatment of hematologic malignancies, and
we may pursue orphan drug designation for certain of our future product candidates. Under the Orphan Drug Act, the FDA may designate
a drug or biologic product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population
of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no
reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European
Union, the EMA’s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development
of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition
affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended
for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when,
without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment
in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment,
or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax advantages, and application fee waivers. In addition, if a product receives the first FDA approval for
the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may
not approve any other application to market the same drug for the same indication for a period of seven years, except in limited
circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is
unable to assure sufficient product quantity the orphan patient population. In the European Union, orphan drug designation entitles
a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or
biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met,
including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
though we have obtained orphan drug designation for omidubicel from the FDA and the EMA for the treatment of hematologic malignancies,
we may not be the first to obtain marketing approval for such indication due to the uncertainties associated with developing pharmaceutical
products. Further, orphan drug exclusivity may not effectively protect the product candidate from competition because different
drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA or
EMA can subsequently approve the same drug with the same active moiety for the same condition if the FDA or EMA concludes that
the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan
drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic
any advantage in the regulatory review or approval process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Enacted
and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize
our product candidates and may affect the prices we may set.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number
of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations.
In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce
healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care
Act, as amended by the Health Care and Education Reconciliation Act, or collectively the PPACA, was enacted, which substantially
changed the way healthcare is financed by both governmental and private payers. Among the provisions of the PPACA, those of greatest
importance to the pharmaceutical and biotechnology industries include the following: an annual, non-deductible fee payable by
any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as
orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
                                         requirements to report certain financial arrangements with physicians and teaching hospital
                                         personnel including transplant teams, including reporting “transfers of value”
                                         made or distributed to physicians, as defined by such law, and reporting investment interests
                                         held by physicians and their immediate family members;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate
                                         Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                         of eligibility criteria for Medicaid programs by, among other things, allowing states
                                         to offer Medicaid coverage to certain individuals with income at or below 133% of the
                                         federal poverty level, thereby potentially increasing a manufacturer’s Medicaid
                                         rebate liability;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         licensure framework for follow-on biologic products;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         new Patient-Centered Outcomes Research Institute to oversee, identify priorities in,
                                         and conduct comparative clinical effectiveness research, along with funding for such
                                         research; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
                                         of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services,
                                         or CMS, to test innovative payment and service delivery models to lower Medicare and
                                         Medicaid spending, potentially including prescription drug spending.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been judicial and Congressional challenges to certain aspects of the PPACA. For example, tax legislation enacted on December
22, 2017, titled “an Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget
for fiscal year 2018,” or the Tax Act, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility
payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year
that is commonly referred to as the “individual mandate”. On June 17, 2021, the U.S. Supreme Court dismissed a challenge
on procedural grounds that argued the PPACA is unconstitutional in its entirety because the “individual mandate” was
repealed by Congress. Thus, the PPACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling,
on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 26, 2021
through August 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to
healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements,
and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA.
It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges
and the healthcare reform measures of the Biden administration.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. In August
2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2%
per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute,
will remain in effect through 2031 with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 unless
additional action is taken by Congress. Under current legislation, the actual reduction in Medicare payments will vary from 1%
in 2022 to up to 3% in the final fiscal year of this sequester. In January 2013, the American Taxpayer Relief Act of 2012 was
signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals,
imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. Additionally, Congress is considering additional health reform measures. These new laws
or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding,
which could negatively affect our customers and accordingly, our financial operations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
payment methodologies are subject to changes in healthcare legislation and regulatory initiatives. For example, CMS has developed
value-based payment models for a variety of care settings, including the inpatient prospective payment system used for reimbursing
inpatient hospital services. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers
set prices for their marketed products, which has resulted in several U.S. Presidential executive orders, Congressional inquiries
and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing,
reduce the cost of prescription drugs under government payer programs, and review the relationship between pricing and manufacturer
patient programs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform,
including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September
13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement
several of the administration’s proposals. As a result, the FDA concurrently released a final rule and guidance in September2020,
providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS
finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors
under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation
of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation.
The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for
certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been
delayed by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing
the Trump administration’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered
drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation
challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinds the Most Favored Nation
model interim final rule. Additionally, in July 2021, the Biden administration released an executive order, “Promoting Competition
in the American Economy,” with multiple provisions aimed at prescription drugs. In response to Biden’s executive order,
on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing
reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these
principles. It is unclear whether these or similar policy initiatives will be implemented in the future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts
that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. Legally mandated price controls on payment amounts by third- party payers or other restrictions
could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities
and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers
will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product
candidates or put pressure on our product pricing.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize
our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments
at the European Union or member state level may result in significant additional requirements or obstacles that may increase our
operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services
and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and
policy. National governments and health service providers have different priorities and approaches to the delivery of health care
and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most
European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service
providers. Any increase in European Union and national regulatory burdens on those wishing to develop and market products could
prevent or delay marketing approval of our product candidates, restrict or regulate post- approval activities and affect our ability
to commercialize our product candidates, if approved. In markets outside of the United States and European Union, reimbursement
and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products
and therapies.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
action in the United States, the European Union or any other jurisdiction. It is also possible that additional government action
is taken in response to the COVID-19 pandemic. If we or any third parties we may engage are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain
regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve
or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party
payers, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to
penalties.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party
payers, patient organizations and customers, may expose us to broadly applicable fraud and abuse, privacy and security and other
healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which
we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws
include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities
                                         from knowingly and willfully soliciting, offering, receiving or providing any remuneration
                                         (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or
                                         covertly, in cash or in kind, to induce or reward, or in return for, either the referral
                                         of an individual for, or the purchase, lease, order or recommendation of, any good, facility,
                                         item or service, for which payment may be made, in whole or in part, under any U.S. federal
                                         healthcare program, such as Medicare and Medicaid. A person or entity does not need to
                                         have actual knowledge of the statute or specific intent to violate it in order to have
                                         committed a violation;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         U.S. federal civil and criminal false claims, including the civil False Claims Act, which
                                         prohibit, among other things, including through civil whistleblower or qui tam actions,
                                         and civil monetary penalties laws which prohibit individuals or entities from knowingly
                                         presenting, or causing to be presented, to the U.S. federal government, claims for payment
                                         or approval that are false or fraudulent, knowingly making, using or causing to be made
                                         or used, a false record or statement material to a false or fraudulent claim, or from
                                         knowingly making a false statement to avoid, decrease or conceal an obligation to pay
                                         money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims
                                         to be presented to the U.S. federal government by engaging in impermissible marketing
                                         practices, such as the off-label promotion of a product for an indication for which it
                                         has not received FDA approval. In addition, the government may assert that a claim including
                                         items and services resulting from a violation of the U.S. federal Anti-Kickback Statute
                                         constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         Health Insurance Portability and Accountability Act, or HIPAA, which imposes criminal
                                         and civil liability for, among other things, knowingly and willfully executing, or attempting
                                         to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully
                                         falsifying, concealing or covering up a material fact or making any materially false
                                         statement, in connection with the delivery of, or payment for, healthcare benefits, items
                                         or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does
                                         not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA
                                         or specific intent to violate it in order to have committed a violation;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                         as amended by the Health Information Technology for Economic and Clinical Health Act,
                                         or HITECH, and its implementing regulations, which also imposes certain obligations,
                                         including mandatory contractual terms, with respect to safeguarding the privacy and security
                                         of individually identifiable health information of covered entities subject to the rule,
                                         such as health plans, healthcare clearinghouses and certain healthcare providers, as
                                         well as their business associates, independent contractors of a covered entity that perform
                                         certain services involving the use or disclosure of individually identifiable health
                                         information on their behalf and their subcontractors that use, disclose, access, or otherwise
                                         process individually identifiable health information;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         Food Drug and Cosmetic Act, or the FDCA, which prohibits, among other things, the adulteration
                                         or misbranding of drugs, biologics and medical devices;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         U.S. Public Health Service Act, which prohibits, among other things, the introduction
                                         into interstate commerce of a biological product unless a biologics license is in effect
                                         for that product;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         U.S. Physician Payments Sunshine Act and its implementing regulations, which requires
                                         certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable
                                         under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific
                                         exceptions, to report annually to the government information related to certain payments
                                         and other transfers of value to physicians (defined to include doctors, dentists, optometrists,
                                         podiatrists, and chiropractors), certain other healthcare professionals (such as physician
                                         assistants and nurse practitioners), and teaching hospitals, as well as ownership and
                                         investment interests held by physicians and their immediate family members;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
                                         U.S. state laws and regulations, including: state anti-kickback and false claims laws,
                                         which may apply to our business practices, including but not limited to, research, distribution,
                                         sales and marketing arrangements and claims involving healthcare items or services reimbursed
                                         by any third-party payer, including private insurers; state laws that require pharmaceutical
                                         companies to comply with the pharmaceutical industry’s voluntary compliance guidelines
                                         and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise
                                         restrict payments that may be made to healthcare providers and other potential referral
                                         sources; state laws and regulations that require drug manufacturers to file reports
                                         relating to pricing and marketing information, which requires tracking gifts and other
                                         remuneration and items of value provided to healthcare professionals and entities;
                                         state and local laws requiring the registration of pharmaceutical sales representatives;
                                         and state laws governing the privacy and security of health information in certain circumstances,
                                         many of which differ from each other in significant ways and often are not preempted
                                         by HIPAA, thus complicating compliance efforts; the U.S. Foreign Corrupt Practices
                                         Act of 1977, as amended, which prohibits, among other things, U.S. companies and their
                                         employees and agents from authorizing, promising, offering, or providing, directly or
                                         indirectly, corrupt or improper payments or anything else of value to non-U.S. government
                                         officials, employees of public international organizations and non-U.S. government owned
                                         or affiliated entities, candidates for non-U.S. political office, and non-U.S. political
                                         parties or officials thereof; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">similar
                                         healthcare laws and regulations in the European Union and other jurisdictions, including
                                         reporting requirements detailing interactions with and payments to healthcare providers.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not
comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other
governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal
and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid
or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations
of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment
or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business
are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including
exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business.
Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore,
even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legislative
or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance
or approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing
the regulatory clearance or approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition,
FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business
and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or
lengthen review times of our product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation
or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other
things, require:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         to manufacturing methods;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
                                         in protocol design;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                         treatment arm (control);</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall,
                                         replacement, or discontinuance of one or more of our products; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                         recordkeeping.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
face competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete
effectively.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.
We face competition from major multinational pharmaceutical companies, established and early-stage biotechnology companies, and
universities and other research institutions. Many of our competitors have greater financial and other resources, such as larger
research and development staff and more experienced marketing and manufacturing organizations. Large pharmaceutical companies,
in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing
pharmaceutical products. These companies also have significantly greater research, sales and marketing capabilities and collaborative
arrangements in our target markets with leading companies and research institutions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license
novel therapeutics that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors
may succeed in obtaining patent protection or FDA approval or discovering, developing and commercializing treatments in the rare
disease indications that we are targeting before we do. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large, established companies.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doctors
may recommend that patients undergo stem cell transplantation using cells from matched related donors, matched or mismatched unrelated
donors, haploidentical donors or unmodified umbilical cord blood instead of using omidubicel or may choose other therapy options
instead of our other NAM-derived product candidates. In addition, there are several clinical-stage development programs that seek
to improve umbilical cord blood transplantation through the use of ex vivo expansion technologies to increase the quantity of
hematopoietic stem cells for use in HSCT or the use of ex vivo differentiation technologies to increase the quantity of hematopoietic
progenitor cells for use in HSCT. We are aware of several other companies with product candidates in various stages of development
for allogeneic HSCT grafts, including Magenta Therapeutics, ExCellThera, Garuda Therapeutics and Bellicum Pharmaceuticals, and
for NK cells, including, Takeda Pharmaceutical Company Limited, Fate Therapeutics, Artiva, Sanofi, MiNK Therapeutics, ONK Therapeutics,
Shoreline, Cellularity, NKarta, Wugen, Century Therapeutics, Appia Bio and FujiFilm Cellular Dynamics. In addition, many universities
and private and public research institutes may develop technologies of interest to us but license them to our competitors. Our
competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and drug products that are more
effective or less costly than omidubicel or any other product candidates that we are currently developing or that we may develop,
which could render our products obsolete and noncompetitive.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ability to successfully compete will depend on, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         results of our preclinical studies and clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to recruit and enroll patients for our clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         efficacy, safety and reliability of our product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         speed at which we develop our product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to design and successfully execute appropriate clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to protect, develop and maintain intellectual property rights related to our
                                         products;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to maintain a good relationship with regulatory authorities;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing and scope of regulatory approvals, if any;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to commercialize and market any of our product candidates that receive regulatory
                                         approval;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                         perception and acceptance of stem cell therapeutics;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                         of our product candidates by physicians and institutions that perform HSCT procedures;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         price of our products;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">coverage
                                         and adequate levels of reimbursement under private and governmental health insurance
                                         plans, including Medicare; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to manufacture and sell commercial quantities of any approved products to the
                                         market.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our competitors market products that are more effective, safer or less expensive than our future products, if any, or that reach
the market sooner than our future products, if any, we may not achieve commercial success. Any inability to successfully compete
effectively will adversely impact our business and financial prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Even
if we obtain and maintain approval for omidubicel or our other product candidates from the FDA, we may never obtain approval outside
of the United States, which would limit our market opportunities and adversely affect our business.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities
in other countries or jurisdictions, and approval by non-U.S. regulatory authority does not ensure approval by regulatory authorities
in other countries or by the FDA. However, the failure to obtain approval from the FDA or other regulatory authorities may negatively
impact our ability to obtain approval in non-U.S. countries. Sales of omidubicel or our other product candidates outside of the
United States will be subject to the regulatory requirements of other jurisdictions governing clinical trials and marketing approval.
Even if the FDA grants marketing approval for a product candidate, comparable regulatory authorities in other countries also must
approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions
and can involve requirements and administrative review periods different from, and more onerous than, those in the United States,
including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate
must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend
to charge for our product candidates, if approved, is also subject to approval.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to submit a marketing authorization application to the EMA for approval of omidubicel in the European Union, but obtaining
such approval from the European Commission following the opinion of the EMA is a lengthy and expensive process. Even if a product
candidate is approved, the applicable regulatory agency may limit the indications for which the product may be marketed, require
extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as
conditions of approval. Regulatory authorities in countries outside of the United States and the European Union also have requirements
for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining non-U.S. regulatory
approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for
us and could delay or prevent the introduction of our product candidates in certain countries.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval
for a product candidate may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced
and our ability to realize the full market potential of omidubicel or our other product candidates will be harmed and our business,
financial condition, results of operations and prospects will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability
suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion
of these uses, any of which could be costly to our business.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initially intend to seek marketing approval for omidubicel for the treatment of hematologic malignancies. We will train our marketing
and sales personnel or the marketing and sales personnel of any strategic partner to not promote our products, if approved, for
any other uses outside of any FDA-cleared indications for use, known as “off-label use.”</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot, however, prevent a physician from using our products off-label, when in the physician’s independent professional
medical judgment, he or she deems it appropriate. As a result, there may be increased risk of injury to patients if physicians
attempt to use our products for these uses for which they are not approved. Furthermore, the use of our products for indications
other than those approved by the FDA or any non-U.S. regulatory body may not effectively treat such conditions, which could harm
our reputation in the marketplace among physicians and patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>



</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">If
the FDA, EMA or any other regulatory body in a jurisdiction in which we operate determines that our promotional materials or training
constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us
to regulatory or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators
that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other
federal, state or non-U.S. enforcement authorities might take action under other regulatory authority, such as false claims laws,
if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties,
including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation
in government healthcare programs and the curtailment of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Collection
and use of data, including personal information, is governed by restrictive regulations that could lead to government enforcement
actions, private litigation, adverse publicity, or other adverse actions that could negatively affect our operating results of
business</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
collection and use of personal health data in the European Union are governed by the provisions of the General Data Protection
Regulation ((EU) 2016/679), or GDPR. This legislation imposes requirements relating to (a) having legal bases for processing personal
information relating to identifiable individuals and transferring such information outside the European Economic Area including
to the United States, (b) providing details to those individuals regarding the processing of their personal information, (c) keeping
personal information secure and confidential, (d) having data processing agreements with third parties who process personal information,
(e) responding to individuals’ requests to exercise their rights in respect of their personal information, (f) reporting
security breaches involving personal data to the competent national data protection authority and, possibly, affected individuals,
(g) appointing data protection officers, (h) conducting data protection impact assessments and (i) recordkeeping. The GDPR imposes
additional responsibilities and liabilities in relation to personal data that we process and we may be required to put in place
additional mechanisms ensuring compliance with the new data protection rules. Further, the GDPR prohibits the transfer of personal
data to countries outside the European Economic Area, such as the United States, which are not considered by the European Commission
to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms
to allow for the transfer of personal data from the EEA and Switzerland to the United States, they are subject to legal challenges
and uncertainty regarding compliance with the European Union data protections laws. Failure to comply with the requirements of
the GDPR and related national data protection laws of the member states of the European Union may result in substantial fines
(up to or the great of €20 million or 4% of annual global revenue), other administrative penalties and civil claims being
brought against us, which could have a material adverse effect on our business, results of operations and financial condition.
Such civil claims, based on a private right of actions in the GDPR, allow data subjects and consumer associations to lodge complaints
with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to our Reliance on Third Parties</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
rely on third parties to conduct certain elements of our preclinical studies and clinical trials and perform other tasks for us.
If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory
requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon, and plan to continue to rely upon, third-party vendors, including CROs, to monitor and manage data for our ongoing
preclinical studies and clinical trials. We rely on these parties for execution of our preclinical studies and clinical trials,
and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies
is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the vendors
and CROs does not relieve us of our regulatory responsibilities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our CROs and other vendors are required to comply with good clinical practice, or GCP, cGMP, the Helsinki Declaration, the
International Council for Harmonization Guideline for Good Clinical Practice, applicable European Commission Directives on Clinical
Trials, laws and regulations applicable to clinical trials conducted in other territories, good laboratory practices, or GLP,
which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic
Area, or EEA, and comparable regulatory authorities for all our product candidates in clinical development as well as rules and
regulations regarding the collection and use of personal data such as the GDPR.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites and
other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, including GCP and cGMP regulations,
the clinical data generated in our clinical studies may be deemed unreliable and the FDA, EMA or comparable regulatory authorities
may require us to perform additional clinical studies before approving our marketing applications. Our failure to comply with
these regulations may require us to repeat clinical studies, which would delay the regulatory approval process.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs or vendors terminate, we may not be able to enter into arrangements with
alternative CROs or vendors or do so on commercially reasonable terms. In addition, our CROs are not our employees, and, except
for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time
and resources to our ongoing clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual
duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data
they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons,
our clinical studies may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. CROs may also generate higher costs than anticipated, which could adversely affect our results
of operations and the commercial prospects for our product candidates, increase our costs and delay our ability to generate revenue.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Replacing
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical
development timelines. Though we carefully manage our relationships with our CROs, we may encounter similar challenges or delays
in the future, which could have a material adverse impact on our business, financial condition and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Independent
clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our
clinical trials or be able to repeat their past success.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to depend on third parties, including independent clinical investigators and CROs, to conduct our clinical
trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers
and vendors that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing
performance of third-party service providers can be difficult, time consuming and cause delays in our development programs.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
investigators and CROs will not be our employees and we will not be able to control, other than through contract, the amount of
resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs
fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may
delay or compromise the prospects for approval and commercialization of any product candidates that we develop.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigators
for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other
regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and an investigator
has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authorities
may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical
trial itself may be jeopardized. This could result in a delay in approval or rejection of our marketing applications by the FDA
or other regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more
of our product candidates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which
could increase the risk that this information will be misappropriated. Further, the FDA and other regulatory authorities require
that we comply with standards, commonly referred to as GCP, for conducting, recording and reporting clinical trials to assure
that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects
are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely
affect the clinical development of our product candidates and harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
rely on a limited number of suppliers to provide the raw materials other than cord blood (serum and growth factor) needed to produce
our product candidates. We have a relationship with a single supplier, Miltenyi Biotec GmbH, for certain equipment (columns and
beads) necessary to create our product candidates. </i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any control over the availability of these raw materials or pieces of equipment. If we or our providers are unable
to purchase these raw materials or equipment on acceptable terms, at sufficient quality levels, or in adequate quantities, if
at all, the development and commercialization of our product candidates or any future product candidates, could be delayed or
there could be a shortage in supply, which could impair our ability to meet our development objectives for our product candidates
or generate revenue from the sale of any approved products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
following our establishment of our own planned cGMP-compliant manufacturing capabilities, we intend to continue to rely on third-party
suppliers for these raw materials and pieces of equipment, which will expose us to risks including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         of any supplier to become or maintain its status as a cGMP-compliant manufacturer of
                                         raw materials, which status is a prerequisite to our attainment of a BLA for omidubicel
                                         and our other product candidate;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
                                         or nonrenewal of supply or service agreements with third parties in a manner or at a
                                         time that is costly or damaging to us; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
                                         to the operations of our third-party suppliers and service providers caused by conditions
                                         unrelated to our business or operations, including the bankruptcy of the supplier or
                                         service provider.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
rely on a single facility located in Kiryat Gat, Israel to manufacture omidubicel. Severe natural or other disaster, power outages
or disruption at this site could have a material adverse effect on our ability to manufacture sufficient commercial supply.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">After
the termination of the Services Agreement with Lonza and unless and until we establish an alternative supplier, we will be solely dependent
on our facility in Kiryat Gat, Israel for the manufacture of the commercial supply of omidubicel, if omidubicel is approved. We have
completed construction on the facility in Kiryat Gat and we are now working to qualify our manufacturing process and facility with the
FDA’s cGMP regulations. Severe natural or other disasters, power outages, ongoing or revived hostilities or other political or
economic factors could severely disrupt our manufacturing operations at our Kiryat Gat facility. If any event occurred that prevented
us from using all or a significant portion of this facility or otherwise disrupted operations, it may be difficult or, in certain cases,
impossible for us to continue manufacturing omidubicel for a substantial period of time in sufficient quantities, or at all. The disaster
recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate to guarantee a sufficient
continuation of supply in the event of a serious disaster or similar event. Although we intend to establish an alternative source supplier
or manufacturer for the commercial supply of omidubicel, we cannot guarantee that we will be able to establish an alternative source,
supplier or partner for the manufacturing of omidubicel at acceptable commercial terms, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
reliance on third parties requires us to share our trade secrets and other intellectual property, which increases the possibility
that a competitor will discover them or that our trade secrets and other intellectual property will be misappropriated or disclosed.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we rely on third parties to provide us with the materials that we use to develop and manufacture our product candidates, we may,
at times, share trade secrets and other intellectual property with such third parties. We seek to protect our proprietary technology
in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements,
consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose
our confidential information, such as trade secrets and intellectual property. Despite the contractual provisions employed when
working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade
secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used
in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a
competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position
and may have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our efforts to protect our trade secrets, our competitors or other third parties may discover our trade secrets, either through
breach of these agreements, independent development or publication of information including our trade secrets by third parties.
A competitor’s or other third party’s discovery of our trade secrets would impair our competitive position and have
an adverse impact on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
face a variety of challenges and uncertainties associated with our dependence on the availability of human umbilical cord blood
units, or CBUs, at cord blood banks for the manufacture of omidubicel.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBUs
are one of the raw materials for the manufacture of omidubicel. The CBUs currently used in the manufacture of omidubicel are procured
directly by the clinical cell processing facilities from cord blood banks, which hold more than 800,000 CBUs that have been donated,
processed and cryopreserved. However, the availability of CBUs for the manufacture of omidubicel depends on a number of regulatory,
political, economic and technical factors outside of our control, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
                                         policies relating to the regulation of CBUs for clinical use;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         availability of government funding for cord blood banks;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pregnancy
                                         and birth rates, which we expect to decline temporarily in response to the COVID-19 pandemic,
                                         and the willingness of mothers to consent to the donation of CBUs and the terms of such
                                         consent;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">individual
                                         cord blood bank policies and practices relating to CBU acquisition and banking;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         pricing of CBUs;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         methods used in searching for and matching CBUs to patients, which involve emerging technology
                                         related to current and future CBU parameters that guide the selection of an appropriate
                                         CBU for transplantation; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">methods
                                         for the procurement and shipment of CBUs and their handling and storage at clinical sites,
                                         any or all of which may have been complicated by public health policies aimed at slowing
                                         the spread of the COVID-19 virus.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we do not have control over the types of CBUs used in the manufacture of omidubicel. We rely heavily on these clinical cell processing
facilities to procure CBUs from cord blood banks that are compliant with government regulations and within the current standard
of care. In addition, we may identify specific characteristics of CBUs, such as their volume and red blood cell content, that
may limit their ability to be used to manufacture omidubicel even though these CBUs may otherwise be suitable for use in allogeneic
transplant. As a result, the requirement for CBUs to meet our specifications may limit the potential inventory of CBUs eligible
for use in the manufacture of omidubicel. There is a large variability in the tests, methods and equipment utilized by cord blood
banks in testing CBUs before storage. This could result in CBUs that are found to be unsuitable for production after their arrival
at the manufacturing site. In the United States, cord blood banks are required to file a BLA and meet certain continued regulatory
requirements in order to bank and provide CBUs for transplantation. Despite these requirements, most of the cord blood banks in
the United States are not licensed. While the FDA currently allows CBUs from unlicensed cord blood banks to be used for transplantation
and we have used CBUs from such facilities in the manufacture of omidubicel for our clinical trials, the FDA may later prohibit
the use of such CBUs for transplantation. Additionally, although CBUs from non-U.S. cord blood banks, which are generally unlicensed,
are currently available in the United States for use in transplantation and we have used CBUs from non-U.S. cord blood banks in
our clinical trials, we anticipate we will not be able to use cord blood from non-U.S. cord blood banks for the manufacturing
of omidubicel. Any inability to procure adequate supplies of CBUs will adversely impact our ability to develop and commercialize
omidubicel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Intellectual Property</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
we are unable to obtain, maintain or protect intellectual property rights related to any of our product candidates or any future
product candidates, we may not be able to compete effectively in our market.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property
related to our technologies and product candidates. Our success depends in large part on our ability to obtain and maintain patent
and other intellectual property protection in the United States and in other countries with respect to our proprietary technology
and product candidates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have sought to protect our proprietary position by filing patent applications in the United States and in other countries, with
respect to our novel technologies and product candidates, which are important to our business. Patent prosecution is expensive
and time consuming. We may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable
cost or in a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our
research and development activities before it is too late to obtain patent protection.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the patent position of biopharmaceutical companies generally is highly uncertain and involves complex legal and factual questions
for which legal principles remain unsettled. This renders the patent prosecution process particularly expensive and time-consuming.
There is no assurance that all potentially relevant prior art relating to our patent applications has been found and that there
are no material defects in the form, preparation, or prosecution of our patent applications, which can invalidate a patent or
prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents
cover our product candidates, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability,
our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad,
which may result in such patents being narrowed, found unenforceable or invalidated. For example, we may be subject to a third
party pre-issuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in post-grant
review procedures, oppositions, derivations, reexaminations, inter parts review, or IPR, or interference proceedings, in the United
States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges
may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part,
which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit
the duration of the patent protection of our technology and products. Furthermore, even if they are unchallenged, our patent applications
and any future patents may not adequately protect our intellectual property, provide exclusivity for our product candidates, or
prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third
parties, which may have an adverse impact on our business.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively and
our business and results of operations would be harmed.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by any patents that have been or may be granted, we rely on trade secret protection and confidentiality
agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents
are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary
know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek
to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees,
consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data, trade
secrets and intellectual property by maintaining the physical security of our premises and physical and electronic security of
our information technology systems. Notwithstanding these measures, organizations and systems, agreements or security measures
may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets and intellectual property
may otherwise become known or be independently discovered by competitors. Although we expect all our employees and consultants
and other third parties who may be involved in the development of intellectual property for us to assign their inventions to us,
and all of our employees, consultants, advisors and any third parties who have access to our proprietary knowhow, information,
or technology to enter into confidentiality agreements, we cannot provide any assurances that we have entered into such agreements
with all applicable third parties or that all such agreements have been duly executed. Even if we have entered into such agreements,
we cannot assure you that our counterparties will comply with the terms of such agreements or that the assignment of intellectual
property rights under such agreements is self-executing. We may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting
or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even
if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction
to our senior management and scientific personnel.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>



</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">We
also cannot assure you that our trade secrets and other confidential proprietary information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.
Misappropriation or unauthorized disclosure of our trade secrets and intellectual property could impair our competitive position
and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets and intellectual
property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.
Any of the foregoing could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
reform legislation and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of any issued patents.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain patents is highly uncertain because, to date, some legal principles remain unsettled, there has not been a consistent
policy regarding the breadth or interpretation of claims allowed in patents in the United States and the specific content of patents
and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature
of the relevant legal, scientific, and factual issues. Changes in either patent laws or interpretations of patent laws in the
United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith
Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent
applications will be prosecuted and may also affect patent litigation. The USPTO has developed new and untested regulations and
procedures to govern the full implementation of the Leahy-Smith Act and many of the substantive changes to patent law associated
with the Leahy-Smith Act, and in particular, the first to file provisions only became effective in March 2013. Prior to March
2013, in the United States, the first to invent was entitled to the patent. As of March 2013, assuming the other requirements
for patentability are met, the first to file a patent application is generally entitled to the patent. Publications of discoveries
in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions
are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we
were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file
for patent protection of such inventions. The Leahy-Smith Act has also introduced procedures making it easier for third parties
to challenge issued patents, as well as to intervene in the prosecution of patent applications. Finally, the Leahy-Smith Act contains
new statutory provisions that require the USPTO to issue new regulations for their implementation, and it may take the courts
years to interpret the provisions of the new statute. It is too early to tell what, if any, impact the Leahy-Smith Act will have
on the operation of our business and the protection and enforcement of our intellectual property.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents. Further, the U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights
of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in
the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending
on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have owned or licensed or
that we might obtain in the future. Any inability to obtain, enforce, and defend patents covering our proprietary technologies
would materially and adversely affect our business prospects and financial condition.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
changes in patent laws and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce
them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain
new patents or to enforce patents that we own or that we may obtain in the future. Further, the laws of some countries do not
protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter
significant problems in protecting and defending our intellectual property both in the United States and abroad. For example,
if the issuance to us, in a given country, of a patent covering an invention is not followed by the issuance, in other countries,
of patents covering the same invention, or if any judicial interpretation of the validity, enforceability, or scope of the claims,
or the written description or enablement, in a patent issued in one country is not similar to the interpretation given to the
corresponding patent issued in another country, our ability to protect our intellectual property in those countries may be limited.
Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish
the value of our intellectual property or narrow the scope of our patent protection. Any of the foregoing could significantly
harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets
of interest and our business may be adversely affected.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined
to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to
build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to
establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business
may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights
to ours, it could interfere with our use of our current trademarks throughout the world.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidate. Such litigation or licenses
could be costly or not available on commercially reasonable terms.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is inherently difficult to conclusively assess our freedom to operate without infringing on or otherwise violating third-party
rights. Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights
cover our product candidates or elements thereof, or our manufacturing or uses relevant to our development plans. In such cases,
we may not be in a position to develop or commercialize products or our product candidates unless we successfully pursue litigation
to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual
property right holder, if available on commercially reasonable terms.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be pending patent applications that if they result in issued patents, could be alleged to be infringed by our product
candidates. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages,
including treble damages and attorneys’ fees if we are found to have willfully infringed, we may be forced to cease the
development and commercialization of and otherwise abandon our product candidates, or we may need to seek a license from any patent
holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all. Even if we were
able to obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third parties
access to the same technologies licensed to us.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications
filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain
confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the
earliest filing to which priority is claimed, with such earliest filing date being commonly referred to as the priority date.
Therefore, patent applications covering our product candidates or platform technology could have been filed by others without
our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later
amended in a manner that could cover our platform technologies, our product candidates or the use of our product candidates. Third-party
intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be
able to successfully defend, settle or otherwise resolve such infringement claims. If we are unable to successfully settle future
claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation
and may be prevented from or experience substantial delays in pursuing the development of and/or marketing of our product candidates.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from
commercializing our product candidates that are held to be infringing. We might, if possible, also be forced to redesign our product
candidates so that we no longer infringe the third-party intellectual property rights, which may not be commercially feasible.
Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business and otherwise significantly harm our business, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our avoiding infringing or otherwise violating the patents and proprietary rights of third
parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology
and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, post grant review, IPR, and
reexamination proceedings before the USPTO and corresponding non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates.
As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject
to claims of infringement of the patent rights of third parties or other intellectual property claims.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents
or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the
use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently
pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third
parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party
patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any
materials formed during the manufacturing process or any final product itself, the holders of any such patents may be able to
block our ability to commercialize such product candidates unless we obtain a license under the applicable patents, or until such
patents expire or are finally determined to be invalid or unenforceable.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for
manufacture, or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize
the applicable product candidate unless we obtain a license or until such patent expires or is finally determined to be invalid
or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a
successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’
fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares. Any of the
foregoing could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our programs may require the use of intellectual property or proprietary rights held by third parties, the growth of our business
will likely depend in part on our ability to acquire, in-license, or use these intellectual property and proprietary rights. In
addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these
formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or
other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The
licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established
companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive.
These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development
and commercialization capabilities. In addition, the Indenture governing our Notes contain restrictions that may limit our ability
to enter into acquisition or in-licensing agreements.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written
agreements with these institutions, some of which provide that the applicable institution will own certain rights in any technology
developed thereunder.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Typically,
these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting
from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under
terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other
parties, potentially blocking our ability to pursue our program.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We are also subject
to certain restrictions regarding obtaining licenses of third-party intellectual property pursuant to the terms of the indenture
governing the Notes, and we may be unable to license or acquire third-party intellectual property rights on terms that would allow
us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual
property rights, we may have to abandon development of that program and our business and financial condition could suffer.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe, misappropriate or otherwise violate our intellectual property or that of our licensors that we may acquire in the
future. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and
time-consuming. If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates,
the defendant could counterclaim that the patent covering our product or product candidate is invalid and/or unenforceable. In
patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are common, and there
are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. In an infringement proceeding,
a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the
technology at issue on the grounds that our patents do not cover the technology in question. Third parties may also raise similar
claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
re-examination, post grant review, inter parties review, or IPR, and equivalent proceedings in non-U.S. jurisdictions (e.g., opposition
proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover
our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel,
and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or
unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. An adverse
result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted
narrowly, could put our patent applications at risk of not issuing and could have a material adverse impact on our business.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to
our patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license
rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially
reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial
costs and distract our management and other employees. We may not be able to prevent misappropriation of our intellectual property
rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares. Any of the
foregoing could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential
information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including
our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors
do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our
employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including
trade secrets or other proprietary information, of any of our employees’ former employers or other third parties. Litigation
may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
Any of the foregoing could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may be subject to claims challenging the inventorship of our intellectual property.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to claims that former employees, collaborators or other third parties have an interest in or right to compensation
with respect to our current patent and patent applications, future patents or other intellectual property as an inventor or co-inventor.
For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in
developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship
or claiming the right to compensation. If we fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such
an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees. To the extent that our employees have
not effectively waived the right to compensation with respect to inventions that they helped create, they may be able to assert
claims for compensation with respect to our future revenue. As a result, we may receive less revenue from future products if such
claims are successful which in turn could impact our future profitability, business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could
result in litigation and adversely affect our business.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant portion of our intellectual property has been developed by our employees in the course of their employment for us.
Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee in the course and as a result
of or arising from his or her employment with a company are regarded as “service inventions,” which belong to the
employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent
Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties
Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration
for his inventions. Case law clarifies that the right to receive consideration for “service inventions” can be waived
by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will examine,
on a case-by-case basis, the general contractual framework between the parties, using interpretation rules of the general Israeli
contract laws. Further, the Committee has not yet determined one specific formula for calculating this remuneration (but rather
uses the criteria specified in the Patent Law). Although we generally enter into assignment-of-invention agreements with our employees
pursuant to which such individuals assign to us all rights to any inventions created in the scope of their employment or engagement
with us, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims,
we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to litigate
such claims, which could negatively affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be
paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and/or
applications and any patent rights we may own or license in the future. We rely on our outside counsel or third-party service
providers to pay these fees due to the USPTO and non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies
require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application
process. We employ reputable law firms and other professionals to help us comply. In many cases, an inadvertent lapse can be cured
by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance
can result in abandonment or lapse of the patents or patent applications, resulting in partial or complete loss of patent rights
in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance
could harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual
property rights throughout the world.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
and prosecuting patent applications and defending patents covering our product candidates in all countries throughout the world
would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection
to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection,
but enforcement rights are not as strong as that in the United States. These products may compete with our product candidates,
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may decide to abandon national and regional patent applications before grant. The examination of each national or
regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents
in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may even be refused
in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the
same product candidate or technology. The laws of some jurisdictions do not protect intellectual property rights to the same extent
as the laws or rules and regulations in the United States, and many companies have encountered significant difficulties in protecting
and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries,
do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult
for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.
Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs
and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert
claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may
not be commercially meaningful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual
property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts
in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual
property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize
our product candidates in all our expected significant non-U.S. markets. If we encounter difficulties in protecting, or are otherwise
precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the
value of these rights may be diminished and we may face additional competition from others in those jurisdictions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties.
In addition, some countries limit the enforceability of patents against government agencies or government contractors. In those
countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced
to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is
generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a
patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent
life has expired for a product candidate, we may be open to competition from competitive medications, including biosimilar and
generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As
a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates
similar or identical to ours.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents
may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred
to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent
term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during
product development and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise due
diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior
to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension
could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent
term beyond 14 years from approval and only those claims covering the approved drug, a method for using it or a method for manufacturing
it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request,
the period during which we can enforce our patent rights for the applicable product candidate will be shortened and our competitors
may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further,
if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and
preclinical data and launch their product earlier than might otherwise be the case, and our competitive position, business, financial
condition, results of operations, and prospects could be materially harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples
are illustrative:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                         may be able to make products that are similar to our product candidates but that are
                                         not covered by the claims of the patents that we own;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         might not have been the first to invent the inventions covered by our patents or the
                                         first to file patent applications covering our inventions;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                         may independently develop similar or alternative technologies or duplicate any of our
                                         technologies without infringing our intellectual property rights;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                         is possible that our pending patent applications will not lead to issued patents;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
                                         patents that we own may be held invalid or unenforceable as a result of legal challenges
                                         by our competitors;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
                                         patents that we own may not provide coverage for all aspects of our product candidates
                                         in all countries;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         competitors might conduct research and development activities in countries where we do
                                         not have patent rights and then use the information learned from such activities to develop
                                         competitive products for sale in our major commercial markets;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may not develop additional proprietary technologies that are patentable; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         patents of others may have an adverse effect on our business.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Business Operations</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
future success depends in part on our ability to retain our senior management team and to attract, retain and motivate other qualified
personnel.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the members of our senior management team. The loss of their services without a proper replacement may
adversely impact the achievement of our objectives. Our employees may leave our employment at any time. Recruiting and retaining
other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also
be critical to our success. There is currently a shortage of skilled personnel in our industry, which is likely to continue for
the foreseeable future. This is particularly the case in Israel and Boston, Massachusetts, where our operations are focused and
where there is a “war for talent” between members in our industry. As a result, competition for skilled personnel
is intense, and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the
competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in
preclinical or clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to recruit
and retain qualified personnel, or the loss of the services of any members of our senior management team without proper replacement,
may impede the progress of our research, development and commercialization objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part,
on our ability to effectively manage any future growth. As our development and commercialization plans and strategies develop,
we expect to need additional managerial, operational, sales, marketing, financial and legal personnel. Our management may need
to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time
to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result
in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity
among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources
from other projects, such as the development of additional product candidates. If our management is unable to effectively manage
our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced, and we
may not be able to implement our business strategy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Due
to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product
candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenue.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and
the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and
financial resources toward particular product candidates may not lead to the development of viable commercial products and may
divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties
in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities.
For instance, we made the decision to prioritize the development of omidubicel for the treatment of hematologic malignancies over
SCD because our hematologic malignancy program is at a more advanced stage of development, while our sickle cell program remains
exploratory. In addition, we are evaluating alternatives for commercialization of omidubicel, if approved, which may include commercializing
omidubicel ourselves or entering into potential strategic alliances or licensing arrangements with pharmaceutical companies and
other partners. If we make the decision to commercialize omidubicel ourselves, we may have to significantly expand our commercial
organization in time for omidubicel approval, which may jeopardize the success of a timely commercial launch and may reduce or
delay our anticipated revenue from sales of omidubicel. Commercializing omidubicel ourselves will also require additional capital
to fund an increase in workforce as well as operating expenses and capital expenses to expand our manufacturing facility in Kiryat
Gat, Israel. If we decide to enter into licensing arrangements or other forms of collaboration, the potential for us to generate
revenue from royalties on sales of such out-licensed products depends on the performance of our partners. If our partners do not
perform in the manner we expect, fail to fulfill their responsibilities in a timely manner or at all, if the FDA, EMA or other
similar regulatory authorities decline to grant a marketing authorization to them, or provide them with a restricted authorization,
if our agreements with them terminate, they abandon the collaboration or if the quality or accuracy of the clinical data they
obtain is compromised, the clinical development, regulatory approval and commercialization efforts related to our out-licensed
product candidates could be delayed or terminated, and it could become necessary for us to assume the responsibility at our own
expense, or seek new partners on reduced commercial terms, for the clinical development of such product candidates. If we make
incorrect determinations regarding the market potential of our product candidates or misread trends in the pharmaceutical industry,
in particular for our lead product candidate, our business, financial condition and results of operations could be materially
adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Business disruptions
could seriously harm our future revenue and financial condition and increase costs and expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our operations and those
of our third-party suppliers and collaborators could be subject to earthquakes, power shortages, telecommunications failures, water shortages,
floods, hurricanes or other extreme weather conditions, medical epidemics, labor disputes, war or other business interruptions. Although
we have limited business interruption insurance policies in place, any interruption could come with high costs for us, as salaries and
loan payments would usually continue. Moreover, any interruption could seriously harm one or more of our research, development or manufacturing
programs, the commercialization of any approved product or our clinical trial operations. For example, the current COVID-19 pandemic has,
at points, caused an interruption in our ongoing and planned clinical trials activities. In addition, the initial timeline for submission
of our BLA for omidubicel was delayed, in part, as a result of the impact of the COVID-19 pandemic on our operations. Moreover, at the
end of 2021 and into 2022, tensions between the United States and Russia escalated when Russia amassed large numbers of military ground
forces and support personnel on the Ukraine-Russia border and, in February 2022, Russia invaded Ukraine. In response, North Atlantic Treaty
Organization, or NATO has deployed additional military forces to Eastern Europe, including to Lithuania, and the Biden administration
implemented certain sanctions against Russia. The invasion of Ukraine and the retaliatory measures that have been taken, or could be taken
in the future, by the United States, NATO, and other countries have created global security concerns that could result in a regional conflict
and otherwise have a lasting impact on regional and global economies, any or all of which could disrupt our supply chain, adversely affect
our ability to conduct ongoing and future clinical trials of our product candidates or commercialize our products. In addition, the conflict
has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms
or at all.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may not be successful in our efforts to identify, discover or license additional product candidates.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of omidubicel
and GDA-201, the success of our business also depends upon our ability to identify, discover or license additional product candidates,
including within our NK-cell pipeline. Our research programs or licensing efforts may fail to yield additional product candidates
for clinical development for a number of reasons, including but not limited to the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         research or business development methodology or search criteria and process may be unsuccessful
                                         in identifying potential product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may not be able or willing to assemble sufficient resources to acquire or discover additional
                                         product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         product candidates may not succeed in preclinical or clinical testing;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         product candidates may be shown to have harmful side effects or may have other characteristics
                                         that may make the products unmarketable or unlikely to receive marketing approval;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors
                                         may develop alternatives that render our product candidates obsolete or less attractive;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                         candidates we develop may be covered by third parties’ patents or other exclusive
                                         rights;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         market for a product candidate may change during our development program so that such
                                         product may become unprofitable to continue to develop;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         product candidate may not be capable of being produced in commercial quantities at an
                                         acceptable cost, or at all; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         product candidate may not be accepted as safe and effective by patients, the medical
                                         community, or third-party payers.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able
to identify, license, or discover additional product candidates, which would have a material adverse effect on our business and
could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical,
financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately
prove to be unsuccessful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cybersecurity.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable
to damage from a variety of causes, including computer viruses, malware, intentional or accidental mistakes or errors by users
with authorized access to our computer systems, natural disasters, terrorism, war, telecommunication and electrical failures,
cyber-attacks or cyber-intrusions over the Internet, or attachments to emails. The risk of a security breach or disruption, particularly
through cyber-attacks or cyber intrusions, including by computer hackers, non-U.S. governments, extra-state actors and cyber terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world
have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our drug development programs. For example, the loss or compromise of clinical trial data from completed or ongoing or planned
clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage
to our reputation, and the further development of our drug candidates could be delayed. Further, any breach, loss or compromise
of clinical study participant personal data may also subject us to civil fines and penalties, including under GDPR and relevant
member state law in the European Union, or, potentially, other relevant state and federal privacy laws in the United States.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the current environment, there are numerous and evolving risks to cybersecurity and privacy, including criminal hackers, hacktivists,
state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error. High-profile security
breaches at other companies and in government agencies have increased in recent years, and security industry experts and government
officials have warned about the risks of hackers and cyber-attacks targeting businesses such as ours. Computer hackers and others
routinely attempt to breach the security of technology products, services and systems, and to fraudulently induce employees, customers,
or others to disclose information or unwittingly provide access to systems or data. We can provide no assurance that our current
IT systems, software, or third party services, or any updates or upgrades thereto will be fully protected against third-party
intrusions, viruses, hacker attacks, information or data theft or other similar threats.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
or regulatory action in these areas is also evolving, and we may be unable to adapt our IT systems to accommodate these changes.
We have experienced and expect to continue to experience sophisticated attempted cyber-attacks of our IT networks. Although none
of these attempted cyber-attacks has had a material adverse impact on our operations or financial condition, we cannot guarantee
that any such incidents will not have such an impact in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
incur significant costs as a result of operating as a public company in the United States, and our management is required to devote
substantial time to compliance initiatives.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company whose ordinary shares are listed in the United States, we are subject to an extensive regulatory regime, requiring
us, among other things, to maintain various internal controls and facilities and to prepare and file periodic and current reports
and statements, including reports on the effectiveness of our internal control over financial reporting pursuant to Section 404
of the Sarbanes-Oxley Act of 2002. Complying with these requirements is costly and time consuming. In the event that we are unable
to demonstrate compliance with our obligations as a public company in a timely manner, or are unable to produce timely or accurate
financial statements, we may be subject to sanctions or investigations by regulatory authorities, such as the Securities and Exchange
Commission, or the SEC, or The Nasdaq Global Market, and investors may lose confidence in our operating results and the price
of our ordinary shares could decline.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm is not engaged to perform an audit of our internal control over financial reporting,
and as long as we remain an emerging growth company, as such term is defined in the Jumpstart Our Business Startups Act of 2012,
or the JOBS Act, we will be exempt from the requirement to have an independent registered public accounting firm perform such
audit. Accordingly, no such opinion was expressed or will be expressed any during any such period. Once we cease to qualify as
an emerging growth company, our independent registered public accounting firm will be required to attest to our management’s
annual assessment of the effectiveness of our internal controls over financial reporting, which will entail additional costs and
expenses.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we organize significant management functions in Boston, Massachusetts, where business expenses and salaries exceed the
level of such expenses in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated
with doing business outside of the United States or Israel.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Other
than substantial operations in Israel (as further described below), we currently have limited international operations, but our business
strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product candidates.
We plan to retain sales representatives and third-party distributors and conduct physician, infectious disease specialist, hospital pharmacist
and patient association outreach activities, as well as clinical trials, outside of the United States, EU and Israel. Doing business
internationally involves a number of risks, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple,
                                         conflicting and changing laws and regulations such as privacy regulations, tax laws,
                                         export and import restrictions, employment laws, regulatory requirements and other governmental
                                         approvals, permits, and licenses;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         by us to obtain regulatory approvals for the use of our product candidates in various
                                         countries;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                         potentially relevant third-party patent or other intellectual property rights;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
                                         and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
                                         in staffing and managing international operations;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
                                         associated with managing multiple payer reimbursement regimes, government payers, price
                                         controls or patient self-pay systems;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits
                                         in our ability to penetrate international markets;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
                                         risks, such as longer payment cycles, difficulty collecting accounts receivable, the
                                         impact of local and regional financial crises on demand and payment for our products
                                         and exposure to foreign currency exchange rate fluctuations;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
                                         disasters, political and economic instability, including wars, terrorism, and political
                                         unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                         expenses including, among others, expenses for travel, translation and insurance;
                                         and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         and compliance risks that relate to maintaining accurate information and control over
                                         sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices
                                         Act its books and records provisions, or its anti-bribery provisions.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of
operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may be subject to extensive environmental, health and safety, and other laws and regulations in multiple jurisdictions.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business involves the controlled use, directly or indirectly through our service providers, of hazardous materials, various biological
compounds and chemicals; therefore, we, our agents and our service providers may be subject to various environmental, health
and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the
use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites.
The risk of accidental contamination or injury from these materials cannot be eliminated. If an accident, spill or release of
any regulated chemicals or substances occurs, we could be held liable for resulting damages, including for investigation, remediation
and monitoring of the contamination, including natural resource damages, the costs of which could be substantial. We are also
subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures,
exposure to blood-borne pathogens and the handling of biohazardous materials and chemicals. Although we maintain workers’
compensation insurance to cover the costs and expenses that may be incurred because of injuries to our employees resulting from
the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Additional or more
stringent federal, state, local or non-U.S. laws and regulations affecting our operations may be adopted in the future. We may
incur substantial capital costs and operating expenses and may be required to obtain consents to comply with any of these or certain
other laws or regulations and the terms and conditions of any permits or licenses required pursuant to such laws and regulations.
For instance, we have undergone inspections and obtained approvals from various governmental agencies. We hold a general business
license from the City of Jerusalem that is valid until December 31, 2022.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also hold a toxic substances
permit from the Ministry of Environmental Protection (the Hazardous Material Division) and a Certificate of GMP Compliance of a Manufacturer
from the Israeli Ministry of Health - Pharmaceutical Administration. Failure to renew any of the foregoing licenses and permits may harm
our on-going and future operations. In addition, fines and penalties may be imposed for noncompliance with environmental, health and safety
and other laws and regulations or for the failure to have, or comply with the terms and conditions of our business license, or required
environmental or other permits or consents.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
employees and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of fraud or other misconduct by our employees and independent contractors. Misconduct by these parties
could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing
standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information
or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs and other business arrangements. Employee and independent contractor
misconduct could also involve the improper use of information obtained in the course of clinical trials, including individually
identifiable information, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of
product candidates. If our operations are found to be in violation of any of these laws, we may be subject to significant penalties,
including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs,
such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations
to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits
and the curtailment or restructuring of our operations. It is not always possible to identify and deter misconduct by employees
and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government
could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are
not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of significant fines or other sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Under
current Israeli law, we may not be able to enforce employees’ covenants not to compete and therefore may be unable to prevent
our competitors from benefiting from the expertise of some of our former employees.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally enter into non-competition agreements with our key employees, in most cases within the framework of their employment
agreements.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
agreements prohibit our key employees, if they cease working for us, from competing directly with us or working for our competitors
for a limited period. Under applicable Israeli law, we may be unable to enforce these agreements or any part thereof. If we cannot
enforce our noncompetition agreements with our employees, then we may be unable to prevent our competitors from benefiting from
the expertise of our former employees, which could materially adversely affect our business, results of operations and ability
to capitalize on our proprietary information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
are vulnerable to interest rate risk with respect to the grants received from the Israel Innovation Authority</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our incorporation, we have received grants from the IIA relating to various projects. We were members of Bereshit Consortium,
sponsored by IIA in which certain of our technologies were developed, such program does not require payments of royalties to the
IIA, but all other restrictions under the Innovation Law, such as local manufacturing obligations and know-how transfer limitations,
as further detailed hereunder, are applicable to the know how developed by us with the funding received in such consortium program.
No royalties have been paid to the IIA in respect of any grant. Our total outstanding obligation to the IIA, including the interest
accrued through December 31, 2021, amounts to approximately $44.7 million.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United Kingdom’s Financial Conduct Authority, which regulates the London Interbank Offered Rate, or LIBOR, announced that
it will no longer persuade or require banks to submit rates for LIBOR after January 1, 2022. The grants received from the IIA
bear an annual interest rate based on the 12-month LIBOR. Accordingly, there is considerable uncertainty regarding the interest
accrued to the IIA grants. While it is not currently possible to determine precisely whether, or to what extent, the withdrawal
and replacement of LIBOR would affect us, the implementation of alternative benchmark rates to LIBOR may increase our financial
liabilities to the IIA. Management continues to monitor the status and discussions regarding LIBOR. We are not yet able to reasonably
estimate the expected impact. To date, the IIA has not issued any clarification regarding an alternative interest to be used instead
of the LIBOR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Commercialization of Our Product Candidates</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
do not have experience producing our product candidates at commercial levels or operating
a cGMP manufacturing facility and may not obtain the necessary regulatory approvals or produce our product candidates at the quality,
quantities, locations and timing needed to support commercialization.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli Ministry of Health issued a GMP certificate for our manufacturing facility at Kiryat Gat, Israel in July 2021 and we are
working to establish cGMP compliance under the FDA’s regulations. We do not have an extensive number of employees with the
experience or ability to manufacture our product candidates at commercial levels. We may encounter technical or scientific issues
related to manufacturing or development that we may be unable to resolve in a timely manner or with available funds. We also have
not completed all of the characterization and validation activities necessary for commercialization and regulatory approval of
omidubicel. If we do not conduct all such necessary activities this year, our commercialization efforts will be delayed.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may encounter problems hiring and retaining the experienced specialist scientific, quality control and manufacturing personnel
needed to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance
with applicable regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive
collaborator for potential partners, including larger pharmaceutical companies, which could limit our access to additional attractive
development programs. Problems in our manufacturing process or facilities also could restrict our ability to meet market demand
for our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected,
and our business may suffer.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
projections of the number of people who have the potential to benefit from treatment with our product candidates are based on
our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys
of clinics and other market research, and may prove to be incorrect. Our target patient populations may be lower than expected,
may not be otherwise amenable to treatment with our product candidates or patients may become increasingly difficult to identify
and access, all of which would adversely affect our business, financial condition, results of operations and prospects. In addition,
medical advances may reduce our target markets. For example, new processes and advances in oral antibiotic medications or new
operative procedures may limit the need for localized delivery systems like our product candidates. Further, advances in treatments
in the fields in which we are conducting research programs that reduce side effects and have better deliverability to target organs
may limit the market for our future product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
currently have limited marketing and sales organization. If we are unable to establish adequate sales and marketing capabilities
to support the potential commercial launch of omidubicel or enter into agreements with third parties to market and sell omidubicel,
if approved, we may be unable to generate any product revenue.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have a chief commercialization officer to lead our efforts to commercialize omidubicel should it receive regulatory approval
and we decide to commercialize omidubicel ourselves, we currently have a limited sales and marketing organization, and we have
limited experience selling and marketing our product candidates. To successfully commercialize any product candidates that may
result from our development programs, we will need to develop these capabilities, either on our own or with others. If omidubicel
or any other product candidate receives regulatory approval, we may establish a sales and marketing organization independently
or by utilizing experienced third parties with technical expertise and supporting distribution capabilities to commercialize our
product candidates in major markets, all of which will be expensive, difficult and time consuming. Any failure or delay in the
development of our internal sales, marketing and distribution capabilities or identification of appropriate strategic partnering
would adversely impact our ability to commercialize our product candidates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force actually
required to effectively commercialize our product candidates. As such, we may be required to hire sales representatives and third-party
partners to adequately support the commercialization of our product candidates, or we may incur excess costs if we hire more sales
representatives than necessary. With respect to certain geographical markets, we may enter into collaborations with other entities
to utilize their local marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable
terms, if at all. We also may enter into collaborations with large pharmaceutical companies to develop and commercialize product
candidates. If our future collaborators do not commit sufficient resources to develop and commercialize our future products, if
any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product
revenue to sustain our business. We may compete with companies that currently have extensive and well-funded marketing and sales
operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable
to compete successfully against these more established companies.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
efforts to educate the medical community, including physicians, hospital pharmacists and infectious disease specialists, and third-party
payers on the benefits of our product candidates may require significant resources and may never be successful. If any of our
product candidates are approved, but fail to achieve market acceptance among physicians, patients or third-party payers, we will
not be able to generate significant revenue from such product, which could have a material adverse effect on our business, financial
condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Delays
in establishing and obtaining regulatory approval of our manufacturing process and facility or disruptions in our manufacturing
process may delay or disrupt our product development and commercialization efforts.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working to establish our own cGMP compliant manufacturing facility at Kiryat Gat, Israel. We have completed construction on
the facility, and we are now working to qualify our manufacturing process and facility with the FDA’s cGMP regulations.
Before we can begin to commercially manufacture omidubicel or any product candidate in our facility, we must pass a pre-approval
inspection of our manufacturing facility by the FDA before omidubicel or any product candidate can obtain marketing approval.
A manufacturing authorization must also be obtained from the appropriate regulatory authorities in the European Union, Israel
and worldwide. Such manufacturing authorizations must also be obtained for any third-party manufacturing facility and process.
In order to obtain approval, we will need to ensure that all our processes, methods and equipment are compliant with cGMP, and
perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers
is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these
third parties to remedy the violation or while we work to identify suitable replacement vendors. If we do not demonstrate to the
satisfaction of the applicable regulator that our manufacturing facilities, or those of our contract manufacturers, are in compliance
with applicable requirements, we may be materially delayed in the development of our product candidates, which would materially
harm our business. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures.
In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control
to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements,
we would be subject to possible regulatory action and may not be permitted to sell any product candidate that we may develop.
While we continue to work to establish the cGMP compliance of our manufacturing facility at Kiryat Gat in Israel, we do not have
another long-term partner for the manufacturing of omidubicel.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualifying
our manufacturing facility is subject to other delays, including because of COVID-19 related shortages of labor and governmentally
imposed shut-downs. Unexpected problems in the qualification of our manufacturing facility may adversely impact our ability to
provide supply for the development and commercialization of omidubicel as well as our financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
we receive marketing approval for our product candidates, sales will be limited unless the product achieves broad market acceptance
by physicians, patients, third-party payers, hospital pharmacists and others in the medical community.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our product candidates will depend upon the acceptance of the product by the medical community, including
physicians, patients, healthcare payers and hospital personnel, including transplant teams and pharmacists. The degree of market
acceptance of any approved product will depend on a number of factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         demonstration of clinical safety and efficacy of our product candidates in clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         efficacy, potential and perceived advantages of our product candidates over alternative
                                         treatments;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         prevalence and severity of any adverse side effects;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                         labeling or product insert requirements of the FDA or other regulatory authorities, including
                                         any limitations or warnings contained in a product’s approved labeling;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution
                                         and use restrictions imposed by the FDA or agreed to by us as part of a mandatory or
                                         voluntary risk management plan;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to obtain third-party payer coverage and adequate reimbursement for our products;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         willingness of patients to pay for drugs out of pocket in the absence of third-party
                                         coverage;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         demonstration of the effectiveness of our product candidates in reducing the cost of
                                         treatment;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         strength of marketing and distribution support;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing of market introduction of competitive products;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         availability of products and their ability to meet market demand; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity
                                         concerning our product candidates or competing products and treatments.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of alternatives to our product candidates, including stem cell transplantation using cells from matched related donors,
matched unrelated donors, haploidentical donors or unmodified umbilical cord blood. If our product candidates are approved but
do not achieve an adequate level of acceptance by physicians, patients, healthcare payers and hospital personnel, including transplant
teams and pharmacists, we may not generate sufficient revenue from the product, and we may not become or remain profitable. In
addition, our efforts to educate the medical community and third-party payers on the benefits of our product candidates may require
significant resources and may never be successful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>It
may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited
by government authorities and/or third-party payer policies.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.
In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial
sale will depend, in part, on the extent to which third-party payers provide coverage, and establish adequate reimbursement levels,
for such products. In the United States, third-party payers include federal and state healthcare programs, private managed care
providers, health insurers and other organizations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process for determining whether a third-party payer will provide coverage for a product may be separate from the process for setting
the price of a product or for establishing the reimbursement rate that such a payer will pay for the product. Third-party payers
may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the
FDA-approved products for a particular indication.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical
products, therapies and services, in addition to questioning their safety and efficacy.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of
our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically
necessary or cost-effective. Payer’s decision to provide coverage for a product does not imply that an adequate reimbursement
rate will be approved. Further, the determination of one payer to provide coverage for a product does not assure that other payers
will also provide such coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain
price levels sufficient to realize an appropriate return on our investment in product development.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Different
pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products
through their pricing and reimbursement rules and control of national health care systems that in some countries subsidize a large
part of the cost of those products for consumers. Some jurisdictions operate positive and negative list systems under which products
may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries
may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to then available
therapies. Other EU member states allow companies to fix their own prices for medicines, but monitor and control company profits.
The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected
to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial
pressure on pricing within a country.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any of our product candidates for which we receive regulatory approval for commercial sale may suffer if the
government and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in
the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies
and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for
one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be
implemented in the future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to any healthcare reform measures that may affect reimbursement, market acceptance and sales of our product candidates,
if approved, will depend on, in part, the extent to which the procedures utilizing our product candidates, performed by health
care providers, will be covered by third-party payers, such as government health care programs, commercial insurance and managed
care organizations. In the event health care providers and patients accept our product candidates as medically useful, cost effective
and safe, there is uncertainty on how exactly our products will be reimbursed. Third-party payers determine the extent to which
new products will be covered as a benefit under their plans and the level of reimbursement for any covered product or procedure
that may utilize a covered product. Coverage will be dependent on FDA-approval and other factors; reimbursement may vary
across payers which is a risk for our product candidates. Establishment of reimbursement guidelines for products is difficult
to predict at this time what third-party payers will decide with respect to the coverage and reimbursement for our product candidates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
primary trend in the U.S. healthcare industry and elsewhere has been cost containment, including price controls, restrictions
on coverage and reimbursement and requirements for substitution of less expensive products. Third-party payers decide which products
and procedures they will pay for and establish reimbursement and co-payment levels. Government and other third-party payers are
increasingly challenging the prices charged for health care products and procedures, examining the cost effectiveness of procedures,
and the products used in such procedures, in addition to their safety and efficacy, and payers limit coverage and reimbursement
to the appropriate patient per a products label. We cannot be sure that coverage will be available for our product candidates,
if approved, or, if coverage is available, the level of direct or indirect reimbursement.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed
healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure
on healthcare costs in general, particularly prescription drugs and other treatments, has become increasingly intense. As a result,
high barriers exist to the successful commercialization of new products. Further, the adoption and implementation of any future
governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we
may receive for any approved product.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
by a third-party payer may depend upon a number of factors including the third-party payer’s determination that use of a
product is:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         covered benefit or part of a covered benefit under its health plan;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
                                         effective and medically necessary;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
                                         for the specific patient;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
                                         and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
                                         experimental nor investigational.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States,
the principal decisions about reimbursement are typically made by The Centers for Medicare &amp; Medicaid Services, or CMS, an
agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent products, and the procedures
that utilize such products, will be covered and reimbursed under Medicare. Private payers may follow CMS, but have their own methods
and approval processes for determining reimbursement for new products and the procedures that utilize such products. It is difficult
to predict what CMS as well as other payers will decide with respect to reimbursement for fundamentally novel products such as
ours, as there is no body of established practices and precedents for these new products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under current Medicare hospital inpatient reimbursement policies CMS offers a process whereby manufacturers may apply
for the temporary New Technology Add-on Payment or NTAP program for a new medical technology when the applicable Diagnosis-Related
Group, or DRG, based inpatient prospective payment rate is inadequate to cover the cost of a new product. As part of our commercialization
efforts, we are evaluating the potential application for omidubicel to be eligible under the NTAP program. To obtain add-on payment,
a technology must be considered “new,” represent an advance in medical technology that substantially improves, relative
to technologies previously available, the diagnosis or treatment of Medicare beneficiaries, and data reflecting the cost of the
new technology must not yet be available in the data used to recalibrate the DRGs and the sponsor much show that admissions involving
the furnishing of the technology exceed cost thresholds established by CMS for each applicable DRG. If an application is approved,
new technology add-on payments are made to hospitals for no less than two years and no more than three years. We must demonstrate
the safety and effectiveness of our technology to the FDA in addition to meeting CMS’s requirements for the NTAP program
before add-on payments can be made, and we cannot assure that CMS will agree to provide such incremental payments for omidubicel
or any of our other product candidates.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement approval for a product from a government or other third-party payer is a time-consuming and costly
process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products
to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. Further,
no uniform policy requirement for coverage and reimbursement exists among third-party payers in the United States. Similarly,
health care providers enter into participation agreements with third-party payers wherein reimbursement rates are negotiated.
Therefore, coverage and reimbursement can differ significantly from payer to payer and health care provider to health care provider.
As a result, we cannot be sure that coverage or adequate reimbursement will be available for our product candidates, if approved
or procedures utilizing such products. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the
price of, our future products. If reimbursement is not available, or is available only to limited levels, we may not be able to
commercialize our product candidates, or achieve profitably at all, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a
material effect on our business, financial condition, results of operations or prospects.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of
therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed
in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing
processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action,
limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the
merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs
to defend the related litigation, a diversion of management’s time and our resources, substantial monetary awards to trial
participants or patients and a decline in our share price. We do not currently have product liability insurance and do not anticipate
obtaining product liability insurance until such time as we have received FDA or other comparable authority approval for a product
and there is a product that is being provided to patients outside of clinical trials. Any insurance we have or may obtain may
not provide sufficient coverage against potential liabilities. Furthermore, product liability insurance is becoming increasingly
expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused
by product liability claims that could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Ownership of our Ordinary Shares</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
executive officers, directors and principal shareholders maintain the ability to exert significant control over matters submitted
to our shareholders for approval.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain of our executive
officers, directors and holders of more than 5% of our voting securities beneficially owned as of December 31, 2021 hold shares representing
approximately 38.8% of our share capital. As a result, if these shareholders were to act together, they would be able to control all matters
submitted to our shareholders for approval, as well as our management and affairs. For example, these persons, if they act together, would
control the election of directors and approval of any merger, consolidation or sale of all or substantially all our assets. This concentration
of voting power could delay or prevent an acquisition of our company on terms that other shareholders may desire or result in management
of our company that our public shareholders disagree with.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
market price of our ordinary shares may fluctuate significantly, which could result in substantial losses by our investors.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock market in general, and the market for pharmaceutical companies in particular, has experienced extreme volatility that has
often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able
to sell your ordinary shares at or above the initial public offering price. The following factors, in addition to other risk factors
described in this section, may have a significant impact on the market price of our ordinary shares:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                         to obtain the approvals necessary to commence marketing of omidubicel or initiate further
                                         clinical trials of GDA-201;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory
                                         results of clinical trials;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                         of regulatory approvals or the failure to obtain them, or specific label indications
                                         or patient populations for their use, or changes or delays in the regulatory review process;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                         of therapeutic innovations or new products by us or our competitors;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
                                         actions taken by regulatory agencies with respect to our clinical trials, manufacturing
                                         supply chain or sales and marketing activities;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         or developments in laws or regulations, and payer reimbursement requirements applicable
                                         to any candidate product in any of our platforms;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         adverse changes to our relationship with manufacturers or suppliers, especially manufacturers
                                         of candidate products;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         intellectual property infringement, misappropriation or other actions in which we may
                                         become involved;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                         concerning our competitors or the pharmaceutical industry in general;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement
                                         of expected product sales and profitability or our failure to meet expectations;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         commencement of, or involvement in, litigation;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         changes in our board of directors or management; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         other factors described in this “Risk Factors” section.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our quarterly operating results fall below the expectations of investors or securities analysts, the price of our ordinary shares
could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of
our shares to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful
and should not be relied upon as an indication of our future performance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the stock market in general, the Nasdaq Global Market and the market for biotechnology companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies
like ours, including due to coordinate buying and selling activities and market manipulation. Broad market and industry factors
may negatively affect the market price of our ordinary shares regardless of our actual operating performance. In addition, a systemic
decline in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly.
Price volatility of our ordinary shares might be worse if the trading volume of our ordinary shares is low. In the past, following
periods of market volatility, shareholders have often instituted securities class action litigation. If we were involved in securities
litigation, it could have a substantial cost and divert resources and attention of management from our business, even if we are
successful.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our ordinary shares in the public market, or the perception that these sales might occur,
could depress the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional
equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our ordinary shares.
In addition, we have registered all ordinary shares that we may issue under our equity compensation plans, and, as such, these
shares can be freely sold in the public market upon issuance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the liquidity of our ordinary shares may be limited, not only in terms of the number of ordinary shares that can be bought and
sold at a given price, but by potential delays in the timing of executing transactions in our ordinary shares and a reduction
in security analyst and media’s coverage of our company, if any. These factors may result in lower prices for our ordinary
shares than might otherwise be obtained and could also result in a larger spread between the bid and ask prices for our ordinary
shares. In addition, without a large float, our ordinary shares will be less liquid than the stock of companies with broader public
ownership and, as a result, the trading prices of our ordinary shares may be more volatile. In the absence of an active public
trading market, an investor may be unable to liquidate its investment in our ordinary shares. Trading of a relatively small volume
of our ordinary shares may have a greater impact on the trading price of our ordinary shares than would be the case if our public
float were larger. We cannot predict the prices at which our ordinary shares will trade in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences
as a result.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable
to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized
as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income
includes dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition
of assets which produce passive income (including amounts derived by reason of the temporary investment of funds raised in offerings
of our shares) and rents and royalties other than rents and royalties which are received from unrelated parties in connection
with the active conduct of a trade or business. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax
consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital
gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders,
and having interest charges apply to distributions by us and gains from the sales of our shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which
may be determined based on the fair market value of each asset, with the value of goodwill and going concern value determined
in large part by reference to the market value of our common shares, which may be volatile). Based upon the value of our assets,
including any goodwill, and the nature and composition of our income and assets, we do not believe that we were classified as
a PFIC for the taxable year ending December 31, 2021. Because the determination of whether we are a PFIC for any taxable year
is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered
a PFIC in any taxable year. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for our taxable
year ended December 31, 2021, and also expresses no opinion with regard to our expectations regarding our PFIC status in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences that would apply if we are classified as a PFIC would also be different from those described above if a U.S.
shareholder were able to make a valid qualified electing fund, or QEF, election. At this time, we do not expect to provide U.S.
shareholders with the information necessary for a U.S. shareholder to make a QEF election. Prospective investors should assume
that a QEF election will not be available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income
tax consequences.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a United States person is treated as owning (directly, indirectly or constructively through the application of attribution rules)
at least 10% of the value or voting power of our shares, such person may be treated as a “United States shareholder”
with respect to each “controlled foreign corporation” in our group (if any). Because our group includes one or more
U.S. subsidiaries, certain of our current or future non-U.S. subsidiaries could be treated as controlled foreign corporations
(regardless of whether we are or are not treated as a controlled foreign corporation). A United States shareholder of a controlled
foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of the controlled
foreign corporation’s “Subpart F income”, “global intangible low-taxed income” and investments in
U.S. property, whether or not such controlled foreign corporation makes any distributions. An individual that is a United States
shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign
tax credits that would be allowed to a United States shareholder that is a U.S. corporation. A failure to comply with these reporting
obligations may subject you to significant monetary penalties and may prevent the statute of limitations with respect to your
U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we
will assist investors in determining whether any of our current or future non-U.S. subsidiaries are treated as a controlled foreign
corporation or whether such investor is treated as a United States shareholder with respect to any of such controlled foreign
corporations or furnish to any United States shareholders information that may be necessary to comply with the aforementioned
reporting and tax paying obligations. A United States investor should consult their own advisors regarding the potential application
of these rules to its investment in the shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various
jurisdictions and on how we operate our business.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course
of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. For example,
our effective tax rates could be adversely affected by changes in foreign currency exchange rates or by changes in the relevant
tax, accounting and other laws, regulations, principles and interpretations. As we intend to operate in numerous countries and
taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax
authorities of these jurisdictions. It is not uncommon for taxing authorities in different countries to have conflicting views,
for instance, with respect to, among other things, the manner in which the arm’s length standard is applied for transfer
pricing purposes, or with respect to the valuation of intellectual property.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
tax authorities in any of the countries in which we operate were to successfully challenge our transfer prices as not reflecting
arms’ length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect
these revised transfer prices, which could result in a higher tax liability to us. In addition, if the country from which the
income is reallocated does not agree with the reallocation, both countries could tax the same income, potentially resulting in
double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation
or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our financial
condition, results of operations and cash flows. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction
where we believe we have not established a taxable connection, often referred to as a “permanent establishment” under
international tax treaties, and such an assertion, if successful could increase our expected tax liability in one or more jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Future
changes to tax laws could materially adversely affect our company and reduce net return to our shareholders</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
laws are dynamic and subject to change as new laws are passed and interpretations of the law are issued or applied. Such changes
may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific
context of withholding tax) dividends paid. We are unable to predict what tax reform may be proposed or enacted in the future
or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation,
regulations, policies or practices, could affect our financial position and overall or effective tax rates in the future in countries
where we have operations, reduce post-tax returns to our shareholder, and increase the complexity, burden and cost of tax compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
tax benefits that are available to us require us to continue to meet various conditions and may be terminated or reduced in the
future, which could increase our costs and taxes.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our operations in Israel may entitle us to certain tax benefits under the Law for the Encouragement of Capital Investments,
5719-1959, or the Investment Law, once we begin to produce revenue. If we do not meet the requirements for maintaining these benefits,
they may be reduced or cancelled and the relevant operations would be subject to Israeli corporate tax at the standard rate, which
is set at 23% in 2021 and thereafter. In addition to being subject to the standard corporate tax rate, we could be required to
refund any tax benefits that we will receive, plus interest and penalties thereon. Even if we continue to meet the relevant requirements,
the tax benefits that our current “Preferred Enterprise” is entitled to may not be continued in the future at their
current levels or at all. If these tax benefits were reduced or eliminated, the amount of taxes that we will pay would likely
increase, as all our operations would consequently be subject to corporate tax at the standard rate, which could adversely affect
our results of operations. Additionally, if we increase our activities outside of Israel, for example, by way of acquisitions,
our increased activities may not be eligible for inclusion in Israeli tax benefits programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings
for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the
foreseeable future. As a result, capital appreciation, if any, of our ordinary shares will be investors’ sole source of
gain for the foreseeable future. In addition, Israeli law limits our ability to declare and pay dividends, and may subject our
dividends to Israeli withholding taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or
if they adversely change their recommendations or publish negative reports regarding our business or our ordinary shares, our
share price and trading volume could be negatively impacted.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our ordinary shares is influenced by the research and reports that industry or securities analysts publish
about us, our business, our market or our competitors. We do not have any control over these analysts, and we cannot provide any
assurance that analysts will continue to cover us or provide favorable coverage. If any of the analysts who cover us adversely
change their recommendation regarding our shares, or provide more favorable relative recommendations about our competitors, our
share price would likely decline. If any analyst who cover us were to cease coverage of our company or fail to regularly publish
reports on us, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume
to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary
shares less attractive to investors.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements
that are applicable to other public companies that are not emerging growth companies. For as long as we remain an emerging growth
company, which we expect to continue until we are permitted and intend to rely on exemptions from certain disclosure requirements
that are applicable to other public companies that are not “emerging growth companies.” These exemptions include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                         permitted to provide only two years of audited financial statements, in addition to any
                                         required unaudited condensed consolidated interim financial statements, with correspondingly;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                         being required to comply with the auditor attestation requirements in the assessment
                                         of our internal control over financial reporting;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                         being required to comply with any requirement that may be adopted by the Public Company
                                         Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to
                                         the auditor’s report providing additional information about the audit and the financial
                                         statements;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                         disclosure obligations regarding executive compensation; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
                                         from the requirements of holding a nonbinding advisory vote on executive compensation
                                         and shareholder approval of any golden parachute payments not previously approved.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of these provisions until such time that we are no longer an emerging growth company. We will cease to be an
emerging growth company upon the earlier to occur of: (1) the last day of our fiscal year following the fifth anniversary of the
date of our October 2018 initial public offering; (2) the last day of the fiscal year in which we have total annual gross revenue
of $1.07 billion or more; (2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous
three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose
to take advantage of some but not all of these reduced burdens, and therefore the information that we provide holders of our ordinary
shares may be different than the information you might receive from other public companies in which you hold equity. In addition,
Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period
for complying with new or revised accounting standards applicable to public companies. However, given that we currently report
and expect to continue to report under IFRS as issued by the IASB, the extended transition period available to emerging growth
companies that report under GAAP is inapplicable to us.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed
above. We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions
under the JOBS Act. If some investors find our ordinary shares less attractive as a result, there may be a less active trading
market for our ordinary shares and our share price may be more volatile.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
must meet the Nasdaq Global Market’s continued listing requirements and comply with the other Nasdaq rules, or we may risk
delisting. Delisting could negatively affect the price of our ordinary shares, which could make it more difficult for us to sell
securities in a financing and for you to sell your ordinary shares<span style="font-weight: normal">.</span></i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to meet the continued listing requirements of the Nasdaq Global Market and comply with the other Nasdaq rules, including
those regarding director independence and independent committee requirements, minimum shareholders’ equity, minimum share
price and certain other corporate governance requirements. If we do not meet these continued listing requirements, our ordinary
shares could be delisted. Delisting of our ordinary shares from the Nasdaq Global Market would cause us to pursue eligibility
for trading on other markets or exchanges, or on the pink sheets. In such case, our shareholders’ ability to trade, or obtain
quotations of the market value of, our ordinary shares would be severely limited because of lower trading volumes and transaction
delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices for our securities. There
can be no assurance that our ordinary shares, if delisted from the Nasdaq Global Market in the future, would be listed on a national
securities exchange or quoted on a national quotation service, the OTCBB or the pink sheets. Delisting from the Nasdaq Global
Market, or even the issuance of a notice of potential delisting, would also result in negative publicity, make it more difficult
for us to raise additional capital, adversely affect the market liquidity of our ordinary shares, reduce security analysts’
coverage of us and diminish investor, supplier and employee confidence. In addition, as a consequence of any such delisting, our
share price could be negatively affected and our shareholders would likely find it more difficult to sell, or to obtain accurate
quotations as to the prices of, our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Israeli Law and Our Operations in Israel</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Significant parts of our operations are
located in Israel and, therefore, our results may be adversely affected by political, economic and military conditions in Israel.</i></b></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have substantial operations
in Israel, including our research and development facilities and our manufacturing facilities, that may be influenced by regional instability
and extreme military tension. Accordingly, political, economic and military conditions in Israel and the surrounding region could directly
affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or
the interruption or curtailment of trade between Israel and its present trading partners could affect adversely our operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing
and revived hostilities or other Israeli political or economic factors, could prevent or delay shipments of our products, harm
our operations and product development and cause any future sales to decrease. In the event that hostilities disrupt the ongoing
operation of our facilities or the airports and seaports on which we depend to import and export our supplies and products, our
operations may be materially adverse affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
operations may be disrupted as a result of the obligation of management or key personnel or consultants to perform military service.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until
they reach the age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event
of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods
of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future.
Our operations could be disrupted by such call-ups, which may include the call-up of members of our management. Such disruption
could materially adversely affect our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Because
we incur a portion of our expenses in currencies other than the U.S. dollar, our financial condition and results of operations
may be harmed by currency fluctuations and inflation.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our reporting and functional currency is the U.S. dollar, we pay a meaningful portion of our expenses in NIS, Euros and other
currencies. All of the salaries of our employees, our general and administrative expenses (including rent for our real property
facility in Israel), and the fees that we pay to certain of our partners, are denominated in NIS. Certain of our suppliers are
located in Europe and are paid in Euros. As a result, we are exposed to the currency fluctuation risks relating to the denomination
of our future expenses in U.S. dollars. More specifically, if the U.S. dollar becomes devalued against the NIS or the Euro, our
NIS- or Euro- denominated expenses will be greater than anticipated when reported in U.S. dollars. Inflation in Israel compounds
the adverse impact of such devaluation by further increasing the amount of our Israeli expenses. Israeli inflation may also (in
the future) outweigh the positive effect of any appreciation of the U.S. dollar relative to the NIS, if, and to the extent that,
it outpaces such appreciation or precedes such appreciation. The Israeli rate of inflation has not had a material adverse effect
on our financial condition during 2020 or 2021. Given our general lack of currency hedging arrangements to protect us from fluctuations
in the exchange rates of the NIS or the Euro and other non-U.S. currencies in relation to the U.S. dollar (and/or from inflation
of such non-U.S. currencies), we may be exposed to material adverse effects from such movements. We cannot predict any future
trends in the rate of inflation in Israel or in Europe or the rate of devaluation (if any) of the U.S. dollar against the NIS
or the Euro.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Provisions
of Israeli law and our amended and restated articles of association may delay, prevent or make undesirable an acquisition of all
or a significant portion of our shares or assets.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of Israeli law and our amended and restated articles of association could have the effect of delaying or preventing
a change in control and may make it more difficult for a third-party to acquire us or for our shareholders to elect different
individuals to our board of directors, even if doing so would be beneficial to our shareholders, and may limit the price that
investors may be willing to pay in the future for our ordinary shares. For example, our amended and restated articles of association
provide that our directors are elected on a staggered basis, such that a potential acquirer cannot readily replace our entire
board of directors at a single annual general shareholder meeting. In addition, Israeli corporate law regulates mergers and requires
that a tender offer be affected when more than a specified percentage of shares in a company are purchased.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country of residence
does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. With respect to certain mergers,
Israeli tax law may impose certain restrictions on future transactions, including with respect to dispositions of shares received
as consideration, for a period of two years from the date of the merger.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as
the Law for the Encouragement of Research and Development in Industry 5744-1984), and the regulations and guidelines promulgated
thereunder, or the Innovation Law, to which we are subject due to our receipt of grants from the Israel Innovation Authority,
or IIA (formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS), a recipient
of IIA grants such as us must report to IIA regarding any change of control of our company or regarding any change in the holding
of the means of control of our company which results in any non- Israeli citizen or resident becoming an “interested party”,
as defined in the Innovation Law, in our company, and in the latter event, the non-Israeli citizen or resident will be required
to execute an undertaking in favor of IIA, in a form prescribed by IIA, acknowledging the restrictions imposed by such law and
agreeing to abide by its terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investors
may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal
securities laws against us, or our executive officers and directors or asserting U.S. securities laws claims in Israel.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
all our directors or officers are residents of the United States and most of their and our assets are located outside the United
States. Service of process upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the
United States against us or our non-U.S. directors and executive officers may be difficult to obtain within the United States.
We have been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original
actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli
courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our non-U.S. officers and directors
because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear
a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable,
the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters
of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described
above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments
rendered against us or our non-U.S. officers and directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
among other reasons, including but not limited to, fraud or absence of due process, or the existence of a judgment which is at
variance with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending
before a court or tribunal in Israel, an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose
laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is
likely to prejudice the sovereignty or security of the State of Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Your
liabilities and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from
the U.S. law that governs the liabilities and responsibilities of shareholders of U.S. corporations.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under Israeli law. The rights and responsibilities of holders of our ordinary shares are governed by our amended
and restated articles of association and the Israeli Companies Law 5759-1999, or Companies Law. These rights and responsibilities
differ in some respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant
to the Companies Law each shareholder of an Israeli company has to act in good faith in exercising his or her rights and fulfilling
his or her obligations toward the company and other shareholders and to refrain from abusing his or her power in the company,
including, among other things, in voting at the general meeting of shareholders and class meetings, on amendments to a company’s
articles of association, increases in a company’s authorized share capital, mergers, and transactions requiring shareholders’
approval under the Companies Law. In addition, a controlling shareholder of an Israeli company or a shareholder who knows that
it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint or prevent the appointment
of a director or officer in the company, or has other powers toward the company, has a duty of fairness toward the company. However,
Israeli law does not define the substance of this duty of fairness.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
Israeli corporate law has undergone extensive revision in recent years, there is little case law available to assist in understanding
the implications of these provisions that govern shareholder behavior.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><div><a id="a_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
1B. UNRESOLVED STAFF COMMENTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_006"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
2. PROPERTIES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our principal executive offices are located at 116 Huntington Avenue,
Boston, Massachusetts 02116. We also maintain an office at 5 Nahum Heftsadie Street, Givaat Shaul, Jerusalem 91340, Israel, where we lease
an approximately 1,300 square foot facility. This facility houses our administrative headquarters, research and development laboratories
and pilot manufacturing facility. Additionally, we maintain an office at 673 Boylston Street, Boston, Massachusetts.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that our existing
facilities are adequate to meet our current needs, and that suitable additional or alternative spaces will be available in the future
on commercially reasonable terms.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have a lease agreement for an approximately 52,000 square foot facility in Kiryat Gat, Israel, where we recently completed
construction for a planned commercial-grade manufacturing facility. The Israeli Ministry of Health issued a GMP certificate and
we are working to establish cGMP compliance under the FDA’s regulations for this facility.&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
3. LEGAL PROCEEDINGS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become party to litigation or other legal proceedings that we consider to be part of the ordinary course
of business. We are not currently party to any material legal proceedings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
4. MINE SAFETY DISCLOSURE</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">PART
II</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
Information and Holders</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares have been listed on the Nasdaq Global Market under the symbol “GMDA” since October 26, 2018.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 24, 2022, we
had 10,724 shareholders of record.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Israeli Tax Considerations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us.
This section also contains a discussion of some Israeli tax consequences to persons owning our ordinary shares. This summary does
not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment
circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor
include traders in securities or persons that own, directly or indirectly, 10% or more of our outstanding voting capital, all
of whom are subject to special tax regimes not covered in this discussion. Some parts of this discussion are based on a new tax
legislation which has not been subject to judicial or administrative interpretation. The discussion should not be construed as
legal or professional tax advice and does not cover all possible tax considerations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHAREHOLDERS
ARE URGED TO CONSULT THEIR OWN TAX ADVISORS AS TO THE ISRAELI OR OTHER TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION
OF OUR ORDINARY SHARES, INCLUDING, IN PARTICULAR, THE EFFECT OF ANY NON-U.S., STATE OR LOCAL TAXES.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Corporate Tax Structure in Israel</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
resident companies are generally subject to corporate tax on their taxable income at the rate of 23% in 2021 tax year and thereafter.
However, the effective tax rate payable by a company that derives income from a Preferred Enterprise or a Technology Enterprise
(as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are subject to tax at the
prevailing corporate tax rate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Law
for the Encouragement of Industry (Taxes), 1969</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law, provides certain tax benefits for an “Industrial
Company”. The Industry Encouragement Law defines an “Industrial Company” as an Israeli resident company incorporated
in Israel, of which 90% or more of its income in any tax year, other than income from certain government loans, is derived from
an “Industrial Enterprise” owned by it and located in Israel or in the “Area”, in accordance with the
definition in the section 3A of the Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance. An “Industrial Enterprise”
is defined as an enterprise which is held by an Industrial Company whose principal activity in any given tax year is industrial
production.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tax benefits, among others, are available to Industrial Companies:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization
    over an eight-year period of the cost of patents and rights to use a patent and know-how that were purchased in good faith
    and are used for the development or advancement of the Industrial Enterprise, commencing from the tax year where the Industrial
    Enterprise began to use them;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
    certain conditions, the right to elect to file consolidated tax returns with Israeli Industrial Companies controlled by it;
    and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    related to a public offering are deductible in equal amounts over three years commencing on the year of the initial public
    offering.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we qualify as an “Industrial Company” within the meaning of the Industry Encouragement Law. There can
be no assurance that we will continue to qualify as an Industrial Company or that the benefits described above will be available
to us in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
Benefits under the Law for the Encouragement of Capital Investments, 1959</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Law for the Encouragement of Capital Investments, 1959, generally referred to as the “Investment Law”, provides certain
incentives for capital investments in production facilities (or other eligible assets).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Investment Law was significantly amended several times over the recent years, with the three most significant changes effective
as of April 1, 2005, referred to in this annual report on Form 20-F as the 2005 Amendment, as of January 1, 2011, referred to
in this annual report on Form 20-F as the 2011 Amendment, and as of January 1, 2017, referred to in this annual report on Form
20-F as the 2017 Amendment. Pursuant to the 2005 Amendment, tax benefits granted in accordance with the provisions of the Investment
Law prior to its revision by the 2005 Amendment remain in force but any benefits granted subsequently are subject to the provisions
of the amended Investment Law. Similarly, the 2011 Amendment introduced new benefits to replace those granted in accordance with
the provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits under the
Investment Law as in effect prior to January 1, 2011 were entitled to choose to continue to enjoy such benefits, provided that
certain conditions are met, or elect instead, irrevocably, to forego such benefits and have the benefits of the 2011 Amendment
apply. The 2017 Amendment introduces new benefits for Technology Enterprises, alongside the existing tax benefits. We did not
utilize any of the benefits for which we were eligible under the Investment Law prior to the 2011 Amendment, and starting in the
2017 tax year we elected to apply for the new benefits under the 2011 Amendment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
benefits under the 2011 Amendment</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 29, 2010, the
Israeli Parliament approved the 2011 Amendment. The 2011 Amendment significantly revised the tax incentive regime in Israel and commenced
on January 1, 2011.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2011 Amendment introduced new tax benefits for income generated by a “Preferred Company” through its “Preferred
Enterprise” (as such terms are defined in the Investment Law) as of January 1, 2011. The definition of a Preferred Company
includes a company incorporated in Israel that is not fully owned by a governmental entity, and that has, among other things,
Preferred Enterprise status and is controlled and managed from Israel.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Preferred Company is entitled to a reduced corporate tax rate with respect to the income attributed to the Preferred Enterprise,
at the following rates:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Tax
    Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Development<br>
    Region “A”</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Other
    Areas<br> within&nbsp;Israel</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2011-2012</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">15</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2013</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">12.5</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2014-2016</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017
    onwards<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">7.5</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </tbody></table><div>


</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%; font-family: Times New Roman, Times, Serif"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         December 2016, the Israeli Parliament (the Knesset) approved an amendment to the Investments
                                         Law pursuant to which the tax rate applicable to Preferred Enterprises in Development
                                         Region “A” would be reduced to 7.5% as of January 1, 2017.</span></p></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
classification of income generated from the provision of usage rights in know-how or software that were developed in the Preferred
Enterprise, as well as royalty income received with respect to such usage, as preferred income is subject to the issuance if a
pre-ruling from the Israel Tax Authority stipulates that such income is associated with the productive activity of the Preferred
Enterprise in Israel.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed from income which is attributed to a “Preferred Enterprise” will be subject to withholding tax at source
at the following rates: (i) Israeli resident corporations – 0%, (although, if such dividends are subsequently distributed
to individuals or a non-Israeli company, the below will apply) (ii) Israeli resident individuals – 20% (iii) non-Israeli
residents (individuals and corporations) - 20%(subject to the receipt in advance of a valid certificate from the Israel Tax Authority
allowing for a reduced tax rate, 20%, or such lower rate as may be provided in an applicable tax treaty).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2011 Amendment also revised the grant track to apply only to the approved programs located in Development Region “A”
and shall provide not only cash grants (as prior to the 2011 Amendment) but also the granting of loans. The rates for grants and
loans shall not be fixed but up to 20% of the amount of the approved investment (may be increased with additional 4%). In addition,
a company owning a Preferred Enterprise under the grant track may be entitled also to the tax benefits which are prescribed for
a Preferred Enterprise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
Tax Benefits under the 2017 Amendment that became Effective on January 1, 2017.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment was enacted as part of the Economic Efficiency Law that was published on December 29, 2016, and is effective as
of January 1, 2017. The 2017 Amendment provides new tax benefits for two types of “Technology Enterprises”, as described
below, and is in addition to the other existing tax beneficial programs under the Investment Law.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment provides that a technology company satisfying certain conditions will qualify as a “Preferred Technology
Enterprise” and will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as “Preferred Technology
Income”, as defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technology Enterprise
located in Development Region “A”. In addition, a Preferred Technology Company will enjoy a reduced corporate tax
rate of 12% on capital gain derived from the sale of certain “Benefitted Intangible Assets” (as defined in the Investment
Law) to a related foreign company if the Benefitted Intangible Assets were acquired from a foreign company on or after January
1, 2017 for at least NIS 200 million, and the sale receives prior approval from IIA.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment further provides that a technology company satisfying certain conditions will qualify as a “Special Preferred
Technology Enterprise” (an enterprise for which, among others, total consolidated revenues of its parent company and all
subsidiaries is at least NIS 10 billion) and will thereby enjoy a reduced corporate tax rate of 6% on “Preferred Technology
Income” regardless of the company’s geographic location within Israel. In addition, a Special Preferred Technology
Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain “Benefitted Intangible
Assets” to a related foreign company if the Benefitted Intangible Assets were either developed by the Special Preferred
Technology Enterprise or acquired from a foreign company on or after January 1, 2017, and the sale received prior approval from
IIA. A Special Preferred Technology Enterprise that acquires Benefitted Intangible Assets from a foreign company for more than
NIS 500 million will be eligible for these benefits for at least ten years, subject to certain approvals as specified in the Investment
Law.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed by a Preferred Technology Enterprise or a Special Preferred Technology Enterprise to Israeli shareholders, paid out
of Preferred Technology Income, are generally subject to withholding tax at source at the rate of 20% (in the case of non-Israeli
shareholders - subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax
rate, 20%, or such lower rate as may be provided in an applicable tax treaty). However, if such dividends are paid to an Israeli
company, no tax is required to be withheld (although, if such dividends are subsequently distributed to individuals or a non-Israeli
company, the aforesaid will apply). If such dividends are distributed to a foreign company and other conditions are met, the withholding
tax rate will be 4% (or a lower rate under a tax treaty, if applicable, subject to the receipt in advance of a valid certificate
from the Israel Tax Authority allowing for a reduced tax rate).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are examining the impact of the 2017 Amendment and the degree to which we will qualify as a Preferred Technology Enterprise or
Special Preferred Technology Enterprise, and the amount of Preferred Technology Income that we may have, or other benefits that
we may receive from the 2017 Amendment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation
of the Company Shareholders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
Gains</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gain tax is imposed on the disposal of capital assets by an Israeli resident, and on the disposal of such assets by a non-Israel
resident if those assets are either (i) located in Israel, (ii) are shares or a right to a share in an Israeli resident corporation,
or (iii) represent, directly or indirectly, rights to assets located in Israel, unless a tax treaty between Israel and the seller’s
country of residence provides otherwise. The Ordinance distinguishes between “Real Capital Gain” and the “Inflationary
Surplus”. Real Capital Gain is the excess of the total capital gain over Inflationary Surplus computed generally on the
basis of the increase in the Israeli Consumer Price Index (“CPI”) between the date of purchase and the date of disposal.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Real Capital Gain accrued by individuals on the sale of our ordinary shares (that were purchased after January 1, 2012, whether
listed on a stock exchange or not) will be taxed at the rate of 25%. However, if such shareholder is a “Controlling Shareholder”
(i.e., a person who holds, directly or indirectly, alone or together with such person’s relative or another person who collaborates
with such person on a permanent basis, 10% or more of one of the Israeli resident company’s means of control) at the time
of sale or at any time during the preceding twelve (12) months period and/or claims a deduction for interest and linkage differences
expenses in connection with the purchase and holding of such shares, such gain will be taxed at the rate of 30%.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Real Capital Gain derived by corporations will be generally subject to the ordinary corporate tax (23% in 2021 and thereafter).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
shareholders dealing in securities, or to whom such income is otherwise taxable as ordinary business income are taxed in Israel
at their marginal tax rates applicable to business income (up to 47% in 2021 and thereafter).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, capital gain derived from the sale of our ordinary shares by a non-Israeli resident (whether an individual or
a corporation) shareholder generally should be exempt under the Ordinance from Israeli taxation provided, among other things,
that the following conditions are met: (i) the shares were purchased upon or after the Company was listed for trading on
Nasdaq; (ii) such gains were not derived from a permanent business or business activity that the non-Israeli resident
maintains in Israel, and (iii) neither such shareholders nor the particular gain are not subject to the Israeli Income Tax
Law (Inflationary Adjustments) 5745-1985. These provisions dealing with capital gain are not applicable to a person whose
gains from selling or otherwise disposing of the shares are deemed to be business income. In addition, non-Israeli
corporations will not be entitled to the foregoing exemptions if an Israeli resident (i) has a controlling interest of more
than 25% in such non-Israeli corporation or (ii) is the beneficiary of or is entitled to 25% or more of the revenue or
profits of such non-Israeli corporation, whether directly or indirectly.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty (subject
to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for an exemption). For example, the U.S.-Israel
Double Tax Treaty generally exempts U.S. resident holding the shares as a capital asset and is entitled to claim the benefits
afforded to such a resident by the U.S.-Israel Double Tax Treaty, or a Treaty U.S. Resident, from Israeli capital gain tax in
connection with such sale, provided that (i) the U.S. resident owned, directly or indirectly, less than 10% of an Israeli resident
company’s voting power at any time within the 12 month period preceding such sale, subject to certain conditions; (ii) the
seller, being an individual, is present in Israel for a period or periods of less than 183 days in the aggregate at the taxable
year; and (iii) the capital gain from the sale, exchange or disposition was not derived through a permanent establishment that
the U.S. resident maintains in Israel, (iv) the capital gains arising from such sale, exchange or disposition is not attributed
to real estate located in Israel; or (v) the capital gains arising from such sale, exchange or disposition is not attributed to
royalties. If any such case occurs, the sale, exchange or disposition of our ordinary shares would be subject to Israeli tax,
to the extent applicable. However, under the U.S.-Israel Tax Treaty, such Treaty U.S. Resident would be permitted to claim a credit
for such taxes against U.S. federal income tax imposed on any gain from such sale, exchange or disposition, under the circumstances
and subject to the limitations specified in the U.S.-Israel Double Tax Treaty.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration
may be subject to withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from
tax on their capital gains in order to avoid withholding at source at the time of sale. Specifically, in transactions involving
a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may
require from shareholders who are not liable for Israeli tax to sign declarations in forms specified by this authority or obtain
a specific exemption from the Israel Tax Authority to confirm their status as non-Israeli resident, and, in the absence of such
declarations or exemptions, may require the purchaser of the shares to withhold taxes at source.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
the purchaser, the Israeli stockbrokers or financial institution through which the shares are held is obliged, subject to the
above mentioned exemptions, to withhold tax upon the sale of securities on the amount of the consideration paid upon the sale
of the securities at the rate of 25% in respect of an individual, or at a rate of corporate tax, in respect of a corporation (23%
in 2021 and thereafter).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the sale of securities traded on a stock exchange a detailed return, including a computation of the tax due, must be filed and
an advanced payment must be paid on January 31 and July 31 of every tax year in respect of sales of securities made within the
previous six months. However, if all tax due was withheld at source according to applicable provisions of the Ordinance and regulations
promulgated thereunder the aforementioned return need not be filed provided that (i)&nbsp;such income was not generated from business
conducted in Israel by the taxpayer, (ii)&nbsp;the taxpayer has no other taxable sources of income in Israel with respect to which
a tax return is required to be filed and (iii) the taxpayer is not obliged to pay excess tax (as further explained below); and
no advance payment must be paid. Capital gain is also reportable on the annual income tax return.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
Policy</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends to our shareholders of our ordinary shares, and we do not anticipate or intend
to pay cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of
our board of directors in compliance with applicable legal requirements and will depend on a number of factors, including future
earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, our
strategic goals and plans to expand our business, applicable law and other factors that our board of directors may deem relevant.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli Companies Law imposes further restrictions on our ability to declare and pay dividends. Payment of dividends may be subject
to Israeli withholding taxes.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance, generally provides that a non-Israeli resident (either individual
or corporation) is subject to an Israeli income tax on the receipt of dividends at the rate of 25% (30% if the dividends recipient
is a “Controlling Shareholder” (as defined above), at the time of distribution or at any time during the preceding
12 months period) or 20% if the dividend is distributed from income attributed to Preferred Enterprise. Such dividends are generally
subject to Israeli withholding tax at a rate of 25% so long as the shares are registered with a Nominee Company (whether the recipient
is a Controlling Shareholder or not), and 20% if the dividend is distributed from income attributed to a Preferred Enterprise
(in the case of non-Israeli shareholders - subject to the receipt in advance of a valid certificate from the ITA allowing for
a reduced tax rate, 20%, or such lower rate as may be provided in an applicable tax treaty); If the dividend is attributable
partly to income derived from a Preferred Enterprise, and partly from other sources of income, the income tax rate will be a blended
rate reflecting the relative portions of the types of income. We cannot assure you that we will designate the profits that we
may distribute in a way that will reduce shareholders tax liability.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, under the U.S.-Israel Double Tax Treaty the following rates will apply in respect of dividends distributed by an Israeli
resident company to a Treaty U.S. Resident: (i) if the Treaty U.S. Resident is a corporation which holds during that portion of
the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at
least 10% of the outstanding shares of the voting shares of the Israeli resident paying corporation and not more than 25% of the
gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain type of interest
or dividends – the maximum tax rate of withholding is 12.5%, and (ii) in all other cases, the tax rate is 25%, or the domestic
rate (if such is lower). The aforementioned rates under the Israel U.S. Double Tax Treaty will not apply if the dividend income
was derived through a permanent establishment that the Treaty U.S. Resident maintains in Israel. U.S. residents who are subject
to Israeli withholding tax on a dividend may be entitled to a credit or deduction for United States federal income tax purposes
in the amount of the taxes withheld, subject to detailed rules contained in U.S. tax legislation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-Israeli resident who receives dividend income derived from or accrued from Israel, from which the full amount of tax was withheld
at source, is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that (i)
such income was not generated from business conducted in Israel by the taxpayer, and (ii) the taxpayer has no other taxable sources
of income in Israel with respect to which a tax return is required to be filed and (iii) the taxpayer is not obliged to pay excess
tax (as further explained below).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payers
of dividends on our shares, including the Israeli shareholder effectuating the transaction, or the financial institution through
which the securities are held, are generally required, subject to any of the foregoing exemption, reduced tax rates and the demonstration
of a shareholder of his, her or its foreign residency, to withhold taxes upon the distribution of dividends at a rate of 25% provided
that the shares are registered with a Nominee Company (for corporations and individuals).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Excess
Tax</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individuals
who are subject to tax in Israel (whether any such individual is an Israeli resident or non-Israeli resident) are also subject
to an additional tax at a rate of 3% on annual income exceeding NIS 647,640 for 2021, which amount is linked to the annual change
in the Israeli consumer price index, including, but not limited to, dividends, interest and capital gain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Exchange Regulations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-residents
of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation
and winding up of our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion.
However, Israeli income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework
for the potential imposition of currency exchange control has not been eliminated, and may be restored at any time by administrative
action.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Estate
and Gift Tax</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
law presently does not impose estate or gift taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
Sales of Unregistered Securities</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On
February 16, 2021, Gamida Cell Inc. sold&nbsp;$75 million&nbsp;of 5.875% convertible senior notes due in 2026 (the “notes”)
to certain funds managed by&nbsp;Highbridge Capital Management, LLC, which funds were accredited investors and qualified institutional
buyers. The notes were sold at 100% of the principal amount thereof, are senior unsecured obligations of&nbsp;ours and will accrue interest
at a rate of 5.875% per year. Subject to certain limitations, the holders of the notes can elect to exchange the notes for our ordinary
shares at an initial exchange rate of 56.3063 shares per&nbsp;$1,000&nbsp;principal amount of notes (equivalent to an exchange price
of&nbsp;$17.76&nbsp;per share). The sale was made in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities
Act.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At-the-Market
Ordinary Shares Offering</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2021, we entered into an Open Market Sale Agreement under which we have the option to offer and sell our ordinary
shares having an aggregate gross sales price of up to $50 million from time to time through Jefferies LLC. Pursuant to the Open
Market Sales Agreement and upon delivery of notice by the Company, Jefferies may sell our ordinary shares under an “at the
market offering.” From inception through to December 31, 2021 we did not sell any shares under this facility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
6. [RESERVED]</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion of our financial condition, changes in financial condition, plan of operations and results of operations
should be read in conjunction with (i) our audited consolidated financial statements as at December 31, 2021 and December 31,
2020 and (ii) the section entitled “Business” included in this annual report. The discussion contains forward-looking
statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated
in these forward-looking statements as a result of many factors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Overview</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases. We harness our cell
expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. While
cell therapies have the potential to address a variety of diseases, they are limited by availability of donor cells, matching
a donor to the patient, and the decline in donor cell functionality when expanding the cells to achieve a therapeutic dose. We
have leveraged our NAM platform, or nicotinamide cell expansion technology platform to develop a pipeline of product candidates
designed to address the limitations of other cell therapies. Our proprietary technology allows for the proliferation and enhancement
of donor cells, which allows for maintaining the cells’ functional therapeutic characteristics, providing a treatment alternative
for patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omidubicel,
our lead product candidate, is designed to address the limitations of hematopoietic stem cell transplantation. Omidubicel consists
of NAM-expanded and enhanced hematopoietic stem cells and differentiated immune cells, including T cells. The final cell therapy
product is cryopreserved until the patient is ready to begin the transplant, when it is thawed and infused. Omidubicel has the
potential to be a universal stem cell graft in two broad patient groups: (i) patients with high-risk leukemias and lymphomas who
require HSCT but who lack access to an appropriate matched related donor; and (ii) patients with severe hematologic disorders
such as severe aplastic anemia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the complete results from our pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic
malignancies were published in the peer-reviewed medical journal <i>Blood</i>. The trial achieved its primary endpoint of time
to neutrophil engraftment as well as all three of the prespecified secondary endpoints. These secondary endpoints were the proportion
of patients who achieved platelet engraftment by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive
fungal infections in the first 100 days following transplant, and the number of days alive and out of the hospital in the first
100 days following transplant. All three secondary endpoints demonstrated statistical significance in an intent-to-treat analysis.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we also reported data from an analysis of a subset of 37 patients from the Phase 3 randomized trial of omidubicel
at Annual Meeting of the American Society of Hematology, or ASH. The analysis was aimed at investigating the reduced infection
rates observed in the study and showed that the omidubicel-treated patients had more rapid recovery of a wide variety of immune
cells including CD4+ T cells, B cells, NK cells and dendritic cell subtypes. The robust recovery of the immune system provides
rationale for fewer severe bacterial, fungal and viral infections in patients treated with omidubicel. Additional analyses are
ongoing to further characterize the immune recovery following omidubicel transplantation. In early 2022, the FDA agreed that the
initiation of our rolling BLA submission for omidubicel was appropriate and we initiated the rolling submission process. We plan
to submit the full BLA for omidubicel to the FDA in the first half of 2022.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have applied our NAM cell expansion technology to natural killer, or NK, cells, to develop our initial NK product
candidate, GDA-201, an investigational, NK cell-based immunotherapy for the treatment of hematologic and solid tumors in combination
with standard of care antibody therapies. GDA-201 is currently being evaluated in a Phase 1/2 investigator-sponsored trial for
the treatment of relapsed or refractory non-Hodgkin lymphoma, or NHL, and multiple myeloma, or MM. Data from the trial demonstrate
that GDA-201 was well-tolerated and no dose-limiting toxicities were observed in 19 patients with NHL and 16 patients with MM.
The data show that therapy using GDA-201 with monoclonal antibodies demonstrated significant clinical activity in heavily pretreated
patients with advanced NHL. Of the 19 patients with NHL, 13 complete responses and one partial response were observed, with an
overall response rate of 74% and a complete response rate of 68%. At the December 2021 Annual Meeting of ASH, we reported two-year
follow-up data from this clinical trial and reported on two-year outcomes and cytokine biomarkers associated with survival. The
data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at two years of 78% (95%
CI, 51%–91%) and a safety profile similar to that reported previously.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2021, we submitted
an investigational new drug application, or IND, for a Phase 1/2 clinical trial of GDA-201 in patients with follicular and diffuse large
B-cell lymphomas. The FDA placed this IND on clinical hold prior to the initiation of patient dosing. The FDA has requested modifications
in donor eligibility procedures and sterility assay qualification. We are in active communication with the FDA with the objective to promptly
address these requests to enable the requirements for IND acceptance and study initiation. We expect to initiate our Phase 1/2 study of
GDA-201 in patients with follicular and diffuse large B-cell lymphomas in 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred significant
net losses since our formation in 1998. Our net losses were $89.8 million and $61.6 million for the years ended December 31, 2021 and
2020, respectively. As of December 31, 2021, our accumulated deficit was $337.5 million. We expect to continue to incur losses for the
foreseeable future, and our losses may fluctuate significantly from year to year. We expect that our expenses will increase substantially
in connection with our ongoing activities as we:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submit
                                         our BLA on a rolling basis to seek regulatory approval for omidubicel;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                         a sales, marketing and distribution infrastructure, if we do not pursue a strategic partnership
                                         for commercialization, and scale up manufacturing capabilities to commercialize omidubicel
                                         upon obtaining regulatory approval;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
                                         our planned Phase 1/2 clinical trial of GDA-201 in patients with NHL;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                         the preclinical development of our other product candidates;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
                                         expand and protect our intellectual property portfolio;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
                                         equipment and physical infrastructure to support our research and development and commercialization
                                         efforts;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                         additional clinical development, regulatory, commercial, quality control and manufacturing
                                         personnel; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
                                         operational, financial and management information systems and personnel, including personnel
                                         to support our product development and planned future commercialization.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we completed two equity financing transactions in 2020 and a convertible debt financing in 2021, we will need substantial additional
funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory
approval and prepare for and, if any of our product candidates are approved, proceed to commercialization. Adequate funding may
not be available to us on acceptable terms, or at all.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue to fund our operations, we expect to continue to raise capital. We may obtain additional financing in the future through
the issuance of our ordinary shares, through other equity or debt financings or through collaborations or partnerships with other
companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital
as and when needed could compromise our ability to execute on our business plan. Although it is difficult to predict future liquidity
requirements, we believe that our current total existing funds will be sufficient to fund our operations into mid-2023. However,
our ability to successfully transition to profitability will be dependent upon achieving a level of revenue adequate to support
our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any products approved for sale and, to date, we have not recognized any revenue. In the future, we may generate
revenue from a combination of product sales, reimbursements, up-front payments and future collaborations. If we fail to achieve
clinical success or obtain regulatory approval of any of our product candidates in a timely manner, our ability to generate future
revenue will be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
largest component of our total operating expenses has historically been, and we expect will continue to be, research and development.
Our research and development expenses, net of IIA grants, consist primarily of:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries
    and related costs, including share-based compensation expense, for our personnel in research and development functions;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with third parties, including CROs, subcontractors, suppliers and consultants, for the conduct of
    our preclinical studies and clinical trials;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred to acquire, develop and manufacture preclinical study and clinical trial materials; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility
    and equipment costs, including depreciation expense, maintenance and allocated direct and indirect overhead costs.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and development expenses (net of grants) are recognized
in the consolidated statements of operations when incurred. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Through December 31, 2021,
we have received an aggregate of approximately $37.3 million in grants from the Israeli Innovation Authority, or the IIA, including from
the Bereshit Consortium sponsored by the IIA, of which $34.7 million is royalty-bearing grants, and $2.6 million is non-royalty-bearing
grants, and all of which was awarded for research and development funding. Pursuant to the terms of the royalty-bearing grants, we are
obligated to pay the IIA royalties at the rate of between 3% to 3.5% on all our revenue, up to a limit of 100% of the amounts of the U.S.
dollar-linked grants received, plus annual interest calculated at a rate based on the 12-month LIBOR. We have not paid any royalties to
the IIA to date. The Bereshit Consortium program does not require payments of royalties to the IIA, but all other restrictions under the
Innovation Law, such as local manufacturing obligations and know-how transfer limitations, as further detailed hereunder, are applicable
to the know how developed by us with the funding received in such consortium program.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United Kingdom’s Financial Conduct Authority, which regulates the London Interbank Offered Rate, or LIBOR, announced in
July 2017 that it will no longer persuade or require banks to submit rates for LIBOR after 2021. The grants received from the
IIA bear an annual interest rate based on the 12-month LIBOR. Accordingly, there is considerable uncertainty regarding the publication
of LIBOR beyond the end of 2021. While it is not currently possible to determine precisely whether, or to what extent, the withdrawal
and replacement of LIBOR would affect us, the implementation of alternative benchmark rates to LIBOR may increase our financial
liabilities to the IIA.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to paying any royalties due, we must abide by other restrictions associated with receiving such grants under the Encouragement
of Research, Development and Technological Innovation in the Industry Law 5744-1984, which will also continue to apply to us following
the repayment in full of the amounts due to the IIA. The Innovation Law restricts our ability to manufacture products and transfer
technologies outside of Israel, and may impair our ability to enter into agreements that involve IIA-funded products or know-how
without the approval of the IIA. Any approval, if given, will generally be subject to additional financial obligations by us.
Failure to comply with the requirements under the Innovation Law may subject us to mandatory repayment of grants received by us,
together with interest and penalties, as well as expose us to criminal proceedings.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2017, new rules, or the Licensing Rules, were published by the IIA allowing a grant recipient to enter into licensing arrangements
or grant other rights in know-how developed under IIA programs outside of Israel, subject to the prior consent of the IIA and
payment of license fees, calculated in accordance with the Licensing Rules. The amount of the license fees is based on various
factors, including the consideration received by the licensor in connection with the license, and shall not exceed six times the
amount of the grants received by the grant recipient (plus accrued interest) for the applicable know-how being licensed. In certain
cases, such as when the license consideration includes nonmonetary compensation or when a “special relationship” exists
between the licensor and licensee (<i>e.g.</i> when a party controls the other party or is the other party’s exclusive distributor),
or when the agreed upon consideration does not reflect, in the IIA’s opinion, the market value of the license, the IIA may
base the value of the transaction on an economic assessment that it obtains for such purpose.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently focused on advancing our product candidates, and our future research and development expenses will depend on their
clinical success. Research and development expenses will continue to be significant and will increase over at least the next several
years as we continue to develop our product candidates and conduct preclinical studies and clinical trials of our product candidates.
Government grants received from the IIA are recognized as a reduction of the related research and development expenses.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not believe that it
is possible at this time to accurately project total expenses required for us to reach commercialization of omidubicel or any of our other
product candidates. However, with the objective of extending our cash runway into mid-2023, consistent with the anticipated timeline for
potential U.S. approval of omidubicel, we are reducing operating expenses primarily by implementing a workforce reduction of approximately
10% and delaying other hiring and planned spending in 2022. A majority of the anticipated savings is in research and development expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commercial
expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Commercial expenses consist
primarily of personnel costs, including share-based compensation, related to executive and commercial functions, and external consulting
service fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and administrative expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive,
finance, and administrative functions, facility costs and external professional service costs, including legal, accounting and
audit services and other consulting fees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will incur increased expenses related to audit, legal, regulatory and tax-related services associated with
additional reporting requirements as a result of losing our status as a foreign private issuer at the end of the 2021 fiscal year,
and maintaining compliance with the Nasdaq and SEC requirements, director and officer insurance premiums, executive compensation,
and other customary costs associated with being a public company subject to US domestic issuer listing requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
expenses, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial expenses, net,
is our financing expenses from convertible senior notes after deducting financing income from deposits and marketable securities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We have yet to generate
taxable income in Israel, as we have historically incurred operating losses resulting in carry forward tax losses totaling approximately
$237.4 million (including capital losses of $0.5 million) as of December 31, 2021. In addition, the US subsidiary has net operating losses
carryforward of $33.1 million for federal tax purposes as of December 31, 2021. We anticipate that we will continue to generate tax losses
for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly,
we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. We provided
a full valuation allowance, to reduce deferred tax assets to their estimated realizable value, since it is more likely than not that all
of the deferred tax assets will not be realized.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Analysis
of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the years ended December 31, 2021 and 2020</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Year
    ended <br> December&nbsp;31,</span></td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">(in
    thousands)</span></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Operating
    Expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses, net<sup>(1)</sup></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">50,177</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">38,873</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial
    expenses<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">20,013</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">8,894</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">16,977</span></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">13,158</span></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Operating
    loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">87,167</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">60,925</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Financial
    expenses, net</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2,626</span></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">648</span></td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">89,793</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 4pt double; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">61,573</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></p><div>





</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    share-based compensation expense as follows:</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br> December&nbsp;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses, net</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,384</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">1,099</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Commercial expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">947</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">376</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,902</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,893</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total share-based compensation</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,233</td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right">3,368</td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and development expenses, net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Research
and development expenses, net, increased by approximately $11.3 million to $50.2 million in the year ended December 31, 2021 from $38.9
million in the year ended December 31, 2020. The increase was attributable mainly to a $5.4 million increase in clinical activities relating
to the conclusion of our Phase 3 clinical trial and advancing our GDA 201 clinical program and an increase of $5.9 million in salaries
and benefits, consisting primarily of additional headcount focused on clinical development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Commercial </i>expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial expenses increased
by approximately $11.1 million to $20.0 million in the year ended December 31, 2021 from $8.9 million in the year ended December 31, 2020.
The increase was attributable mainly to an approximate $6.5 million increase in professional services and a $4.6 million increase in salaries
and benefits resulting from increased headcount within our commercial organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by approximately $3.8 million to $17.0 million in the year ended December 31, 2021, up from
$13.2 million in the year ended December 31, 2020. The increase was attributable to a $2.6 million increase in professional services
expenses related to general company growth and of $1.2 million increase in salaries and benefits resulting from increased headcount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financial expenses, net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
expenses, net, increased by approximately $2.0 million to $2.6 million in the year ended December 31, 2021, compared to $0.6 million
in the year ended December 31, 2020. The increase was primarily due to $4.4 million in financing expenses from our convertible
senior notes, which was offset by $1.7 million in non-cash capitalization of finance costs, non-cash expenses related to leasing
liability of $0.4 million and a $0.3 million increase in interest income from cash management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our consolidated financial statements has been prepared in accordance with generally accepted accounting
principles in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards
Codification, or ASC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to 2021, we prepared our financial statements in accordance with International Financial Reporting Standards, or IFRS, as issued
by the International Accounting Standards Board, or IASB, as permitted in the United States, based on our status as a foreign
private issuer. At the end of the 2021 fiscal year, we lost our status as a foreign private issuer, and became subject to the
U.S. domestic filer requirements, one of which requires us to prepare our consolidated financial statements in accordance with
U.S. generally accepted accounting principles, or U.S. GAAP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We are devoting substantially all of our efforts toward research and
development activities. In the course of such activities, we have sustained operating losses and we expect such losses to continue in
the foreseeable future. Our accumulated deficit as of December 31, 2021 was $337.5 million and negative cash flows from operating activities
during the year ended December 31, 2021 was $81.8 million. We are planning to finance our operations from our existing and potential future
working capital resources and we continue to evaluate additional sources of capital and financing. However, there is no assurance that
additional capital and/or financing will be available to us, and even if available, whether it will be on acceptable terms or in the amounts
required. Based on our assessment of our financial position at the date of issuance of our consolidated financial statements for the year
ended December 31, 2021, we believe that our existing capital resources will be adequate to satisfy our expected liquidity requirements
for at least twelve months from the issuance of the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are more fully described in the notes to our consolidated financial statements appearing elsewhere
in this annual report on Form 10-K, we believe that the accounting policies discussed below are critical to our financial results
and to the understanding of our past and future performance, as these policies relate to the more significant areas involving
management’s estimates and assumptions. We consider an accounting estimate to be critical if: (i) it requires us to make
assumptions because information was not available at the time or it included matters that were highly uncertain at the time we
were making our estimate; and (ii) changes in the estimate could have a material impact on our financial condition or results
of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
senior notes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2021, we entered into a Note Purchase Agreement, pursuant to which Gamida Cell Ltd.’s wholly owned U.S. subsidiary,
Gamida Cell Inc., issued convertible senior notes with an aggregate original principal amount of $75.0 million in a private placement.
The notes are guaranteed by Gamida Cell Ltd. pursuant to an Indenture, dated February 16, 2021, between Gamida Cell Inc., Gamida
Cell Ltd., and Wilmington Savings Fund Society, FSB, which is filed as exhibit to this annual report on Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notes were issued on a senior unsecured basis, have a maturity date of February 15, 2026, bear 5.875% interest, and may be exchanged,
at the election of the holder, for ordinary shares of Gamida Cell Ltd. at an initial per share price of $17.76, subject to adjustments.
The net proceeds from the private placement were approximately $70.8 million after deducting placement agent fees, escrowed amounts
and other expenses, and the transaction closed on February 16, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for our convertible senior notes in accordance with ASC 470-20 “Debt with Conversion and Other Options.” We
early adopted ASU 2020-06 using the modified retrospective approach. The convertible senior notes are accounted for as a single
liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives according
to ASC 815-40.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
convertible senior notes are included in the calculation of diluted earnings per share, or EPS, if the assumed conversion into
ordinary shares is dilutive, using the “if-converted” method. This involves adding back the periodic  interest
expense net of taxes associated with the convertible senior notes to the numerator and by adding the shares that would be issued
in an assumed conversion (regardless of whether the conversion option is in or out of the money) to the denominator for the purposes
of calculating diluted EPS. Since the effect of the convertible senior notes on the diluted EPS was antidilutive, we did not include
them in our calculation of the diluted EPS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-based
compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for share-based compensation in accordance with ASC No. 718 “Compensation - Stock Compensation,” or ASC No.
718, which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing
model. The value of the award is recognized as an expense over the requisite service periods, which is the vesting period of the
respective award, on a straight-line basis when the only condition to vesting is continued service. We selected the binominal
option-pricing model as the most appropriate fair value method for our option awards. The fair value of restricted shares, is based on the closing market value of the underlying shares at the date of grant. Since our initial public offering,
the fair value of our ordinary shares has been determined based on the closing price of our ordinary shares on the Nasdaq Global
Market. We recognize forfeitures of equity-based awards as they occur. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
note 2 of the accompanying audited consolidated financial statements for the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Internal
Control over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, or Section
404, could have a material adverse effect on our business, results of operation or financial condition. In addition, current and
potential shareholders could lose confidence in our financial reporting, which could have a material adverse effect on the price
of our ordinary shares. Pursuant to Section 404 and the related rules adopted by the SEC and the Public Company Accounting Oversight
Board, our management is required to report on the effectiveness of our internal control over financial reporting. In addition,
once we no longer qualify as an “emerging growth company” under the JOBS Act and lose the ability to rely on the exemptions
related thereto discussed above, our independent registered public accounting firm will also need to attest to the effectiveness
of our internal control over financial reporting under Section 404. We have completed the process of determining whether our existing
internal controls over financial reporting systems are compliant with Section 404 and whether there are any material weaknesses
or significant deficiencies in our existing internal controls. Based on this process, our management concluded that our internal
controls over financial reporting were effective as of December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Liquidity</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Since
our inception, we have incurred losses and negative cash flows from our operations. For the years ended December 31, 2021 and December
31, 2020, we incurred a net loss of $89.8 million and $61.6 million, respectively, and net cash of $81.8 million and $50.2 million, respectively,
was used in our operating activities. As of December 31, 2021 and December 31, 2020 we had working capital of $73.2 million and $108.8
million, respectively, and an accumulated deficit of $337.5 million and $247.7 million, respectively. Our principal sources of liquidity
as of December 31, 2021 and December 31, 2020 consisted of cash and cash equivalents and trading financial assets of $95.9 million and
$127.2 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
Resources</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overview</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
December 31, 2021, we have financed our operations primarily through private placements and public offerings of equity securities
and through the grants received from the IIA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
flows</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our statement of cash flows for the years ended December 31, 2021 and 2020:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended <br>
December&nbsp;31,</b></span></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="6" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by (used in)</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 76%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating activities</span></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81,760</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,219</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing activities</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(60,921</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,589</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing activities</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,403</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,962</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in operating activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash used in operating activities during the aforementioned periods resulted primarily from our net losses incurred during such
periods, as adjusted for non-cash charges and measurements and changes in components of working capital. Adjustments to net losses
for non-cash items mainly share based compensation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Net
cash used in operating activities was $81.8 million during the year ended December 31, 2021, compared to $50.2 million used in operating
activities during the year ended December 31, 2020. The $31.6 million increase in cash used was attributable primarily due to an increase
in our spend related to research and development activities, including with respect to completion of our Kiryat Gat manufacturing facility
and conclusion of our pivotal Phase 3 clinical trial of omidubicel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash provided by (used in) investing activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Net
cash used in investing activities was $60.9 million during the year ended December 31, 2021, compared to $1.6 million provided by investing
activities during the year ended December 31, 2020. The $62.5 million increase is primarily related to increase of $59.2 million of proceeds
from maturity and purchase of marketable securities and changes in bank deposits, and, by an increase of $3.3 million from the purchase
of property and equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash provided by financing activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $71.4 million during the year ended December 31, 2021, compared to $134.0 million during
the year ended December 31, 2020. The $62.6 million decrease is primarily related to net proceeds of $70.8 million received from
the 2021 issuance of our convertible senior notes compared to $133.3 million in net proceeds received from the issuance of our
ordinary shares in public offerings in 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Funding
Requirements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing funds will enable us to fund our operating expenses and capital expenditure requirements through mid-2023.
We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently
expect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
present and future funding requirements will depend on many factors, including, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of the rolling submission of our BLA for omidubicel;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress, timing and completion of preclinical studies and clinical trials for GDA-201 or any of our other product candidates;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs related to obtaining regulatory approval for omidubicel and any of our other product candidates, and any delays we may
    encounter as a result of regulatory requirements or adverse clinical trial results with respect to any of these product candidates;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selling,
    marketing and patent-related activities undertaken in connection with the commercialization of omidubicel, if we determine
    to internally commercialize the product, if approved;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending
    against claims or infringements raised by third parties, and license royalties or other amounts we may be required to pay
    to obtain rights to third-party intellectual property rights; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    a sales, marketing and distribution infrastructure and scaling up manufacturing capabilities to commercialize any products
    for which we obtain regulatory approval and determine to commercialize internally.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We
have annual operating lease obligations related to our Haddasah production facility of approximately $1.0 million, which is included
in research and development expense. We additionally have annual operating lease obligations related to our Boston and Kiryat Gat facilities
in aggregate of $1.1 million, which is included in general and administrative expense.</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we expect to continue to incur additional costs associated with operating as a public company subject to US domestic filer regulations.
Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable
to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development
programs or future commercialization efforts.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we may finance our cash needs through a combination of equity
offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of any
additional securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through additional
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be
favorable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additional financing may
not be available when we need it or may not be available on terms that are favorable to us. If we are unable to raise additional funds
through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market
ourselves. For more information as to the risks associated with our future funding needs, see “Item 1A. Risk Factors—Principal
Risk Factors.”</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audited consolidated
financial statements for the years ended December 31, 2021 and 2020 are incorporated herein by reference to pages F-1 to F-28 at the
end of this report and the supplementary data is not applicable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had no changes in, or disagreements with our principal independent accountants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
9A. CONTROLS AND PROCEDURES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
of Disclosure Controls and Procedures</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act
of 1934. Under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of
our disclosure controls and procedures as of December 31, 2021 to ensure that the information required to be disclosed by us in
the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported
within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit
under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive
officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Our management,
with participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our
disclosure controls and procedures as of December 31, 2021. Based on that evaluation, our principal executive officer and principal
financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2021 to provide reasonable
assurance that the information required to be disclosed by us in this annual report was (a) reported within the time periods specified
by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer and Chief Financial
Officer, to allow timely decisions regarding any required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s
Report on Internal Control Over Financial Reporting</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is
defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including
our principal executive, financial and accounting officer, we conducted an evaluation of the effectiveness of our internal control
over financial reporting as of December 31, 2021 based on the framework in Internal Control—Integrated Framework 2013 issued
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, our management concluded
that our internal control over financial reporting was effective as of December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attestation
Report of the Registered Public Accounting Firm</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report does not include an attestation report of our registered public accounting firm due to the Company’s emerging
growth company status which provides an exemption.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize information technology for internal and external communications with vendors, clinical sites, banks, investors and shareholders.
Loss, disruption or compromise of these systems could significantly impact operations and results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any material cybersecurity violation or occurrence. We believe our efforts toward prevention of such violation
or occurrence, including system design and controls, processes and procedures, training and monitoring of system access, limit,
but may not prevent unauthorized access to our systems.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than temporary disruption to operations that may be caused by a cybersecurity breach, we consider cash transactions to be the
primary risk for potential loss. We and our financial institution take steps to minimize the risk by requiring multiple levels
of authorization and other controls.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in Internal Control Over Financial Reporting</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during
the fiscal quarter ended December 31, 2021 that materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inherent
Limitations on Effectiveness of Internal Controls</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial
reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide
only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to
their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions. Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure
controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving
their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure
controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
9B. OTHER INFORMATION</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENTS INSPECTIONS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">PART
III</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and Executive Officers.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below sets forth
our directors and executive officers as of March 15, 2022. The business address for each of our executive officers and directors is c/o
116 Huntington Avenue, Boston, Massachusetts 02116.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
<tbody><tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Julian Adams</span></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 59%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chief Executive Officer</span></td></tr>
<tr style="vertical-align: bottom;  font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michele
    Korfin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">51</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating and Chief Commercial Officer</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh
    Patterson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">46</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Counsel and Chief Compliance Officer</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    I. Blum</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anat
    Cohen-Dayag</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ofer
    Gonen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naama
    Halevi Davidov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    I. Moch</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shawn
    C. Tomasello</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    T. Wills</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
</tbody></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive
Officers</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Julian
Adams, Ph.D.,</i> joined our board of directors in August 2016 and has served as our Chief Executive Officer since November 2017.
Dr. Adams has more than 35 years of experience in drug discovery and development. From 2003 to 2016, Dr. Adams held roles of increasing
responsibility at Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), where he built and led the company’s R&amp;D efforts which
ultimately led to the approval of duvelisib, also known as Copiktra®, for the treatment of certain leukemias and lymphomas.
From 1999 to 2003, Dr. Adams served as a Senior Vice President at Millenium Pharmaceuticals, Inc., a subsidiary of the biopharmaceutical
company Takeda Pharmaceutical Company Limited since 2008, where he led the development of bortezomib, also known as Velcade®,
for the treatment of multiple myeloma. He has served on the boards of directors of numerous biotechnology companies, and currently
serves as the Chairman of the board of directors of Elicio Therapeutics Inc. Dr. Adams received a B.S. from McGill University
and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shai
Lankry </i>has served as our Chief Financial Officer since April 2018. Mr. Lankry has more than 15 years of senior management
experience in finance. Prior to joining Gamida Cell, from 2016 to 2018, Mr. Lankry served as a Finance Director at West Pharmaceutical
Services Inc., leading the R&amp;D and operations financials for the Israeli subsidiary. From 2013 to 2017, Mr. Lankry was the
Chief Financial Officer and Israeli Site Manager of Macrocure Ltd. where he played an integral role in the company’s 2014
US initial public offering and its 2017 acquisition by Leap Therapeutics Inc. Mr. Lankry is a licensed Israeli CPA and holds an
M.B.A. in Finance from Tel-Aviv University.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Michele
Korfin </i>has served as our Chief Operating and Chief Commercial Officer since August 2020. Prior to joining Gamida Cell, Ms.
Korfin served as Chief Operating Officer at TYME Technologies, Inc. (Nasdaq: TYME), a biotechnology company focused on therapeutic
candidates that target cancer metabolism, from 2018 until 2020. From 2016 until 2018, she was Vice President of Market Access
at Kite Pharma, Inc., or Kite, a biotechnology company engaged in the development of cancer immunotherapy products that is now
part of Gilead Sciences. At Kite, she oversaw the market access strategy, including payer relations, reimbursement and government
affairs for Yescarta®, the first approved CAR-T therapy in lymphoma. She also worked closely with the manufacturing and supply
chain teams at Kite to prepare for FDA approval and commercialization. Before joining Kite, Ms. Korfin spent more than a decade
at Celgene Corporation (now part of Bristol Myers Squibb) in a variety of key strategic and operational roles, including overseeing
the global development programs for Revlimid® in lymphoma and chronic lymphocytic leukemia. She also led Celgene Corporation’s
oncology sales force of over 120 representatives responsible for Abraxane®, which is now a standard of care in pancreatic
cancer. Ms. Korfin holds an M.B.A. from Harvard Business School and a B.S. in Pharmacy from Rutgers University. She is a Registered
Pharmacist in New Jersey. She is also on the Board of Trustees of BioNJ, the organization that represents the biotechnology industry
for New Jersey.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Josh
Patterson </i>has served as our General Counsel and Chief Compliance officer since August 2021. Prior to joining Gamida Cell,
Mr. Patterson served as General Counsel between March 2020 and August 2021 and as Vice President, Legal and Corporate Secretary
between March 2018 and March 2020 for Akcea Therapeutics, Inc., a biotechnology company that merged with Ionis Pharmaceuticals,
Inc. in 2020. Between December 2006 and March 2018, Mr. Patterson served in various leadership positions at Ionis Pharmaceuticals,
Inc. (Nasdaq: IONS), a biotechnology company that specializes in discovering and developing RNA-targeted therapeutics, including
as Executive Director and Deputy General Counsel. Mr. Patterson holds a B.A. from Carthage College and a J.D. from the Syracuse
University College of Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Employee
Directors</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Robert
I. Blum</i> joined our board of directors as Chairman in September 2018. Since January 2007, Mr. Blum has served as the President
and Chief Executive Officer of Cytokinetics, Inc. (Nasdaq: CYTK), a late stage biopharmaceutical company that develops potential
treatments for people with diseases characterized by impaired muscle function which Mr. Blum helped to found. Prior to Cytokinetics,
Mr. Blum served in senior business development and marketing positions at COR Therapeutics, Inc. (which was acquired by Millennium
Pharmaceuticals, Inc.) and in various commercial and business planning roles at Marion Laboratories, Inc. (now part of Sanofi
S.A.) and Syntex Corporation (now part of Roche Holding AG). Mr. Blum received B.A. degrees in Human Biology and Economics from
Stanford University and an M.B.A. from Harvard Business School.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Anat
Cohen-Dayag, Ph.D.</i>, has served on our board of directors since January 2022. Dr. Cohen-Dayag has over 25 years of experience
in the biotech industry, both in R&amp;D and executive leadership roles. Since 2010, Dr. Cohen-Dayag has served as President and
Chief Executive Officer and a member of the Board of Directors of Compugen Ltd. (Nasdaq: CGEN). Under her leadership, Compugen
transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing
an innovative immuno-oncology pipeline originating from the company’s computational discovery platforms. Prior to Compugen,
Dr. Cohen-Dayag served as Head of R&amp;D and was a member of the executive management team of Mindsense Biosystems Ltd., a biotechnology
company engaged in the development of biomarkers for mental disorders. She also serves on the board of Pyxis Diagnostics Ltd.,
an Israeli biotechnology company focused on developing a unique platform to identify predictive biomarkers in the field of immuno-oncology.
Dr. Cohen-Dayag holds a B.Sc. in Biology from Ben-Gurion University, an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology,
both from the Weizmann Institute of Science.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Ofer Gonen</i> joined
our board of directors as a director in February 2015. Mr. Gonen currently serves as Chief Executive Officer at Call Biotechnology Industries,
or CBI, (TASE: CBI). Mr. Gonen has more than 20 years of experience in managing life science investments and business collaborations in
both the United States and Israel. Mr. Gonen serves as a board member of several private and publicly-traded portfolio companies of CBI,
including MediWound (Nasdaq: MDWD) and Cactus (Nasdaq: CCTS), as well as a managing partner at the Anatomy Medical Fund. Before joining
CBI, Mr. Gonen was the General Manager of Biomedical Investments Ltd., a Partner at Arte Venture Group, as well as a technology consultant
to various Israeli venture capital funds. Mr. Gonen gained extensive experience in R&amp;D and management of defense-oriented projects
within the prestigious “Talpiot” program of the Israeli Defence Forces. Mr. Gonen holds a B.Sc. in Physics, Mathematics and
Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Naama
Halevi Davidov, Ph.D.,</i> has served on our board of directors since January 2022. Dr. Halevi Davidov has served as strategic
financial advisor to Joytunes Ltd., a business-to-consumer wellbeing education app, since April 2021. She also served as a strategic
financial advisor to Gloat Pty Ltd., a global talent marketplace platform, from March 2020 through November 2021, and to Healthy
IO Ltd., a manufacturer and marketer of medical equipment from March 2019 through April 2021. Prior to that, Dr. Halevi Davidov
was Chief Financial Officer of Kaltura, Inc. (Nasdaq: KLTR), a global software company, from November 2012 to August 2017. Dr.
Halevi Davidov has served on the board of directors of Kaltura, Inc. since July 2021. Dr. Halevi Davidov is a Certified Public
Accountant in Israel. She received a Ph.D. in Strategy, an M.B.A. and a B.A. in Accounting and Economics, all from Tel Aviv University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Kenneth I. Moch </i>has
served on our board of directors since July 2016. Mr. Moch has more than 35 years of experience in managing and financing biomedical technologies,
and has played a key role in building five life science companies. He currently serves as president of Euclidean Life Science Advisors,
LLC, where he provides management and advisory services for early-stage biotechnology companies. From 2016 to 2020, Mr. Moch served as
the president and chief executive officer of Cognition Therapeutics, Inc., a company developing therapies for Alzheimer’s disease.
He previously was the managing partner of The Salutramed Group, LLC, and serves as the chief executive officer of several life sciences
companies, including of Chimerix, Inc., an antiviral therapeutics company focused on stem cell transplantation, and Biocyte Corporation,
which pioneered the use of cord blood stem cell storage and transplantation. He began his career in biotech as a co-founder of The Liposome
Company, the first lipid nanoparticle company. Mr. Moch also serves as a director of Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE). In
the public policy arena, Mr. Moch served for over 15 years as a member of the governing board of the Biotechnology Innovation Organization,
or BIO, including serving as Chair of BIO’s Bioethics Committee and is a previous Chairman of BioNJ. He is a Founding Member of
the New York University Working Group on Compassionate Use and Pre-Approval Access, and a Faculty Affiliate of the Division of Medical
Ethics, Department of Population Health, NYU School of Medicine. Mr. Moch holds an A.B. in Biochemistry from Princeton University and
an M.B.A. with emphasis in Finance and Marketing from the Stanford Graduate School of Business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shawn
C. Tomasello</i> has served on our board of directors since June 2019. From 2015 to 2018, Ms. Tomasello as the Chief Commercial
Officer of Kite Pharma. Prior to joining Kite Pharma, from 2014 to 2015, Ms. Tomasello served as the Chief Commercial Officer
of Pharmacyclics Inc. (Nasdaq: PCYC), a pharmaceutical manufacturer acquired by Abbvie, Inc. From April 2005 to August 2014, Ms.
Tomasello was employed at Celgene Corporation, most recently as President of the Americas, Hematology and Oncology, where she
was responsible for all aspects of the commercial organization encompassing multiple brands spanning 11 indications. Ms. Tomasello
serves on the board of directors of Urogen Pharma Ltd. (NASDAQ: URGN), Mesoblast Limited (ASX: MSB), Centrexion Therapeutics,
TCR2, and 4DMT. Ms. Tomasello earned her B.S. in Marketing from the University of Cincinnati and her M.B.A. from Murray State
University, Kentucky.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stephen
T. Wills</i> has served on our board of directors since June 2019. Mr. Wills currently serves as the Chief Financial Officer (since
1997), and Chief Operating Officer (since 2011), of Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company developing
targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial
potential. Mr. Wills has served on the boards of directors of MediWound Ltd. (Nasdaq: MDWD), since April 2017, and as Chairman
since January 2018, and of Amryt Pharma, plc (Nasdaq: AMYT), a biopharmaceutical company focused on developing and delivering
treatments to help improve the lives of patients with rare and orphan diseases, since September 2019 (Chairman of audit committee
and member of the finance committee). Mr. Wills also serves on the board of trustees and executive committee of The Hun School
of Princeton, a college preparatory day and boarding school, since 2013, and its Chairman since June 2018. Mr. Wills served on
the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and
as Chairman from December 2016 to December 2019, when Caliper was acquired by PSI Corporation. Mr. Wills, a certified public accountant,
earned a B.S. in accounting from West Chester University, and an M.S. in taxation from Temple University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diversity
of the Board of Directors.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Diversity Matrix (As of March 15, 2022)</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; font-size: 10pt; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Number of Directors</b></span></td>
    <td style="font-size: 10pt; width: 2%">&nbsp;</td>
    <td style="text-align: justify; font-size: 10pt; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8</b></span></td></tr>
  </tbody></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="text-align: center; vertical-align: top; width: 54%">&nbsp;</td>
    <td style="text-align: center; width: 2%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female</b></span></td>
    <td style="text-align: center; width: 2%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male</b></span></td>
    <td style="text-align: center; width: 2%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Binary</b></span></td>
    <td style="text-align: center; width: 2%">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Did Not Disclose Gender</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 2%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="9" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part I: Gender Identity</b></span></td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part II: Demographic Background</b></span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">African American or Black</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alaskan Native or Native American</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asian</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hispanic or Latinx</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two or More Races or Ethnicities</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did Not Disclose Demographic Background</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  </tbody></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>



</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delinquent
Section 16(a) Reports</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
of Ethics</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our
principal executive officer, principal financial and accounting officer or controller, or persons performing similar functions,
known as the Code of Ethics and Business Conduct. The Code of Ethics and Business Conduct is available on our website at https://www.gamida-cell.com
under the Corporate Governance section of our Investors &amp; Media page. If we make any substantive amendments to, or grant any
waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment
or waiver on our website or in a current report on Form 8-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
Changes to Procedures by which Shareholders may Recommend Nominees</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Practices</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association provide that we may have between 5 and 11 directors. Our board of directors currently
consists of eight directors. Our directors are divided into three classes with staggered three-year terms. Each class of directors
consists, as nearly as possible, of one-third of the total number of directors constituting the entire board of directors. At
each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term
of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting
following such election or re-election, such that from 2019 and after, at each annual general meeting the term of office of only
one class of directors will expire. Each director will hold office until the annual general meeting of our shareholders in which
his or her term expires, unless they are removed by a vote of 60% of the total voting power of our shareholders at a general meeting
of our shareholders or upon the occurrence of certain events, in accordance with the Israeli Companies Law and our amended and
restated articles of association.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are divided among the three classes as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Class I directors are Shawn C. Tomasello and Stephen T. Wills, and their terms will expire at the annual general meeting of
the shareholders to be held in 2022 and when their successors are elected and qualified;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the Class II directors are Kenneth I. Moch, Anat Cohen-Dayag and Naama Halevi Davidov, and their term will expire at the annual
general meeting of the shareholders to be held in 2023 and when his successors are elected and qualified; and</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the Class III directors are Robert I. Blum, Julian Adams and Ofer Gonen, and their terms will expire at the annual general meeting
of the shareholders to be held in 2024 and when their successors are elected and qualified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our ordinary shares do not have cumulative voting rights in the election of directors, the holders of a majority of the voting
power represented at a shareholders meeting have the power to elect all our directors up for election or re-election.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if a director’s office becomes vacant, the remaining serving directors may continue to act in any manner, provided
that their number is not less than the minimum number specified in our amended and restated articles of association. If the number
of serving directors is lower than five, then our board of directors may only act in an emergency or to fill the office of director
which has become vacant up to a number equal to the minimum number provided for in our amended and restated articles of association,
or in order to call a general meeting of the Company’s shareholders for the purpose of electing directors to fill any of
our vacancies. In addition, the directors may appoint, immediately or of a future date, additional director(s) to serve until
the annual general meeting of our shareholders at which the term of the applicable class to which such director was assigned expires,
provided that the total number of directors in office shall not exceed 11 directors. The office of a director that was appointed
by our board of directors to fill any vacancy shall only be for the remaining period of time during which the director whose service
has ended and so filled would have held office.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law and our amended and restated articles of association, a resolution proposed at any meeting of our board of
directors at which a quorum is present is adopted if approved by a vote of a majority of the directors present and eligible to
vote. A quorum of the board of directors requires at least a majority of the directors then in office who are lawfully entitled
to participate in the meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the chief executive officer of a public company may not serve as the chairman of the board of directors of
the company unless approved by the holders of a majority of the shares of the company represented at the meeting in person or
by proxy or written ballot, for a period that shall not exceed three years for each shareholder approval, provided that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    least a majority of the shares of non-controlling shareholders or shareholders that do not have a personal interest in the
    approval voted at the meeting are voted in favor (disregarding abstentions); or</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    total number of shares of non-controlling shareholders or shareholders that do not have a personal interest in the approval
    voted against the proposal does not exceed 2% of the aggregate voting rights in the company.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Companies Law, our board of directors must determine the minimum number of directors who are required to have
financial and accounting expertise. Under applicable regulations, a director with financial and accounting expertise is a director
who, by reason of his or her education, professional experience and skill, has a high level of proficiency in and understanding
of business accounting matters and financial statements. He or she must be able to thoroughly comprehend the financial statements
of the listed company and initiate debate regarding the manner in which financial information is presented. In determining the
number of directors required to have such expertise, the board of directors must consider, among other things, the type and size
of the company and the scope and complexity of its operations. Our board of directors has determined that we require at least
one director with the requisite financial and accounting expertise. Robert Blum has such financial and accounting expertise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Observers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novartis
Pharma A.G., or Novartis, has the right to appoint a non-voting observer to our board of directors, subject to them holding at
least 4% of the total voting power of our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alternate
directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association provide, as allowed by the Companies Law, that any director may, by written notice
to us, appoint another person who is qualified to serve as a director to serve as an alternate director. The alternate director
will be regarded as a director. Under the Companies Law, a person who is not qualified to be appointed as a director, a person
who is already serving as a director or a person who is already serving as an alternate director for another director, may not
be appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate
director for a member of a committee of the board of directors as long as he or she is not already serving as a member of such
committee. The term of appointment of an alternate director may be for one meeting of the board of directors or until notice is
given of the cancellation of the he appointment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>External
directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, companies incorporated under the laws of the State of Israel that are “public companies,” including
companies with shares listed on The Nasdaq Global Market, are required to appoint at least two external directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to regulations promulgated under the Companies Law, companies with shares traded on a U.S. stock exchange, including The Nasdaq
Global Market, may, subject to certain conditions, “opt out” from the Companies Law requirements to appoint external
directors and related Companies Law rules concerning the composition of the audit committee and compensation committee of the
board of directors. In accordance with these regulations, we elected to “opt out” from the Companies Law requirement
to appoint external directors and related Companies Law rules concerning the composition of the audit committee and compensation
committee of the board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
these regulations, the exemptions from such Companies Law requirements will continue to be available to us so long as: (i) we
do not have a “controlling shareholder” (as such term is defined under the Companies Law), (ii) our shares are traded
on a U.S. stock exchange, including The Nasdaq Global Market, and (iii) we comply with the director independence requirements,
the audit committee and the compensation committee composition requirements, under U.S. laws (including applicable Nasdaq Rules)
applicable to U.S. domestic issuers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
and talent committee</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of any public company must appoint a compensation committee. Our compensation and talent
committee, which consists of Ofer Gonen, Stephen T. Wills, Kenneth I. Moch and Shawn C. Tomasello, assists our board of directors
in determining compensation for our directors and officers. Mr. Moch serves as chairperson of the committee. Our board of directors
has determined that each member of our compensation committee is independent under the Nasdaq Rules, including the additional
independence requirements applicable to the members of a compensation committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
function of the compensation and talent committee is described in the approved charter of the committee and includes, among other
things, (a) assisting the board in fulfilling its oversight responsibilities with respect to our compensation policies, plans
and programs, and to review and recommend to the board for approval the compensation to be paid to our executive officers and
directors; (b) assisting the board in fulfilling its responsibilities to ensure processes and programs are in place to attract,
motivate, reward and retain top talent to the our executive officer ranks; (c) preparing and reviewing, as applicable, certain
reports and disclosures as required by applicable rules and regulations in effect from time to time; (d) assisting the board in
fulfilling its responsibilities related to the compensation of directors, the chief executive officer and other “office
holders” (as defined under the Companies Law); (e) assisting the Board in administering the Company’s equity incentive
plans; and (f) making such other determinations in respect of compensation, compensation practices and related matters as may
be required by a compensation committee under the rules of Nasdaq Stock Market or the Companies Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the compensation and talent committee charter is available on the “Investors &amp; Media – Corporate Governance
– Documents&nbsp;&amp; Charters” page of our website www.gamida-cell.com.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and corporate governance committee</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee consists of Robert Blum and Ofer Gonen. Mr. Blum serves as chairperson of the committee.
The function of the nominating and corporate governance committee is described in the approved charter of the committee and includes,
among other things, (a) identifying, reviewing and evaluating candidates to serve as members of the board of directors, (b) recommending
nominees for election as directors, and reviewing and evaluation of incumbent members of the board of directors; (b) making recommendations
to the board of directors regarding corporate governance guidelines and matters; and (c) overseeing all aspects of the Company’s
corporate governance functions and ethical conduct.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the nominating and corporate governance committee charter is available on the “Investors &amp; Media – Corporate
Governance – Documents&nbsp;&amp; Charters” page of our website www.gamida-cell.com.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Science
and technology committee</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, the board of directors formed a science and technology committee, which initially consisted of Michael S. Perry and
Julian Adams. Dr. Perry served as chairperson of the committee until his resignation. Anat Cohen-Dayag was appointed to serve
as chairperson of the science and technology committee in January 2022. The function of the science and technology committee is
described in the approved charter of the committee, and includes the review of Company matters relating to scientific and technologic
capabilities and programs, reporting to the board of directors regarding such review to help facilitate the board of director’s
oversight of the Company’s scientific strategic direction and investment in R&amp;D and technology. The committee also discusses
significant emerging trends and issues in science and technology and considers the potential impact thereof on the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compliance
committee </i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2021, the board of directors formed a compliance committee, which consists of Shawn C. Tomasello and Robert Blum. Ms. Tomasello
serves as chairperson of the committee. The function of the compliance committee is described in the approved charter of the committee
and includes assisting the board of directors in overseeing the Company’s development, operation and monitoring of a compliance
program consistent with the Office of Inspector General’s compliance program guidance for pharmaceutical manufacturers (and
any foreign equivalent guidance provided by relevant authorities outside the United States), as well as the identification and
evaluation of the Company’s principal legal and regulatory compliance risks attendant to operating in the health care and
life sciences industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
committee </i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of any public company must appoint an audit committee. Our audit committee consists
of Stephen Wills, Kenneth I. Moch and Naama Halevi Davidov. Mr. Wills serves as chairperson of the committee. Our board of directors
affirmatively determined that Stephen Wills is an audit committee financial expert as defined by the SEC rules and has the requisite
financial experience as defined by the Nasdaq Stock Market Listing Rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
function of the audit committee is described in the approved charter of the committee and includes, among other things, (a) overseeing
our accounting and financial reporting processes, the audit of our financial statements, the effectiveness of our internal control
over financial reporting, systems of disclosure controls and procedures, the quality and integrity of our financial statements
and reports, and prepare such reports as may be required of an audit committee under applicable rules and regulations, and the
pre-approval of all audit, audit-related and all permitted non-audit services, if any, by our independent auditor, and the compensation
therefor; (b) deciding whether to approve certain acts and transactions requiring the approval of the committee under the Companies
Law; (c) assisting the board of directors in its oversight of (i) the integrity of our financial statements and other published
financial information, (ii) our compliance with applicable financial and accounting related standards, rules and regulations and
(iii) the selection, retention (subject to shareholder approval), and termination of our independent auditor; (d) determining
whether there are delinquencies in our business management practices, inter alia, by consulting with our internal auditor or independent
auditor, and to suggesting corrective measures to the board of directors; and (e) fulfilling any other duties of the committee
as shall be required under the Companies Law, the applicable rules and regulations promulgated under the Exchange Act or applicable
Nasdaq rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the audit committee charter is available on the “Investors &amp; Media – Corporate Governance – Documents&nbsp;&amp;
Charters” page of our website www.gamida-cell.com.&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval
of transactions with related parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the approval of the audit committee is required to effect specified actions and transactions with office holders
and controlling shareholders and their relatives, or in which they have a personal interest. See “Fiduciary duties and approval
of specified related party transactions under Israeli law” below. The term “controlling shareholder” means any
shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder
is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in a company or has the
right to appoint 50% or more of the directors of the company or its chief executive officer. For the purpose of approving transactions
with controlling shareholders, the term “controlling shareholder” also includes any shareholder that holds 25% or
more of the voting rights of the company if no other shareholder holds more than 50% of the voting rights in the company. For
purposes of determining the holding percentage stated above, two or more shareholders who have a personal interest in a transaction
that is brought for the company’s approval are deemed as joint holders. As of the date of this annual report on Form 20-F,
we do not have a controlling shareholder as defined under the Companies Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Internal
auditor</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of
the audit committee. The role of the internal auditor is, among other things, to examine whether a company’s actions comply
with applicable law and orderly business procedure. Under the Companies Law, the internal auditor cannot be an interested party
or an office holder or a relative of an interested party or an office holder, nor may the internal auditor be the company’s
independent auditor or its representative. An “interested party” is defined in the Companies Law as: (i) a holder
of 5% or more of the issued share capital or voting power in a company, (ii) any person or entity who has the right to designate
one or more directors or to designate the chief executive officer of the company, or (iii) any person who serves as a director
or as a chief executive officer of the company. Our internal auditor is Yisrael Gewirtz, who serves as a partner at Fahn Kanne
Control Management Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiduciary
duties and approval of specified related party transactions under Israeli law</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fiduciary
duties of office holders</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law imposes a duty of care and a duty of loyalty on all office holders of a company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of care of an office holder is based on the duty of care set forth in connection with the tort of negligence under the Israeli
Torts Ordinance (New Version), 5728-1968. The duty of care requires an office holder to act with the degree of proficiency with
which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes,
among others, a duty to use reasonable means, in light of the circumstances, to obtain:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    other important information pertaining to these actions.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of loyalty requires an office holder to act in good faith and for the benefit of the company, and includes, among others,
the duty to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any act involving a conflict of interest between the performance of his or her duties in the company and his or her other
    duties or personal affairs;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any activity that is competitive with the business of the company;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from exploiting any business opportunity of the company for the purpose of gaining a personal benefit for himself or herself
    or for others; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    to the company any information or documents relating to the company’s affairs which the office holder received as a
    result of his or her position as an office holder.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may approve an act specified above that would otherwise constitute a breach of the duty of loyalty of an office holder, provided,
that the office holder acted in good faith, the act or its approval does not harm the company, and the office holder discloses
his or her personal interest, including any related material information or document, a sufficient time before the approval of
such act. Any such approval is subject to the terms of the Companies Law, setting forth, among other things, the stakeholders
of the company entitled to provide such approval, and the methods of obtaining such approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of personal interests of an office holder and approval of acts and transactions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may have and
all related material information or documents relating to any existing or proposed transaction with the company. An interested
office holder’s disclosure must be made promptly and, in any event no later than the first meeting of the board of directors
at which the transaction is considered. An office holder is not obliged to make such disclosure if the personal interest of the
office holder derives solely from the personal interest of his or her relative in a transaction that is not considered as an extraordinary
transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, once an office holder has complied with the above disclosure requirements, a company may approve a transaction
between the company and the office holder or a third-party in which the office holder has a personal interest, or approve an action
by the office holder that would otherwise be deemed a breach of duty of loyalty; however, a company may not approve a transaction
or action that is not performed by the office holder in good faith or unless it is in the company’s interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, unless the articles of association of a company provide otherwise, a transaction with an office holder or a
transaction with a third party in which the office holder has a personal interest and an action of an office holder that would
otherwise be deemed a breach of duty of loyalty, which is not an extraordinary transaction, requires approval of the board of
directors. Our amended and restated articles of association do not provide otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an extraordinary transaction in which an office holder has a personal interest requires approval first by the
company’s audit committee and subsequently by the board of directors. The compensation of, or an undertaking to indemnify
or insure, an office holder who is not a director requires approval first by the company’s compensation committee, then
by the company’s board of directors, and, if such compensation arrangement or an undertaking to indemnify or insure is inconsistent
with the company’s stated compensation policy or if the office holder is the chief executive officer (subject to a number
of exceptions), then such arrangement is subject to a Special Approval for Compensation. Arrangements regarding the compensation,
indemnification or insurance of a director or the chief executive officer of the company require the approval of the compensation
committee, board of directors and, subject to certain exceptions, shareholders by an ordinary majority, in that order, and in
the case of the chief executive officer or under certain circumstances, a Special Approval for Compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director who has a personal interest in a matter that is considered at a meeting of the board of directors or the audit committee
may generally not be present at the meeting or vote on the matter unless a majority of the directors or members of the audit committee
have a personal interest in the matter, or unless the chairman of the audit committee or board of directors (as applicable) determines
that he or she should be present to present the transaction that is subject to approval. If a majority of the directors have a
personal interest in the matter, such matter also requires approval of the shareholders of the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the definition of a “personal interest” includes the personal interest of a person in an action
or a transaction of a company, including the personal interest of such person’s relative or the interest of any corporation
in which the person and/or such person’s relative is a director or chief executive officer, a 5% or more shareholder or
holds 5% or more of the voting rights, or has the right to appoint at least one director or the chief executive officer, but excluding
a personal interest stemming solely from the fact of holding shares in the company. A personal interest also includes (1) a personal
interest of a person who votes according to a proxy of another person, including in the event that the other person has no personal
interest, and (2) a personal interest of a person who gave the proxy to another person to vote on his or her behalf, regardless
of whether the proxy holder has discretion how to vote on the matter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an “extraordinary transaction” which requires approval is defined as any of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction other than in the ordinary course of business;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction that is not on market terms; or</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction that may have a material impact on the company’s profitability, assets or liabilities.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
extraordinary transaction in which an office holder has a personal interest requires approval of the company’s audit committee
followed by the approval of the board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of personal interests of a controlling shareholder and approval of transactions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public
company. See “Item 10. Directors, Executive Officers and Corporate Governance—Board Practices — Audit committee—Approval
of transactions with related parties” for a definition of controlling shareholder. Unless exempted under the Companies Law,
extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, which
includes transactions for the provision of services by a controlling shareholder or his or her relative, whether directly or indirectly,
including through a company controlled by such controlling shareholder, and if such controlling shareholder or relative thereof
is an office holder in the company, any transactions regarding his or her terms of office, require the approval of the audit committee,
the board of directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter
in a shareholders’ meeting. In addition, the shareholder approval must fulfill one of the following requirements, which
we refer to as a Special Majority:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    least a majority of the shares held by shareholders who do not have a personal interest in the transaction and are voting
    at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    shares voted by shareholders who do not have a personal interest in the transaction who vote against the transaction represent
    no more than 2% of the voting rights in the company.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest
with a term of more than three years requires approval once every three years, unless, with respect to certain transactions that
are not related to provision of services or terms of office, the audit committee determines that the longer duration of the transaction
is reasonable given the circumstances related thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arrangements
regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an office holder
require the approval of the compensation committee, board of directors and shareholders by a Special Majority and the terms thereof
may not be inconsistent with the company’s stated compensation policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to regulations promulgated under the Companies Law, certain transactions and arrangements with a controlling shareholder or his
or her relative, or with directors or office holders, which would otherwise require approval of a company’s shareholders,
may be exempt from shareholder approval under certain conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors and Executive Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Directors</i>.
Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent
approval of the board of directors and, unless exempted under regulations promulgated under the Companies Law, the approval of
the shareholders at a general meeting. If the compensation of our directors is inconsistent with our stated compensation policy,
then, those provisions that must be included in the compensation policy according to the Companies Law must have been considered
by the compensation committee and board of directors, and shareholder approval will also be required, provided that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest
    in such matter, present and voting at such meeting, are voted in favor of the compensation package, excluding abstentions;
    or</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter
    voting against the compensation package does not exceed 2% of the aggregate voting rights in the company.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive
officers other than the chief executive officer</i>. The Companies Law requires the approval of the compensation of a public company’s
executive officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company’s
board of directors, and (iii) if such compensation arrangement is inconsistent with the company’s stated compensation policy,
the company’s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation).
However, if the shareholders of the company do not approve a compensation arrangement with an executive officer that is inconsistent
with the company’s stated compensation policy, the compensation committee and board of directors may override the shareholders’
decision if each of the compensation committee and the board of directors provide detailed reasons for their decision.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
amendment to an existing arrangement with an office holder who is not the chief executive officer or a director requires only
the approval of the compensation committee, if the compensation committee determines that the amendment is not material in comparison
to the existing arrangement. However, according to regulations promulgated under the Israeli Companies Law, an amendment to an
existing arrangement with an office holder who is subordinate to the chief executive officer (and who is not a director) shall
not require the approval of the compensation committee, if (i) the amendment is approved by the chief executive officer and the
company’s compensation policy determines that a non-material amendment to the terms of service of an office holder (other
than the chief executive officer) may be approved by the chief executive officer and (ii) the engagement terms are consistent
with the company’s compensation policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
executive officer</i>. Under the Companies Law, the compensation of a public company’s chief executive officer is required
to be approved by: (i) the company’s compensation committee; (ii) the company’s board of directors, and (iii) the
company’s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation).
However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the
compensation committee and board of directors may override the shareholders’ decision if each of the compensation committee
and the board of directors provide a detailed report for their decision. The approval of each of the compensation committee and
the board of directors should be in accordance with the company’s stated compensation policy; however, in special circumstances,
they may approve compensation terms of a chief executive officer that are inconsistent with such policy provided that they have
considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder
approval was obtained (by a special majority vote as discussed above with respect to the approval of director compensation). In
addition, the compensation committee may waive the shareholder approval requirement with regards to the approval of the engagement
terms of a candidate for the chief executive officer position, if they determine that the compensation arrangement is consistent
with the company’s stated compensation policy, and that the chief executive officer did not have a prior business relationship
with the company or a controlling shareholder of the company and that subjecting the approval of the engagement to a shareholder
vote would impede the company’s ability to employ the chief executive officer candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Duties
of Shareholders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an
acceptable manner in exercising its rights and performing its obligations to the company and other shareholders, including, among
other things, when voting at general meetings of shareholders on the following matters:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    amendment to the articles of association;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in the company’s authorized share capital;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    merger; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder also has a general duty to refrain from discriminating against other shareholders.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The remedies generally available
upon a breach of contract will also apply to a breach of the above-mentioned shareholder duties, and in the event of discrimination against
other shareholders, additional remedies are available to the injured shareholder.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote
and any shareholder that, under a company’s articles of association, has the power to appoint or prevent the appointment
of an office holder, or any other power with respect to the company, has a duty to act with fairness towards the company. The
Companies Law does not describe the substance of this duty, except to state that the remedies generally available upon a breach
of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholder’s position
in the company into account.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval
of Private Placements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law and the regulations promulgated thereunder, a private placement of securities does not require approval at a
general meeting of the shareholders of a company; provided however, that in special circumstances, such as a private placement
completed in lieu of a special tender offer or a private placement which qualifies as a related party transaction (see “Item
10. Directors, Executive Officers and Corporate Governance—Board Practices—Fiduciary duties and approval of specified
related party transactions under Israeli law”), approval at a general meeting of the shareholders of a company is required.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exculpation,
Insurance and Indemnification of Office Holders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. A company
may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of the duty of care but only if a provision authorizing such exculpation is included in its articles of
association. Our amended and restated articles of association include such a provision. An Israeli company may not exculpate a
director from liability arising out of a breach of the duty of care with respect to a dividend or distribution to shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law and the Securities Law, 5738—1968, or the Securities Law, a company may indemnify an office holder in
respect of the following liabilities, payments and expenses incurred for acts performed as an office holder, either pursuant to
an undertaking made in advance of an event or following an event, provided a provision authorizing such indemnification is contained
in its articles of association:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability incurred by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement
    or arbitrator’s award approved by a court. However, if an undertaking to indemnify an office holder with respect to
    such liability is provided in advance, then such undertaking must be limited to certain events which, in the opinion of the
    board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and
    to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such
    undertaking shall detail the foreseen events and described above amount or criteria;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including reasonable attorneys’ fees, incurred by the office holder as (1) a result of an investigation
    or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided
    that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial
    liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding
    or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal
    intent; or (2) in connection with a monetary sanction; a monetary liability imposed on him or her in favor of an injured party
    at an Administrative Procedure (as defined below) pursuant to Section 52(54)(a)(1)(a) of the Securities Law;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder or certain compensation payments made to an injured party that were instituted against an office
    holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and
    reasonable attorneys’ fees; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys’ fees, incurred by the office holder or imposed by a court in proceedings instituted
    against him or her by the company, on its behalf or by a third party or in connection with criminal proceedings in which the
    office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal intent.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">“Administrative
Procedure” is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4
(Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or
Interruption of procedures subject to conditions) to the Securities Law.&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law and the Securities Law, a company may insure an office holder against the following liabilities incurred for
acts performed by him or her as an office holder if and to the extent provided in the company’s articles of association:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct
    of the office holder;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to
    believe that the act would not harm the company;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on the office holder in favor of a third party;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section
    52(54)(a)(1)(a) of the Securities Law; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder in connection with an Administrative Procedure instituted against him or her, including reasonable
    litigation expenses and reasonable attorneys’ fees.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to
    the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the
    company;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct
    of the office holder;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    act or omission committed with intent to derive illegal personal benefit; or</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fine, monetary sanction or forfeit levied against the office holder.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee
and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.
See “Item 10. Directors, Executive Officers and Corporate Governance—Board Practices—Fiduciary duties and approval
of specified related party transactions under Israeli law.”</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association permit us to, exculpate, indemnify and insure our office holders as permitted under
the Companies Law. Our office holders are currently covered by a directors and officers’ liability insurance policy. As
of the date of this registration statement, no claims for directors’ and officers’ liability insurance have been filed
under this policy, we are not aware of any pending or threatened litigation or proceeding involving any of our directors or officers
in which indemnification is sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification
by any director or officer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into agreements with each of our directors and executive officers exculpating them, to the fullest extent permitted
by law, from liability to us for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them
to the fullest extent permitted by law. The insurance is subject to our discretion depending on its availability, effectiveness
and cost. Effective as November 17, 2021, the maximum amount set forth in such agreements is (1) with respect to indemnification
in connection with a public offering by the Company of our securities, the gross proceeds raised by us and/or any selling shareholder
in such public offering, and (2) with respect to all other permitted indemnification, the greater of (i) an amount equal to 25%
of our shareholders’ equity on a consolidated basis, according to the Company’s most recent financial statements as
of the time of the actual payment of indemnification; (ii) $150 million and (iii) 40% of the Company Total Market Cap, which means
the average closing price of the Company’s ordinary shares over the 30 trading days prior to the actual payment of indemnification
multiplied by the total number of issued and outstanding shares of the Company as of the date of actual payment). In the opinion
of the SEC, indemnification of directors and executive officers for liabilities arising under the Securities Act however, is against
public policy and therefore unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
11. EXECUTIVE COMPENSATION</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
Compensation Table</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information with respect to the fiscal years ended December 31, 2021 and 2020 regarding the compensation
of the principal executive officer, the two most highly paid executive officers, and two additional individuals for whom disclosure
would have been provided but for the fact that they were not serving as an executive officer at the end of fiscal year 2021. <span>In
addition, the table below reflects the compensation granted to our five most highly compensated office holders (as defined in
the Companies Law) during or with respect to the year ended December 31, 2020 and 2021, or the </span>Covered Executives:</span></p><div>

</div><p style="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Name
    and Principal Position<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Year</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Salary</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Non-Equity
    Incentive Plan Compensation</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Share
    Awards<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Option
    Awards<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>All
    Other Compensation<sup>(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td></tr>
  <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td>
    <td colspan="25" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>In
    thousands USD</b></span></td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 30%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Dr. Julian Adams –</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 8%; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">547</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">125</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">296</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">1,049</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">35</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2,053</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">532</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">155</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">804</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">31</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">1,522</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Shai Lankry –</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">321</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">132</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">234</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">350</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">111</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">1,148</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Chief Financial Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">253</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">53</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">313</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">638</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Michele Korfin –</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">429</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">106</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">866</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Chief Operating and Commercial Officer<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">159</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">267</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">438</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Jas
Uppal –</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">409</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">65</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">176</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">163</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">815</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Chief Regulatory and Quality Officer<sup>(5)</sup></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">453</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">163</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">650</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
    <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Dr. Ronit Simantov –</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">434</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">113</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">305</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">1,186</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Chief Medical and Chief Scientific Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">390</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">120</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">269</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">829</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table><div>


</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%; font-family: Times New Roman, Times, Serif"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                         Covered Executives were employed on a full time (100%) basis during their term of employment
                                         in 2021.</span></td>
</tr></tbody></table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="text-align: justify; width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                         further information about the assumption used for the valuation of the Share Awards and
                                         Option awards, see note 11 – Share-based Compensation in the financial statements
                                         included elsewhere in this annual report.</span></td>
</tr></tbody></table><div>


</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: justify; width: 0px"></td>
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Includes leased car expenses, relocation related expenses, medical and other insurance, and 401(k) contributions made by the Company.</span></td></tr>
  </tbody></table><div>
</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="text-align: justify; width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
                                         Korfin joined us as Chief Commercial and Chief Operating Officer in August 2020.</span></td>
</tr></tbody></table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="text-align: justify; width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
                                         Uppal joined us as Chief Regulatory and Quality Officer in January 2020.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to&nbsp;Summary&nbsp;Compensation&nbsp;Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our executive compensation
program is designed to attract, motivate and retain highly experienced leaders who will contribute to our success and enhance shareholder
value, while demonstrating professionalism in a highly achievement-oriented culture. Our program is based on merit and rewards excellent
performance in the long term, and it aims to embed our core values within our leadership team’s behavior.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
that end, our program is designed:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         closely align the interests of the executive officers with those of our shareholders
                                         in order to enhance shareholder value;</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         align a significant portion of the executive officers’ compensation with our short
                                         and long-term goals and performance;</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         provide the executive officers with a structured compensation package, including competitive
                                         salaries, performance-motivating cash and equity incentive programs and benefits;</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         strengthen the retention and the motivation of executive officers in the long term, and
                                         to be able to present to each executive officer an opportunity to advance in a growing
                                         organization;</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         provide appropriate awards in order to incentivize superior individual performance; and</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         maintain consistency in the way executive officers are compensated.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive compensation program was prepared taking into account our size and business and financial characteristics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Role
of the Compensation Committee and Executive Officers in Setting Executive Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee of our board of directors is responsible for determining our executives’ compensation. During the
past fiscal year, after taking into consideration the six factors described above, the compensation committee engaged Radford,
which is part of Aon plc, as its compensation consultant. Our compensation committee selected Radford based on Radford’s
general reputation in the industry. The compensation committee requested that Radford:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluate
                                         the efficacy of our existing compensation strategy and practices in supporting and reinforcing
                                         our long-term strategic goals; and</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assist
                                         in refining our compensation strategy and in developing and implementing an executive
                                         compensation program to execute that strategy.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of its engagement, the compensation committee also requested that Radford develop a group of comparator companies and to
perform analyses of competitive performance and compensation levels for that group, and finally, to develop recommendations for
our executive compensation program that were presented to the compensation committee for its consideration. Following an active
dialogue with Radford, the compensation committee approved the recommendations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the compensation committee has made significant adjustments to annual compensation, determined bonus and equity awards and established
new performance objectives at one or more meetings held during the first quarter of the year. However, the compensation committee
also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level
strategic issues, such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends,
plans or approaches to compensation, at various meetings throughout the year. Generally, the compensation committee’s process
comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the
current year. For all executives other than the chief executive officer, our compensation committee typically reviews and discusses
each executive’s performance and his or her proposed compensation with our chief executive officer. Based on those discussions
and at its discretion, the compensation committee then determines the compensation of each executive officer for approval by the
board of directors. The chief executive officer may not participate in, or be present during, any deliberations or determinations
of the compensation committee regarding his compensation and his compensation is subjected to shareholder approval. The compensation
committee evaluates the chief executive officer and makes recommendations to the board of directors regarding the chief executive
officer’s compensation, which is then approved by the full board of directors in its discretion. In determining the performance
and compensation of all executives and directors, as part of its deliberations, the compensation committee may review and consider,
as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets
that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director
stock ownership information, company stock performance data, analyses of historical executive compensation levels and current
company-wide compensation levels, as well as recommendations from the committee’s compensation consultant, including analyses
of executive and director compensation paid at other companies identified by the consultant.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee also evaluates our executive compensation program in light of our shareholders’ views and our transforming
business needs and expects to continue to consider the outcome of our “say on pay” votes and our shareholders’
views when making future executive compensation decisions. The compensation programs for our executives are also subject to the
approval of our board of directors and in the case of our chief executive officer and directors, and certain other cases, the
approval of our shareholders. For additional information regarding our executive compensation program, see “Item 10. Directors,
Executive Officers and Corporate Governance—Compensation of Directors and Executive Officers.”</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive&nbsp;Compensation&nbsp;Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual compensation arrangements for our named executive officers consist of an annual base salary and long-term incentive compensation
in the form of equity awards. Our named executive officers are also eligible to receive short-term incentive compensation in the
form of annual incentive awards, which may be paid in cash or equity-based awards. We have historically emphasized the use of
equity to provide incentives for our named executive officers, to focus on the growth of our overall enterprise value and, correspondingly,
to create sustainable value for our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Annual
Base Salary</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into agreements with each of our named executive officers that establish annual base salaries, which are generally
reviewed and approved in the first quarter of the fiscal year by our compensation committee. Annual base salaries are intended
to provide a fixed component of compensation to our named executive officers, in order to compensate our named executive officers
for the satisfactory performance of their duties, reflecting their experience, expertise, roles and responsibilities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals
with superior talent. Merit-based increases to salaries are based on our chief executive officer’s assessment of the individual
executive’s performance, the recommendations made by the chief executive officer and the competitive market in which the
Company operates for talent.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the annual base salaries for each of our named executive officers for 2021 and 2020, as determined by
the board of directors or compensation committee, as applicable:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021
    Base Salary<br> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2020
    Base Salary<br> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Dr.
    Julian Adams – Chief Executive Officer</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">550,020</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">534,000</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Shai
    Lankry – Chief Financial Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">315,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">243,810</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Michele
    Korfin – Chief Operating and Commercial Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">429,781</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">425,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Jas
    Uppal – Chief Regulatory and Quality Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">380,800</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">374,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Dr. Ronit Simantov – Chief Medical and Chief Scientific Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">442,960</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">392,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Annual
Incentive Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers are eligible to receive annual incentive compensation based on the satisfaction of individual and corporate
performance objectives established by the board of directors. Each named executive office has a target annual incentive opportunity,
calculated as a&nbsp;percentage of annual base salary, and may earn more or less than the target amount based on our company’s
and his or her individual performance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2021, the target annual incentive opportunities as a percentage of base salary for our named executive officers were 50% for Dr.
Julian Adams, 40% for Michele Korfin, 35% for Shai Lankry, 35% for Dr. Ronit Simantov and 25% for Jas Uppal. The amounts of any
annual incentives earned are determined after the end of the year, based on the achievement of the designated corporate and individual
performance objectives, and may be paid in cash or equity.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2021 and 2020, annual incentives were earned based on the compensation committee’s assessment of each executive’s
respective performance. The amounts of such annual incentives, which are set forth in the “Summary Compensation Table”
above, were recommended by the compensation committee and approved by the board of directors in January&nbsp;2022 and February&nbsp;2021
based on each executive’s and our corporate performance in 2021 and 2020, respectively.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors determined that we attained our corporate goals for 2021 and 2020 at the levels of 25% and 50%, respectively,
and approved individual performance incentives for each named executive officer for each such year. The annual incentives paid
to the named executive officers for performance in 2021 and 2020 are included in the “Non-Equity Incentive Plan&nbsp;Compensation”
column of the Summary Compensation Table above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity-Based
Awards</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
equity-based incentive awards granted to our named executive officers are designed to align the interests of our named executive
officers with those of our shareholders. Vesting of equity awards is generally tied to each officer’s continuous service
with us and serves as an additional retention measure. Our executives generally are awarded an initial new hire grant upon commencement
of employment and thereafter on an annual basis, subject to the discretion of the Board or Compensation Committee, as applicable.
The equity awards described in this section are included in the “Option Awards” column of the Summary Compensation
Table above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Retirement&nbsp;Benefits&nbsp;and&nbsp;Other&nbsp;Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers did not participate in, or otherwise receive any benefits under, any pension, retirement or deferred
compensation plan sponsored by us during 2021 or 2020, except for customary 401K matching contribution for our U.S. based named
executive officers. Our named executive officers are eligible to participate in our benefit programs on the same basis as all
employees of our company. We generally do not provide perquisites or personal benefits to our named executive officers except
in limited circumstances, and we did not provide any perquisites or personal benefits to our named executive officers in 2021
or 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agreements
with Our Named Executive Officers and Potential Payments upon Termination or Change in Control</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement or a consulting with each of our named executive officers that provide for the basic
terms of their employment, including base salary, annual incentive opportunity and equity grants, as well as certain severance
and change of control benefits. Each of our named executive officers other than Shai Lankry is employed at will and may be terminated
at any time for any reason.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Julian Adams</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an at-will employment agreement with Dr. Julian Adams in November 2017, which agreement has been amended from time
to time. Under the terms of his amended employment agreement, Dr. Adams is eligible to receive a base salary of $550,000 with
an annual target incentive opportunity of up to 50% of his annual base salary. In connection with his employment agreement, Dr.
Adams entered into a covenant not to disclose our confidential information during his employment term and an assignment of intellectual
property rights. Subject to certain conditions, Dr. Adams is also subject to non-competition and non-solicitation provisions during
his employment term and for a period of 12&nbsp;months thereafter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential
Payments Upon Termination or Change in Control</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination of his employment, subject to certain conditions, Dr. Adams is entitled to (i) for a period of eight months following
the date on which his employment is terminated, if such termination is by the company without cause, or if he resigns for good
reason (each, as defined in his amended employment agreement); and (ii) for a period of three months following the date termination
if he resigns or is terminated for any other reason: (a) a lump-sum payment of his annual cash incentive target gross bonus (pro-rated
for the portion of that year until his last day of employment), and (b) monthly payments equal to Dr. Adams’s monthly base
salary as well as health insurance and disability benefit premiums.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a change in control of the company, if Dr. Adams’s employment is terminated by the company without cause, or
if he resigns on account of good reason (each, as defined in Dr. Adams’s employment agreement), in each case within 12 months
following such change in control, Dr. Adams will be entitled to a payment equal to his annual target bonus, as well as to acceleration
of the vesting of all of his outstanding equity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shai
Lankry</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Mr.&nbsp;Shai Lankry in April&nbsp;2018 and following Mr. Lankry’s relocation
to the United States on November 1, 2021, he signed a new employment agreement dated December 15, 2021, or the US Agreement. Under
the terms of his US Agreement, Mr.&nbsp;Lankry is eligible to receive a base salary of $315,000 and an annual target incentive
opportunity of 35% of his annual base salary. In addition, Mr. Lankry is entitled to reimbursement of the expenses and fees associated
with Mr. Lankry’s obtaining authorization to work in the United States and relocation expenses of up to $100,000. In connection
with his employment agreement, Mr.&nbsp;Lankry entered into a covenant not to disclose our confidential information during his
employment term and an assignment of intellectual property rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential
Payments Upon Termination or Change in Control</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Lankry’s employment may be terminated (i) by us at any time for cause (as defined in Mr. Lankry’s employment agreement),
or (ii) following November 1, 2022, by us or Mr. Lankry for any reason. In the event of a termination by the company for any reason
other than for cause, the company will give Mr. Lankry six months’ notice of such termination, and in the event of Mr. Lankry’s
resignation for any reason, he shall give the company one month’s notice. In addition, in the event that the Mr. Lankry
is terminated by the company or a successor entity without cause prior to the six-month anniversary of a change in control of
the company, Mr. Lankry will be entitled to accelerated vesting of any then unvested outstanding equity he holds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Michele
Korfin</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Ms.&nbsp;Korfin in August 2020 for an unspecified time period, with a notice period
of one month. Under the terms of her employment agreement, Mrs.&nbsp;Korfin is eligible to receive a base salary of $429,781 and
an annual target incentive opportunity of 40% of her annual base salary. In connection with her employment agreement, Mrs. Korfin
entered into a covenant not to disclose our confidential information during her employment term and an assignment of intellectual
property rights. Ms. Korfin is also subject to a non-competition provision for 18 months following a termination for cause or
resignation for good reason, and for 12 months following a termination for any other reason.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential
Payments Upon Termination or Change in Control</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Ms. Korfin’s employment is terminated by the company at any time without cause, or if she resigns on account of good reason
(each, as defined in Ms. Korfin’s employment agreement), subject to certain conditions, Ms. Korfin will be entitled to a
lump sum severance payment equal to six months’ base salary, as well as additional monthly payments of her base salary and
COBRA coverage for six months following the date of her termination.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a change in control of the company, 50% of Ms. Korfin’s unvested equity awards will vest as of immediately
prior to such change in control, and if Ms. Korfin is terminated by the company without cause or she resigns for good reason,
in either case, within twelve months following a change in control of the company, all of her equity awards shall fully vest as
of immediately prior to such termination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jas
Uppal</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a consulting agreement with Ms. Jas Uppal in January 2020. Under the terms of the consulting agreement, Ms. Juppal
is paid a consulting fee of £1,150 per day. She is also eligible to receive a discretionary success fee under such conditions
as the Company may determine. The consulting agreement includes covenants not to disclose our confidential information during
her employment term and an assignment of intellectual property rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Ronit Simantov</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Dr.&nbsp;Ronit Simantov in April 2017 for an unspecified time period, with a notice
period of one month. Under the terms of her employment agreement, Dr.&nbsp;Simantov is eligible to receive a base salary of $442,960
and an annual target incentive opportunity of 35% of her annual base salary, as well as a one-time signing bonus of $50,000. In
connection with her employment agreement, Dr.&nbsp;Simantov entered into a covenant not to disclose our confidential information
during her employment term and an assignment of intellectual property rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential
Payments Upon Termination or Change in Control</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Dr.&nbsp;Simantov’s employment is terminated by the company at any time without cause, or if she resigns for good reason
(each, as defined in Dr. Simantov’s employment agreement), Dr. Simatov will be entitled to six months of severance payments
equal to her monthly base salary as well as health insurance and disability benefit premiums, in each case as in effect on the
date of Dr. Simantov’s termination of employment.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the event that the Dr. Simantov is terminated by the company or a successor entity without cause prior to the 12-month
anniversary of a change in control of the company, Dr. Simantov will be entitled to accelerated vesting of any then unvested outstanding
equity she holds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
Equity Awards at Fiscal Year End 2021</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                         Awards</b></span></p>

</td><td style="padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
                                         Awards</b></span></p>

</td><td style="padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                         of securities underlying unexercised options (#) exercisable</b></span></p>

</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                         of securities underlying unexercised options (#) unexercisable</b></span></p>

</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                         exercise price ($)</b></span></p>

</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                         expiration date</b></span></p>

</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                         of shares</b></span></p>
                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or
                                         units of stock</b></span></p>
                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>that
                                         have not vested (#)</b></span></p>

</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
                                         value of shares of units of stock that have not vested ($)</b></span></p>

</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Julian
    Adams</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">60,000</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">7.50</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 18%; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                         2, 2027</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Julian
    Adams</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">596,574</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.90</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                         28, 2027</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julian
    Adams<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">94,875</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">43,125</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">11.01</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                         11, 2029</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julian
    Adams<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">43,125</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">94,875</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.70</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
                                         10, 2030</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julian
    Adams<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">31,150</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">296,237</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julian
    Adams<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">186,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">9.51</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
                                         25, 2031</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry<sup>(5)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">163,118</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">23,303</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.90</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
                                         14, 2028</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry<sup>(6)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">26,125</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">11,875</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">11.01</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                         14, 2029</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">16,625</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">21,375</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.70</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
                                         24, 2030</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">62,052</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">9.51</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
                                         25, 2031</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10,344</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">98,371</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">35,601</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">135,284</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michele
    Korfin<sup>(9)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">156,250</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">343,750</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.36</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
                                         31, 2030</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michele
    Korfin<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3,358</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">30,130</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michele
    Korfin<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">20,147</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">9.51</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
                                         25, 2031</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michele
    Korfin<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">62,514</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">220,285</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jas
    Uppal<sup>(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">37,187</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">47,813</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.75</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                         12, 2030</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jas
    Uppal<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">29,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">9.51</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
                                         25, 2031</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jas
    Uppal<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4,400</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">41,844</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jas
    Uppal<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">35,207</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">133,787</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Dr.
    Ronit Simantov</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">186,574</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.90</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
                                         16, 2027</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronit Simantov<sup>(11)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">33,962</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">15,438</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">11.01</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                         11, 2029</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronit Simantov<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">21,437</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">27,563</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.70</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
                                         24, 2030</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronit Simantov<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">54,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">9.51</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
                                         25, 2031</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronit Simantov<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">9,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">85,590</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronit Simantov<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">56,377</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">214,233</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table><div>


</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%; font-family: Times New Roman, Times, Serif"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on June 4, 2020, and
                                         one twelfth (1/12th) of the remaining shares subject to the option award vested or shall
                                         vest in equal quarterly installments thereafter, subject to the officer’s continuous
                                         service through such vesting date.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on September 10, 2021,
                                         and one twelfth (1/12th) of the remaining shares subject to the option award vested or
                                         shall vest in equal quarterly installments thereafter, subject to the officer’s
                                         continuous service through such vesting date.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         restricted shares shall vest in three equal annual installments on February 25, 2022,
                                         February 25, 2023, and February 25, 2024, subject to the officer’s continuous service
                                         through such vesting date.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&nbsp;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award shall vest on February 25, 2022,
                                         and one twelfth (1/12th) of the remaining shares subject to the option award shall vest
                                         in equal quarterly installments thereafter, subject to the officer’s continuous
                                         service through such vesting date.</span></td>
</tr></tbody></table><div>



</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on April 15, 2019, and
                                         one twelfth (1/12th) of the remaining shares subject to the option award vested or shall
                                         vest in equal quarterly installments thereafter, subject to the officer’s continuous
                                         service through such vesting date.</span></td>
</tr></tbody></table><div>



</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on March 13, 2020, and
                                         one twelfth (1/12th) of the remaining shares subject to the option award vested or shall
                                         vest in equal quarterly installments thereafter, subject to the officer’s continuous
                                         service through such vesting date.</span></td>
</tr></tbody></table><div>



</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on February 24, 2021,
                                         and one twelfth (1/12th) of the remaining shares subject to the option award vested or
                                         shall vest in equal quarterly installments thereafter, subject to the officer’s
                                         continuous service through such vesting date.</span></td>
</tr></tbody></table><div>



</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20%
                                         of the restricted shares shall vest upon the omidubicel BLA acceptance, an additional
                                         30% of the Restricted Shares shall vest upon BLA Approval, and the remaining 50% shall
                                         vest on the one-year anniversary of the BLA Approval; provided, in each case, that such
                                         applicable vesting event actually occurs (which is uncertain and not assured) and subject
                                         to the officer’s continuous service through such vesting date.</span></td>
</tr></tbody></table><div>



</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on August 15, 2021, and
                                         one twelfth (1/12th) of the remaining shares subject to the option award vested or shall
                                         vest in equal quarterly installments thereafter, subject to the officer’s continuous
                                         service through such vesting date.</span></td>
</tr></tbody></table><div>



</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on January 12, 2021,
                                         and one twelfth (1/12th) of the remaining shares subject to the option award vested or
                                         shall vest in equal quarterly installments thereafter, subject to the officer’s
                                         continuous service through such vesting date.</span></td>
</tr></tbody></table><div>



</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                         fourth (1/4th) of the shares subject to the option award vested on March 14, 2020, and
                                         one twelfth (1/12th) of the remaining shares subject to the option award vested or shall
                                         vest in equal quarterly installments thereafter, subject to the officer’s continuous
                                         service through such vesting date.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
Narrative Disclosure</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employee
Share and Option Plan (1998)</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1998, our board of directors adopted our Employee Share and Option Plan (1998), or the 1998 Plan. There are currently no options
outstanding or options available for issuance under the 1998 Plan. There are currently 180,329 ordinary shares, which resulted
from the exercise of certain options granted under the 1998 Plan, held in trust in favor of the employees who exercised such options.
The 1998 Plan remains in effect in order to allow our employees to enjoy certain tax benefits under Israeli tax law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
Option Plan (1999)</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1999, our board of directors adopted our Stock Option Plan (1999), or the 1999 Plan. There are currently no options outstanding
or options available for issuance under the 1999 Plan. There are currently 5,000 ordinary shares, which resulted from the exercise
of certain options granted under the 1999 Plan, held in trust in favor of the employees who exercised such options. The 1999 Plan
remains in effect in order to allow our employees to enjoy certain tax benefits under Israeli tax law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2003
Israeli Share Option Plan</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2003, our board of directors adopted our 2003 Israeli Share Option Plan, or the 2003 Plan. There are currently no options
outstanding or options available for issuance under the 2003 Plan. There are currently 54,569 ordinary shares, which resulted
from the exercise of certain options granted under the 2003 Plan, held in trust in favor of the employees who exercised such options.
The 2003 Plan remains in effect in order to allow our employees to enjoy certain tax benefits under Israeli tax law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2014
Israeli Share Incentive Plan</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In November 2014 and December
2014, respectively, our board of directors adopted and our shareholders approved our 2014 Israeli Share Incentive Plan, or the 2014 Plan.
The 2014 Plan replaced our 2003 Plan. We are no longer granting options under the 2014 Plan because it was superseded by our 2017 Share
Incentive Plan, or the 2017 Plan, although previously granted awards remain outstanding. As of December 31, 2021, we had options to purchase
17,282 Ordinary Shares outstanding under the 2014 Plan with a weighted-average exercise price of $0.25.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2014 Plan provides for the grant of options to the Company’s and affiliates’ directors, employees, officers, consultants,
advisors and service providers, and any other person whose services are considered valuable to us or our affiliates, to encourage
a sense of proprietorship of such persons, and to stimulate the active interest of such persons in the development and financial
success of the Company by providing them with opportunities to purchase shares in the Company.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2014 Plan is administered by our board of directors directly or upon recommendation of a committee designated by the board of
directors, which determines, subject to Israeli law, the grantees of awards and the terms of the grant, including, exercise prices,
vesting schedules, acceleration of vesting and the other matters necessary in the administration of the 2014 Plan. The 2014 Plan
enables us to issue awards under various tax regimes, including, without limitation, pursuant to Section 102 of the Israeli Income
Tax Ordinance (New Version) 1961, or the Ordinance, and under Section 3(i) of the Ordinance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102 of the Ordinance allows employees, directors and officers, who are not controlling shareholders, to receive favorable tax
treatment for compensation in the form of shares or options. Section 102 of the Ordinance includes two alternatives for tax treatment
involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative
for the issuance of options or shares directly to the grantee. Section 102(b)(2) of the Ordinance, which provides the most favorable
tax treatment for grantees, permits the issuance to a trustee under the “capital gain track.” Note however, that according
to Section 102(b)(3) of the Ordinance, if the company granting the shares or options is a publicly traded company or is listed
for trading on any stock exchange within a period of 90 days from the date of grant, any difference between the exercise price
of the Awards (if any) and the average closing price of the company’s shares at the 30 trading days preceding the grant
date (when the company is listed on a stock exchange) or 30 trading days following the listing of the company, as applicable,
will be taxed as “ordinary income” at the grantee’s marginal tax rate. In order to comply with the terms of
the capital gain track, all securities granted under a specific plan and subject to the provisions of Section 102 of the Ordinance,
as well as the shares issued upon exercise of such securities and other shares received following any realization of rights with
respect to such securities, such as share dividends and share splits, must be registered in the name of a trustee selected by
the board of directors and held in trust for the benefit of the relevant grantee. The trustee may not release these securities
to the relevant grantee before 24 months from the date of grant and deposit of such securities with the trustee. However, under
this track, we are not allowed to deduct an expense with respect to the issuance of the options or shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2014 Plan provides that options granted to our employees, directors and officers who are not controlling shareholders and who
are considered Israeli residents may be intended to qualify for special tax treatment under the “capital gain track”
provisions of Section 102(b) of the Ordinance as detailed above. Our Israeli non-employee service providers and controlling shareholders
may only be granted options under Section 3(i) of the Ordinance, which does not provide for similar tax benefits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
options granted under the 2014 Plan are currently fully vested.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
expiry is determined by the specific option agreement or at the end of an extended period following the termination of the grantee’s
employment or service. In the event of the death of a grantee while employed by or performing service for us or a subsidiary,
or in the event of termination of a grantee’s employment or services for reasons of disability, the grantee, or in the case
of death, his or her legal successor, may exercise options that have vested prior to termination within the twelve (12) month
period from the date of disability or death. If a grantee’s employment or service is terminated by reason of retirement
in accordance with applicable law, the grantee may exercise his or her vested options within the twelve (12) month period after
the date of such retirement. If we terminate a grantee’s employment or service for cause, all of the grantee’s vested
and unvested options will expire on the date of termination. If a grantee’s employment or service is terminated for any
other reason, the grantee may generally exercise his or her vested options within 90 days of the date of termination.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may not be assigned, transferred or given as collateral nor may any right with respect to the options be given to a third party.
As long as options and/or shares are held by the Section 102 trustee, all rights of the grantee over the shares may not be transferred,
assigned, pledged or mortgaged, except by will or the laws of descent and distribution.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a merger, acquisition or reorganization of our company, or a sale of all, or substantially all, of our shares or
assets or other transaction having a similar effect on us, then without the consent of the option holder, our board of directors
or its designated committee, as applicable, may but is not required to (i) cause any outstanding options to be assumed or an equivalent
award to be substituted by such successor corporation, or (ii) in case the successor corporation does not assume or substitute
the award (a) if provided for in the relevant option agreement – all unvested options of the applicable grantee shall become
vested and such grantee shall have the right to exercise such options in connection with such transaction or (b) cancel the options
and substitute for any other type of asset or property determined by the board of directors or the committee as fair under the
circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2017
Share Incentive Plan</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In January 2017 and February
2017, respectively, our board of directors adopted and our shareholders approved our 2017 Plan. The 2017 Plan replaced our 2014 Plan.
We are no longer granting options under the 2014 Plan because it was superseded by the 2017 Plan, although previously granted awards remain
outstanding. As of December 31, 2021, we had options to purchase 4,925,619 ordinary shares outstanding under the 2017 Plan with a weighted-average
exercise price of $5.38. On February 25, 2021 and November 17, 2021, the board and shareholders, respectively, approved an amendment and
restatement of the 2017 Plan.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2021,
our 2017 Plan, as amended, has up to 1,520,066 ordinary shares available for issuance. The 2017 Plan, as amended, also contains an “evergreen”
provision, which provides for an automatic allotment of ordinary shares to be added every year to the pool of ordinary shares available
for grant under the 2017 Plan. Under the evergreen provision, on January 1 of each year (beginning January 1, 2022), the number of ordinary
shares available under the 2017 Plan automatically increases by the lesser of the following: (i) 4% of our outstanding ordinary shares
on the last day of the immediately preceding year; and (ii) an amount determined in advance of January 1 by the board.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Plan provides for the grant of awards, including options, restricted shares and RSUs, to the Company’s and affiliates’
directors, employees, officers, consultants, advisors, and any other person whose services are considered valuable to us or our
affiliates, to increase their efforts on our and our affiliates’ behalf, and to promote the success of the Company’s
business by providing them with opportunities to acquire a proprietary interest in the Company.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Plan is administered by a committee designated by the board of directors, which determines, subject to Israeli law, the grantees
of awards and the terms of the grant, including, exercise prices, vesting schedules, acceleration of vesting and conditions and
restrictions applicable to an award, as well other matters necessary in the administration of the 2017 Plan. In the event that
the Board does not appoint or establish a committee, the 2017 Plan shall be administered by the Board. The 2017 Plan enables us
to issue awards under various tax regimes, including, without limitation, pursuant to Section 102 of the Ordinance as discussed
under “2014 Israeli Share Option Plan” above, and under Section 3(i) of the Ordinance and Section 422 of the United
States Internal Revenue Code of 1986, as amended, or the Code.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Plan provides that awards granted to our employees, directors and officers who are not controlling shareholders and who are
considered Israeli residents are intended to qualify for special tax treatment under the “capital gain track” provisions
of Section 102(b) of the Ordinance as detailed above. Our Israeli non-employee service providers and controlling shareholders
may only be granted awards under Section 3(i) of the Ordinance, which does not provide for similar tax benefits.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
granted under the 2017 Plan to U.S. residents may qualify as “incentive stock options” within the meaning of Section
422 of the Code, or may be non-qualified. The exercise price for “incentive stock options” must not be less than the
fair market value on the date on which an option is granted, or 110% of the fair market value if the option holder holds more
than 10% of our share capital.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vesting schedule of options granted under the 2017 Plan is set forth in each grantee’s grant letter.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
terminate upon the date set out in the grantee’s specific award agreement or at the end of an extended period following
the termination of the grantee’s employment or service. In the event of the death of a grantee while employed by or performing
service for us or an affiliate, or within the three (3) month period after the termination, or in the event of termination of
a grantee’s employment or services for reasons of disability, the grantee (or his or her estate or legal successor (in the
case of death) or the person who acquired legal rights to exercise such awards (in the case of death or disability)), may exercise
awards that have vested prior to termination within a period of one (1) year from the date of disability or death but in any event
no later than the expiration date of the awards. If a grantee’s employment or service is terminated by reason of retirement
in accordance with applicable law, the grantee may exercise his or her vested awards within the three (3) month period after the
date of such retirement. If we terminate a grantee’s employment or service for cause, all of the grantee’s vested
and unvested awards will expire on the date of termination. If a grantee’s employment or service is terminated for any other
reason, all unvested awards shall expire and the grantee may exercise his or her vested awards within three (3) months after the
date of termination. Any expired or unvested awards return to the pool and become available for reissuance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may not be assigned or transferred other than by will or laws of descent, unless otherwise determined by the committee.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a merger or consolidation of our company, or a sale of all, or substantially all, of our shares or assets or other
transaction having a similar effect on us, or liquidation or dissolution, or such other transaction or circumstances that the
Board determines to be a relevant transaction, then without the consent of the grantee, our board of directors or its designated
committee, as applicable, may but is not required to (i) cause any outstanding award to be assumed or substituted by such successor
corporation, or (ii) regardless of whether or not the successor corporation assumes or substitutes the award (a) provide the grantee
with the option to exercise the award as to all or part of the shares, and may provide for an acceleration of vesting of unvested
awards, or (b) cancel the award and pay in cash, shares of the company, the acquirer or other corporation which is a party to
such transaction or other property as determined by the board of directors or the committee as fair in the circumstances. Notwithstanding
the foregoing, our board of directors or its designated committee may upon such event amend, modify or terminate the terms of
any award as the board of directors or the committee shall deem, in good faith, appropriate.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2021,
outstanding awards under our Equity Incentive Plans totaled 4,942,901 ordinary shares and 1,524,255 ordinary shares remained available
for grant. Of the 531,477 outstanding restricted share awards, none of the restricted ordinary shares were vested as of December 31, 2021.
Of the 4,441,424 outstanding options, options to purchase 2,171,616 ordinary shares were vested as of December 31, 2021, with a weighted
average exercise price of $5.57 per share, and will expire between January 18, 2022 and November 17, 2030.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Employee
Director Compensation</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Director
Compensation Table</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows for the fiscal year ended December 31, 2021 certain information with respect to the compensation of our
non-employee directors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Fees
    Earned or<br> Paid in Cash<br> ($)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Share
    Awards<br> ($)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Option
    Awards<br> ($)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Total<br>
    ($)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    I. Blum<sup>(1)</sup></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">67,500</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">5,040</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">20,014</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">92,554</span></td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nurit
    Benjamini<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">48,503</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">48,502</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anat
    Cohen-Dayag<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Fox<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">44,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">44,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ofer
    Gonen<sup>(5)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">55,181</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">5,040</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">15,210</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">75,432</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naama
    Halevi Davidov<sup>(6)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    I. Moch<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">65,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">5,040</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">15,210</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">85,250</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Perry<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">25,495</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">25,495</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shawn
    C. Tomasello<sup>(9)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">5,040</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">15,210</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">70,250</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    T. Wills<sup>(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">61,250</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">5,040</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">15,210</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">81,500</span></td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
</tbody></table><div>


</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%; font-family: Times New Roman, Times, Serif"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         Blum was awarded (i) 2,000 restricted shares and (ii) options to purchase 12,500 ordinary
                                         shares. This option vests in equal quarterly installments over a twelve-month period
                                         commencing on November 1, 2021, subject to the continued service as of the applicable
                                         vesting date. In aggregate, Mr. Blum had 2,000 restricted shares and options to purchase
                                         72,500 ordinary shares outstanding as of December 31, 2021.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
                                         Benjamini resigned from the board in August 2021 and did not exercise her options to
                                         purchase ordinary shares that had been awarded to her. The options have been expired.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Ms. Cohen-Dayag was appointed to the board of directors on January 28, 2022 and received no compensation for the fiscal year ended December 31, 2021.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Fox resigned from the board
in November 2021 and did not exercise his options to purchase ordinary shares that had been awarded to him. The options have expired.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted shares and options to purchase ordinary shares reflected in this line were awarded directly to Clal Biotechnology Industries Ltd. Mr. Gonen disclaims ownership in these shares and options.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(6)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Ms. Halevi Davidov was appointed to the board of directors on January 27, 2022 and received no compensation for the fiscal year ended December 31, 2021.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         Moch was awarded (i) 2,000 restricted shares and (ii) options to purchase 9,500 ordinary
                                         shares. This option vests in equal quarterly installments over a twelve-month period
                                         commencing on November 1, 2021, subject to the continued service as of the applicable
                                         vesting date. In aggregate, Mr. Moch had 2,000 restricted shares and options to purchase
                                         57,500 ordinary shares outstanding as of December 31, 2021.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         Perry resigned from the board in May 2021 and did not exercise his options to purchase
                                         ordinary shares that had been awarded to him. The options have expired.</span></td>
</tr></tbody></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         Tomasello was awarded (i) 2,000 restricted shares and (ii) options to purchase 9,500
                                         ordinary shares. This option vests in equal quarterly installments over a twelve-month
                                         period commencing on November 1, 2021, subject to the continued service as of the applicable
                                         vesting date. In aggregate, Ms. Tomasello had 2,000 restricted shares and options to
                                         purchase 39,500 ordinary shares outstanding as of December 31, 2021.</span></td>
</tr></tbody></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         Wills was awarded (i) 2,000 restricted shares and (ii) options to purchase 9,500 ordinary
                                         shares. This option vests in equal quarterly installments over a twelve-month period
                                         commencing on November 1, 2021, subject to the continued service as of the applicable
                                         vesting date. In aggregate, Mr. Wills had 2,000 restricted shares and options to purchase
                                         39,500 ordinary shares outstanding as of December 31, 2021.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Narrative
Disclosure to Director Compensation Table </i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Company’s non-executive directors is entitled to the following payments, which are paid in arrears, in quarterly
installments: (i) an annual fee of $40,000 plus VAT, if applicable, (ii) for audit committee or compensation committee membership,
an additional annual fee of $10,000 plus VAT, if applicable, (iii) for nominating and corporate governance committee members,
an additional annual fee of $4,000 plus VAT, if applicable, (iv) for chairmanship of the board of directors an additional annual
fee of $20,000 plus VAT, if applicable, (v) for each chairmanship of the audit committee and the compensation committee, an additional
annual fee of $5,000 plus VAT, if applicable and (vi) for chairmanship of the nominating and corporate governance committee, an
additional annual fee of $3,500 plus VAT, if applicable. In addition, each of the Company’s non-executive directors, other
than the current chairman of the board of directors, shall be entitled to receive an initial grant (upon his or her first appointment
to election to the Board) of 4,000 restricted ordinary shares of the Company and options to purchase 19,000 ordinary shares of
the Company, and an annual grant of 2,000 restricted ordinary shares of the Company and options to purchase 9,500 ordinary shares
of the Company, and the current chairman of the board of directors shall be entitled to receive an annual grant of 2,000 restricted
ordinary shares of the Company and options to purchase 12,500 ordinary shares of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
and Talent Committee</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee Interlocks and Insider Participation</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of any public company must appoint a compensation committee. Our compensation and talent
committee, which consists of Ofer Gonen, Stephen T. Wills, Kenneth I. Moch and Shawn C. Tomasello, assists our board of directors
in determining compensation for our directors and officers. Mr. Moch serves as Chairman of the committee. Our board of directors
has determined that each member of our compensation committee is independent under the Nasdaq Rules, including the additional
independence requirements applicable to the members of a compensation committee.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Companies Law, the roles of the compensation and talent committee are, among others, as follows:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to the board of directors with respect to the approval of the compensation policy for office holders and,
    once every three years, regarding any extensions to a compensation policy that was adopted for a period of more than three
    years;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the implementation of the compensation policy and periodically making recommendations to the board of directors with respect
    to any amendments or updates to the compensation policy;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resolving
    whether or not to approve arrangements with respect to the terms of office and employment of office holders; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exempting,
    under certain circumstances, a transaction with our chief executive officer from the approval of the general meeting of our
    shareholders.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a compensation committee charter setting forth the responsibilities of the committee consistent
with the Nasdaq Rules, which include among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                         a compensation policy to our board of directors for its approval, in accordance with
                                         the requirements of the Companies Law, as well as making recommendations to the board
                                         of directors with respect to other compensation policies, incentive-based compensation
                                         plans and share-based compensation plans, overseeing the development and implementation
                                         of such policies and recommending to our board of directors any amendments or modifications
                                         that the committee deems appropriate, including as required under the Companies Law;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         and approving the granting of options and other incentive awards to the chief executive
                                         officer and other executive officers, including reviewing and approving corporate goals
                                         and objectives relevant to the compensation of our chief executive officer and other
                                         executive officers, and evaluating their performance in light of such goals and objectives;</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
                                         and exempting certain transactions regarding office holders’ compensation pursuant
                                         to the Companies Law; and</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
                                         our share-based compensation plans, including without limitation, approving the adoption
                                         of such plans, amending and interpreting such plans and the awards and agreements issued
                                         pursuant thereto, and making awards to eligible persons under the plans and determining
                                         the terms of such awards.</span></td></tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee Report</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gamida
Cell’s compensation committee has reviewed and discussed the compensation discussion and analysis with the management of
the company and, based on the review and discussions recommended the board of directors that the compensation discussion and analysis
be included in this annual report.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation and talent committee consists of Ofer Gonen, Stephen T. Wills, Kenneth I. Moch and Shawn C. Tomasello.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under the Companies Law, a public company must have a compensation policy approved by the board of directors after receiving
and considering the recommendations of the compensation committee. In addition, our compensation policy must be approved at least
once every three years, first, by our board of directors, upon recommendation of our compensation and talent committee, and second,
by a simple majority of the ordinary shares present, in person or by proxy, and voting at a shareholders meeting, provided that
either:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and shareholders
    who do not have a personal interest in such compensation arrangement and who are present and voting (excluding abstentions);
    or</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation
    arrangement and who vote against the arrangement, does not exceed 2% of the company’s aggregate voting rights.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
refer to this as the Special Approval for Compensation. Under the Companies Law, subject to certain conditions, the board of directors
may ratify the compensation policy even if it is not ratified by the shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law, under special circumstances, the board of directors may approve the compensation policy despite the objection
of the shareholders on the condition that the compensation committee and then the board of directors decide, on the basis of detailed
grounds and after discussing again the compensation policy, that approval of the compensation policy, despite the objection of
the shareholders, is for the benefit of the company.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a company that initially offers its securities to the public adopts a compensation policy in advance of its initial public offering
and describes it in its prospectus for such offering, as in the case of our company, then such compensation policy shall be deemed
a validly adopted policy in accordance with the Companies Law requirements described above. Furthermore, if the compensation policy
is established in accordance with the aforementioned relief, then it will remain in effect for term of five years from the date
such company becomes a public company. We have adopted our compensation policy pursuant to the foregoing relief.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office
holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment
or engagement. The compensation policy must be determined and later reevaluated according to certain factors, including: the advancement
of the company’s objectives, business plan and long-term strategy; the creation of appropriate incentives for office holders,
while considering, among other things, the company’s size, the nature of its operations and risk management policy; and,
with respect to variable compensation, the contribution of the office holder towards the achievement of the company’s long-term
goals and the maximization of its profits, all with a long-term objective and according to the position of the office holder.
The compensation policy must furthermore consider the following additional factors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    education, skills, experience, expertise and accomplishments of the relevant office holder;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    office holder’s position, responsibilities and prior compensation agreements with him or her;</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of
    the company, including employees employed through contractors who provide services to the company, in particular the ratio
    between such cost to the average and median salary of such employees of the company, as well as the impact of disparities
    between them on the work relationships in the company;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the terms of employment include variable components—the possibility of reducing variable components at the discretion
    of the board of directors and the possibility of setting a limit on the value of non-cash variable share-based components;
    and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the terms of employment include severance compensation—the term of employment or office of the office holder, the terms
    of his or her compensation during such period, the company’s performance during such period, his or her individual contribution
    to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is
    leaving the company.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must also include, inter alia, with regards to variable components:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    the exception of office holders who report directly to the chief executive officer, determining the variable components on
    long-term performance basis and on measurable criteria; however, the company may determine that an immaterial part of the
    variable components of an office holder’s compensation package shall be awarded based on non-measurable criteria, if
    such amount is not higher than three months’ salary per annum, while taking into account such office holder’s
    contribution to the company;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ratio between variable and fixed components, as well as the limit of the values of variable components at the time of their
    payment, or in the case of share-based compensation, at the time of grant;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    condition under which the office holder will return to the company, according to conditions to be set forth in the compensation
    policy, any amounts paid as part of his or her terms of employment, if such amounts were paid based on information later to
    be discovered to be wrong, and such information was restated in the company’s financial statements;</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    minimum holding or vesting period of variable share-based components to be set in the terms of office or employment, as applicable,
    while taking into consideration long-term incentives; and</span></td></tr>
</tbody></table><div>
</div><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limit to retirement grants.</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy, which was amended on September 10, 2020, is designed to promote retention and motivation of directors and
executive officers, incentivize individual excellence, align the interests of our directors and executive officers with our long-term
performance and provide a risk management tool. To that end, a portion of an executive officer compensation package is targeted
to reflect our short and long-term goals, as well as the executive officer’s individual performance. On the other hand,
our compensation policy includes measures designed to reduce the executive officer’s incentives to take excessive risks
that may harm us in the long-term, such as limits on the value of cash bonuses and share-based compensation, limitations on the
ratio between the variable and the total compensation of an executive officer and minimum vesting periods for share-based compensation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy also addresses our executive officers’ individual characteristics (such as their respective positions,
education, scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation
among our executive officers, and considers the internal ratios between compensation of our executive officers and directors and
other employees. Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include:
base salary, annual bonuses and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements,
such as outstanding personal achievement, outstanding personal effort or outstanding company performance), share-based compensation,
benefits, retirement and termination of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive
officer’s base salary. In addition, the total variable compensation components (cash bonuses and shared-based compensation)
may not exceed 90% of each executive officer’s total compensation package with respect to any given calendar year.&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets.
The annual cash bonus that may be granted to our executive officers other than our chief executive officer will be based on performance
objectives and a discretionary evaluation of the executive officer’s overall performance by our chief executive officer
and subject to minimum thresholds. The annual cash bonus that may be granted to executive officers other than our chief executive
officer may be based entirely on a discretionary evaluation. Furthermore, our chief executive officer will be entitled to recommend
performance objectives, and such performance objectives will be approved by our compensation committee (and, if required by law,
by our board of directors).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measurable performance objectives of our chief executive officer will be determined annually by our compensation committee and
board of directors, will include the weight to be assigned to each achievement in the overall evaluation. A non-material portion
of the chief executive officer’s annual cash bonus may be based on a discretionary evaluation of the chief executive officer’s
overall performance by the compensation committee and the board of directors based on quantitative and qualitative criteria.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based compensation under our compensation policy for our executive officers (including members of our board of directors)
is designed in a manner consistent with the underlying objectives in determining the base salary and the annual cash bonus, with
its main objectives being to enhance the alignment between the executive officers’ interests with our long-term interests
and those of our shareholders and to strengthen the retention and the motivation of executive officers in the long term. Our compensation
policy provides for executive officer compensation in the form of share options or other share-based awards, such as restricted
shares and restricted share units, in accordance with our share incentive plan then in place. All share-based incentives granted
to executive officers shall be subject to vesting periods in order to promote long-term retention of the awarded executive officers.
The share-based compensation shall be granted from time to time and shall be individually determined and awarded according to
the performance, educational background, prior business experience, qualifications, role and personal responsibilities of each
executive officer.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our compensation policy contains compensation recovery provisions which allow us under certain conditions to recover
bonuses paid in excess, enables our chief executive officer to approve an immaterial change in the terms of employment of an executive
officer who reports directly to the chief executive officer (provided that the changes of the terms of employment are in accordance
with our compensation policy) and allows us to exculpate, indemnify and insure our executive officers and directors to the maximum
extent permitted by Israeli law, subject to certain limitations set forth therein.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy also provides for compensation to the members of our board of directors either (i) in accordance with the
amounts provided in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000,
as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such
regulations may be amended from time to time, or (ii) in accordance with the amounts determined in our compensation policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_022"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
ownership of certain beneficial owners and management</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table sets forth certain information regarding the ownership
of the Company’s ordinary shares as of March 15, 2022 by: (i) each director and nominee for director; (ii) each named executive
officer; (iii) all executive officers and directors of the Company as a group; and (iv) all those known by the Company to be beneficial
owners of more than five percent of its ordinary shares. Beneficial ownership, for purposes of this table, includes options and warrants
to purchase ordinary shares that are either currently exercisable or will be exercisable within 60 days of March 15, 2022.</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Unless
otherwise noted below, the address of each shareholder, director and executive officer is c/o Gamida Cell Ltd., 116 Huntington Avenue,
Boston, Massachusetts 02116.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>As of<br> March&nbsp;15,<br> 2022<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ordinary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1.5pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Holders of more than 5% of our voting securities:</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Access Industries<sup>(2)</sup></span></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">9,929,975</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">16.5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Novartis Pharma A.G.<sup>(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,194,054</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Fidelity Management &amp; Research<sup>(4)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,603,945</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Federated Global Investment Management Corp.<sup>(5)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,363,315</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Directors and executive officers who are not 5% holders:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Dr. Julian Adams</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">901,457</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shai Lankry</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">237,369</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Michele Korfin</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">193,656</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Josh Patterson</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Robert I. Blum</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">66,250</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Anat Cohen-Dayag</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Ofer Gonen</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Naama Halevi Davidov</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Kenneth I. Moch</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">52,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shawn Tomasello</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">34,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stephen Wills</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">34,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt"><b>All directors and executive officers as a group (11 persons)<sup>(6)</sup></b></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,547,732</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%; font-family: Times New Roman, Times, Serif"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
                                         beneficial ownership of less than 1% of the total ordinary shares outstanding.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The percentages shown are based on 59,989,886 ordinary shares issued and outstanding as of March 15, 2022.</span></td></tr>

<tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of: (i) 1,533,744 ordinary shares and 160,743 ordinary shares
issuable upon exercise of outstanding warrants held by Clal Biotechnology Industries Ltd., or CBI; (ii) 1,374,377 ordinary shares held
by Bio Medical Investment (1997) Ltd., or Bio Medical, a wholly owned subsidiary of CBI; (iii) 3,750,000 ordinary shares by AI Gamida
Holdings LLC and (iv) 3,111,111 ordinary shares held by AI biotechnology LLC. Clal Industries Ltd. owns 47% of the outstanding shares
of, and controls, CBI. Clal Industries Ltd. is wholly owned by Access AI Ltd., which is owned by AI Diversified Holdings S.à r.l.,
which is owned by AI Diversified Parent S.à r.l., which is owned by AI Diversified Holdings Limited (“AIDH Limited”).
AIDH Limited is controlled by AI SMS L.P (“AI SMS”). Access Industries Holdings LLC (“AIH”) owns a majority of
the equity of AI SMS, and Access Industries, LLC (“LLC”), holds a majority of the outstanding voting interests in AIH. Access
Industries Management, LLC (“AIM”) controls LLC and AIH, and Len Blavatnik controls AIM. AIM controls AIH LLC and Len Blavatnik
controls AIM. The address of each of Clal Industries Ltd., CBI and Bio Medical is the Triangular Tower, 3 Azrieli Center, Tel Aviv 67023,
Israel and the address of each of foregoing other than Bio Medical, CBI, and Clal Industries Ltd. is 730 Fifth Avenue, 20th Floor, New
York, NY 10019.</p></td>
</tr></tbody></table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                         of 4,336,759 ordinary shares and 857,295 ordinary shares issuable upon exercise of outstanding
                                         warrants. The principal address of Novartis A.G. is Lichtstrasse 35 4056 Basel, Switzerland.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="text-align: left; font-family: Times New Roman, Times, Serif">(4)</td><td style="text-align: justify; font-family: Times New Roman, Times, Serif">The principal address of Fidelity Management &amp; Research is 245
Summer Street, Boston, Massachusetts 02210. This information is based solely on the information reported on the Schedule 13G/A filed on
February 9, 2022 by FMR LLC.</td></tr>
<tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="text-align: left; font-family: Times New Roman, Times, Serif">(5)</td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The principal address of Federated Global Investment Management is
1001 Liberty Avenue, Pittsburgh, PA 15222-3779. This information is based solely on the information reported on the Schedule 13G/A filed
on February 14, 2022 by Federated Hermes, Inc. Federated Hermes, Inc. is the parent holding company of Federated Global Investment Management
Corp.</p></td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of options to purchase 1,547,732 ordinary shares, which are currently exercisable or will become exercisable within 60 days of March 15, 2022.</span></td></tr>
  </tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
authorized for issuance under equity compensation plans.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our equity compensation plan information as of December 31, 2021. Information is included for equity
compensation plans approved by our shareholders. We do not have any equity compensation plans not approved by our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="width: 58%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan Category</b></span></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 12%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of<br>
    securities to&nbsp;be<br>
    issued upon<br>
    exercise of<br>
    outstanding<br>
    options,<br>
    warrants<br>
    and rights</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(a)</b></p></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 12%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-<br>
    average<br>
    exercise<br>
    price of<br>
    outstanding<br>
    options,<br>
    warrants<br>
    and rights</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(b)</b></p></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br>
securities<br>
remaining<br>
available for<br>
future<br>
issuance<br>
under equity<br>
compensation<br>
plans<br>
(excluding<br>
securities<br>
reflected in<br>
column<br>
(a))</b></span></td>
    <td style="width: 1%">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by shareholders</span></td>
    <td>&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;4,942,901</span></td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;5.95</span></td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,524,255</span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by shareholders</span></td>
    <td>&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;-</span></td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;-</span></td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;-</span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;4,942,901</span></td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;5.95</span></td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom">&nbsp;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,524,255</span></td>
    <td>&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><div><a id="a_023"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to enter into transactions with related parties on terms that, on the whole, are no more favorable, or no less favorable
than those available from unaffiliated third parties. Based on our experience in the business sectors in which we operate and
the terms of our transactions with unaffiliated third parties, we believe that all of the transactions described below met this
policy standard at the time they occurred. The following is a description of material transactions, or series of related material
transactions since January 1, 2020, to which we were or will be a party and in which the other parties included or will include
our directors, executive officers, holders of more than 10% of our voting securities or any member of the immediate family of
any of the foregoing persons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
Rights Agreements with Shareholders</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As part of our initial public offering and effective
as of its closing, we entered into an information rights agreement with an affiliate of one of our principal shareholders, Access Industries.
The information rights agreement provides the counterparty with rights to receive our annual and quarterly financial statements, auditor
consent letters and valuation reports, and other information reasonably required by such counterparty to enable it to prepare its financial
statements. The information rights agreement also requires that we provide the counterparty with information material to us and mandated
to be disclosed by the requirements applicable to such counterparty, as well as certain other material information of ours. The information
rights agreement contains customary confidentiality provisions and terminates when the counterparty, and any company that controls such
counterparty, is no longer required to issue public reports pursuant to the Israeli Securities Law or the Securities Exchange Act of 1934,
as amended.&nbsp;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreements
and Arrangements with Directors and Executive Officers</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Company’s non-executive directors is entitled to the following payments, which are paid in arrears, in quarterly
installments: (i) an annual fee of $40,000 plus VAT, if applicable, (ii) for audit committee or compensation committee membership,
an additional annual fee of $10,000 plus VAT, if applicable, (iii) for nominating and corporate governance committee members,
an additional annual fee of $4,000 plus VAT, if applicable, (iv) for chairmanship of the board of directors an additional annual
fee of $60,000 plus VAT, if applicable, (v) for each chairmanship of the audit committee and the compensation committee, an additional
annual fee of $5,000 plus VAT, if applicable and (vi) for chairmanship of the nominating and corporate governance committee, an
additional annual fee of $3,500 plus VAT, if applicable. In addition, each of the Company’s non-executive directors, other
than the current chairman of the board of directors, shall be entitled to receive an initial grant (upon his or her first appointment
to election to the Board) of 4,000 restricted ordinary shares of the Company and options to purchase 19,000 ordinary shares of
the Company, and an annual grant of 2,000 restricted ordinary shares of the Company and options to purchase 9,500 ordinary shares
of the Company, and the current chairman of the board of directors shall be entitled to receive an annual grant of 2,000 restricted
ordinary shares of the Company and options to purchase 12,500 ordinary shares of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive
Officers Employment Agreements.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into written employment agreements with each of our executive officers. These agreements provide for notice periods
of varying duration for termination of the agreement by us or by the relevant executive officer, during which time the executive
officer will continue to receive base salary and benefits (except for the accrual of vacation days). These agreements also contain
customary provisions regarding non-competition, confidentiality of information and assignment of inventions. However, the enforceability
of the non-competition provisions may be limited under applicable law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Options
and Restricted Share Awards</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have granted options to purchase our ordinary shares and/or restricted share awards to our officers and certain
of our directors. Such agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions.
We describe our equity incentive plans under “Item 11.—Executive Compensation—Additional Narrative Disclosure.”
If the relationship between us and an executive officer or a director is terminated, except for cause (as defined in the equity
incentive plans), all options that are vested will generally remain exercisable for ninety days after such termination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification
Agreements</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and office holders
to the fullest extent permitted by Israeli law. In connection with the loss of our status as a foreign private issuer effective
on January 1, 2022, we entered into amended and restated indemnification agreements with each of our directors and executive officers,
exculpating them, to the fullest extent permitted by law, from liability to us for damages caused to us as a result of a breach
of duty of care, and undertaking to indemnify them to the fullest extent permitted by Israeli law. We have also obtained directors
and officers insurance for each of our executive officers and directors. The indemnification obligations under the agreements
are limited to certain maximum amounts. For further information see “Exculpation, Insurance and Indemnification of Office
Holders” in Item 10 above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><div><a id="a_024"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid the following fees for professional services rendered by Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young
Global, located at Tel-Aviv, Israel, Auditor firm ID: 1281, an independent registered public accounting firm for the years ended
December 31, 2021 and 2020:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$ in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$ in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Audit Fees<sup>(1)</sup></span></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">365</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">315</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Audit-Related Fees<sup>(2)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Tax Fees<sup>(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">All Other Fees<sup>(4)</sup></span></td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right">373</td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right">343</td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%; font-family: Times New Roman, Times, Serif"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page --><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
                                         fees are the aggregate fees billed for the audit of our annual financial statements,
                                         quarterly review, statutory audits, issuance of consents and assistance with and review
                                         of documents filed with the SEC.</span></td>
</tr></tbody></table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related
                                         fees would be assurance and related services by our independent registered public accounting
                                         firm that are reasonably related to the performance of the audit or review of our consolidated
                                         financial statements and are not reported under item (1).</span></td>
</tr></tbody></table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
                                         fees relate to tax compliance, planning and advice.</span></td>
</tr></tbody></table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif"></td><td style="width: 0.25in; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                         other fees would be fees billed for services provided by our independent registered public
                                         accounting firm, with respect to government incentives and other matters.</span></td>
</tr></tbody></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
Committee Pre-Approval Policies and Procedures</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving
our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed
by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control
over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions
that it deems necessary to satisfy itself that the accountants are independent of management. Our audit committee has authorized
all auditing and non-auditing services provided by Kost Forer Gabbay &amp; Kasierer during 2021 and 2020 and the fees paid for
such services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">PART
IV</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="a_026"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The documents filed as part of this report are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The financial statements and accompanying report of independent registered public accounting firm are set forth immediately following
the signature page of this report on pages F-1 through </span>F-28.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
All financial statement schedules are omitted because they are inapplicable, not required or the information is included elsewhere
in the financial statements or the notes thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="white-space: nowrap; text-align: left; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="7" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated
    by Reference</b></span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed/<br>
Furnished</b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="white-space: nowrap; vertical-align: top; border-bottom: black 1.5pt solid; width: 7%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; width: 51%; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 7%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 7%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 7%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 7%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing&nbsp;Date</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 7%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Herewith</b></span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex3-1_gamidacell.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Association of the Registrant, as currently in effect</span></a></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex3-4.htm" tabindex="18">Memorandum
    of Association of the Registrant (unofficial English translation from Hebrew original), as amended on September 14, 2006</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex4-3_gamidacell.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-1_gamidacell.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement</span></a></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex10-2.htm" tabindex="18">Employee
    Share and Option Plan (1998)</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex10-3.htm" tabindex="18">Stock
    Option Plan (1999)</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex10-4.htm" tabindex="18">2003
    Israeli Share Option Plan</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex10-5.htm" tabindex="18">2014
    Israeli Share Option Plan</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-6_gamidacell.htm" tabindex="18">2017 Share Incentive Plan, as amended</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex10-10.htm" tabindex="18">Lease
    Agreement, dated December 13, 2017, by and between the Registrant and Y.D.B. Investments Ltd. (unofficial English translation
    from Hebrew original)</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex10-11.htm" tabindex="18">Lease
    Agreement, dated March 14, 2000, as amended on June 5, 2000 and May 30, 2010, by and between the Registrant and Traub Group
    Investments Ltd. (formerly P.P.D. Diamonds Ltd.) (unofficial English translation from Hebrew original)</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118040749/s002295x9_ex10-12.htm" tabindex="18">Form
    of Letter Agreement re: Information Rights</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1/A</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/17/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390021014284/f20f2020ex4-9_gamidacellltd.htm" tabindex="18">Gamida Cell Ltd. Compensation Policy, as amended</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">20-F</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">001-38716</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.9</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3/09/2021</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390021009280/ea135675ex4-1_gamidacell.htm" tabindex="18">Indenture
    dated February 16, 2021, by and among Gamida Cell Inc., Gamida Cell Ltd. and Wilmington Savings Fund Society, FSB</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38716</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/16/2021</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390021009280/ea135675ex4-1_gamidacell.htm" tabindex="18">Form of Exchangeable Senior Note (included as an exhibit to Exhibit 4.13)</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38716</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/16/2021</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390021009280/ea135675ex10-2_gamidacell.htm" tabindex="18">Registration
    Rights Agreement dated February 16, 2021, by and among Gamida Cell Inc., Gamida Cell Ltd., Highbridge Convertible Dislocation
    Fund, L.P., and Highbridge Tactical Credit Master Fund, L.P.</a> </span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38716</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/16/2021</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390021047491/ea147112ex1-2_gamidacell.htm" tabindex="18">Open
    Market Sale Agreement dated September 10, 2021, by and among Gamida Cell Ltd. and Jefferies LLC</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-259472</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/13/2021</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-15_gamidacell.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment agreement, dated November 20, 2017, by and between Gamida Cell Inc. and Dr. Julian Adams</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-16_gamidacell.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment agreement, dated December 15, 2021, by and between Gamida Cell Inc. and Shai Lankry</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-17_gamidacelll.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment agreement, dated July 20, 2020, by and between Gamida Cell Inc. and Michele Korfin</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-18_gamidacell.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment agreement, dated April 30, 2017, by and between Gamida Cell Inc. and Ronit Simantov</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-19_gamidacelll.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting agreement, dated January 7, 2020, by and between Gamida Cell Limited and Uppal Healthcare Limited</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex21-1.htm" tabindex="18">Subsidiaries
    of the Registrant</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-227601</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2018</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex23-1_gamidacell.htm" tabindex="18">Consent of KOST, FORER, GABBAY &amp; KASIERER, a Member of Ernst &amp; Young Global, Independent Registered Accounting Firm</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="margin: 0">&nbsp;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: bottom;  font-family: Times New Roman, Times, Serif">
    <td style="white-space: nowrap; text-align: left; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="7" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated
    by Reference</b></span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed/<br>
Furnished</b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="white-space: nowrap; vertical-align: top; border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing&nbsp;Date</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Herewith</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif; width: 51%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex31-1_gamidacell.htm" tabindex="18">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style=" font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex31-2_gamidacell.htm" tabindex="18">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif; width: 51%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex32-1_gamidacell.htm" tabindex="18">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex32-2_gamidacell.htm" tabindex="18">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif">104</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Times New Roman, Times, Serif">*</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td></tr>
</tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">**</td><td style="text-align: justify">Furnished herewith and not deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, the Exchange Act, and shall not be deemed to be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date
of the Form 10-K), irrespective of any general incorporation language contained in such filing.</td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 24, 2022</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gamida
    Cell Ltd.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 4%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Julian Adams</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julian
    Adams, Ph.D.</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Shai Lankry</p></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
    Lankry</span></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial and Accounting Officer)</span></td></tr>
</tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POWER
OF ATTORNEY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the undersigned officers and directors of Gamida Cell Ltd., hereby constitutes and appoints Julian Adams and Shai Lankry, their
true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their
name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with
the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing
necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally
present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be
done by virtue hereof.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on March 24, 2022 on behalf of the registrant and in the capacities indicated.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Julian
Adams</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Julian Adams</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Shai Lankry</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Chief Financial Officer </span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Shai Lankry</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Robert I.
Blum</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Chairman of the Board of Directors</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Robert I. Blum</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Anat Cohen-Dayag</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp;24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Anat Cohen-Dayag </span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Ofer Gonen</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Ofer Gonen</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Naama Halevi
Davidov</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Naama Halevi Davidov</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Kenneth
I. Moch</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Kenneth I. Moch</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Shawn Tomasello</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Shawn Tomasello</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Stephen
T. Wills</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March&nbsp; 24, 2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Stephen T. Wills</span></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>



</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Gamida
Cell ltd. and its subsidiary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: center"><b>AS OF DECEMBER 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: center"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>U.S. DOLLARS IN THOUSANDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INDEX</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tbody><tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; width: 90%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; font-weight: bold"><b>Page</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center"><b>&nbsp;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#f_001" tabindex="18"><b>Report of Independent Registered Public Accounting Firm (PCAOB ID #<span><ix:nonnumeric contextref="c0" name="dei:AuditorFirmId" inside-table="true" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1281</ix:nonnumeric></span>)</b></a></td> <td>&nbsp;</td> <td style="text-align: center"><b>F-2</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center"><b>&nbsp;</b></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left"><a href="#f_002" tabindex="18"><b>Consolidated Balance Sheets</b></a></td> <td>&nbsp;</td> <td style="vertical-align: bottom; text-align: center"><b>F-3 - F-4</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center"><b>&nbsp;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#f_003" tabindex="18"><b>Consolidated Statements of Operations </b></a></td> <td>&nbsp;</td> <td style="text-align: center"><b>F-5</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center"><b>&nbsp;</b></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left"><a href="#f_004" tabindex="18"><b>Consolidated Statements of Changes in Shareholders’ Equity</b></a></td> <td>&nbsp;</td> <td style="vertical-align: bottom; text-align: center"><b>F-6</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center"><b>&nbsp;</b></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left"><a href="#f_005" tabindex="18"><b>Consolidated Statements of Cash Flows </b></a></td> <td>&nbsp;</td> <td style="vertical-align: bottom; text-align: center"><b>F-7 - F-8</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center"><b>&nbsp;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#f_006" tabindex="18"><b>Notes to Consolidated Financial Statements</b></a></td> <td>&nbsp;</td> <td style="text-align: center"><b>F-9 - F-28</b></td></tr> </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - - - - -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: left; width: 20%; vertical-align: bottom">&nbsp;<img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/fin_001.jpg" src="https://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/fin_001.jpg"></td>
    <td style="text-align: left; white-space: nowrap; width: 30%; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Kost Forer Gabbay &amp; Kasierer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">144 Menachem Begin Road, Building A,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel-Aviv 6492102, Israel&nbsp;</p></td>
    <td style="padding-left: 4pt; text-align: left; width: 25%; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +972-3-6232525</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: +972-3-5622555</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ey.com</p></td>
    <td style="text-align: left; width: 25%; vertical-align: bottom">&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>To the Shareholders and the Board of Directors
of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Gamida
Cell ltd. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">We have audited the accompanying
consolidated balance sheets of Gamida Cell Ltd. and its subsidiary (the Company) as of December 31, 2021 and 2020, the related consolidated
statements of operations, changes in shareholders’ equity, and cash flows, for each of the two years in the period ended December&nbsp;31,
2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and
the results of its operations and cash flows for each of the two years in the period ended December&nbsp;31, 2021, in conformity with
U.S. generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">These financial statements
are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">We conducted our audits
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform an audit of its internal control over financial reporting. As part of our audits, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company’s internal control over financial reporting. Accordingly, we express no opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">/s/ <span><ix:nonnumeric contextref="c0" name="dei:AuditorName" inside-table="true" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">KOST FORER GABBAY &amp; KASIERER</ix:nonnumeric></span></td> <td style="padding-left: 2.85pt; text-align: center; direction: rtl; unicode-bidi: embed; font-weight: bold">&nbsp;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 60%; text-align: justify">KOST FORER GABBAY &amp; KASIERER</td> <td style="width: 40%; padding-left: 2.85pt; text-align: center; direction: rtl; unicode-bidi: embed; font-weight: bold">&nbsp;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">A Member of Ernst &amp; Young Global</td> <td style="padding-left: 2.85pt; text-align: center; direction: rtl; unicode-bidi: embed; font-weight: bold">&nbsp;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&nbsp;</td> <td style="padding-left: 2.85pt; text-align: center; direction: rtl; unicode-bidi: embed; font-weight: bold">&nbsp;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">We have served as the Company’s auditor since 2000.</td> <td style="padding-left: 2.85pt; text-align: center; direction: rtl; unicode-bidi: embed; font-weight: bold">&nbsp;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span><ix:nonnumeric contextref="c0" name="dei:AuditorLocation" inside-table="true" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Tel-Aviv, Israel</ix:nonnumeric></span></td> <td style="padding-left: 2.85pt; text-align: center">&nbsp;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">March 24, 2022</td> <td style="padding-left: 2.85pt; text-align: center">&nbsp;</td></tr> </tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&nbsp;</p><div>

</div><!-- Field: Page; Sequence: 2; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&nbsp;</b></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CONSOLIDATED BALANCE SHEETS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: 0.125in; text-align: left">ASSETS</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">CURRENT ASSETS:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,892</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127,170</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Marketable securities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,034</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2"><span><ix:nonfraction contextref="c4" id="fact-identifier-37" name="us-gaap:MarketableSecuritiesCurrent" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,688</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,087</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98,614</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">130,257</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Restricted deposits</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,961</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3"><span><ix:nonfraction contextref="c4" id="fact-identifier-43" name="us-gaap:RestrictedInvestmentsNoncurrent" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Property, plant and equipment, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,180</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,238</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Operating lease right-of-use assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitref="usd" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,236</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitref="usd" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,841</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Severance pay fund</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermInvestments" scale="3" unitref="usd" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,148</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermInvestments" scale="3" unitref="usd" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,191</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other long-term assets</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,647</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">786</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,172</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,056</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitref="usd" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">148,786</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitref="usd" inside-table="true" id="fact-identifier-55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">158,313</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">CONSOLIDATED
BALANCE SHEETS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in">LIABILITIES AND SHAREHOLDERS’ EQUITY</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">CURRENT LIABILITIES:</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Trade payables</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,272</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,331</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Employees and payroll accruals</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,957</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,705</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Operating lease liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,699</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,475</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Accrued interest of convertible senior notes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,640</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4"><span><ix:nonfraction contextref="c4" id="fact-identifier-63" name="us-gaap:NotesPayableCurrent" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Accrued expenses and current liabilities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,865</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,988</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,433</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,499</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">NON-CURRENT LIABILITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Convertible senior notes, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" unitref="usd" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,417</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5"><span><ix:nonfraction contextref="c4" id="fact-identifier-69" name="us-gaap:ConvertibleLongTermNotesPayable" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Accrued severance pay</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,396</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,426</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Long-term operating lease liabilities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,603</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,517</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79,416</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,943</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">CONTINGENT LIABILITIES AND COMMITMENTS</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6"><span><ix:nonfraction contextref="c3" id="fact-identifier-76" name="us-gaap:CommitmentsAndContingencies" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7"><span><ix:nonfraction contextref="c4" id="fact-identifier-77" name="us-gaap:CommitmentsAndContingencies" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">SHAREHOLDERS’ EQUITY:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Ordinary shares of NIS <span><ix:nonfraction contextref="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="ilsPershares" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction contextref="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="ilsPershares" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span></ix:nonfraction></span> par value - Authorized: <span><ix:nonfraction contextref="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitref="shares" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000,000</ix:nonfraction></span> and <span><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitref="shares" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span> shares at December 31, 2021 and 2020, respectively; Issued and outstanding: <span><ix:nonfraction contextref="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitref="shares" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction contextref="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitref="shares" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,970,389</ix:nonfraction></span></ix:nonfraction></span> and <span><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitref="shares" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitref="shares" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,000,153</ix:nonfraction></span></ix:nonfraction></span> shares at December&nbsp;31, 2021 and 2020, respectively</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">169</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Additional paid-in capital</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitref="usd" inside-table="true" id="fact-identifier-88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">381,225</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitref="usd" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,369</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">337,457</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">247,664</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total shareholders’ equity</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,937</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,871</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total liabilities and shareholders’ equity</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitref="usd" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">148,786</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitref="usd" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">158,313</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&nbsp;</b></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">CONSOLIDATED
STATEMENTS OF OPERATIONS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Research and development expenses, net</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ResearchAndDevelopmentExpensesNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,177</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ResearchAndDevelopmentExpensesNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">38,873</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Commercial expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CommercialExpenses" scale="3" unitref="usd" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,013</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CommercialExpenses" scale="3" unitref="usd" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8,894</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GeneralAndAdministrativeExpenses" scale="3" unitref="usd" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">16,977</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GeneralAndAdministrativeExpenses" scale="3" unitref="usd" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">13,158</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Total operating loss</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,167</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,925</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Financial expenses, net</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,626</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">648</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Loss</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,793</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,573</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Net loss per share attributable to ordinary shareholders, basic and diluted</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.52</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.41</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitref="shares" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,246,803</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitref="shares" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,725,584</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary shares</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Total shareholders’</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">paid-in capital</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equity</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: 0pt; padding-left: 0pt">Balance as of January 1, 2020</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitref="shares" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,670,926</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">239,577</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<span><ix:nonfraction contextref="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">186,091</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,578</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8"><span><ix:nonfraction contextref="c10" id="fact-identifier-117" name="us-gaap:NetIncomeLoss" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9"><span><ix:nonfraction contextref="c11" id="fact-identifier-118" name="us-gaap:NetIncomeLoss" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,573</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,573</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of Ordinary shares, net of issuance expenses of $<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="gmda:NetOfIssuanceExpenses" scale="3" unitref="usd" inside-table="true" id="fact-identifier-121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,902</ix:nonfraction></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitref="shares" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,677,084</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitref="usd" inside-table="true" id="fact-identifier-123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitref="usd" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,776</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10"><span><ix:nonfraction contextref="c12" id="fact-identifier-125" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitref="usd" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,848</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Exercise of options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitref="shares" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">652,143</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">648</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11"><span><ix:nonfraction contextref="c12" id="fact-identifier-130" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">650</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Share-based compensation</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12"><span><ix:nonfraction contextref="c10" id="fact-identifier-132" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,368</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13"><span><ix:nonfraction contextref="c12" id="fact-identifier-134" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,368</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Balance as of December 31, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitref="shares" inside-table="true" id="fact-identifier-136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,000,153</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,369</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">247,664</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,871</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Loss</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14"><span><ix:nonfraction contextref="c16" id="fact-identifier-141" name="us-gaap:NetIncomeLoss" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15"><span><ix:nonfraction contextref="c17" id="fact-identifier-142" name="us-gaap:NetIncomeLoss" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,793</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,793</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Grant of restricted shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitref="shares" inside-table="true" id="fact-identifier-145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">531,477</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16"><span><ix:nonfraction contextref="c18" id="fact-identifier-148" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17"><span><ix:nonfraction contextref="c0" id="fact-identifier-149" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Exercise of options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitref="shares" inside-table="true" id="fact-identifier-150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">438,759</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">625</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18"><span><ix:nonfraction contextref="c18" id="fact-identifier-153" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">626</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Share-based compensation</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span><ix:nonfraction contextref="c16" id="fact-identifier-155" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,233</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span><ix:nonfraction contextref="c18" id="fact-identifier-157" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,233</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitref="shares" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,970,389</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">169</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">381,225</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<span><ix:nonfraction contextref="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">337,457</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,937</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&nbsp;</b></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">CONSOLIDATED
STATEMENTS OF CASH FLOWS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="padding-bottom: 1.5pt; text-align: right">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="3" style="padding-bottom: 1.5pt; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left; text-indent: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Loss</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,793</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,573</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Adjustments to reconcile loss to net cash used in operating activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Depreciation of property, plant and equipment</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitref="usd" inside-table="true" id="fact-identifier-166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">431</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitref="usd" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">357</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Financing expense, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" unitref="usd" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">359</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" unitref="usd" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Share-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitref="usd" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,233</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitref="usd" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,368</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Amortization of debt discount and issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" unitref="usd" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">638</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21"><span><ix:nonfraction contextref="c5" id="fact-identifier-173" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Operating lease right-of-use assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitref="usd" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,109</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitref="usd" inside-table="true" id="fact-identifier-175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,891</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Operating lease liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,193</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,318</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued severance pay, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPostemploymentObligations" scale="3" unitref="usd" inside-table="true" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22"><span><ix:nonfraction contextref="c5" id="fact-identifier-179" name="us-gaap:IncreaseDecreaseInPostemploymentObligations" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Decrease (increase) in prepaid expenses and other assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,008</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitref="usd" inside-table="true" id="fact-identifier-181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,630</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Increase in trade payables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitref="usd" inside-table="true" id="fact-identifier-182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,941</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitref="usd" inside-table="true" id="fact-identifier-183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,066</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Increase (decrease) in accrued expenses and current liabilities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">505</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,454</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-186" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,760</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,219</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from investing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Purchase of property, plant and equipment</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitref="usd" inside-table="true" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,054</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitref="usd" inside-table="true" id="fact-identifier-189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,804</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Purchase of marketable securities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">102,179</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23"><span><ix:nonfraction contextref="c5" id="fact-identifier-191" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Proceeds from maturity of marketable securities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,534</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,551</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Investment in restricted deposits</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" unitref="usd" inside-table="true" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,222</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" unitref="usd" inside-table="true" id="fact-identifier-195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">158</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,921</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,589</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">CONSOLIDATED
STATEMENTS OF CASH FLOWS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cash flows from financing activities:</span></td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Proceeds from issuance of ordinary shares, net</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24"><span><ix:nonfraction contextref="c0" id="fact-identifier-198" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitref="usd" inside-table="true" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">133,312</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Proceeds from exercise of options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">626</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitref="usd" inside-table="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">650</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Proceeds from issuance of convertible senior notes, net</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="3" unitref="usd" inside-table="true" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,777</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25"><span><ix:nonfraction contextref="c5" id="fact-identifier-203" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,403</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">133,962</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Increase (decrease) in cash and cash equivalents</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,278</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" unitref="usd" inside-table="true" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85,332</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents at beginning of year</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd" inside-table="true" id="fact-identifier-208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127,170</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd" inside-table="true" id="fact-identifier-209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,838</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents at end of year</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd" inside-table="true" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,892</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd" inside-table="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127,170</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; text-indent: 0pt; padding-left: 0pt">Significant non-cash transactions:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Lease liabilities arising from new right-of-use asset</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:LeaseLiabilitiesArisingFromNewRightofuseAsset" scale="3" unitref="usd" inside-table="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,503</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="gmda:LeaseLiabilitiesArisingFromNewRightofuseAsset" scale="3" unitref="usd" inside-table="true" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,373</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Issuance expenses on credit</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26"><span><ix:nonfraction contextref="c0" id="fact-identifier-214" name="gmda:IssuanceExpensesOnCredit" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="gmda:IssuanceExpensesOnCredit" scale="3" unitref="usd" inside-table="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">468</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Purchase of property, plant and equipment on credit</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" unitref="usd" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">634</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" unitref="usd" inside-table="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">415</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; text-indent: 0pt; padding-left: 0pt">Supplemental disclosures of cash flow information:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Cash paid for interest</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,572</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-220" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;1:</td><td style="text-align: justify">GENERAL</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">a.</td><td style="text-align: justify">Gamida Cell Ltd. (the “Company”), founded in 1998, is an advanced cell therapy company committed
to finding cures for patients with blood cancers and serious blood diseases. The Company develops novel curative treatments using stem
cells and Natural Killer (NK) cells.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.2pt; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">b.</td><td>The Company has created a novel NAM cell expansion technology platform that is designed to enhance the
number and functionality of allogenic donor cells. This proprietary therapeutic platform may enable the development of therapies with
the potential to improve treatment outcomes beyond what is possible with current donor-derived therapies.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The lead product candidate, omidubicel,
is an advanced cell therapy in development as a potential life-saving treatment option for patients in need of a bone marrow transplant
(BMT). In May 2020, the Company reported that omidubicel met its primary endpoint in an international, randomized, multi-center Phase
3 clinical study in 125 patients with high-risk hematologic malignancies undergoing bone marrow transplant and who had no available matched
donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT with a graft derived from
bone marrow or peripheral blood cells of a matched donor is currently the standard of care treatment for many of these patients, but there
is a significant unmet need for patients who cannot find a fully matched donor.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.75pt; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In October 2020, the Company reported
that omidubicel met all three of its secondary endpoints.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In October 2021, the complete results
from our pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic malignancies were published in the peer-reviewed
medical journal Blood. The trial achieved its primary endpoint of time to neutrophil engraftment as well as all three of the prespecified
secondary endpoints. These secondary endpoints were the proportion of patients who achieved platelet engraftment by day 42, the proportion
of patients with grade 2 or grade 3 bacterial or invasive fungal infections in the first 100 days following transplant, and the number
of days alive and out of the hospital in the first 100 days following transplant. All three secondary endpoints demonstrated statistical
significance in an intent-to-treat analysis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Omidubicel is the first bone marrow
transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has received orphan drug
designation in the U.S. and in Europe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85pt; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition to omidubicel, the
Company is developing GDA-201, an investigational NK cell-based cancer immunotherapy to be used in combination with standard-of-care
therapeutic antibodies. NK cells have potent anti-tumor properties and have the advantage over other oncology cell therapies of not
requiring genetic matching, potentially enabling NK cells to serve as a universal donor-based therapy when combined with certain
antibodies. GDA-201 is currently in an investigator-sponsored Phase 1/2 study for the treatment of relapsed or refractory
non-Hodgkin lymphoma (NHL). In December 2020, the Company reported updated and expanded results from the Phase 1 clinical study at
the Annual Meeting of the American Society of Hematology, or ASH. The data from the first 35 patients demonstrated that GDA-201 was
clinically active and generally well tolerated. Among the 19 patients with NHL, 13 complete responses and one partial response were
observed, with an overall response rate of 74 percent and a complete response rate of 68 percent.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></p></ix:continuation></span><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85pt; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;1:</td><td style="text-align: justify">GENERAL (Cont.)</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85pt; text-align: justify">&nbsp;</p><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">At the December
2021 Annual Meeting of ASH, the Company reported two-year follow-up data from this clinical trial on outcomes and cytokine biomarkers
associated with survival. <span><ix:nonnumeric contextref="c0" name="gmda:ClinicalTrialOnOutcomes" inside-table="false" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at
two years of 78% (95% CI, 51%–91%) and a safety profile similar to that reported previously.</ix:nonnumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tbody><tr style="vertical-align: top"> <td style="width: 0.75in">&nbsp;</td> <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">c.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The Company is devoting substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficit as of December&nbsp;31, 2021 was $<span><ix:nonfraction contextref="c3" decimals="0" format="ixt:num-dot-decimal" name="gmda:AccumulatedDeficit" scale="0" unitref="usd" inside-table="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">337,457</ix:nonfraction></span> and negative cash flows from operating activities during the year ended December 31, 2021 was $<span><ix:nonfraction contextref="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsAndCash" scale="0" unitref="usd" inside-table="true" id="fact-identifier-232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,760</ix:nonfraction></span>. The Company is planning to finance its operations from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. However, there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in amounts required. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements for at least twelve months from the issuance of the consolidated financial statements.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">d.</td><td style="text-align: justify">The Company has a wholly-owned U.S. subsidiary, Gamida Cell Inc. (the “Subsidiary”), which was
incorporated in 2000, under the laws of the State of Delaware. The Company has <span><ix:nonfraction contextref="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitref="pure" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span> operating segment and reporting unit.</td></tr></tbody></table></ix:continuation></span><div>

</div><p style="margin-top: 0; margin-bottom: 0">&nbsp;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -28.35pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -28.35pt">&nbsp;</p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-235" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE 2:</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-237" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">a.</td><td style="text-align: justify">Basis of presentation of the financial statements:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span>The
Company’s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles
(U.S. GAAP) as set forth in the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (ASC).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Prior to 2021, the&nbsp;Company prepared
its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting
Standards Board (IASB), as permitted in the United States based on the Company’s qualification as a “foreign private issuer”
under the rules and regulations of the U.S Securities and Exchange Commission (the “SEC”). In connection with the loss of
the Company’s status as a foreign private issuer effective on January 1, 2022, the Company, as a domestic filer, prepared its consolidated
financial statements in accordance with U.S. GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-243" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">b.</td><td style="text-align: justify">Use of estimates:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_UseOfEstimates-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span>The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions
that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management
believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are
made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the
consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ
from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-247" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">c.</td><td style="text-align: justify">Principles of consolidation:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-251" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">d.</td><td style="text-align: justify">Consolidated financial statements in U.S dollars:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The functional currency is the currency
that best reflects the economic environment in which the Company and its subsidiary operates and conducts their transactions. Most of
the Company’s costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars.
The Company’s management believes that the functional currency of the Company is the U.S. dollar.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Accordingly, monetary
accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC No. 830 “Foreign
Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the statements
of operations as financing income or expenses as appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;2:</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</p><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-257" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">e.</td><td style="text-align: justify">Cash and cash equivalents:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Cash equivalents
are short-term highly liquid deposits that are readily convertible to cash with original maturities of three months or less, at the date
acquired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 1in">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-261" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">f.</td><td style="text-align: justify">Investments in marketable securities:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-size: 10pt">The
Company’s investment in marketable securities consist primarily of trading bonds with a quoted market price that are classified
as trading securities pursuant to ASC </span>No. <span style="font-size: 10pt">320 “Investments — Debt Securities.”
Marketable securities are stated at fair value as determined by the closing price of each security at balance sheet date. Unrealized gains
and losses on these securities are included in financing income in the consolidated statements of operations. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_RestrictedShorttermAndLongtermDepositsPolicyTextBlock-c0_cont_1" escape="true" name="gmda:RestrictedShorttermAndLongtermDepositsPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-265" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">g.</td><td style="text-align: justify">Restricted short-term and long-term deposits:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_RestrictedShorttermAndLongtermDepositsPolicyTextBlock-c0_cont_2" id="_RestrictedShorttermAndLongtermDepositsPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Restricted short-term deposits are
deposits with maturities of up to one year and are used as security for the Company’s credit cards. Restricted short-term deposits
amounted to $<span><ix:nonfraction contextref="c3" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="6" unitref="usd" inside-table="false" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500</ix:nonfraction></span> and $<span><ix:nonfraction contextref="c4" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="6" unitref="usd" inside-table="false" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152</ix:nonfraction></span> as of December 31, 2021 and 2020, respectively, and are included in prepaid expenses and other current assets
in the consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span><ix:continuation id="_RestrictedShorttermAndLongtermDepositsPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Restricted long-term deposits are
deposits with maturities of more than one year and are used as guarantee for the Israeli Investment Center grant expected in 2022 and
as security for the rental of premises and for the Company’s credit cards.</ix:continuation></span> Restricted long-term deposits amounted to $<span><ix:nonfraction contextref="c3" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndInvestments" scale="6" unitref="usd" inside-table="false" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,961</ix:nonfraction></span> as of
December 31, 2021, as presented in the consolidated balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-274" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">h.</td><td style="text-align: justify">Property, plant and equipment:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Property, plant
and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses
and any related investment grants, excluding day-to-day servicing expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Depreciation is
calculated on a straight-line basis over the useful life of the assets at annual rates as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="gmda:ScheduleOfUsefulLifeOfTheAssetsAtAnnualRateTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:continuation continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 89%; text-align: justify">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 9%; text-align: center">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machinery</td><td>&nbsp;</td>
    <td style="text-align: center"><span><ix:nonfraction contextref="c22" decimals="2" format="ixt:num-dot-decimal" name="gmda:DepreciationRatesPropertyPlantAndEquipment" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span> - <span><ix:nonfraction contextref="c23" decimals="2" format="ixt:num-dot-decimal" name="gmda:DepreciationRatesPropertyPlantAndEquipment" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Office, furniture and equipment</td><td>&nbsp;</td>
    <td style="text-align: center"><span><ix:nonfraction contextref="c24" decimals="2" format="ixt:num-dot-decimal" name="gmda:DepreciationRatesPropertyPlantAndEquipment" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6</ix:nonfraction></span> - <span><ix:nonfraction contextref="c25" decimals="2" format="ixt:num-dot-decimal" name="gmda:DepreciationRatesPropertyPlantAndEquipment" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">33</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Leasehold improvements</td><td>&nbsp;</td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-27"><span><ix:nonfraction contextref="c26" id="fact-identifier-286" name="gmda:DepreciationRatesPropertyPlantAndEquipment" unitref="pure" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">(*)</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Project in process- manufacturing plant</td><td>&nbsp;</td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-28"><span><ix:nonfraction contextref="c27" id="fact-identifier-287" name="gmda:DepreciationRatesPropertyPlantAndEquipment" unitref="pure" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">(**)</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span></ix:nonnumeric></span></ix:continuation></span><div>




</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tbody><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 0.5in">(*)</td><td style="text-align: justify">Over the shorter of the term of the lease or its useful life.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="text-align: left; width: 0.5in">(**)</td><td style="text-align: justify">As of December 31, 2021, the manufacturing plant is under
validation process and therefore is not yet ready for production. Depreciation of the manufacturing plant will commence upon completion
of the validation process.</td>
</tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;2:</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt">&nbsp;</p><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-293" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">i.</td><td style="text-align: justify">Impairment of long-lived assets:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company’s
long-lived assets are reviewed for impairment in accordance with ASC No. 360 “Property, Plant and Equipment,” whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist and
the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company
reduces the carrying amount of the assets through an impairment charge, to their estimated fair values. During the years ended December
31, 2021 and 2020, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-297" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">j.</td><td style="text-align: justify">Research and development expenses:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Research and development expenses
net of grants are recognized in the consolidated statements of operations when incurred. Research and development expenses consist of
personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors,
costs associated with obtaining regulatory approvals, and executing pre-clinical and clinical studies. In addition, research and development
expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research
and development expenses as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_ResearchAndDevelopmentExpensePolicy-c0_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Royalty-bearing grants from the Israeli
Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development
projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a
reduction from research and development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; ">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; ">Since the payment of royalties
is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related
revenues are recognized.&nbsp;In the event of failure of a project that was partly financed by the IIA, the Company will not be obligated
to pay any royalties or repay the amounts received. The Company recognized the amounts of grants received in research and development
as a reduction from research and development expenses in the amount of $<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitref="usd" inside-table="false" id="fact-identifier-304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,189</ix:nonfraction></span> and $<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitref="usd" inside-table="false" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,204</ix:nonfraction></span> for the years ended December&nbsp;31, 2021 and
2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_ConvertibleSeniorNotesPolicyTextBlock-c0_cont_1" escape="true" name="gmda:ConvertibleSeniorNotesPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-307" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">k.</td><td style="text-align: justify">Convertible senior notes:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_ConvertibleSeniorNotesPolicyTextBlock-c0_cont_2" id="_ConvertibleSeniorNotesPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for its convertible
senior notes in accordance with ASC 470-20 “Debt with Conversion and Other Options”. The Company early adopted ASU 2020-06
using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized
cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;2:</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_ConvertibleSeniorNotesPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company’s convertible senior
notes are included in the calculation of diluted earnings per share (the “EPS”) if the assumed conversion into ordinary shares
is dilutive, using the “if-converted” method. This involves adding back the periodic non-cash interest expense net of taxes
associated with the convertible senior notes to the numerator and by adding the shares that would be issued in an assumed conversion (regardless
of whether the conversion option is in or out of the money) to the denominator for the purposes of calculating diluted EPS. Since the
effect of the convertible senior notes on the diluted EPS was antidilutive, the Company did not include them in the calculation of the
diluted EPS.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-313" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">l.</td><td style="text-align: justify">Share-based compensation:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company accounts
for share-based compensation in accordance with ASC No. 718, “Compensation - Stock Compensation”, which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award is
recognized as an expense over the requisite service periods, which is the vesting period of the respective award, on a straight-line basis
when the only condition to vesting is continued service.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0pt">The Company has
selected the binominal option-pricing model as the most appropriate fair value method for its option awards. The fair value of restricted
shares is based on the closing market value of the underlying shares at the date of grant. The Company recognizes forfeitures of equity-based
awards as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-weight: normal">&nbsp;</span></p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_1" escape="true" name="gmda:EmployeeBenefitLiabilitiesPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-319" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">m.</td><td style="text-align: justify">Employee benefit liabilities:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&nbsp;</span></p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_2" id="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company
has several employee benefit plans:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_3" id="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">Short-term employee benefits</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt"><b>&nbsp;</b></p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_4" id="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Short-term employee
benefits are benefits that are expected to be settled entirely before twelve months after the end of the annual reporting period in which
the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social
security contributions and are recognized as expenses as the services are rendered.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_5" id="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">Severance pay</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_6" id="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0pt">The majority of
the Company’s employees who are Israeli citizens have subscribed to Section&nbsp;14 of Israel’s Severance Pay Law, 5723-1963
(the “<span>Severance Pay Law</span>”). Pursuant to Section&nbsp;14 of the <span>Severance
Pay Law</span>, employees covered by this section are entitled to monthly deposits at a rate of <span><ix:nonfraction contextref="c0" decimals="4" format="ixt:num-dot-decimal" name="gmda:SeverancePayPercentage" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.33</ix:nonfraction></span>% of their monthly salary, made on
their behalf by the Company. Payments made to employees in accordance with this section release the Company from any future severance
liabilities with respect to such employees. Neither severance pay liability nor severance pay fund under Section 14 of the Severance Pay
Law is recorded on the Company’s consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -28.35pt"><b>&nbsp;</b></p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;2:</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</p><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_7" id="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0pt"><span>For
the Company’s employees in Israel who are not subject to Section 14 of the Severance Pay Law, the Company has a liability for severance
pay pursuant to the Severance Pay Law based on the most recent salary of these employees multiplied by the number of years of employment
as of the balance sheet date. The Company’s liability for these employees is fully provided for by monthly deposits with severance
pay funds, insurance policies and accruals. The deposited funds include profits accumulated up to the balance sheet date. The deposited
funds&nbsp;may&nbsp;be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The
severance pay fund amounted to $<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitref="usd" inside-table="false" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,148</ix:nonfraction></span> and $<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitref="usd" inside-table="false" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,191</ix:nonfraction></span> as of December 31, 2021 and 2020, respectively. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109.8pt; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_EmployeeBenefitLiabilitiesPolicyTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0pt">Accrued severance
pay is $<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:AccruedSeveranceCost" scale="3" unitref="usd" inside-table="false" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,396</ix:nonfraction></span> and $<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="gmda:AccruedSeveranceCost" scale="3" unitref="usd" inside-table="false" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,426</ix:nonfraction></span> as of December 31, 2021 and 2020, <span>respectively.</span> Severance expense
for the years ended December 31, 2021 and 2020, is $<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" scale="3" unitref="usd" inside-table="false" id="fact-identifier-339" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">427</ix:nonfraction></span> and $<span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" scale="3" unitref="usd" inside-table="false" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-342" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">n.</td><td style="text-align: justify">Fair value of financial instruments:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span>The
accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands
disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer
a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes
a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Level 1: Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority
to Level 1 inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Level 2: Observable inputs that are
based on inputs not quoted on active markets but corroborated by market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Level 3: Unobservable inputs are used
when little or no market data are available.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The carrying amounts of cash and cash
equivalents, marketable securities, other receivables, short-term deposits, prepaid expenses and other current assets, trade payables,
accrued expenses and other payables approximate their fair value due to the short-term maturity of such instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-354" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">o.</td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0pt">Leases:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for leases according
to ASC 842, “Leases”. The Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not
recognize right-of-use (“ROU”) assets and lease liabilities in respect of those agreements. The Company also elected the practical
expedient to not separate lease and non-lease components for its leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>


</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;2:</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">An ROU asset represents the right
to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising
from the lease agreement. An ROU asset is measured based on the discounted present value of the remaining lease payments, plus any initial
direct costs incurred and prepaid lease payments, excluding lease incentives. The lease liability is measured at lease commencement date
based on the discounted present value of the remaining lease payments. The implicit rate within the operating leases is generally not
determinable, therefore the Company uses the Incremental Borrowing Rate (“IBR”) based on the information available at commencement
date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate for collateralized
borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options
to extend the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when
it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain
that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Payments under the Company’s
lease arrangements are primarily fixed however, certain lease agreements contain variable payments, which are expensed as incurred and
not included in the operating lease right-of-use assets and liabilities. Variable lease payments are primarily comprised of payments affected
by common area maintenance and utility charges.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt; ">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-362" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">p.</td><td style="text-align: justify">Income taxes:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0in; text-align: justify">The Company accounts for income taxes in accordance with ASC&nbsp;740, “Income Taxes”, which prescribes the use of the liability
method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value,
if needed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt; ">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; ">ASC 740 offers
a&nbsp;two-step&nbsp;approach for recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the
tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more
likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any
related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than <span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50</ix:nonfraction></span>% likely
to be realized upon ultimate settlement. As of December 31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as
a result of ASC 740.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; ">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</p><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-369" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">q.</td><td style="text-align: justify">Basic and diluted net loss per share: </td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; ">The Company computes net loss per
share using the&nbsp;two-class&nbsp;method required for participating securities. The&nbsp;two-class&nbsp;method requires income available
to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective
rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating
securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary
shares, on a&nbsp;pro-rata&nbsp;basis. These participating securities do not contractually require the holders of such shares to participate
in the Company’s losses. As such, net loss for the periods presented was not allocated to the Company’s participating securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: -27.75pt">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; ">The Company’s basic net loss
per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary
shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated
by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the&nbsp;if-converted&nbsp;method
based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects
of potentially dilutive ordinary shares are anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</p></ix:continuation></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-375" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">r.</td><td style="text-align: justify">Recently issued accounting standards:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_61" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In August 2020, the FASB issued Accounting
Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU
2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including
convertible instruments and contracts on an entity’s own equity. This guidance also eliminates the treasury stock method to calculate
diluted earnings per share for convertible instruments and requires the use of the if-converted method. ASU 2020-06 will be effective
for fiscal years beginning after December 15, 2021, with early adoption permitted. Effective January 1, 2021, the Company early adopted
ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the financial statements.</p></ix:continuation></span></ix:continuation></span><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-378" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;3:</td><td style="text-align: justify">MARKETABLE SECURITIES</td>
</tr></tbody></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-c0_cont_2" id="_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The following table
details the fair value of trading marketable securities as of December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: left; text-indent: 0in">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:MarketableSecuritiesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br>
 December&nbsp;31, <br>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Corporate debentures</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c28" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CorporateDebentures" scale="3" unitref="usd" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">19,605</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Government debentures</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c28" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GovernmentDebentures" scale="3" unitref="usd" inside-table="true" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,429</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&nbsp;<span><ix:nonfraction contextref="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,034</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span></ix:continuation></span><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.7pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-385" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;4:</td><td style="text-align: justify">PROPERTY, PLANT AND EQUIPMENT, NET</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&nbsp;</b></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The composition
of property, plant and equipment is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Cost:</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Machinery</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,345</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,545</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Leasehold improvements</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,447</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,542</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Office, furniture and equipment</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">800</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">627</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 19.85pt">Production plant in process</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOther" scale="3" unitref="usd" inside-table="true" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,644</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOther" scale="3" unitref="usd" inside-table="true" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,149</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,236</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd" inside-table="true" id="fact-identifier-398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,863</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 8.5pt">Less - accumulated depreciation</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitref="usd" inside-table="true" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,056</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitref="usd" inside-table="true" id="fact-identifier-400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,625</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 8.5pt">Depreciated cost</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,180</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd" inside-table="true" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,238</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Depreciation expense amounted to $<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1" scale="3" unitref="usd" inside-table="false" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">431</ix:nonfraction></span>
and $<span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1" scale="3" unitref="usd" inside-table="false" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">357</ix:nonfraction></span> for the years ended December 31, 2021 and 2020, respectively.</p></ix:continuation></span><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-406" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;5:</td><td style="text-align: justify">LEASES</td>
</tr></tbody></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">The Company entered
into operating leases primarily for its in-process production plant, and its laboratories and offices. The leases have remaining lease
terms of up&nbsp;to&nbsp;<span><ix:nonnumeric contextref="c3" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" inside-table="false" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">six years</ix:nonnumeric></span>, The Company does not assume renewals in its determination of the lease term unless the renewals are
considered as reasonably certain at lease commencement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">The components of
operating lease costs were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.7pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>December 31, </b></p></td><td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease costs</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitref="usd" inside-table="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,391</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitref="usd" inside-table="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,140</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitref="usd" inside-table="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">103</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitref="usd" inside-table="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitref="usd" inside-table="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,494</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitref="usd" inside-table="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,183</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><b>&nbsp;</b></p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_LesseeOperatingLeasesTextBlock-c0_cont_5" id="_LesseeOperatingLeasesTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Supplemental
balance sheet information related to operating leases is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.7pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_LesseeOperatingLeasesTextBlock-c0_cont_6" id="_LesseeOperatingLeasesTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, </b></p></td><td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Weighted average remaining lease term (in years)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><span><ix:nonnumeric contextref="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" inside-table="true" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.31</ix:nonnumeric></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><span><ix:nonnumeric contextref="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" inside-table="true" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.17</ix:nonnumeric></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average discount rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.54</ix:nonfraction></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.45</ix:nonfraction></span></td><td style="text-align: left">%</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.7pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_LesseeOperatingLeasesTextBlock-c0_cont_7" id="_LesseeOperatingLeasesTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Maturities of lease
liabilities were as follows<span style="font-family: Times New Roman, Times, Serif">:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br>
December&nbsp;31,<br>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left">2022</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitref="usd" inside-table="true" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,771</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitref="usd" inside-table="true" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,801</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" unitref="usd" inside-table="true" id="fact-identifier-430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,808</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" unitref="usd" inside-table="true" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,316</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:LesseeOperatingLeaseLiabilityPaymentsDueYearSix" scale="3" unitref="usd" inside-table="true" id="fact-identifier-432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">790</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" unitref="usd" inside-table="true" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">613</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total undiscounted lease payments</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,099</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Less: Imputed interest</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitref="usd" inside-table="true" id="fact-identifier-435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">797</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">Present value of lease liabilities</td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" scale="3" unitref="usd" inside-table="true" id="fact-identifier-436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,302</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span></ix:continuation></span><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>GAMIDA CELL LTD. <span style="text-transform: uppercase">and
its subsidiary</span></b></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. dollars in thousands (except share and
per share data and unless otherwise indicated)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_1" escape="true" name="gmda:DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-437" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE&nbsp;6:</td><td style="text-align: justify">CONVERTIBLE SENIOR NOTES, NET</td>
</tr></tbody></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_2" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">On February 16, 2021,
the Subsidiary issued convertible senior notes (the “Convertible Notes”) due in 2026, in the aggregate principal amount of
$<span><ix:nonfraction contextref="c0" decimals="-6" format="ixt:num-dot-decimal" name="gmda:PrincipalAmount" scale="6" unitref="usd" inside-table="false" id="fact-identifier-439" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75</ix:nonfraction></span> million, pursuant to an Indenture between the Company, the Subsidiary, and Wilmington Savings Fund Society, FSB, dated February 16,
2021 (the “Indenture”). The Convertible Notes bear interest payable semiannually in arrears, at a rate of <span><ix:nonfraction contextref="c0" decimals="5" format="ixt:num-dot-decimal" name="gmda:AnnualInterestPercentage" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.875</ix:nonfraction></span>% per year.
The Convertible Notes will mature on February 15, 2026, unless earlier converted, redeemed or repurchased in accordance with their terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.7pt 0pt 0; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_3" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Subject to the provisions
of the Indenture, the holders of the Convertible Notes have the right, prior to the close of business on the second scheduled trading
day immediately preceding February 15, 2026, to convert any Convertible Notes or portion thereof that is $<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="3" unitref="usd" inside-table="false" id="fact-identifier-442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000</ix:nonfraction></span> or an integral multiple
thereof, into the Company’s ordinary shares at an initial conversion rate of <span><ix:nonfraction contextref="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitref="shares" inside-table="false" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56.3063</ix:nonfraction></span> shares per $<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" unitref="usd" inside-table="false" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000</ix:nonfraction></span> principal amount of Convertible
Notes (equivalent to an exchange price of $<span><ix:nonfraction contextref="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitref="usdPershares" inside-table="false" id="fact-identifier-445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17.76</ix:nonfraction></span> per share). The conversion rate is subject to adjustment in specified events.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5in 0pt 0; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_4" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Upon the occurrence
of a fundamental change (as defined in the Indenture), holders of the Convertible Notes may require the Company to repurchase for cash
all or a portion of their Convertible Notes, in multiples of $<span><ix:nonfraction contextref="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" unitref="usd" inside-table="false" id="fact-identifier-447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000</ix:nonfraction></span> principal amount, at a repurchase price equal to <span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100</ix:nonfraction></span>% of the principal
amount of the Convertible Notes, plus any accrued and unpaid interest, if any, to, but excluding, interest accrued after the date of such
repurchase notice. If certain fundamental changes referred to as make-whole fundamental changes occur, the conversion rate for the Convertible
Notes may be increased.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5in 0pt 0; text-align: justify; text-indent: -28.35pt">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_5" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Subject to the provisions
of the Indenture, the Subsidiary may redeem for cash all or a portion of the Convertible Notes for cash, at its option, at a redemption
price equal to <span><ix:nonfraction contextref="c40" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100</ix:nonfraction></span>% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest on the notes to
be redeemed, if the last reported closing price of the Company’s ordinary shares has been at least <span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="gmda:ExchangePricePercentage" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">130</ix:nonfraction></span>% of the exchange price then
in effect for at least 20 trading days during any 30 consecutive trading day period, and in the event of certain tax law changes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_6" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">The Convertible Notes
are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition
as derivatives according to ASC 815-40.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_7" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-454" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of <br>
December&nbsp;31,</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Liability component:</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Principal amount</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:PrincipalAmount" scale="3" unitref="usd" inside-table="true" id="fact-identifier-455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance costs</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:UnamortizedIssuanceCosts" scale="3" sign="-" unitref="usd" inside-table="true" id="fact-identifier-456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,223</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;Net issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:NetIssuanceCosts" scale="3" unitref="usd" inside-table="true" id="fact-identifier-457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">70,777</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortized issuance costs</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitref="usd" inside-table="true" id="fact-identifier-458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">640</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net carrying amount</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:NetCarryingAmountincludingAccruedInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">71,417</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</p></ix:nonnumeric></span></ix:continuation></span><div>


</div><div>

</div><span><ix:continuation id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-weight: normal">The
total issuance costs of the Convertible Notes amounted to $<span><ix:nonfraction contextref="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" unitref="usd" inside-table="false" id="fact-identifier-461" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,223</ix:nonfraction></span> and are amortized to interest expenses at an annual effective interest
rate of <span><ix:nonnumeric contextref="c0" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate" inside-table="false" id="fact-identifier-462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.37%</ix:nonnumeric></span>, over the term of the Convertible Notes.</span></p></ix:continuation></span><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: right">&nbsp;</p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-463" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;7:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCRUED
EXPENSES AND OTHER PAYABLES</span></td>
</tr></tbody></table><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended <br>
    December&nbsp;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subcontractors</span></td><td style="width: 1%; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:Subcontractors" scale="3" unitref="usd" inside-table="true" id="fact-identifier-466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">517</ix:nonfraction></span></span></td><td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 1%; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:Subcontractors" scale="3" unitref="usd" inside-table="true" id="fact-identifier-467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">609</ix:nonfraction></span></span></td><td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical activities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ClinicalActivities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,445</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ClinicalActivities" scale="3" unitref="usd" inside-table="true" id="fact-identifier-469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,841</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional services</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">740</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,943</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production plant in process</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ProductionPlantInProcess" scale="3" unitref="usd" inside-table="true" id="fact-identifier-472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">983</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ProductionPlantInProcess" scale="3" unitref="usd" inside-table="true" id="fact-identifier-473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">415</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:OtherPayable" scale="3" unitref="usd" inside-table="true" id="fact-identifier-474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180</ix:nonfraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:OtherPayable" scale="3" unitref="usd" inside-table="true" id="fact-identifier-475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180</ix:nonfraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,865</ix:nonfraction></span></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitref="usd" inside-table="true" id="fact-identifier-477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,988</ix:nonfraction></span></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table></ix:nonnumeric></span></ix:continuation></span><div>

</div><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-478" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;8:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FAIR
VALUE MEASUREMENTS</span></td>
</tr></tbody></table><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present the fair value of money market funds and marketable securities for the years ended December 31, 2021 and 2020:</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-481" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    equivalents:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
    market funds</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,021</ix:nonfraction></span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29"><span><ix:nonfraction contextref="c42" id="fact-identifier-483" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,021</ix:nonfraction></span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30"><span><ix:nonfraction contextref="c44" id="fact-identifier-486" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitref="usd" inside-table="true" id="fact-identifier-487" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
    securities:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    debentures</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31"><span><ix:nonfraction contextref="c41" id="fact-identifier-488" name="gmda:CorporateDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c42" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CorporateDebentures" scale="3" unitref="usd" inside-table="true" id="fact-identifier-489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">19,605</ix:nonfraction></span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CorporateDebentures" scale="3" unitref="usd" inside-table="true" id="fact-identifier-490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">19,605</ix:nonfraction></span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32"><span><ix:nonfraction contextref="c43" id="fact-identifier-491" name="gmda:CorporateDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33"><span><ix:nonfraction contextref="c44" id="fact-identifier-492" name="gmda:CorporateDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34"><span><ix:nonfraction contextref="c4" id="fact-identifier-493" name="gmda:CorporateDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
    debentures</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35"><span><ix:nonfraction contextref="c41" id="fact-identifier-494" name="gmda:GovernmentDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c42" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GovernmentDebentures" scale="3" unitref="usd" inside-table="true" id="fact-identifier-495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,429</ix:nonfraction></span></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GovernmentDebentures" scale="3" unitref="usd" inside-table="true" id="fact-identifier-496" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,429</ix:nonfraction></span></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36"><span><ix:nonfraction contextref="c43" id="fact-identifier-497" name="gmda:GovernmentDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37"><span><ix:nonfraction contextref="c44" id="fact-identifier-498" name="gmda:GovernmentDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38"><span><ix:nonfraction contextref="c4" id="fact-identifier-499" name="gmda:GovernmentDebentures" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></ix:nonfraction></span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets measured at fair value</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitref="usd" inside-table="true" id="fact-identifier-500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,021</ix:nonfraction></span></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitref="usd" inside-table="true" id="fact-identifier-501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,034</ix:nonfraction></span></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitref="usd" inside-table="true" id="fact-identifier-502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,055</ix:nonfraction></span></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitref="usd" inside-table="true" id="fact-identifier-503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39"><span><ix:nonfraction contextref="c44" id="fact-identifier-504" name="us-gaap:FairValueNetAssetLiability" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></ix:nonfraction></span></div></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font-size: 10pt; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitref="usd" inside-table="true" id="fact-identifier-505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span></span></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table></ix:nonnumeric></span></ix:continuation></span><div>

</div><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-506" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;9:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTINGENT
LIABILITIES AND COMMITMENTS</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
proceedings:</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time the Company or its subsidiaries may be involved in legal proceedings and/or litigation arising in the ordinary course of
business. While the outcome of these matters cannot be predicted with certainty, the Company does not believe it will have a material
effect on its consolidated financial position, results of operations, or cash flows.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
                                            guarantees:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company obtained bank guarantees in the amount of $<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="3" unitref="usd" inside-table="false" id="fact-identifier-511" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,334</ix:nonfraction></span>, primarily in connection with an Investment Center
grant of up to $<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" scale="3" unitref="usd" inside-table="false" id="fact-identifier-512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,171</ix:nonfraction></span> expected to be received in 2022 which requires a bank guarantee in order to ensure the fulfillment of the grant
terms.</span></p><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left">&nbsp;</p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>



</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><span><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;9:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTINGENT
LIABILITIES AND COMMITMENTS (Cont.)</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governments
                                            grants</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has received grants from the IIA to finance its research and development programs in Israel, through which the Company received
IIA participation payments in the aggregate amount of $<span><ix:nonfraction contextref="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="6" unitref="usd" inside-table="false" id="fact-identifier-516" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37.3</ix:nonfraction></span> million through December&nbsp;31, 2021, of which $<span><ix:nonfraction contextref="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" unitref="usd" inside-table="false" id="fact-identifier-517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34.7</ix:nonfraction></span> million is royalty-bearing
grants and $<span><ix:nonfraction contextref="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfAdvanceRoyalty" scale="6" unitref="usd" inside-table="false" id="fact-identifier-518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.6</ix:nonfraction></span> million is non-royalty-bearing grants. In return, the Company is committed to pay IIA royalties at a rate of&nbsp;<span><ix:nonfraction contextref="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardInterestRate" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-519" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span>-<span><ix:nonfraction contextref="c45" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardInterestRate" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.5</ix:nonfraction></span>%&nbsp;of
future sales of the developed products, up to <span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100</ix:nonfraction></span>% of the amount of grants received plus interest at LIBOR rate. Through December&nbsp;31,
2021, no royalties have been paid or accrued. The Company’s contingent royalty liability to the IIA at December&nbsp;31, 2021,
including grants received by the Company and the associated LIBOR interest on all such grants totaled to $<span><ix:nonfraction contextref="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivable" scale="6" unitref="usd" inside-table="false" id="fact-identifier-522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44.7</ix:nonfraction></span> million.</span></p></ix:continuation></span><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</p><div>



</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-523" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;10:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHAREHOLDERS’
EQUITY</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
                                            shares:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Company’s amended and restated Articles of Association, the holders of the Company’s ordinary shares have the right
to receive notices to attend and vote in general meetings of the Company’s shareholders, and the right to share in dividends and
other distributions upon liquidation.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:nonnumeric contextref="c47" name="gmda:UnderwritersDescription" inside-table="false" id="fact-identifier-526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">In
May 2020, the Company closed a second follow-on offering of its ordinary shares on Nasdaq, which resulted in the sale of a total of 15,333,334
ordinary shares at a public offering price of $4.50 per share, before underwriting discounts and inclusive of the underwriters’
exercise in full of their option to purchase additional shares in the offering. The Company received proceeds in the amount of $63,860
from the offering (net of issuance costs and underwriting discounts of $5,140).</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:nonnumeric contextref="c48" name="gmda:UnderwritersDescription" inside-table="false" id="fact-identifier-528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, the Company closed a third follow-on offering of its ordinary shares on Nasdaq, which resulted in the sale of 9,343,750
ordinary shares at a public offering price of $8.00 per share, before underwriting discounts and inclusive of the underwriters’
exercise in full of their option to purchase additional shares in the offering. The Company received proceeds in the amount of $68,988
from the offering (net of issuance costs and underwriting discounts of $5,762).</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
                                            to investors:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="c0" name="gmda:ExpiryDate" inside-table="false" id="fact-identifier-532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">As
part of its 2017 investment round, the Company granted certain investors <span><ix:nonfraction contextref="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitref="shares" inside-table="false" id="fact-identifier-533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,323,978</ix:nonfraction></span> warrants that will expire in July 2022.</ix:nonnumeric></span> As of December
31, 2021, <span><ix:nonfraction contextref="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitref="shares" inside-table="false" id="fact-identifier-534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,010,466</ix:nonfraction></span> of the warrants have been exercised into the Company’s ordinary shares.</span></p></ix:continuation></span><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>


</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-535" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;11:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARE-BASED
COMPENSATION</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
plans:</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2014, the Company’s Board of Directors approved, subject to the approval of the shareholders, creation of the Company’s
ordinary C share class, with nominal value NIS <span><ix:nonfraction contextref="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitref="ilsPershares" inside-table="false" id="fact-identifier-538" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span> per share and classification of <span><ix:nonfraction contextref="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" scale="0" unitref="shares" inside-table="false" id="fact-identifier-539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span> ordinary shares for such class of shares,
whereby <span><ix:nonfraction contextref="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" scale="0" unitref="shares" inside-table="false" id="fact-identifier-540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,152,044</ix:nonfraction></span> of such shares were allocated to the Company’s employees under the amended 2014 Israel Share Option Plan (the
“2014 Plan”). The exercise price of the options granted under the 2014 Plan may not be less than the nominal value of the
shares into which the options are exercised. The options vest primarily over <span><ix:nonnumeric contextref="c53" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" inside-table="false" id="fact-identifier-541" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three years</ix:nonnumeric></span>. There are no cash settlement alternatives.
On December 29, 2014, the Company’s shareholders ratified and approved the aforesaid actions.</span></p><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2017, the Company’s Board of Directors approved the Company’s 2017 Share Incentive Plan (the “2017 Plan”
and together with the 2014 Plan, the “Option Plans”), and the subsequent grant of options to the Company’s employees,
officers and directors. Pursuant to the 2017 Plan, the Company initially reserved for issuance <span><ix:nonfraction contextref="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares" inside-table="false" id="fact-identifier-543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">312,867</ix:nonfraction></span> ordinary shares, nominal value
NIS <span><ix:nonfraction contextref="c54" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitref="ilsPershares" inside-table="false" id="fact-identifier-544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span> each. On February 28, 2017, the Company’s shareholders approved the 2017 Plan.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"></p><div>



</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Plan provides for the grant of awards, including options, restricted shares and restricted share units to the Company’s directors,
employees, officers, consultants and advisors.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 26, 2017 and on December 28, 2017, the Company’s Board of Directors approved the reservation of <span><ix:nonfraction contextref="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares" inside-table="false" id="fact-identifier-547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">463,384</ix:nonfraction></span> and <span><ix:nonfraction contextref="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares" inside-table="false" id="fact-identifier-548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">559,764</ix:nonfraction></span> additional
ordinary shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of <span><ix:nonfraction contextref="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares" inside-table="false" id="fact-identifier-549" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,338,015</ix:nonfraction></span> ordinary
Shares).</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 25, 2021 and November 17,
2021, the board of directors and shareholders, respectively, approved an amendment and restatement of the 2017 Plan. The 2017 Plan, as
amended, also contains an “evergreen” provision, which provides for an automatic allotment of ordinary shares to be added
every year to the pool of ordinary shares available for grant under the 2017 Plan. Under the evergreen provision, on January 1 of each
year (beginning January 1, 2022), the number of ordinary shares available under the 2017 Plan automatically increases by the lesser of
the following: (i) <span><ix:nonfraction contextref="c3" decimals="2" format="ixt:num-dot-decimal" name="gmda:OrdinarySharesOutstandingPercentage" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-551" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4</ix:nonfraction></span>% of our outstanding ordinary shares on the last day of the immediately preceding year; and (ii) an amount determined
in advance of January 1 by the board of directors. As of December 31, 2021, our 2017 Plan, as amended, has up to <span><ix:nonfraction contextref="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitref="shares" inside-table="false" id="fact-identifier-552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,520,066</ix:nonfraction></span> ordinary shares
available for issuance.</p><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</p></ix:continuation></span><div>

</div><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"></p><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>


</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;11:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARE-BASED
COMPENSATION (Cont.)</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock options granted using the binominal option-pricing model. The option-pricing model requires
a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
volatility was calculated based upon the Company’s historical share price and historical volatilities of similar entities in the
related sector index. The expected term of the options granted is derived from output of the option valuation model and represents the
period of time that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury
bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table lists the inputs to the binomial option-pricing model used for the fair value measurement of equity-settled share options
for the above Options Plans for the years 2021 and 2020:</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: center"><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
ended <br>
December&nbsp;31,</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-558" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span><ix:nonfraction contextref="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility of the share prices</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65</ix:nonfraction></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c60" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74</ix:nonfraction></span>%-<span><ix:nonfraction contextref="c61" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-562" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c58" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.4</ix:nonfraction></span>%-<span><ix:nonfraction contextref="c59" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction contextref="c60" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-565" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span>%-<span><ix:nonfraction contextref="c61" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure" inside-table="true" id="fact-identifier-566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.38</ix:nonfraction></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span><ix:nonnumeric contextref="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-568" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the above inputs, the fair value of the options was determined to be $<span><ix:nonfraction contextref="c58" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitref="usdPershares" inside-table="false" id="fact-identifier-570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.52</ix:nonfraction></span> - $<span><ix:nonfraction contextref="c59" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitref="usdPershares" inside-table="false" id="fact-identifier-571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.64</ix:nonfraction></span> per option at the grant date.</span></p><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>


</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left">&nbsp;</p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 85.05pt; text-align: justify"></p><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>
</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>
</div><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tbody><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"></td><td style="text-align: left; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;11:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARE-BASED
COMPENSATION (Cont.)</span></td>
</tr>
</tbody></table><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>



</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the number of options granted to employees under the Option Plans for the years ended December 31, 2021 and
related information:</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: center"><p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p> <p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of </b></span></p> <p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: center"><p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></p> <p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></p> <p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: center"><p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average remaining contractual term </b></span></p> <p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in years)</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: center"><p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 9pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>intrinsic value</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Balance as of December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,892,714</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;<span><ix:nonfraction contextref="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-576" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.15</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.65</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitref="usd" inside-table="true" id="fact-identifier-578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">608,179</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" scale="0" unitref="shares" inside-table="true" id="fact-identifier-579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,318,351</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.33</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"><span><ix:nonnumeric contextref="c0" id="fact-identifier-581" name="gmda:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonnumeric></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41"><span><ix:nonfraction contextref="c0" id="fact-identifier-582" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:StockIssuedDuringPeriodSharesStockOptionesExercised" scale="0" unitref="shares" inside-table="true" id="fact-identifier-583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">438,759</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-584" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.43</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42"><span><ix:nonnumeric contextref="c0" id="fact-identifier-585" name="gmda:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonnumeric></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"><span><ix:nonfraction contextref="c0" id="fact-identifier-586" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" scale="0" unitref="shares" inside-table="true" id="fact-identifier-587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">217,325</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.20</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"><span><ix:nonnumeric contextref="c0" id="fact-identifier-589" name="gmda:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonnumeric></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"><span><ix:nonfraction contextref="c0" id="fact-identifier-590" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitref="shares" inside-table="true" id="fact-identifier-591" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,557</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-592" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.08</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46"><span><ix:nonnumeric contextref="c0" id="fact-identifier-593" name="gmda:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonnumeric></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47"><span><ix:nonfraction contextref="c0" id="fact-identifier-594" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" unitref="usd" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Balance as of December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,411,424</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span><ix:nonfraction contextref="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-596" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.01</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" inside-table="true" id="fact-identifier-597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.19</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitref="usd" inside-table="true" id="fact-identifier-598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92,507</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Exercisable as of December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" scale="0" unitref="shares" inside-table="true" id="fact-identifier-599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,171,616</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span><ix:nonfraction contextref="c3" decimals="2" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.57</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-601" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.11</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" scale="3" unitref="usd" inside-table="true" id="fact-identifier-602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">92,507</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin-left: 1.25in; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there are $<span><ix:nonfraction contextref="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" unitref="usd" inside-table="false" id="fact-identifier-604" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,739</ix:nonfraction></span> of total unrecognized costs related to share-based compensation that is expected to be recognized
over a period of up to <span><ix:nonnumeric contextref="c0" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" inside-table="false" id="fact-identifier-605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">four years</ix:nonnumeric></span>.</span></p><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;11:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARE-BASED
COMPENSATION (Cont.)</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about the Company’s outstanding and exercisable options granted to employees as of December&nbsp;31,
2021:</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-608" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options outstanding as&nbsp;of</b></span></p> <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&nbsp;31, <br>
2021</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average remaining</b></span></p> <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>contractual
                                            term</b></span><br>
                                            <b>(years)</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options exercisable as&nbsp;of December&nbsp;31,</b></span></p> <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average remaining</b></span></p> <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>contractual term<br>
(years)</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">$ 0.25-3.80</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c62" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">435,346</ix:nonfraction></span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c63" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.18</ix:nonnumeric></span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123,494</ix:nonfraction></span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c65" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.82</ix:nonnumeric></span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$ 4.15- 4.95</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c66" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,331,999</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c67" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.67</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c68" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,578,326</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c69" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.09</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$ 5.21-7.56</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c70" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">546,150</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c71" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.62</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c72" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">210,074</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c73" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.41</ix:nonnumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$ 8.00-11.01</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c74" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,097,929</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c75" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-622" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.70</ix:nonnumeric></span></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c76" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">259,722</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonnumeric contextref="c77" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-624" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.58</ix:nonnumeric></span></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c78" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-625" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,411,424</ix:nonfraction></span></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c79" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-626" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,171,616</ix:nonfraction></span></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of restricted shares activity for the year ended December&nbsp;31, 2021 is as follows:</span></td>
</tr></tbody></table><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-629" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p> <p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of </b></span></p> <p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>restricted shares</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></p> <p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>grant date fair value</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Unvested as of December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48"><span><ix:nonfraction contextref="c4" id="fact-identifier-630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitref="shares" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49"><span><ix:nonfraction contextref="c3" id="fact-identifier-631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" unitref="usdPershares" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Granted</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitref="shares" inside-table="true" id="fact-identifier-632" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">549,427</ix:nonfraction></span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-633" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.61</ix:nonfraction></span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vested</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span><ix:nonfraction contextref="c0" id="fact-identifier-634" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitref="shares" xsi:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="hidden-fact-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitref="shares" inside-table="true" id="fact-identifier-635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,950</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-636" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.51</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Unvested as of December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitref="shares" inside-table="true" id="fact-identifier-637" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">531,477</ix:nonfraction></span></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" unitref="usdPershares" inside-table="true" id="fact-identifier-638" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.48</ix:nonfraction></span></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>&nbsp;</b></p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in">&nbsp;</td>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-size: 10pt">e.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; ">The total share-based compensation expense related to all of the Company's equity-based awards, recognized for the years ended December 31, 2021 and 2020 is comprised as follows:</span></td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p></ix:continuation></span><div>
</div><div>

</div><span><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-641" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br> December&nbsp;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses, net</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-642" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,384</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-643" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,099</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Commercial expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitref="usd" inside-table="true" id="fact-identifier-644" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">947</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitref="usd" inside-table="true" id="fact-identifier-645" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-646" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,902</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-647" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,893</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total share-based compensation</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-648" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,233</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitref="usd" inside-table="true" id="fact-identifier-649" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,368</ix:nonfraction></span></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span></ix:continuation></span><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<b>&nbsp;</b></span></p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-650" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&nbsp;12:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES
ON INCOME</b></span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
                                            rates applicable to the income of the Company:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
tax rates</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxable
income of the Israeli parent is subject to the Israeli corporate tax at the rate of <span><ix:nonfraction contextref="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-654" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitref="pure" inside-table="false" id="fact-identifier-655" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23</ix:nonfraction></span></ix:nonfraction></span>% in&nbsp;2021 and 2020.</span></p><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Subsidiary is taxed according to the tax laws in its country of residence.</span></p><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax benefits</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
is subject to tax benefits under the Law for Encouragement of Capital Investments, 1959 (the “Investment Law”), which provides
tax benefits for Israeli companies meeting certain requirements and criteria. The Investment Law has undergone certain amendments and
reforms in recent decades.</span></p><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>


</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;12:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAXES
ON INCOME (Cont.)</span></td>
</tr></tbody></table><div>

</div><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli parliament enacted a reform to the Investment Law, effective January 2011. According to the reform, a flat rate tax applies to
companies eligible for the “Preferred Enterprise” status. In order to be eligible for Preferred Enterprise status, a company
must meet minimum requirements to establish that it contributes to the country’s economic growth and is a competitive factor for
the gross domestic product.</span></p><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s Israeli operations elected “Preferred Enterprise” status, starting in 2017.</span></p><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:nonnumeric contextref="c0" name="gmda:ExplanationOfChangesInApplicableTaxRatesToPreviousAccountingPeriod" inside-table="false" id="fact-identifier-661" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits
granted to a Preferred Enterprise include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment
of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate for Area A will be 7.5% in 2017 onwards. In other regions,
the tax rate is 16%. Preferred Enterprises in peripheral regions will be eligible for Investment Center grants, as well as the applicable
reduced tax rates.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Law for the Encouragement of Industry (Taxation), 1969:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the status of an “industrial company”, under this law. According to this status and by virtue of regulations
published thereunder, the Company is entitled to claim a deduction of accelerated depreciation on equipment used in industrial activities,
as determined in the regulations issued under the law. The Company is also entitled to amortize a patent or knowhow usage right that
is used in the enterprise’s development or promotion, to deduct listed share issuance expenses and to file consolidated financial
statements under certain conditions.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            components of the loss were as follows:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_14" id="_IncomeTaxDisclosureTextBlock-c0_cont_13" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-667" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: center"><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
ended<br>
December&nbsp;31,</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Domestic</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitref="usd" inside-table="true" id="fact-identifier-668" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,853</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitref="usd" inside-table="true" id="fact-identifier-669" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,871</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitref="usd" inside-table="true" id="fact-identifier-670" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,940</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitref="usd" inside-table="true" id="fact-identifier-671" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,702</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-672" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,793</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitref="usd" inside-table="true" id="fact-identifier-673" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,573</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span></ix:continuation></span><div>

</div><div>


</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAMIDA
CELL LTD. <span style="text-transform: uppercase">and its subsidiary</span></b></span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
dollars in thousands (except share and per share data and unless otherwise indicated)</b></span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;12:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAXES
ON INCOME (Cont.)</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_15" id="_IncomeTaxDisclosureTextBlock-c0_cont_14" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
                                            operating losses carryforward:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:nonnumeric contextref="c0" name="gmda:NetCarryforwardTaxLossesDescription" inside-table="false" id="fact-identifier-675" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_16" id="_IncomeTaxDisclosureTextBlock-c0_cont_15" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has net operating losses and capital losses for tax purposes as of December&nbsp;31, 2021 totaling approximately $236,875 and
$507, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period.</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_17" id="_IncomeTaxDisclosureTextBlock-c0_cont_16" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Subsidiary has net operating losses carryforwards of $<span><ix:nonfraction contextref="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitref="usd" inside-table="false" id="fact-identifier-678" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,100</ix:nonfraction></span> for federal tax purposes.</span></p><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_18" id="_IncomeTaxDisclosureTextBlock-c0_cont_17" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final
                                            tax assessments:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_19" id="_IncomeTaxDisclosureTextBlock-c0_cont_18" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin-left: 1in; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s tax assessments through the 2016 tax year are considered final.</span></p><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_20" id="_IncomeTaxDisclosureTextBlock-c0_cont_19" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
                                            taxes:</span></td></tr></tbody></table><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_20" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provided a full valuation allowance, to reduce deferred tax assets to their estimated realizable value, since it is more likely
than not that all of the deferred tax assets will not be realized.</span></p></ix:continuation></span><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" continuedat="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock" inside-table="false" continued-main-taxonomy="true" id="fact-identifier-683" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="font: bold 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE&nbsp;13:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BASIC
AND DILUTED NET LOSS PER SHARE</span></td>
</tr></tbody></table><p style="font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></span><div>

</div><div>

</div><span><ix:continuation continuedat="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Basic
net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted-average number of ordinary shares
outstanding during each year. Diluted net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted
average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during
the period, in accordance with ASC No. 260-10 “Earnings Per Share”. The Company experienced a loss in the year ended December
31, 2021; hence all potentially dilutive ordinary shares were excluded due to their anti-dilutive effect. </span></p><p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation continuedat="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><p style="font: 11pt Times New Roman,serif; margin-left: 0.75in; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the number of shares and loss used in the computation of net loss per share:</span></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></span><div>

</div><div>

</div><span><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-687" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net </b></span></p> <p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>loss attributable to equity holders of the Company</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net </b></span></p> <p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>loss attributable to equity holders of the Company</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 11pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt">For the computation of basic and diluted loss</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c80" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitref="shares" inside-table="true" id="fact-identifier-688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,246,803</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" unitref="usd" inside-table="true" id="fact-identifier-689" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,793</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 9%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c81" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitref="shares" inside-table="true" id="fact-identifier-690" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,725,584</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction contextref="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" unitref="usd" inside-table="true" id="fact-identifier-691" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,573</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span></ix:continuation></span><div>

</div><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - - - - - - - - - - - -</span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-28</span></p><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 11pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>






</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonnumeric id="hidden-fact-0">00-0000000</ix:nonnumeric>
<ix:nonfraction decimals="0" id="hidden-fact-1" unitref="usd">379900000</ix:nonfraction>
<ix:nonfraction id="hidden-fact-2" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-3" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-4" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-5" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-6" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-7" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-8" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-9" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-10" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-11" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-12" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-13" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-14" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-15" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-16" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-17" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-18" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-19" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-20" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-21" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-22" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-23" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-24" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-25" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-26" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-27" unitref="pure" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-28" unitref="pure" xsi:nil="true"></ix:nonfraction>
<ix:footnote id="ix_0_footnote" xml:lang="en-US">As of December 31, 2021, the manufacturing plant is under validation process and therefore is not yet ready for production. Depreciation of the manufacturing plant will commence upon completion of the validation process.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of useful life of the assets at annual rate-->
<ix:footnote id="ix_1_footnote" xml:lang="en-US">Over the shorter of the term of the lease or its useful life.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of useful life of the assets at annual rate-->
<ix:nonfraction id="hidden-fact-29" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-30" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-31" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-32" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-33" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-34" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-35" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-36" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-37" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-38" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-39" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonnumeric id="hidden-fact-40" xsi:nil="true"></ix:nonnumeric>
<ix:nonfraction id="hidden-fact-41" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonnumeric id="hidden-fact-42" xsi:nil="true"></ix:nonnumeric>
<ix:nonfraction id="hidden-fact-43" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonnumeric id="hidden-fact-44" xsi:nil="true"></ix:nonnumeric>
<ix:nonfraction id="hidden-fact-45" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonnumeric id="hidden-fact-46" xsi:nil="true"></ix:nonnumeric>
<ix:nonfraction id="hidden-fact-47" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-48" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-49" unitref="usdPershares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction id="hidden-fact-50" unitref="shares" xsi:nil="true"></ix:nonfraction>
<span><ix:nonnumeric contextref="c0" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
<span><ix:nonnumeric contextref="c0" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-693" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
<span><ix:nonnumeric contextref="c0" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-694" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001600847</ix:nonnumeric></span>
</ix:hidden>
<ix:references><link:schemaref xlink:href="gmda-20211231.xsd" xlink:type="simple"></link:schemaref></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromrefs="hidden-fact-28" torefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromrefs="hidden-fact-27" torefs="ix_1_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SecuritiesFinancingTransactionAxis">gmda:MarketableSecuritiesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gmda:ProductionPlantInProcessMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gmda:ProductionPlantInProcessMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbGzSS2V9veXLez+Xl0dIVqXQZdaaX7U8iZ3lEvQVQ8yavTR5LGMAC/Y6xtwO1cV8fb2TQr9869LtfBN0QiqMAmTafnR89xlfZsiUOfy8keujfIXUhMt6XjMZ6z95zYaEbBdLS+gpQetk+iIBjrA4uZfqc1W7C9E0jXFIZ5bjYBnP6xHb1o37Jr/j9qZTHGD0nI/EXYtdYniQ==] CSR-->
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-05-01</xbrli:startdate>
    <xbrli:enddate>2020-05-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-12-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestorMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-11-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoZeroOneFourIsraelShareOptionPlanMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-11-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2014-11-01</xbrli:startdate>
    <xbrli:enddate>2014-11-23</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeOneMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeOneMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeOneMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeOneMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeTwoMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeTwoMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeTwoMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeTwoMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeThreeMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeThreeMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeThreeMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeThreeMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeFourMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeFourMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeFourMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">gmda:RangeFourMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsOutstandingMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">gmda:OptionsExercisableMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="gmda:LossPerShareAxis">gmda:ForTheComputationOfDilutedLossMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="gmda:LossPerShareAxis">gmda:ForTheComputationOfDilutedLossMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitnumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitnumerator>
    <xbrli:unitdenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitdenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitnumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitnumerator>
    <xbrli:unitdenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitdenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div>

</body>
</html>